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Empirical evidence indicates that clinical trials are the most challenging type of 
research where the recruitment of willing volunteers is required. Insights into the 
process of recruitment are being gained from research examining the perspectives of 
those individuals directly involved, but there is limited comparative work in this 
area. Cystic fibrosis (CF), a serious life-long health condition was chosen as a case 
study for this thesis. It enabled recruitment to be compared across both adult and 
child settings and from both sides of the exchange. Qualitative interviews were 
conducted with 82 informants, comprising 20 adult patients, 22 mothers, eight 
fathers, 12 young people and 20 practitioners, across ten specialist CF centres (five 
paediatric and five adult). Analysis of transcribed recordings was pluralistic, 
drawing on elements of grounded theory and discourse analysis.  
 
Findings from this case study indicated that informants were able to make sense of 
invitations to participate in clinical trials based on personal perceptions of fairness, 
which could be discerned according to three distinct yet interdependent discourses 
namely: a rational; a social and a psycho-moral discourse. Rather than a universal 
ethical principle of fairness, informants made their own judgements of fairness, 
which took different forms depending on their personal sense of responsibility. 
Parents acting on behalf of infants and young children focused on doing the right 
thing and acting in the child’s best interest, balancing both parental responsibilities 
and personal values. Parents of older children focused on negotiating the young 
person’s level of involvement in decisions according to pre-existing family 
dynamics. Adult patients balanced their own health status, past research experience 
and personal values to make sense of and respond to the invitation to enter a trial. 
Practitioners illustrated the delicate balance required for the ‘unbiased marketing’ of 
trials, in which they considered their duty of care to patients, inherent trial 
uncertainty, ‘a pressure of numbers’ and their own personal values. 
 
In the context of this lifelong condition, recruitment was a social exchange as well as 
an informational one, in which hope, trust and a sense of moral responsibility were 
central for informants. Vulnerabilities could arise in relation to these processes, 
where high hopes could lead to disappointment, a sense of responsibility could lead 
to obligation, or trust could turn to acquiescence. The findings have implications for 
enhancing recruitment and raise questions about the appropriateness of generic 
checklist guidelines for enhancing and supporting the recruitment process. 
Individuals and families approached about trials want to be part of something of 
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Origin of thesis 
This thesis was funded by the Medical Research Council North West Hub for Trials 
Methodology Research (NWHTMR) based at the University of Liverpool. It forms 
part of the Patient Perspectives Theme of the Hub, which is aimed at ensuring that 
the design and conduct of clinical trials are informed by patients’ perspectives.  I 
first became involved in this field of research as a qualitative interviewer for the 
RECRUIT study, which examined processes in recruitment to randomised 
controlled trial of medicines for children (Shilling et al., 2011). This thesis builds on 
my prior experience of and interest in clinical trial recruitment.  
Thesis rationale 
Despite extensive research on clinical trial recruitment, it remains unclear why some 
trials recruit well and others do not; furthermore there is a distinct lack of theory to 
unite empirical evidence and direct future research (Sully et al., 2013; Bower et al., 
2009; 2014; Campbell et al., 2007). Examining recruitment from multiple 
perspectives is helping the clinical trials community understand the complexity of 
the recruitment process (Campbell et al., 2007). Furthermore, multi-perspective 
qualitative interviewing is an important methodology for understanding the needs, 
beliefs and experiences of those receiving and providing services (Kendall et al., 
2009). In some sense, recruitment to trials could be thought of as a kind of service, 
forming part of a system meeting a public need, namely to improve healthcare. 
Nevertheless, qualitative research examining recruitment from both sides of the 
exchange is less prevalent and there is no qualitative work of this nature comparing 




been shown to be a valuable analytical tool for providing theoretical insights into 
complex social phenomena (Bradley et al., 2007). Furthermore, much of the 
empirical evidence on trial recruitment is based in oncology with limited work 
involving individuals with chronic conditions such as cystic fibrosis (CF). 
Cystic fibrosis is a genetic disease diagnosed at birth for which treatment requires 
lifelong, intensive interventions in specialist paediatric and adult CF centres; many 
of these are research-active presenting an ideal case for examining clinical trial 
recruitment (Lowton, 2005). At the time my PhD studies commenced, a multicentre 
phase IV clinical trial (TORPEDO-CF:Trial of Optimal TheRapy for Pseudomonas 
Eradication in Cystic Fibrosis) was being managed by the Clinical Trials Research 
Centre (CTRC) in Liverpool. 
This trial, which was open to both adults and children, was identified by the Hub 
management team as a potentially suitable focus to examine current trial 
experiences in CF. Consequently, a qualitative ‘case study’ in CF which examined 
recruitment experiences across adult and paediatric settings, from the perspective of 
those doing the recruiting and those being recruited, was selected to further current 
understanding of trial recruitment. 
Clarifying terms  
The term  ‘informants’  was chosen to refer to all individuals who agreed to take 
part in this qualitative study, and so distinguish them from people with experiences 
of clinical trials or other studies, where I use the term ‘participant’. Individuals 
receiving care from specialist paediatric CF centres were referred to as the child 
sample. This sample was synonymous with the typical definition of a paediatric 




Teenagers with CF typically begin a process of ‘transition’1 to specialist adult CF 
centres from early teenage years, with most being transferred to adult care by the 
age of eighteen (Towns & Bell, 2011; Rosen et al., 2003). The oldest child informant 
in this sample was 17 years old. Children aged seven years and younger who were 
not invited to take part in this study were described as ‘infants’. The remaining 
child sample was referred to as children, although where relevant I have made 
further distinctions between a teenager (≥13 years) and the youngest participants 
(≤9yrs). The term ‘patients’, was also used collectively to refer to all people with CF, 
both children and adults who had agreed to take part in this study. The term 
parents was  used to refer to parents of both infants and children with CF. The term 
‘adults’ or ‘adult informants’ or ‘adult patients’ was used exclusively to describe 
adults with CF. The term practitioner was used to describe any health professional 
who agreed to take part in this study. 
Throughout  the study, I use the term ‘clinical trial’ or ‘trial’ to refer to a randomised 
controlled trial (RCT). Where I use the term clinical study, I am referring to all other 
research that does not involve a randomised design. Where I use the term clinical 
research, I am referring to the collection of clinical studies and trials which require 
the informed consent of human participants.  
Organisation of the thesis 
This thesis is divided into eight chapters. In the first chapter, I provide background 
to the research methodology of clinical trials. This will be followed by a scoping 
                                                     
1 Transition refers to the ‘planned purposeful movement of adolescents and young adults 
with chronic physical and medical conditions from child-centred to adult orientated health-




review of the structure and extent of knowledge on the subject of trial recruitment. 
Finally, within this first chapter, I identify key gaps in the literature and explain 
where my study is positioned. 
In the second chapter, I explore the methodological considerations that guided my 
decision to conduct a qualitative case study in CF. Here I will examine the 
theoretical orientation of this study and the consequences of this orientation for the 
methods that follow. In Chapter Three I provide a description of the methods I 
adopted in this study, describing the process of analysis and interpretation of the 
findings and including an overview of the conceptual framework upon which the 
findings will be organised. Chapter Four provides the context for the study findings, 
detailing the research setting and the sample characteristics. Chapters Five, Six and 
Seven describe the findings, particularly the main conceptual patterns or discourses 
identified in informants’ accounts of recruitment.  These centred on informants’ 
perceptions of the fairness of a research invitation which I grouped according to 
three thematic patterns or discourses:  a rational, a psycho-ethical and a social 
discourse. 
Chapter Five illustrates how informants rationalised research invitations in a 
deliberate ‘weighing up’ of the costs and benefits, assessing how safe or valuable they 
perceived the trial or study to be; this is interpreted as a form of a rational discourse. 
Chapter Six illustrated the consequence of trust and the social context on how 
informants perceived the recruitment process; this is interpreted as a social 
discourse. Chapter Seven describes how informants’ worked to construct a moral 
and psychological account of their recruitment experience, one in which hope and a 
sense of duty were most significant. This is interpreted as a form of psycho-ethical 




setting them in the context of previous empirical and theoretical work. The 
implications of these findings in terms of policy and practice, point to areas for 
future research. Finally, I assess the study’s strengths and limitations and provide a 




CHAPTER 1:  BACKGROUND AND LITERATURE REVIEW 
1.0 Introduction  
The most widely used methodology for evaluating the effectiveness of health care 
involving ‘human subjects’ is the clinical trial (NIHR, 2015). Without willing 
participants, clinical trials could not exist, and without an adequate number of 
appropriately recruited participants, the scientific and ethical integrity of the clinical 
trial is undermined. The focus of this thesis is to gain insights into the process of 
recruitment, which is the gateway to trial participation, a process culminating in an 
individual’s decision to participate (Gul & Ali, 2010). 
Deciding to participate in a clinical trial requires an individual to make a voluntary, 
informed choice to expose themselves to uncertain outcomes. Furthermore, the 
responsibility of recruiting a participant requires a practitioner to invite a patient to 
consider these uncertainties. Empirical evidence indicates that clinical trials are the 
most challenging and problematic type of research with respect to recruitment, due 
to the inherent ethical tension in the conduct of trials surrounding the ‘duties to the 
individuals’ versus the ‘societal value’ of clinical trials (Emanuel et al., 2000; 
Hellman & Hellman, 1991). 
The literature on trial recruitment is vast and diverse, probably reflecting the scale 
of the challenge in recruiting of sufficient patients to these studies (Campbell et al., 
2007; McDonald et al. 2006). Due to the heterogeneity of the literature, compounded 
by methodological issues, meaningful interpretation of the evidence through 
systematic reviews has been difficult (Treweek et al., 2013; de Vries et al., 2011; 




‘robust theory’ to assist in uniting these findings or to guide the direction of trial 
recruitment research (Bower et al., 2009; 2014; Tramm et al., 2013; Gul & Ali, 2010). 
Consequently the aim of this thesis is to contribute to the trial recruitment literature, 
both conceptually and empirically  
 Therefore in reviewing the literature, as opposed to concentrating solely on ‘what 
works’ or what is necessary or ‘right’ regarding trial recruitment, I will focus 
primarily on identifying the dominant approaches to researching the topic of 
recruitment and the consequences of these methods on current knowledge and 
understanding of the phenomenon of trial recruitment. This review is not intended 
to be a systematic review of the evidence, but a scoping review of the structure and 
extent of knowledge on recruitment (Grant & Booth, 2009; Gough et al., 2012). 
Within this review I aim to reflect the diversity in the empirical evidence whilst 
identifying literature which has conceptually defined an aspect of trial recruitment 
or has integrated existing empirical recruitment literature beyond a descriptive 
level. Therefore the aim of this review is to examine how historical and 
philosophical assumptions have shaped the direction of recruitment research and 
the main theoretical insights into this phenomenon and where my research is 
positioned.  
The review was not a ‘one-time event’ with rigidly pre-defined initial review 
questions, but rather an ongoing iterative process which extended throughout my 
PhD studies (Ramalho et al., 2015; Dunne et al., 2011; Charmaz, 2006; 2008). 
Engaging with the literature prior to undertaking my primary research was 
essential to position my study within the wider literature and to support my ethics 
application to conduct empirical work. Nevertheless, owing to my largely inductive 




both the literature review and during the process of data analysis. Therefore within 
my discussion the empirical literature was re-examined more critically in the light of 
my findings.  
1.1 Search strategy 
Locating evidence for this scoping review involved a range of strategies, with 
electronic database searches forming an important component. All the same, I was 
aware of the limitations of solely relying on database and electronic searches, 
especially when the focus includes qualitative and theoretical literature where 
bibliographic databases alone are often not enough (Flemming & Briggs, 2006; 
Greenhalgh & Peacock, 2005; Shaw et al., 2004). At the outset of my PhD, I was 
aware of important literature in the field, acquired through previous work in the 
area of paediatric trial recruitment and I was continually advised about new articles 
by experts in the field. I also used citation tracking and the screening of article 
reference lists for relevant literature (Greenhalgh & Peacock, 2005). The database 
search involved testing and refining various search strategies to balance the 
sensitivity of the search (number of articles recalled), with the precision of the 
search (the relevance of the search).  As I became more familiar with the labels and 
terminology surrounding the trial recruitment literature, I developed a series of 
search terms. These were built on the concepts detailed in Table 1.1 and involved 
combining these search terms according to the database and significance of output. 
The four main abstract and citation databases I used during the electronic searches 
included: 





iii.) PsycINFO  
iv.) SCOPUS 
Together these databases provided coverage of health sciences, life sciences; 
physical sciences and social sciences (see Appendix 1 for details of database 
searches). 




Word group 2  
(clinical trial) 
Word group 3  
(Participant ) 
Word group 4 
(health 
professional) 
Word group 5 
(perception) 
Word group 6 
(methodology) 
recruit*   clinical trial* participant* practitioner* perce*  qualitative  
enrol* controlled 
trial* 
patient* doctor* experienc* Interview* 
particip* trial* public clinician* understand* focus groups 







child* investigator* view* narrat* 
consent clinical 
research 




people nurs* opinion* interpret* 
 research stud* person paediatrician* reason* grounded 
theory 
  parent* paediatrician* account* ethnograph*  
  mother* GP motivat* phenomenolog* 
  father* Professional* Barrier*   
  prox*  attitude*  
  teenager*  view*  
  consumer    
  layperson*    
  subject*    
  volunteer*    
 
In addition to searching the above databases, I searched the Cochrane Library, 
Health Technology Assessment (HTA) NIHR Journal Library, Centre for Reviews 




searches with and without qualitative filters, to examine the extent and diversity of 
the recruitment literature. No date restriction was applied, and searches revealed 
that much of the earlier recruitment research was quantitative in design, with much 
of the qualitative research appearing from the 1990s onwards.  Once I had 
developed search terms which adequately captured the literature, an automatic 
online search (with Scopus) was also set up, enabling me to identify any new 
relevant articles to be included outside the main periods of searching. All relevant 
articles were entered into a bibliographic database (EndNote X7) and grouped 
according to whether they involved primary evidence, discussion papers, review 
articles or articles with a theoretical focus. These categories were further subdivided 
according to the focus of the recruitment research. I only included articles that had 
been published in peer reviewed journals. Both empirical and review articles were 
assessed informally, using the relevant critical appraisal tool CASP (2017). For the 
ethical literature I also included a selection of books. 
1.2 Medicine’s prime way of knowing: randomised control trials (RCTs) 
I will begin this review by examining aspects of the clinical trial design, which are 
significant to understanding the challenges of trial recruitment. A clinical trial 
involves a systematic, highly structured, scientific approach embedded in the 
experimental method, which primarily evaluates treatment effectiveness by 
comparing outcomes of different treatment groups (Kerr et al., 2006; Jadad, 1998). 
Reducing potential bias through randomly assigning participants to different 
treatment groups is the main methodological appeal of this research design (Kerr et 




The first large scale strictly controlled clinical trial was published by the MRC in 
1948 and aimed at establishing the effectiveness of the antibiotic streptomycin for 
the treatment of tuberculosis (Hill, 1963; Marshall et al.,1948). Carried out during 
the economic recovery of the post-war period, random allocation was regarded as 
an ethical way of utilising scarce resources of streptomycin. This trial ‘ushered in the 
new era of medicine’ with the RCT becoming ‘the model in this field’ (Hill, 1963; 
1990). 
Over the years, multiple types of RCT have been developed, and a range of terms 
have evolved. Table 1.2, while not exhaustive, details some of the different types of 
RCTs. 
TABLE 1.2: A range of RCT designs (Jadad, 1998) 
 
Dimension on which RCTs vary Examples  
RCTs according to the aspects of the 
intervention they evaluate  
 
Explanatory & pragmatic trial  
Efficacy & effectiveness trials 
Phase I, II & III 
RCTs according to how participants are 
exposed to the interventions  
Parallel trials  
Crossover trials  
Trials with factorial design 
RCTs according to the number of 
participants  
From n=1 to mega-trials 
Fixed size 
Sequential design 
RCTs according to whether the investigators 
and participants know which intervention is 
being assessed 
Open trials 
Single blind trial 
Double blind trials 
RCTs according to whether the preferences 
of non-randomised individuals & 
participants are taken into account 
Zelen design 
Comprehensive cohort design 
 
 
Interventions that are evaluated in the context of clinical trials are varied and can 
include preventative strategies, diagnostic tests, screening programmes and 




treatments. These trials are categorised according to different stages of the 
evaluation process (Kerr et al., 2006; ICH, 1997). Phase I trials, often referred to as 
‘first-in-human trials’ are conducted after the safety, and potential efficacy of a new 
drug has been documented in animals. The primary purpose of these trials is the 
assessment of the tolerance and safety of the drug in humans (Kerr et al., 2006; ICH, 
1997). These often involve healthy volunteers who receive a financial incentive, or 
patients receiving palliative care within oncology or other serious illnesses. Phase I 
trials involving patients with terminal conditions for which no standard treatment 
protocol exists are often associated with the characterisation of the ‘desperate 
volunteer’ who has nothing to lose (Allmark & Mason, 2006). However, phase I 
trials are also often evaluating safety with small numbers of participants such as the 
case of early gene therapy trials in CF. Phase II trials most typically explore 
therapeutic efficacy, in small groups of patients with a given condition to determine 
the dose(s) and regimen for phase III trials (Kerr et al., 2006; ICH, 1997). The 
primary objective of phase III trials is to demonstrate or confirm therapeutic benefit, 
and these usually involve randomised multi-centred trials involving larger groups 
of patients (Kerr et al., 2006; ICH, 1997). Phase IV trials are performed after drug 
approval and include studies that were not considered necessary for approval but 
are often essential for optimising the drug’s use (ICH, 1997). 
The randomised controlled trial design has become the ‘standard experimental 
design’ or ‘gold standard’ for determining the efficacy of medical treatments 
(Grossman & Mackenzie, 2005; Silverman & Chalmers, 1992; Bloom, 1986), to the 
point where it is often regarded as ‘medicine’s prime way of knowing’ (Oakley, 
1999). However paradoxically the process of randomisation - the cornerstone of the 
clinical trial’s scientific appeal - has raised ethical concerns and has been identified 




et al., 2006; Chard & Ilford, 1998; Lumley & Bastian, 1996). The solution to the 
dilemma posed by randomisation has been an appeal to the principle of equipoise, 
which has become the central assumption governing the ethics of randomised 
controlled trials (Miller & Brody, 2002; 2003). Equipoise is defined as ‘the point 
where a rational, informed person has no preference between two (or more) 
available treatments’ (Lilford & Jackson, 1995). From this position of genuine 
uncertainty about the relative merits of the treatment options, RCTs are considered 
to be consistent with practitioners’ ethical duties to their patients, as no patient is 
knowingly given an inferior intervention (Freedman, 1987). Where equipoise is said 
to exist between two or more given treatments, a person entering a clinical trial of 
those treatments is likely to be no better or worse off through randomisation than 
through deliberate recommendation of treatment (Chalmers & Chalmers, 1994). 
 Whether the concept of equipoise resolves the ethical debates surrounding clinical 
trials remains contentious, and over the last decade the debates have become 
increasingly complex and technical (van der Graff & van Delden, 2011; Djulbegovic, 
2011; Kukla, 2007). Defining the term itself is challenging and varies according to 
whose uncertainty is being considered. Uncertainty  is considered  from the  
position of the individual practitioner, a community of experts, the individual 
patient, a community of patients or the public. Consequently   debate continues on 
this subject (Ubel & Silbergleit, 2011; Veatch, 2007; Miller & Brody, 2002;2003 
Alderson, 1996). 
Nonetheless the RCT has formed the foundation for evidence-based medicine 
(EBM) which is primarily focused on integrating individual clinical expertise with 
clinical evidence through systematic research, (Jadad, 1998b; Sackett, et al., 1996). 




(e.g.Carey & Stiles, 2016; Greenhalgh et al, 204 Grossman, 2008; Goldenberg, 2009; 
Grossman  & Mackenzie, 2005; Ashcroft, 2004; Stradling & Davies, 1997) the sheer 
volume of empirical, theoretical, legislative, institutional, national, and international 
literature available on the subject clearly demonstrates that clinical trials are 
perceived as an indispensable component of medicine and clinical research. For 
example, in 2010 the number of trials recorded in an international trial registry 
(NIH,ClinicalTrials.gov, 2014) was 101,169, with this figure more than doubling in 
2015 to 206,176. Furthermore, disease-orientated health social movements (e.g. HIV, 
cystic fibrosis and breast cancer), have contributed to a shift in the dynamic between 
stakeholders in healthcare. (e.g. Hess, 2004; Prior, 2003; DoH, 2008; INVOLVE, 1996; 
2017; Feenberg 1992). Many patient and professional organisations are strongly 
supportive of clinical trials. Providing the opportunity for children and adult 
patients to benefit from research is now considered an ethical obligation and right. 
This responsibility is reflected in the continual development of informational 
resources, trial registries and media campaigns that aim to help patients access and 
participate in clinical trials e.g. It's OK to Ask’ about clinical research campaign 
(NIHR, 2013),Healthtalk.org, (DIPEx, 2014), International Clinical Trial Registry 
Platform , ICTRP (WHO 2010). 
1.3 Recruitment and accrual 
The NIHR has defined recruitment as the ‘enrollment of an individual person 
meeting specific inclusion criteria into a research study’ (NIHR, 2015).  Trial 
recruitment is viewed as being successful if a trial recruits to a predefined target 
sample or beyond within a specified period (Campbell et al., 2007). The process of 
recruitment has been identified as involving three steps, first identifying eligible 




about the study and finally seeking their agreement and informed consent to join 
the study (Preston et al., 2016). Generally, a patient’s clinician must provide the 
infrastructure for recruitment, by agreeing that their centre will participate in the 
trial and by providing appropriate access to patients. Consequently, conceptions of 
recruitment have extended to include a clinician’s agreement to participate in the 
trial in principle (Bower et al., 2009).  Trial recruitment has also been positioned 
within a broader conceptual framework which extends beyond the perspective of 
patient and the recruiter, to include the ‘strategic ‘proactive’ management of trials 
(Menon et al, 2008; Francis et al; 2007; Campbell et al, 2007; Walson, 1999; Farrell, 
1998). This focus on the importance of trial management has lead to the 
development of a  tentative ‘business model approach’ of the trial process. 
According to this model,  recruitment is viewed as having ‘market segments’ which 
includes recruiting the support or ‘buy in’ of  ‘active sponsors’  clinical teams and 
‘opinion leaders’ (Campbell et al., 2007). Nonetheless, more commonly within the 
literature, the term recruitment is used to refer to the role of practitioners in 
‘offering patients the opportunity to take part in a trial’ (Rendell et al., 2007) which 
is the focus of this review and my subsequent research objective.  
Adequate accrual or recruitment is necessary to uphold the scientific merit of trial 
methodology, as it is heavily dependent on statistical inferences which require 
certain sample sizes (Ashcroft, 2004; Warlow, 2002). Clinical trials, therefore, need to 
be able to meet their recruitment targets, which concern the number of patients 
required to make the study feasible (NIHR, 2015). Inadequate recruitment leads to 
samples being smaller than planned, with reductions in statistical power necessary 
to detect potentially important clinical differences and less precise estimates of 
treatment effects (Warlow, 2002). Moreover, it may be necessary to extend a trial to 




extending the findings to clinical practice, fewer trials being conducted overall and 
consequently reduced availability of evidence to inform patient care (Campbell et 
al., 2007). This scientific concern of adequate accrual is therefore also an ethical 
concern relating to the effective use of health care resources.  
A significant proportion of clinical trials fail to achieve their planned recruitment 
targets for reasons that are not well understood (Sully et al., 2013; Treweek et al., 
2010; Campbell et al., 2007). Inadequate recruitment, whether of adults or children, 
is one of the principal reasons for trial failure (Sully et al., 2013; McDonald et al., 
2006 et al., Prescott et al, 1999) and has a major impact on the value of findings, the 
costs and the workload of trials. 
 In response to this ongoing challenge of ‘poor recruitment’ an extensive, diverse 
and ever-growing evidence base has emerged, centred on improving recruitment 
rates to clinical trials, by identifying factors which may impact on them. A 
significant proportion of this research has examined dimensions of the recruitment 
process as perceived by the patients or recruiting clinician, to identify ‘barriers’ or 
‘facilitators’ to successful recruitment. Surveys and interviews have investigated the 
views of clinicians, adult patients and children and their families, across a range of 
contexts (Luchtenberg et al., 2015; Peeters et al., 2012; Lazovski et al., 2009; Sharp et 
al. 2006; Caldwell et al., 2002). Much of the evidence has been synthesized into 
numerous reviews (e.g. Tromp et al 2016; Sully et al, 2013; Rendell et al, 2007; 
Campbell, 2007; Mills et al., 2006; Fayter et al 2006; Prescott et al, 1999; Lovato et al., 
1997; Hunninghake et al., 1987).  
With regards to clinicians’ perceptions of the factors influencing recruitment 




resource and role issues, concerns with information and consent  as well as the 
importance of the research questions (Fayter et al., 2007; Rendell et al., 2007). 
Repeated evidence is also found of the potential for the clinician to present a barrier 
to patient participation through their position as gatekeepers to trials (Prescott et al., 
1999; Lavato et al., 1997; Fayter et al., 2007). Nevertheless, by far the most prominent 
finding is the multi-dimensional nature of practitioner identified factors, in which a 
collection of numerous issues have been identified as having the potential to 
influence recruitment (Fayter et al., 2007; Rendell et al., 2007). 
Factors that can influence trial recruitment as perceived by adults and children and 
parents have also been identified. Prominent among these is trial burden, including 
physical risk and inconvenience, and concerns about trial uncertainty (Tromp et al., 
2016; Meropol et al., 2007; Abraham et al., 2006; Ross et al., 1999). For adults and 
parents, a preference for a particular treatment (or no treatment) is also prominent 
in the literature (Mills et al., 2011; King et al., 2005). The most prominent personal 
motivators as perceived by adults, children and parents include hope for a personal 
health benefit, contributing to science and helping others (e.g. Dobson et al., 2015; 
Ulrich et al., 2012; Fry & Dwyer, 2001; Broome et al., 2001; Jenkins & Fallowfield, 
2000). Nevertheless, consistent with practitioners’ findings, the multidimensional 
nature of participants’ and relatives’ motives for trial participation is the most 
prominent feature of the literature (Tromp et al., 2016; Ulrich et al., 2012; Truong et 
al., 2011).  
Much of this evidence is based on quantitative methodology involving attitudinal 
surveys administered to patients, parents of children or practitioners, or exploration 
of their views of hypothetical trial scenarios (Brody et al., 2005; Schron et al. 1997; 




predefined fixed response formats, or hypothetical trial scenarios may bear little 
resemblance to how trial recruitment is actually experienced (Fayter et al., 2007). 
Moreover, methodological weakness within many of the studies combined with the 
striking heterogeneity across studies has made a meaningful interpretation of these 
findings problematic (Fayter et al., 2007; Rendell et al., 2007). This existing literature 
has been described as painting ‘a mixed and uncertain picture’ (Ulrich et al., 2012). 
Also, a large body of this evidence exists in the field of oncology, particularly in the 
context of paediatric trials. Therefore there is a concern that issues relevant to this 
setting may not apply to other settings or patient groups (Tramm et al., 2013). These 
findings indicate the complexity of trial recruitment, which is further complicated 
by few authors dealing with ‘the issue holistically’ or conceptually (Gul & Ali, 2010). 
In-depth qualitative approaches have provided further insights (McCann et al., 
2013; O’Cathain et al., 2013; Fisher et al., 2011; Campbell et al., 2007; Donovan et al., 
2002; Broome et al., 2001) and these approaches are increasingly being used to 
elucidate detailed knowledge of potential facilitators and barriers from the 
perspective of those doing the recruiting and those being recruited, across child and 
adult settings ( Mills et al., 2011; Shilling et al., 2011; Madsen et al., 2007; Salmon et 
al., 2007). This evidence has indicated important differences between how some 
practitioners, compared to children and parents perceive the process of recruitment 
(Shilling et al., 2011). Qualitative evidence has also provided insights into the 
underlying mechanisms with regards to the barrier of time for practitioners (Salmon 
et al., 2007) and led to the reconceptualisition of trial treatment preferences from a 
barrier to an integral part of the information exchange (Mills et al., 2011). A move 
from the ethical ideal of promoting autonomy to one that emphasises the ‘loneliness 
of autonomy’, the importance of relational aspects of recruitment and the centrality 




Furthermore, reviews focusing on qualitative empirical evidence examining the 
determinants of recruitment according to patients’ demographic characteristics and 
trials targeting particular health contexts (e.g. Hughes-Morley et al., 2015; 
Limkakeng et al., 2013; Tooher et al., 2008) are helping to identify areas which may 
require special consideration during the recruitment process. For instance, issues 
around confidentiality and ‘social discrimination’ in HIV trials (Mills et al., 2006), 
issues of timing and method in maternal and perinatal trials (Tooher et al., 2008) or 
sensitivity to perceptions of ‘stigma’ in trials recruiting individuals with depression 
(Hughes-Morley et al., 2015).  
Within the family context, when a child is considered old enough to have an 
opinion, issues around managing differing preferences of the involved parties are 
being identified as key. (Madden et al., 2016; Snethen et al., 2006; Broome & 
Richards, 2003; Olechnowicz et al., 2002). Nevertheless, there remains a need for 
further qualitative research extending to diverse populations which are currently 
underrepresented in the evidence-base particularly in the context of chronic 
illnesses such as CF. At the time of submitting my proposal for ethical review; I 
identified one qualitative study examining motivations for clinical research 
participation amongst adults with CF (Lowton, 2005). A further qualitative study 
examining how young people with CF understand their research experience was 
identified during a later search (Dobson et al., 2015). Both studies support the 
observation that recruitment literature in the context of CF is scarce (Tromp et al., 
2016; Dobson et al., 2015; Lowton, 2005). 
1.3.1 Recruitment as an intervention 
Dovetailed with the literature examining factors that influence recruitment, is an 




strategies’ to overcome identified barriers and to promote recruitment (Rick et al., 
2014; Treweek et al., 2010;  Caldwell et al., 2010; Bower et al.,  2009; Campbell et al., 
2007; Watson & Torgerson 2006; McDaid et al., 2006). This evidence base lends itself 
to viewing recruitment as a type of ‘intervention’ or strategy to be tested for 
effectiveness. Recruitment strategies involve any intervention that is aimed at 
improving recruitment rates to a clinical trial and may be directed at potential 
participants, clinicians or the management of the overall trial (Raynor et al., 2009; 
Campbell et al., 2007; Embi et al., 2005). 
 The most robust test of the effectiveness of a recruitment method is considered to 
be a randomised controlled trial, comparing one recruitment method with an 
alternative method ‘nested’ within an ongoing treatment intervention trial (Bower et 
al., 2014; Treweek et al., 2013). So in effect, this methodology constitutes a trial 
within a trial. While this approach is viewed as the most ‘scientific’, it faces the same 
potential barriers as all trials, for instance, a practitioner may have a preferred 
recruitment strategy and have concerns about the effectiveness of the proposed 
strategy (Bower et al., 2009). Other approaches aimed at improving recruitment 
rates evident across the literature include detailed examination and adaptation of 
the trial process and recruitment strategies in ongoing trials and a rise in feasibility 
and development studies (Hoddinott, 2015; Menon et al., 2008; Campbell et al., 2007; 
Vollmer et al., 1992). For example, Kaur and colleagues (2012) have devised a survey 
tool based on the current evidence base on barriers and facilitators to trial 
recruitment. This tool has been proposed as a method to establish the recruitment 
experiences of clinical teams in order to gain relevant information to assess, monitor 




Interventions to improve recruitment have also been the focus of ongoing reviews 
(Preston et al., 2016; Treweek et al., 2010; 2013; Caldwell et al., 2010). These reviews 
have shown some strategies to be effective in improving recruitment rates to trials, 
including telephone reminders to non-respondents, use of opt-out rather than opt-in 
procedures for contacting potential participants and the use of open designs where 
participants know which treatments they are going to receive in the trial (Treweek 
et al. 2010;2013). Having a dedicated trial manager and making a specific member of 
staff responsible for recruiting participants has also been shown to be associated 
with recruitment success (Campbell et al., 2007; Preston et al., 2016). Nevertheless, 
the widespread and often disparate evidence has made conclusive interpretations 
difficult, with the effectiveness of many strategies remaining unclear (Bower et al., 
2014; Treweek et al., 2010). Furthermore, gaining an understanding as to why 
recruitment to a trial is successful appears too complex to be understood by any one 
type of evidence alone and requires other components (Hughes-Morley et al., 2015; 
Bower et al., 2014; Campbell et al., 2007). Qualitative methods ‘nested’ within 
clinical trials have been used to provide further insights into the recruitment process 
and have also led to the development of complex interventions and  frameworks for 
good recruitment practice aimed at improving recruitment rates (Realpe et al., 2016; 
Donovan et al., 2002; 2009; 2014). However, in the absence of a unified theoretical 
framework informing recruitment, translating these findings into generalisable 
impacts on the recruitment process is difficult (Bower et al., 2014). 
1.4 A discourse on protection and understanding  
While the collective impact of clinical trials on the advancement of medical 
knowledge is undisputed, it cannot be assumed that all clinical trials are 




evolved to support and promote the effective implementation of clinical trials 
equally evolved to protect participants from harmful poor quality research. 
Consequently, there are two interrelated discourses, one that primarily focuses on 
achieving recruitment targets regarding adequate ‘accrual’, and another focused on 
strengthening the ethical conduct of recruitment in terms of protecting participants 
from harm. At the heart of this protection discourse is the principal legal instrument 
in the regulation of clinical research - informed consent, aimed at protecting the 
rights and welfare of ‘human subjects’ (WMA, 2013; Bowling, 2009).  
Whatever way recruitment is defined, successful recruitment usually involves 
obtaining informed consent, and the informed consent process cannot begin without 
the process of recruitment. There are some key exceptions, for example, certain 
types of cluster trials2 and trials of emergency treatments (Woolfall et al., 2014; Sim 
& Dawson, 2012). Nevertheless, for the most part, informed consent is regarded as 
an essential ethical and legal requirement in clinical research. Consequently, the 
discourse on informed consent needs to be considered with regard to understanding 
what is known about trial recruitment. The literature on informed consent is 
extensive, complicated and highly debated (Corrigan et al., 2009; Manson & O’Neill, 
2007). 
Informed consent is centred on the ethical principle of respect for autonomy which 
is believed to be upheld by ensuring a patient makes their own decision (Mason et 
al., 2013). An individual’s consent must usually be obtained before a research 
treatment is given and the person consenting must have the capacity to make the 
                                                     
2  In cluster randomised controlled trials the intervention is randomised at the group level (e.g. village, 
hospital, school) rather than the individual patient, making  obtaining consent at the individual level 




decision (Beauchamp & Childress, 2013). This decision has been defined as the 
giving of voluntary permission by an individual who has been informed, in 
language they understand, about the risks and benefits of the proposed research 
(Beauchamp & Childress, 2013; Mason et al., 2013).  
1.4.1 A brief overview and historical origins of informed consent  
To fully appreciate the impetus for and significance of this bioethical discourse on 
protection, it is necessary to briefly trace the historical origins of informed consent. 
The evolution of informed consent and the regulation of clinical research to protect 
vulnerable research subjects from harm has a complex and tragic history dominated 
by abuse and research failings involving both adults and children (Beecher, 1966; 
Brandt, 1978). Focal points in this regulatory discourse typically include Nazi 
human experimentation during World War II (Thieren & Mauron, 2007; Brandt, 
1978) and the non-treatment of individuals with syphilis in the Tuskegee study.  
A pivotal point in this history was the creation of the first internationally agreed 
standard - the 1949 Nuremberg Code – produced following World War II, which set 
the boundaries for ‘permissible experiments’ on human subjects. The Nuremberg 
standards were then developed in the Declaration of Helsinki in 1964, which has 
become the most influential international statement on ethical principles for medical 
research, now on its ninth revision (WMA, 1964; 2013). This set of principles not 
only requires that the clinician/researcher protects the welfare of the ‘human subject’ 
and ensures the scientific integrity of the ‘experiment’, but also establishes that 
subjects can actively protect themselves with the ‘absolutely essential’ requirement 





This early legislation borne out of a responsibility for protection of research 
participants has paved the way for the current intricate array of International, 
European and National guidelines and legislation, which is continually being 
updated and amended to reflect the changing environment (e.g. CIOMS, 2016; NHS; 
HRA, 2014; Regulation (EU) No 536/2014 on Clinical Trials on Medicinal Products 
for Human Use;  DoH, 2009; UK Medicines for Human Use Clinical Trials 
Regulation, 2004; ICH  (E6) Guidelines for Good Clinical Practice, 1996).  
While the emphasis on regulation and protection has remained, the excessive 
burden of legislation has also emerged as a growing concern amongst both patients 
and professionals (Feenberg, 1992). Research ethics committees have increasingly 
come to regard their focal duty as attending to the adequacy of the informed 
consent process (Corrigan et al., 2009). However, more recent research failings 
including: i) the death of Jesse Gelsinger in the US, 1999,the first person  publicly 
identified as having died in a clinical trial for gene therapy (Jenks, 2000); ii) the 
Alder Hey inquiry, involving the unauthorised removal and retention of paediatric 
organs following post-mortem (Redfern et al., 2001; Hall, 2001; Burton & Wells, 
2001) and, iii) the life-changing side-effects experienced by healthy volunteers in a 
phase I trial (trial TGN1412) at Northwick Park hospital (Goodyear, 2006; Attarwala, 
2010) has sustained an emphasis on the adequacy of the informed consent process, 
with the hope that this focus will better protect research participants from potential 
harm (Corrigan et al., 2009). As a result, the doctrine of informed consent in clinical 
research is far-reaching, with extensive attention to procedural detail an essential 
legal and ethical prerequisite for almost all research involving human subjects 
(Boulton & Parker, 2007). Below (Table 1.3) is the information a practitioner is legally 




according to the Good Clinical Practice Guidelines (GCP) that were in place at the 
time of data collection for this study (ICH Working Group, 1996). 
TABLE 1.3:  GCP Guidelines for informed consent (ICH, 1996) 
Both the informed consent discussion and the written informed consent form and any other written 
information to be provided to subjects should include explanations of the following:  
(a) That the trial involves research.  
(b) The purpose of the trial.  
(c) The trial treatment(s) and the probability for random assignment to each treatment.  
(d) The trial procedures to be followed, including all invasive procedures.  
(e) The subject's responsibilities.  
(f) Those aspects of the trial that are experimental.  
(g) The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an 
embryo, fetus, or nursing infant.  
(h) The reasonably expected benefits. When there is no intended clinical benefit to the subject, the 
subject should be made aware of this.  
(i) The alternative procedure(s) or course(s) of treatment that may be available to the subject, and 
their important potential benefits and risks.  
(j) The compensation and treatment available to the subject in the event of trial-related injury.  
(k) The anticipated prorated payment, if any, to the subject for participating in the trial.  
(l) The anticipated expenses, if any, to the subject for participating in the trial.  
(m) That the subject's participation in the trial is voluntary and that the subject may refuse to 
participate or withdraw from the trial, at any time, without penalty or loss of benefits to 
which the subject is otherwise entitled. 
(n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be 
granted direct access to the subject's original medical records for verification of clinical trial 
procedures and/or data, without violating the confidentiality of the subject, to the extent 
permitted by the 16 Guideline for Good Clinical Practice applicable laws and regulations and 
that, by signing a written informed consent form, the subject or the subject's legally acceptable 
representative is authorizing such access. 
(o) That records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. If the results of 
the trial are published, the subject’s identity will remain confidential.  
(p) That the subject or the subject's legally acceptable representative will be informed in a timely 
manner if information becomes available that may be relevant to the subject's willingness to 
continue participation in the trial.  
(q) The person(s) to contact for further information regarding the trial and the rights of trial 
subjects, and whom to contact in the event of trial-related injury. 
(r) The foreseeable circumstances and/or reasons under which the subject's participation in the 
trial may be terminated.  
(s) The expected duration of the subject's participation in the trial.  





1.4.2 A brief overview of informed consent in children 
A further complexity to the regulatory discourse on clinical trials is the case of the 
‘therapeutic orphan’ in which, following the introduction of standards to protect 
‘human subjects’, children were largely excluded from research. Early research 
regulation for human ‘subjects’ (Nuremberg code, 1949) viewed research as a 
potential harm, from which vulnerable people should be protected, and children 
were therefore often deemed inappropriate candidates for research (Kanner et al., 
2004; Steinbeck, 2002).  
Literature concerning the ethical tensions inherent in clinical research involving 
children is extensive and contentious, spanning many decades (e.g. Nuffield 
Council on Biethics, 2015; Laventhal et al., 2012; Alderson, 2007; Diekema, Stapleton, 
2006; Edwards & McNamee, 2005). Integral to this tension is the construction of 
childhood as ‘a vulnerable formative time’ with the duty to protect more apparent, 
and the balancing of harms and benefits more complex than within the adult context 
(Sammons & Starkey, 2012; MRC, 2004). In addition, commercial paediatric trials 
were regarded as having an insufficient return on investments, with priorities being 
adult-focused, due to the greater burden of disease in adults, combined with a lack 
of legal enforcement for paediatric versions of drugs (Klassen et al., 2008; Dunn, 
2007).  
Clinical experience has shown that due to developmental and physiological 
differences between adults and children, children may be exposed to serious 
unintended harms from medications without high-quality paediatric trial evidence 
(Klassen et al., 2008; 2009; Kearns et al., 2003; Caldwell, 2004). Furthermore, the 
potential of paediatric research to address the growing burden of non-




been increasingly recognised (McIntosh et al., 2000). The case of cystic fibrosis is an 
example where the research on the paediatric population is particularly valuable, 
given that survival for many patients now extends well into adulthood. As the 
understanding of the pathology of the disease develops over time, early 
intervention, combined with the continued development of safer more efficacious 
drugs, has been identified as critical for the improved management of the condition 
over the patient’s lifetime (Pinxten et al., 2011).  
Increasing realisation of the necessity of paediatric research, combined with the 
growing influence of EBM, led to changes in legislation, with a requirement to 
increase the number of paediatric trials (Pinxten et al., 2009; 2011). Ethical concerns 
about children participating in clinical trials have not gone away, but they have 
been outweighed by concerns about denying children access to properly tested 
medicines (Dunne, 2007). However, paediatric trials are subject to tighter regulation 
and a more stringent risk-benefit ratio, reflecting children’s special status (Van’t 
Hoff & Offringa, 2015; Modi et al., 2014; Wendler et al., 2005; MRC, 2004; McIntosh 
et al., 2000; Smyth & Weindling 1999).  
Whether children should be viewed as vulnerable per se, has however been 
questioned. Viewing particular groups such as children as vulnerable fails to 
capture the diversity within the group or the reasons why these individuals may be 
at increased risk of harm (Nuffield Council on Bioethics, 2015). Nevertheless, 
children are still widely regarded as being potentially vulnerable in the research 
context, warranting extra protection compared to adults (Nuffield Council on 
Bioethics, 2015; Neill, 2005; MRC, 2004). An important modification in the informed 
consent process in children’s trials requires that a parent or legal guardian consent 




assent process, where they are able. The requirement of a parent or legal guardian’s 
permission is viewed as a way of ensuring a child’s interests are protected as it is 
assumed that these individuals will make a decision in the child’s best interest 
(Diekema & Stapleton, 2006). The latest amendment of the Declaration of Helsinki 
(2013) states: 
‘When a potential research subject who is deemed incapable of giving consent is able 
to give assent to decisions about participation in research, the physician must seek 
that assent in addition to the consent of the legally authorized representative. The 
potential subject’s dissent should be respected. 
Nonetheless, the paediatric regulatory research framework is complicated by how 
researchers deem whether a child is capable of consent or assent, and the intricate, 
convoluted legislative system governing research involving children, which is 
influenced by two legal systems, the trial regulatory system and the common law 
(Nuffield Council on Bioethics, 2015). In the context of clinical trials of 
investigational medicinal products (CTIMPs), a person under the age of 16 is unable 
by law to give informed consent to participate in a clinical trial.  A CTIMP involves 
a clinical study aimed at determining the safety or efficacy of a medicine, foodstuff, 
or placebo in humans as defined by the Medicines for Human Use (Clinical Trials) 
Regulation (2004, 2014). Within clinical research outside the context of a CTIMP, the 
common law applies in which young people aged between 16 and 18 are presumed 
to be competent to give consent (MRC, 2004). In addition, children under 16 can 
decide for themselves whether they wish to take part in a particular study if they are 




The  informed consent process in the paediatric context is therefore considered 
complex (Shilling et al, 2009.,Prichard-Jones et al, 2008; Cadwell et al.,2003;2004; 
Olechnowicz et al., 2002; Miller & Kenny, 2002). However  the underlying principle 
of all current guidelines is that a child should be included in the process as far as 
possible and in accordance with their individual preferences  i.e. children don’t 
have to be involved in the decision if they don’t want to be  (Nuffield Council on 
Bioethics, 2015; Smyth & Weindling, 1999). 
1.4.3 A focus on understanding 
In addition to the broad discourse of protection surrounding research, the clinical 
trial design has its own set of inherent ethical tensions. Allowing treatments to be 
randomly allocated by ‘chance’ has been described as a deviation from culturally 
accepted moral norms in healthcare (Lantos, 1994). Making decisions about trial 
participation is different to making decisions about clinical care outside of trials. 
Trials confront patients with a level of uncertainty. Such uncertainty is less 
prominent in routine (therapeutic) clinical care, where the practitioner would 
typically recommend a standard treatment, and for which there is a likelihood that 
the patient will benefit. In trials, where the primary objective is generalisable 
scientific knowledge, the prospects of individual therapeutic benefits are typically 
unknown, ranging from exploratory (phase 1 trial) to uncertain benefits (phase 3 
trials) (Dupont et al., 2016; Edwards et al., 1998). Consequently, the most widely 
cited ethical concern with regards to clinical trials is that patients ‘sacrifice 
themselves for the benefit of future patients by participating in clinical trials’ 





From the perspective of the practitioner, trials introduce a tension between the duty 
to produce generalisable scientific knowledge, and the duty of care to provide 
optimal individualised care (Kopelman, 1986; Gifford, 1986). The practitioner is 
ethically obligated to view patients as more than a means to an end, even if the end 
is for the benefit of future patients (Lantos, 1994). The primary concern, therefore, is 
whether the practitioner must sacrifice the goal of individualised best treatment, for 
statistical efficiency (Schaffner, 1986). 
While a position of clinical equipoise remains integral to upholding the scientific 
and ethical integrity of a trial, the main focus of the literature with regards to 
countering such ethical tensions has been on upholding the requirements of the 
informed consent process. The most frequently cited requirement for policies 
regarding informed consent in the research context is that the potential participants 
understand the nature of the study to which they are consenting (Beauchamp & 
Childress, 2013; Dawson, 2009). This predominant view of informed consent is often 
understood in terms of rational-choice theory which is regarded by many as a 
normative model of decision-making (Hardman, 2009; Corrigan, 2003; Weinfurt, 
2004). In the context of a clinical trial this position presupposes that if a competent 
individual is provided with accurate, adequate information about the trial, they will 
be able to make a rational decision in their own best interests (Alderson & Goodey, 
1998; Corrigan, 2003; Weinfurt 2004). Consequently, a significant proportion of 
empirical evidence has focused on the provision of information, and on individuals’ 
understanding and recall of the ethical and legal requirements of informed consent, 
to ensure the protection of the participant from harm and protection of sponsors 
from litigation. (e.g. Hunfield & Passchier, 2012; Gammelgaard et al., 2004; Kodish 




This literature is extensive, examining information provision from the perspectives 
of children, parents, adults and practitioners and focusing on issues such as 
competency, understanding, knowledge and communication. This body of work 
includes research examining methods of obtaining informed consent in real trials 
(Hutchinson et al 2007;Allmark & Mason, 2006) and in hypothetical trials (Jeste et al 
2009; Llewellyn-Thomas et al; 1995), and the quality of the communication process 
(Brown et al 2004; Fallowfield et al 2002) and of information leaflets (Barnett et al, 
2005). The effectiveness of strategies to explain abstract concepts of trial design have 
also been examined including randomisation and equipoise (Kerr et al., 2004; Mills 
et al., 2003; Jenkins et al., 2002). Standardised measures to assess the competency 
and capacity of adults and of children’s ability to understand key dimensions of the 
informed consent process have been developed as a means of assessing and 
strengthening the ethical conduct of clinical trials (e.g.  Hein et al., 2012; 2015; Joffe 
et al., 2001; Appelbaum & Grisso, 2004). Within this work on protection and 
understanding, an important theoretical construct has emerged - the therapeutic 
misconception, in which patients are believed to be susceptible to conflating the 
aims of clinical care with the aims of research. This construct has further reinforced 
and sustained the focus on protection of participants through ensuring their 
‘understanding’ of research. 
1.4.4 The therapeutic misconception 
The therapeutic misconception is believed to occur on two key dimensions: i) an 
incorrect belief that individual needs will determine treatment assignment and; ii) 
an overestimation of the likely benefits of entry onto clinical trials during 
randomisation (Appelbaum et al., 2012; Miller & Joffe, 2006; Joffe, 2006; Lidz et al., 
2002). The therapeutic misconception has also been applied to participants’ 




part in clinical trials with ‘only the most modest appreciation of risk’ (Lidz et al., 
2004). This concept was first described by Appelbaum and colleagues (1982) as a 
patient’s assumption that within a clinical research context, decisions about their 
clinical care will be made solely with their personal therapeutic benefit in mind.  
The 1982 article which first proposed the therapeutic misconception was based on 
two psychiatric 3-arm placebo controlled trials. Project A, involved a social skills 
training programme and project B involved psychotropic medication. Within project 
A the informed consent document did not contain details of how an individual’s 
treatment was to be allocated i.e. by randomisation, and this information was also 
routinely omitted during oral consent interviews. Under these conditions, where 
patients were unclear about how treatment was decided, many constructed 
therapeutic accounts of treatment allocation. That is patients assumed that their 
treatment was decided according to what was clinically best for them. It is arguable, 
where no account of treatment allocation was given to patients, whether this 
evidence supports’ a ‘misconception’, as an individual cannot misconceive 
something they are not told in the first place.  In contrast in project B  all individuals 
underwent a nearly ideal consent process in which the method of allocation was 
discussed at length, but only 8 out of 18 patients understood that the assignment 
would be random and 6 believed that the trial would have a therapeutic basis, thus  
lending support to the  notion of a therapeutic misconception.  
In later work, Appelbaum and colleagues stated the importance of distinguishing 
between the therapeutic misconception and a mere lack of understanding on the 
part of the patient (Appelbaum et al., 2004; Lidz et al., 2002). For instance, a patient 
may fully understand the nature and purpose of the study yet still attribute 




the therapeutic misconception is at least in part personally motivated as opposed to 
being simply the result of a misunderstanding. Healthcare norms relating to the 
doctor-patient relationship and an individual’s past health care experiences are 
believed to be the source of the therapeutic misconception, leading patients to 
confuse the goals of research with those of treatment (Lidz et al., 2002).  
Despite extensive research examining the most effective ways to communicate 
about trial participation and risk to maximise understanding, the therapeutic 
misconception remains pervasive (Appelbaum et al., 2008; 2012). This concept is 
especially prominent in phase 1 oncology trials, which are not expected to provide 
any therapeutic benefits and an individual’s fear of death and hope for cure or 
remission are apparent (e.g. Pentz et al., 2012; Daughtery et al., 1995; 1999).  
Nonetheless, the therapeutic misconception has been described in diverse 
populations extending beyond oncology trials and including adults, parents and 
children and practitioners across a range of health contexts (e.g. Tromp et al., 2016; 
Snowdon et al., 2006; Vitello et al., 2005; Gammelgaard et al., 2004).  
1.4.5 Hope beyond the ‘therapeutic misconception’  
The predominant discourse on the therapeutic misconception has focused on the 
accurate provision and understanding of trial information.  However, researchers 
have questioned a purely information processing perspective of the therapeutic 
misconception, where an unrealistic hope for personal benefit is viewed as no more 
than a ‘false belief’ or misunderstanding (Weinfurt, 2004). Consequently, 
interpretations of the therapeutic misconception have been continually redefined 
potentially highlighting the underlying complexity of the concept (Snowdon et al., 




reformulated the therapeutic misconception to include a continuum of hope 
according to how adaptive or inaccurate an individual’s hope for personal benefit is 
perceived to be (Table 1.4). 
TABLE 1.4: Misunderstanding in clinical research (Horng, Grady, 2003) 





research & care 
Rarely tolerable because 
understanding the nature of 
research is necessary for an 
autonomous decision. 
 
Mark believes that the purpose 
of the phase 1 cancer trial is to 








benefits or both. 
Sometimes tolerable because 
understanding the exact 
probability of harm and benefit 
may not be necessary for an 
autonomous decision to 
participate 
Susan estimates that she has a 
30% chance of benefit in the 
Phase 1 cancer trial. A meta-
analysis of a similar study 
shows that the benefit accrues to 





subject hopes for 
the best personal 
outcome  
Always tolerable because hope 
does not always compromise the 
autonomy of a decision to 
participate in research. 
Thomas hopes that he will be 
one of the 5% who benefits from 
the phase 1 cancer trial. 
 
Based on in-depth examination of hope in the context of early phase oncology trials, 
Cox (2002) views hope as a complex multi-dimensional concept that can only be 
fully understood through an interpretative approach (Cox, 2002). Weinfurt (2004) 
has argued that interpretations of the therapeutic misconception vary according to a 
researcher’s theoretical orientation. From a discursive perspective, he proposes that 
patients reporting high expectations can provide alternative interpretations beyond 
indicators of misunderstanding.  Discursive psychology treats talk as social action 
and from this position Weinfurt (2004) considers that a chosen discourse or activity 
may be undertaken by individuals to achieve specific aims, which may have 
multiple goals. For example, an individual may choose to describe high expectations 




positive thinking or as an expression of confidence in care givers (Weinfurt, 2004).  
However, it remains unclear where healthy optimism ends, and a potentially 
deleterious misunderstanding begins. Nevertheless, whichever way the therapeutic 
misconception is defined and understood the construct of hope remains inextricably 
linked to this concept. Horng and Grady’s (2003) account appears to provide some 
way to bridging these diverging views (Table 1.4) 
1.4.6 Limits of informed consent 
This literature on the therapeutic misconception has sustained much empirical 
research examining the provision and understanding of information. It has also 
highlighted the ‘unattainability’ of the comprehension interpretation of informed 
consent (Dawson, 2009; Corrigan et al., 2009). Over 30 years of empirical evidence 
demonstrates substantive problems in realising informed consent in the context of 
clinical trials (Dawson, 2009).  
To explore conceptions of rationality in a clinical trial from the perspective of 
patients and researchers, Djulbegovic & Hozo (2012) employed a trust version of the 
Prisoner’s Dilemma, a widely used example in game theory. Game theory 
comprises a mathematical discipline, which forms part of the broader group of 
rational choice theories for describing and analysing interactive decision-making 
(Hardman, 2009). Researchers have used game theory as an analytical tool to 
understand social interactions and make predictions about how a rational 
individual would behave, including in medical consultations (Tarrant et al., 2004). 
Aware of the often fraught, conflicting interests typical in trial recruitment 




when is it more rational not to cooperate versus cooperate in the context of a clinical 
trial. Under the assumptions of this mathematical model, they reported the 
‘disconcerting‘ finding that trial participation was a rational strategy meeting both 
patients’ and researchers’ interests only 19% of the time. Therefore according to this 
research, from an individual point of view, the most rational behaviour is not to 
trust the researcher and not to enrol in a clinical trial. Nonetheless, the authors 
acknowledged that in this instance they employed a ‘relatively narrow’ view of the 
trust-risk model which did not incorporate broader societal dimensions of trust 
including virtue goodwill or moral integrity.  
It would require a mathematician to fully critique this model but on face value it 
demonstrates the inadequacy of a purely rational-choice model, and its assumption 
that all individuals, if provided with accurate information, will make a rational 
decision in their own best interests (Lidz, 2006; Corrigan, 2003; Alderson & Goodey, 
1998). Consequently, a view of consent, premised on a ‘real’ standard or ideal, 
which can be achieved through the adequate exchange of ‘medico legal’ information 
alone has been criticised as too simplistic (Alderson & Goodey, 1998) and as ‘empty 
ethics’ for stripping consent of its social, cultural, political and clinical context  
(Corrigan et al, 2004;2009). Furthermore questions have arisen around how 
autonomy has been operationalized as informed consent (Corrigan et al., 2009; 
Manson & O’ Neill, 2007; Alderson & Goodhey, 1998; Gillon, 1994) as it fails to 
acknowledge the relational and ongoing nature of autonomy (Kukla, 2005). 
Translating the concept of autonomy into an individual’s ability to engage in 
practical reasoning in order to make an autonomous decision does not take account 
of the rich social context in which people’s life narratives exist (Kukla, 2005). 
Moreover, Kukla (2005) suggests that reducing autonomy to informed consent fails 




and a patients’ autonomy exists. Furthermore, focusing on a patient’s decision made 
in response to a discrete choice may function instead to absolve clinicians (and 
researchers) of certain kinds of responsibility, rather than supporting a patient’s on-
going autonomy (Kukla, 2005).   
Upholding autonomy is further complicated in individuals who are unable to 
provide informed consent, including young children or adults who lack capacity. 
Obtaining the assent of a child and the permission of a parent or guardian is not the 
same process as obtaining informed consent from a competent adult (Nuffield 
Council on Bioethics, 2015; Committee on Bioethics, 1995). When parents are asked 
to consider entering a young child in a trial, they are exercising responsibility on 
behalf of their child and are not directly exposed to the consequence of the trial 
outcome. Parents and trial practitioners face a new set of issues when children are 
considered old enough to have an opinion and be involved in decision-making 
(Broome & Richards, 2003; Olechnowicz et al., 2002). These differences have lead to 
the perception that recruiting children to clinical research is ‘more complex’ 
compared to the adult context (Shilling & Young, 2009; Caldwell et al., 2003; 2004), 
arising from a child’s changeable development status and level of independence 
(Alderson & Morrow, 2011; Manson & O’Neill, 2007; Alderson, 2007). 
Despite conceptual differences in the recruitment process involving children and 
adults, (where a child’s parent or guardian must provide permission in addition to 
the child’s assent if s/he has the maturity to do so) (Caldwell, 2003; 2004; Punch, 
2002) this scoping review identified a paucity of research examining how these 
differences may inform understanding of the phenomenon of trial recruitment. Only 
one study, in the context of informed consent for oncology trials, has directly 




et al., 2004). Adult patients were found to be more fully informed than parents, 
which Simon et al. (2004) attributed to the additional complexity of the family 
context. Simon and colleagues viewed this added complexity as factors relating to 
the parental role of proxy decision-making in which they either make a decision on 
behalf of their child or negotiate their child’s involvement in the decision-making 
process. However, this study did not access the perspectives of children or 
practitioners and was primarily focused on researcher defined concepts of 
understanding, rather than the priorities of those involved. Consequently, an in-
depth account of the psycho-social influences on how individuals viewed trial 
recruitment was unclear.  
1.5 Altruism: cause for celebration or concern? 
Altruism too has become a prominent theoretical construct in this field. It refers to a 
patients’ personal motivation to contribute to the greater good by putting 
themselves out for the benefit of future patients (McCann et al., 2010; Balfour et al., 
2010; Simon et al. 2006; Garcea et al., 2005). While altruistic motives for participation 
in trials have been identified in both adults and children, other motives such as 
personal benefits have also been identified, and it is not always clear how the two 
interrelate (Edwards et al., 1998). Furthermore, there is inconsistency in how 
altruism is constructed by patients, parents and researchers. Altruism may 
encompass: a desire to contribute to scientific knowledge; future benefits for other 
patients with the same condition and patients in a more general sense; the ethic of 
reciprocity to past patients and the investigator; and the social value of participating 
in research (Simon et al., 2006; Garcea et al., 2005). However, in much of the trial 
recruitment research altruism is measured by participants rating the importance of 




medical treatments’ (Tait et al., 2003; Henzlova et al., 1994). This structured 
methodology provides limited insights into patients’ underlying motives. Moreover, 
it remains unclear to what extent altruism is invoked by the self-presentational 
factors and indeed by practitioners during the consent process (Spriggs, 2006). 
Researchers have suggested that the separation of potential benefits to self from the 
motive to help future patients with the same condition, as typified by statements 
such as We cannot promise the study will help you but the information we get from this 
study will help improve the treatment of people with [name of condition] which is found 
in most trial documentation, invokes an expectation of altruism (Simon et al., 2006). 
Nevertheless, the role and significance of altruistic discourse during recruitment 
encounters are debated (Rennie, 2011; Williams et al., 2008; Ladd & Forman, 2006). 
Proponents argue that discussions of altruism are an essential part of the trial 
consultation, helping to dispel the therapeutic misconception and to ensure the 
research goals are clear (Joffe, 2006). Indeed a personal motivation to take part in a 
trial has been viewed as involving a degree of altruism if consent is considered to be 
rational, as the primary aim of a trial by its very nature is to contribute to 
generalisable medical knowledge, rather than to benefit individual participants 
(Hester & Hackler, 2006; Edwards et al., 1998; 1999). 
In contrast, Horrobin (2003) suggests that invoking altruistic considerations for trial 
participation during the consent process is disingenuous and misrepresents the 
nature of research, as clinical trials serve the interests of various parties, including 
commercial sponsors; and the primary motivator for patients is their well being, 
with the greater good being secondary. Nevertheless, empirical evidence has 




participants and practitioners commonly view altruistic considerations as an 
important component of the recruitment process.  
Altruism refers to an individual’s desire to help others at a personal cost and 
without rewards (Batson, 2014; Scott & Seglow, 2008). Nevertheless, psychologists 
and biologists, in particular, have critiqued this singular notion of altruism as 
representing an unattainable ideal that is incompatible with evidence that human 
behaviour is rooted in self-interest (Dawkins, 2016; Silk, 2013; Scott & Seglow, 2008). 
In order to accommodate this disparity between the selfless act of helping others 
and self-interest, biologists have proposed various theories, including the idea 
‘reciprocal altruism’ (Silk, 2013), a form of kindness that results in mutual benefit 
with the belief that it might be beneficial to incur costs, if there is a chance of the 
altruistic act be reciprocated (Trivers, 1971). 
The ‘golden rule’ present in many religious and ethical traditions ‘do unto others as 
you would have them do unto you’ (Scott & Seglow, 2008), is not dissimilar to the 
notion of reciprocal altruism (Trivers, 1971) and in turn is not dissimilar to the 
notion of the ‘gift relationship’, represented by the archetypal altruistic act of blood 
donation (Evans & Ferguson, 2014; Scott & Seglow, 2007; Titmuss, 1970). However, 
the literature on blood donation has conceptualised altruism as multifaceted, 
reflecting a number of related processes as opposed to a singular construct (Evans & 
Ferguson, 2014). 
Whether trial participation can be viewed within the same theoretical or ethical 
framework as blood donation is unclear and the role that altruistic motivation plays 
in the recruitment and decision-making processes for clinical trials continues to be 




primary motivator, empirical evidence indicate that altruism is an important 
motivating force for many trial participants and blood donors (Evans & Ferguson, 
2014; Truong, 2011; Simon et al., 2006). Ideas of kinship have been found to motivate 
blood donation, for example, the belief that ‘If I gave blood there is more chance of 
close relatives receiving it if they need it’ (Evans & Ferguson, 2014). Similarly, the 
ideal of reciprocity or paying back those that previously participated in research has 
been found to motivate trial participation (McCann et al., 2010; Lowton, 2009).  
However, in paediatric oncology trials, findings show that altruistic discourses 
initiated by practitioners did not influence whether parents enrolled their child in 
the trial or the reasons they gave for doing so. In addition, Wasson (2006) poses an 
important question arising from Simon’s (2006) finding - ‘do people weigh altruistic 
consideration differently for themselves versus others’. Spriggs (2006) proposes that 
altruism is not something that another person can volunteer on somebody else’s 
behalf. If this is the case, references to altruistic motives cannot be taken at face 
value.  It is unclear from Simon et al.’s (2006) findings how parents conceptualise 
their altruistic motives in relation to their children.  
In-depth qualitative approaches have distinguished ‘weak’ altruism and 
‘conditional altruism’ (McCann et al., 2010; Canvin & Jacoby, 2006), with the former 
characterising a participants’ desire to maintain self-interest while also expressing a 
desire to help (Canvin & Jacoby, 2006).  ‘Conditional altruism’ characterises a 
similar idea in that while an altruistic tendency may encourage trial participation, 
this motivation is still ‘conditional on perceiving a personal benefit and an absence 




Nevertheless, debates continue about what constitutes altruism, and about 
conceptual differences between ‘altruism-by-proxy’ among parents compared to 
direct altruism among adult patients. Furthermore, most empirical evidence lies in 
the field of oncology (Truong et al 2011; Wendler & Jenkins, 2008; Joffe, 2006) and 
further research is needed to examine the role and conceptualisation of altruism in 
paediatric and adult settings beyond oncology, which includes the perspectives of 





1.6 Developing a model of trial recruitment 
Relative to the volume and diversity of the empirical evidence on recruitment, the 
corresponding literature aimed at developing a theory or conceptual model of 
recruitment is small, with much of this literature published more recently. Within 
this section, I will examine models which have drawn exclusively from empirical 
data and those which used established theory e.g.  Health Belief Model, (Janz & 
Becker, 1984); Social exchange theory (Homans, 1961)  
1.6.1 A personal balance account 
Most models focus solely on one side of the recruitment exchange -the process of 
decision-making, as viewed by a potential participant (e.g. McCann et al., 2013 
Ulrich et al., 2012; Lowton, 2005 Mueller; 2004; Verheggen et al., 1998). These 
models are based on accounts of patients describing factors which influenced their 
chosen course of action when approached to take part in a clinical trial, and attempt 
to explain how potential participants negotiate trial participation decisions. A recent 
example is based on 32 qualitative interviews with adults enrolled in an oncology 
trial. This model incorporates five key dimensions of the potential benefits and 
burdens a patient may navigate before coming to a decision (Figure 1.1). These 
dimensions include health related or physical aspects, psychological aspects; 
familial and support components, economic concerns and societal factors, all of 










Parallels can be drawn between this model and an earlier proposal by King (2000), 
who described the need to differentiate between the types of benefits that 
participants viewed as arising from participation in clinical trials. King (2000) 
suggested that the benefits for potential participants may comprise; direct clinical 
benefits from the intervention itself, indirect benefits from being a participant in a 
trial, such as increased monitoring or personal health information, and what 
King(2000) refers to as ‘aspirational benefits’ i.e. potential future benefits to society 
and future patients. King’s (2000) ‘aspirational benefits’ appear synonymous with 
‘psychological’ motivators described by Ulrich et al., (2012) and the broader 
altruistic discourse in the recruitment literature (e.g. Simon et al., 2006). However, 
Ulrich et al.’s (2012) model captures both burden and benefit across each dimension, 
in contrast to King’s (2000) account which solely focuses on differentiating 




individual’s practical reasoning of medico-legal trial information to include broader 
psycho-social, familial, economic features of the decision-making process. However, 
this model does not provide insight into how individuals weigh the benefits and 
burdens of research participation, or the diverse way participants approached their 
decision to participate. How these dimensions may interrelate or what factors may 
mediate personal judgement of these dimensions requires further evaluation (Ulrich 
et al., 2012). 
Based on a meta-synthesis of 12 qualitative studies, across a range of different health 
contexts (including accounts of patients and parents of child patients) McCann et al. 
(2013) developed a model which provides valuable  insights into how potential 
participants’ health status at the time of recruitment can mediate ‘decision 
influencing judgements’ (Figure 1.2). 
These decision influencing judgements include: 
i) informants’ communication and relationships with recruiters 
ii) personal implications of trial interventions and processes;  
iii) the ‘common good’ and the implications of participation decisions for 









In contrast to models derived from the data Verheggen et al. (1998) used an 
extended form of the Health Belief model to develop an explanatory model based 
on statistical analysis, to understand how patients weigh the benefits and burdens 
of trial participation. The HBM was originally developed in the 1950s to understand 
people’s poor uptake of disease prevention initiatives but has since been developed 
and applied to a range of health context behaviours (Janz & Becker, 1884). 
Verheggen et al. (1998) extended the HBM to include a number of general health 




which incorporates a kind of cost benefit analysis to predict health related 
behaviour.  







From this position trial participation was viewed as ‘illness coping behaviour’. The 
model of explanation detailed in Figure 1.3 was used to form the theoretical basis 
for a survey designed to gain insight into the psycho-social determinants of patients’ 
trial participation decisions.  Based on data obtained from 198 adult patients who 
had been approached to participate in one of 26 clinical trials across a diverse range 
of clinical contexts this model proposed a ‘personal balance account’ in which 
potential participants are viewed as weighing up the physical and emotional value 
they hope to gain through trial participation, against the expected risks and burdens 
associated with the trial.  
A strength of this model is its ability to capture how the factors influencing patients’ 




identifies important mediating factors including the significance of recent medical 
experiences and the nature of an individual’s illness.  
However, not all the determinants of the model were shown to be significant and 
consequently not all the variance was accounted for. For instance, the model 
showed how information disclosure did not appear to be a determinant in 
explaining trial participation and evaluations of ‘medico-legal’ requirements of 
informed consent were not considered as reasons to participate or not. These 
findings highlight the strength of models which are grounded in data (Strauss & 
Corbin, 1998) and the limitation of models solely informed by existing theory, where 
relevant factors may be overlooked.   
Nevertheless, these decision-making models appear to implicitly and explicitly 
draw upon elements of rational choice theory to explain how trial participation 
decisions may be negotiated.  However, models guided by normative models of 
decision-making assume people are ‘rational’ and deliberative in how they 
approach decisions, and therefore may overlook more intuitive relational processes.  
1.6.2 Negotiating risk and uncertainty 
The issue of managing risk and uncertainty has featured prominently in other 
theoretically informed accounts of why people agree to take part in clinical research, 
particularly in the context of chronic health conditions including HIV and CF (Yang 
et al., 2010; Lowton, 2005; Mueller, 2004). Mueller (2004) developed Strauss et al.’s  
(1985) work on contingency to explain how individuals made sense of their 
decisions to participate in a ‘HIV/AIDS’ clinical trial. Strauss et al. (1985) 




health care work that patients and practitioners attempt to manage. Mueller (2004) 
applied this concept to characterise the work or effort a patient engages in to control 
or manage uncertainty by declining or consenting to clinical trials. Qualitative data 
from 24 participants in an HIV/AIDs trial showed how individuals interpret and act 
on the uncertainties intrinsic to clinical research based on negotiations involving 
clinical, social and technical contingencies. Clinical contingencies related to an 
individual’s perception of their health status at the time of the approach and the 
perceived influence of trial participation on their health. For individuals with 
uncertain health, trial participation appeared to act as a way of dealing with this 
uncertainty and offering hope. Social contingencies included perceptions of trust, 
self-interest, and altruism; while technical contingencies referred to the value 
assigned to trial procedures and protocol design, such as design flexibility and level 
of monitoring. Although Mueller (2004) developed this framework in the context of 
HIV/AIDs, she believed it might have wider applicability in offering a conceptual 
framework to bring together disparate literature on patient recruitment to clinical 
research. 
Each of these contingencies was useful in highlighting key features of the decision-
making process from the patients’ perspective. However, this framework did not 
consider the perspective of the recruiter and only included patients who had 
consented to a trial. Mueller (2004) herself also acknowledged that further research 
was needed to gain insight into factors which may influence the prominence of 
certain contingencies and how clinical, social and technical contingencies are 
negotiated between researchers and patients.  
Lowton (2005) also drew on sociological theories of risk to interpret qualitative data 




risk behaviour and risk reduction was used to inform how individuals negotiated 
their course of action when approached to take part in clinical research. Consistent 
with Dixon-Wood & Tarrant’s (2009) work, Lowton’s (2005) study included patients 
who had been approached to take part in all types of medical research, including 
clinical studies and clinical trials. This design enabled patients’ perception of risk 
associated with different research designs to be examined. 
Bloor’s (1995) sets of conceptual oppositions: habituation and calculation, constraint 
and volition were applied to the dataset to represent a range along a continuum of 
risk behaviour rather than absolute distinctions. According to this conceptual 
framework, Lowton (2005) described participants’ calculations about risk behaviour 
as a conscious deliberation of the costs and benefits of individual actions. Lowton 
(2005) defined the notion of risk and constraint as referring to both social and health 
constraints such as age, perception of health and obligations to family or employers. 
Patients’ perceptions of current and anticipated future health states informed their 
assessments of the ‘necessity’ of their research participation. For example, one 
patient perceived that if she were really ill, she would ‘try anything’ and others 
whose health could not be maintained actively sought participation in clinical trials. 
Older patients and patients who viewed their health as controllable were ‘more 
careful’ about decisions to participate, and they were, therefore, less likely to 
participate in RCTs perceiving them as posing more risk than observational studies 
involving the giving of blood samples. Lowton (2005) also proposed that patients 
may become habituated or accustomed to being involved in research, to the point 
where they enrolled in research without seeming to weigh up the costs and benefits. 
The two main factors that were influential in adults’ decisions to habitually accept 
research participation requests were the type of research project and trust in the 




These findings showed that personal motivations were broadly similar in this as in 
other health contexts (e.g. Madsen et al., 2007; Fry & Dwyer, 2001). Nevertheless, 
these findings prioritised patients’ perspectives; clinicians’ perspectives were not 
included. In addition, the patient sample was drawn from one CF centre, so it is 
unclear whether these findings are applicable to the wider CF community or 
whether they could be extended to research experiences within paediatric CF 
settings.  
1.6.3 Recruitment as a social act 
In contrast to models discussed up to now, which have foregrounded individualised 
decision-making; several authors have positioned trial recruitment within a broader 
social context (McGregor et al., 2010; Dixon Woods & Tarrant, 2009; Morris & 
Balmer, 2006). While these authors still base their accounts of recruitment on data 
obtained from potential participants, they emphasise the social exchange dimension 
of recruitment. McGregor et al. (2010) used the principles of social exchange theory 
(SET) to conceptualise the process of trial recruitment and retention. Social exchange 
processes have been found in every documented human culture (Cosmides et al., 
2010; Isacc, 1978). Theories that explain these processes have also been influential 
across disciplines such as anthropology, social psychology and sociology, which are 
united by the underlying assumption that social exchange involves a series of 
interactions that generate obligations (Copranzano & Mitchell, 2005; Emerson, 1976).  
From this position, McGregor et al. (2010) viewed recruitment and retention as 
being dependent on the formation and maintenance of relationships. According to 
the principles of SET, these relationships develop as a result of a mutual exchange of 




each party within the relationship will benefit (Homans, 1958). Participants will 
therefore only be recruited and retained in a trial if doing so involved a mutually 
rewarding exchange, leading to a long-term mutually beneficial relationship 
(McGregor et al., 2010).   
From a SET perspective, the quality of the relationships is emphasised, and 
successful recruitment is viewed as being dependent on a subjective cost-benefit 
analysis by each involved party. For relationships to be established and maintained, 
benefits must outweigh perceived costs for both patient and researcher. 
Furthermore, SET acknowledge the power dynamics of relationships during the 
research process (McGregor et al., 2010) arising from the dependence of one 
individual upon another, with a power dependence assumed to be most apparent at 
the time of recruitment, when the patient may be more vulnerable to exploitation. 
Furthermore, trust is also essential to the establishment and maintenance of 
exchange relationships, however, the exact mechanism as to how trust informs the 
recruitment process remains unclear (Townsend et al., 2008; Lawler, 2001).  
While McGregor provides a convincing argument about the relevance of SET in 
theorising recruitment practice, this theoretical account was based on one particular 
trial, the nature of which may have led to an emphasis on the significance of 
research relationships. This trial evaluated a relatively low risk post-surgical device 
to aid recovery from sternotomy in older patients (Women’s Recovery from 
Sternotomy Trial, WREST). It is conceivable that the elderly retired individuals 
within this trial may have viewed the prospect of regular positive interactions 
during a period of post surgical recovery as a primary benefit and a significant 




and employment commitments, regular interactions with a researcher may not be 
perceived as carrying the same benefits. 
In contrast to a focus on the immediate social relationship between researcher and 
participant, Dixon-Wood & Tarrant (2009) proposed a broader theoretical 
explanation of trial recruitment informed by societal level theories of cooperation 
and social organisation. Based on qualitative evidence of participants’ experiences 
and views of being invited to take part in one of three different clinical research 
studies, Dixon-Wood & Tarrant (2009) argue that participation in research is a 
‘collaboratively oriented action’. In this model, cooperation provides a way of 
thinking about how people come to engage with clinical research that stands in 
contrast to individualist models concerned with cost-benefit analysis and the 
adequacy of consent. While the evidence mirrored other studies in the diversity of 
personal motives, participants’ accounts were unified by a perception that 
individuals would be contributing to the ‘public good’, which Dixon-Wood & 
Tarrant (2009) suggest can be understood as an example of what Olson (1965) terms 
‘collective action’. 
This framework for understanding trial participation decisions illustrates the 
significance of the social structure of research in influencing how individuals made 
sense of their participation decision. According to this account personal judgements 
and actions were institutionally and organisationally structured. Participants’ 
decisions assumed the existence of regulatory and institutional safeguards and 
trustworthiness. Consequently, the symbolism and rituals enacted by qualified 
professionals were more influential in participants’ accounts than the detail or 




A strength of this theoretical explanation of trial recruitment was that it was 
informed by a large, diverse evidence base, including 128 participants, which 
integrated children, parents, pregnant women and adults’ accounts. Furthermore, 
unlike other studies, which have focused primarily on clinical trials, this framework 
of cooperation was based on evidence from three different clinical studies with 
varying cost-benefit ratios. These included: a paediatric study involving surplus 
cancer tissue banking, an RCT of emergency treatment for women experiencing pre-
term labour and a genetic epidemiology study of blood pressure regulation 
involving healthy volunteers. However, this theoretical framework is only informed 
by empirical examination of one side of the ‘cooperative bargain’, that of the 
participant.   
Further research including evidence from both sides of the exchange has the 
potential to examine processes of cooperation and collective action further. Another 
potential limitation is that this theoretical account was informed by evidence from 
people who consented to participate in these studies and it is unclear how evidence 
from decliners would be reconciled with this model of cooperation. Consequently, a 
central facet of Olson’s (1965) logic of ‘collective action’ has not been addressed - 
that where individuals believe they can receive the benefits of cooperation without 
contributing, they may be inclined to ‘free ride’ leaving cooperation to others 
(Olson, 1965). The extent to which an individual who shares a common interest will 
bear the costs of the public good could be informed by exploring the views of 
decliners across varying cost-benefits.   
Further along, this continuum of cooperation is a potentially more controversial 
view of clinical research participation, in which participation is viewed as a moral 




(Schaefer et al., 2009; Harris, 2005; Caplan, 1984). Consistent with Dixon-Wood & 
Tarrant’s (2001) view, this position is also derived from the perspective that 
scientific knowledge derived from clinical research is a ‘public good’ in which all 
people stand to benefit. Therefore, support and participation in clinical research is 
viewed as a social duty or responsibility. Rather than the current social norm that 
people participate only if they have good reason, the public good position implies 
that people should participate unless they have good reason not to (Schaefer et al., 
2009). 
Underpinning this perspective is the idea that there is an obligation to share the 
responsibility of research participation because the benefits of research are available 
to all. This position is clearly subjugated by the dominant view of respect for an 
individual’s autonomous choices and the robust discourse on protection of human 
subjects. Nevertheless, it raises important questions about the potential 
ramifications of recasting research participations in this way (Rennie, 2011). 
Conceptual models identified in the literature which drew on empirical evidence 
from both sides of the recruitment exchange, that is those being recruited and those 
doing the recruiting, were limited (Lengacher et al., 2001; Hughes-Morley et al., 
2015). 
Lengacher et al.’s (2001) work summarised empirical evidence in the literature on 
barriers to recruitment and corresponding strategies to overcome these to illustrate 
a model of successful trial recruitment and retention. Study design, participant 
factors, physician factors and the informed consent process were identified as key 




















While this model is useful in summarising findings within the literature, it does not 
provide any theoretical insights into how these factors can be unified conceptually. 
A more comprehensive conceptual model derived from data obtained from both 
recruiters and participants’ accounts of recruitment is presented by Hughes-Morely 
et al. (2015) (Figure 1.5). Based on a systematic review and meta-synthesis of 
published qualitative studies examining recruitment into depression trials, Hughes-
Morely et al. (2015) proposed an initial explanatory model to summarise factors 
influencing the recruitment process (Figure 1.5). An important aspect of this model 




gatekeeper’s decision about whether or not to inform the patient about the 
opportunity to participate in a clinical trial. The model, therefore, captures the 
‘weighing up’ process from both sides of the recruitment process. In addition, this 
model also identifies significant mediators of the process which includes: health 
context, attitudes towards trials and research interventions and issues around 
engagement. 




Even though this model has been developed from evidence drawn from the distinct 
clinical context of depression, it is conceivable that this framework would have 
wider applicability, as the aspects identified are consistent with those of other 
models and findings within the broader empirical recruitment literature. 




an ‘early effort to develop and explanatory model’ and that further qualitative 
research is required to gain further understanding into the weighing up process. 
1.7 Summary and positioning my case 
This scoping review has confirmed that clinical trials are viewed as indispensable 
for evidence-based medicine, yet recruitment remains challenging and the processes 
involved are inadequately understood.  Distinct discourses on clinical trial 
recruitment have emerged, yet there is a paucity of conceptual frameworks that can 
unite this disparate literature from both sides of the recruitment exchange. The 
dominant discourses have centred on improving accrual of participant numbers or 
the ethical conduct of recruitment. While these discourses are important, they do 
not constitute theories of recruitment that can inform the development of optimal 
recruitment practices and future recruitment research. Neither are they able to 
explain the reported difficulties with recruitment, such as why certain trials recruit 
more effectively than others (Dawson, 2009; Campbell, 2007). Those difficulties can 
be profound, for example, evidence indicates that many ‘perhaps even most’ 
competent adults do not achieve a level of understanding to the degree necessary to 
uphold the ideal of ‘fully informed consent, indicating that this ideal is largely 
unattainable (Dawson, 2009). 
Qualitative research which has focused on understanding and examining the range 
and complexity of perceptions held by individuals who have had direct experience 
of recruitment is providing a more unified in-depth understanding of the process. 
Instead of emphasising generalisability across individuals, groups or settings, 
qualitative research is able to generate rich theoretical concepts enabling the 




Consequently, qualitative evidence has led to the development of important insights 
into how people make sense of research invitations within the context of their 
personal illness trajectory and life circumstances. These insights extend beyond a 
primary concern with the adequacy of informed consent and information exchange. 
However following this scoping review several gaps within this literature were 
identified which this study aims to address. 
1.7.1 Paucity in qualitative studies with a comparative focus   
Despite comparative qualitative research being recognised as an important 
analytical tool for providing theoretical insights into complex social phenomenon 
(Bradley et al., 2007; Stake, 2003; Mason, 2002) there is a distinct lack of qualitative 
research which directly compares recruitment experiences across settings. In 
particular, there are important conceptual differences in the recruitment process 
across adult and child settings (Truong et al., 2011; Simon et al., 2004; Caldwell 2003; 
2004; Punch, 2002). The distinct social and legal differences with regard to the 
position of children, adults and parents in society have the potential to serve as 
important comparative foci within qualitative recruitment research.  
Despite the changing view of childhood in society, Goldstein’s (1977) quote below 
captures a conventional pervasive view of the potential divergence between the role 
of child, adult and parent in society 
To be a child is to be at risk, dependent, and without capacity or authority to decide 
what is "best" for oneself. 
 
To be an adult is to be a risk taker, independent, and with capacity and authority to 





To be an adult who is a parent is to be presumed in law to have the capacity, 
authority, and responsibility to determine and to do what is good for one's children.’ 
It is likely that trial recruitment in the paediatric settings is more complex compared 
to trials involving autonomous adults (Caldwell, 2004); therefore, it is anticipated 
that a comparative focus across adult and child settings in the context of cystic 
fibrosis will fill an important gap in the recruitment literature, providing an 
analytical tool to understand further the nature of recruitment and the psycho-social 
context in which it occurs. 
1.7.2 An underrepresented population 
Much of the evidence base is in the field of oncology, leaving many 
underrepresented populations. Evidence on trial recruitment processes in CF is 
minimal, with no comparative work across adult and child settings despite it having 
proved to be an ideal opportunity to investigate how invitations to participate in 
clinical research are experienced within a defined patient group (Dobson et al., 2015; 
Lowton, 2005).   
CF is the UK’s most common autosomal recessive disease, which is now typically 
diagnosed at birth. Due to advancements in treatment, children born in the 2000s 
are now predicted to reach the fourth or fifth decade of life (Dodge et al., 2007) and 
CF care has changed from being mainly a paediatric speciality to both a child and 
adult specialty (Thomson & Harris, 2008; Robinson & Robertson, 2003). Clinical 
trials are critical for assessing the effectiveness of therapies for CF, and 
consequently, adults and children with long-term conditions such as CF are an 




recruitment (Dobson et al., 2015; Briggs et al., 2006; Lowton, 2005). Moreover, it is a 
promising time for the CF community, as over the past ten years basic science 
research has resulted in some potential new therapies for CF. However; it is also a 
challenging time with a large number of international multicentre trials attempting 
to recruit patients. Patients and their families will be faced with a bewildering range 
of clinical trials offering new therapies, including those funded by pharmaceutical 
companies, and often involving complex or early phase designs. These treatment 
advancements depend on adequate recruitment to clinical trials, which remains a 
significant challenge (Cheng et al., 2000; Briggs et al., 2006). Furthermore, despite 
the widespread involvement of children in CF trials, this review did not identify any 
qualitative research comparing recruitment experiences across adult and paediatric 
settings within the context of CF, making this a significant gap in the recruitment 
literature. 
1.7.3 A paucity of literature incorporating recruitment from both sides of the 
exchange  
While some conceptual models do exist with more recent models informed by 
qualitative evidence, most of these have focused on the decision-making process of 
the potential participants rather than aiming to understand  recruitment as a 
process, including individuals from both sides of the exchange. Qualitative research 
examining recruitment from both sides of the exchange is less prevalent, and there 
is no qualitative work of this nature comparing across adult and child settings.  
Examining recruitment from ‘multiple’ perspectives is providing a greater 
understanding of the complexity and interrelation of factors involved (Campbell et 
al., 2007). Furthermore ‘multi-perspective’ qualitative interviewing is a critical 
methodology for understanding the needs, beliefs and experiences of those 




 To address these key gaps identified in the literature, this study will explore 
experiences of trial recruitment from the perspective of: 
 adult patients with CF 
 children with CF 
 parents of children with CF 
 practitioners involved in recruiting children or adults with CF to clinical 
trials 
This thesis aims to contribute to the trial recruitment literature both conceptually 
and empirically through a comparative exploration of experiences of recruitment in 
the context of CF across adult and paediatric settings. It also aims to contribute to 
uniting recruitment evidence conceptually, empirically and pragmatically while 




CHAPTER 2: METHODOLOGICAL CONSIDERATIONS 
2.0 Introduction 
How researchers proceed with any project depends on their assumptions including; 
their beliefs about the nature of reality (ontology), the nature of knowledge and how 
it can be acquired (epistemology) and the purpose and goals of the research 
(Silverman, 2013; Travers, 2001). There is a general agreement that understanding 
and acknowledging the philosophical and theoretical backgrounds associated with 
different approaches to social science research will contribute to better practice and 
provide ways of assessing the integrity and authenticity of research (Ritchie et al., 
2014). A researcher must find the best orientation for achieving the aims of the 
research through a detailed examination of the purpose and context of the study, 
combined with an examination of the researcher’s own personal orientation 
(Merriam, 2009).  
The case study conducted in this thesis was primarily exploratory aimed at 
increasing understanding about the phenomenon of recruitment from the 
perspectives of those with firsthand experience of the process. A qualitative case 
study in a stable underrepresented population enabled a detailed, in-depth study or 
investigation into the nature and complexity of the phenomenon of trial 
recruitment. In this chapter, I will provide a rationale for adopting this 
methodology. I will examine key epistemologies and theoretical perspectives which 
have influenced this case study. Finally, I will orientate my study in relation to these 




2. 1 Case study and theoretical influences 
The case study has a long and varied history and is associated with several 
disciplines including history, anthropology, sociology, education, medicine and 
psychology (Thomas, 2011; Platt, 2007 Hamel et al., 1993). It should also be noted 
that the term ‘case study’ can be used in a variety of ways and not all of them are 
clear. For instance, the term can be confused with casework in social services,  case 
studies in teaching and case report in medicine (Merriam, 2009; Platt, 2007; Hamel et 
al., 1993). Among social scientists, a case study has a range of interpretations, and it 
remains unclear whether the case study constitutes a methodological choice, a 
design strategy or an approach to the study of single entities (Baxter & Jack, 2008; 
Platt, 2007; Hamel et al., 1993). Descriptions of case study include: the study of an 
issue explored through one or more instances within a bounded system such as a 
particular setting (Cresswell, 2007) ‘an empirical inquiry that investigates a 
contemporary phenomenon within its real life context’ (Yin, 2009) and an  in-depth 
investigation and analysis of a single or collective case, intended to capture the 
‘particularity and complexity’ of the object of study (Stake, 1995). 
Different advocates of case study appear to emphasise particular ways of defining 
the ‘case’ with the use of varying terminology. Debates exists about whether the 
case should be defined at the outset or emerge as the inquiry progress (Thomas, 
2011a; 2011b). Suggestions of how to define a case may include time, place, context, 
activity or situation (Yin, 2009; Stake, 2003; Creswell; 2003; Miles & Huberman, 
1994). Thomas (2011a) defines the ‘thing’ to be explained as the ‘object’ of the study 
and the ‘thing’ doing the explaining as the ‘subject’ of the case study, and a case 
must be ‘of’ something. Regardless of definitional problems, most accounts view 




which can be an event, situation or experience and may involve the use of diverse 
methods of data collection and analysis (Simmons, 2009; Willig, 2008). Indeed much 
social science research could be conceived as a form of case study because it usually 
involves the analysis of social phenomena specific to time and place (Ragin, 1992). 
Unlike other approaches, case study does not emerge from a particular social 
scientific tradition - for example, ethnography has its roots in anthropology with a 
special focus on culture. Varying approaches to case studies place emphasis on 
different features of the methodology, whether it is exploratory, explanatory, 
descriptive, empirical, or evaluative (Thomas, 2011a). Furthermore case studies are 
neither new nor essentially qualitative and may include quantitative as well as 
qualitative data (Hyett et al., 2014). Ultimately the way a case is defined is dictated 
by what the researcher aims to achieve or wants to know. However different ideas 
about what constitutes a case study methodology to some extent reflect the diversity 
of epistemological starting points of researchers who use this approach (Thomas, 
2011b).  
Many researchers using case study have mostly situated their work within either a 
largely post-positivist paradigm or constructionist or interpretive paradigm (Hyett 
et al., 2014; Thomas 2011b; Brown, 2008). Some authors have positioned case studies 
somewhat outside particular paradigms, as a flexible, pragmatic approach or 
‘bridge across paradigms’ (Luck et al., 2006). However, many inconsistencies exist 
with regards to interpretations of epistemological and theoretical perspectives, and 
how these terms are used and defined within the literature (Seale et al., 2004; Patton, 
2002). Therefore I considered it necessary to make explicit my understanding and 
interpretation of these positions to ensure integrity and coherence in my 




2.1.1 Defining positivism and post-positivism 
To fully comprehend the position of positivism and post-positivism it helped to 
briefly trace the evolution of this term and its relationship to ideas about objectivity 
and scientific realism. Crotty (1998) uses the term ‘objectivism’ to describe what 
other authors have termed objectivity or scientific realism (Smith, 1998; Hacking, 
1983), in which truth is believed to reside in the object of analysis and can be known 
through systematic study (Crotty, 1998).  A belief in an objective account of reality 
forms the foundation of western science and has strongly influenced the field of the 
natural or physical sciences. Scientific inquiry is perceived as progressing towards 
universal truths about nature (Smith, 1998).  The world described by objective 
scientific inquiry adopts a form of ‘realism’ which assumes the world described 
through systematic study is the ‘real’ world that exists independently of our beliefs 
and understanding of it (Crotty, 1998; Smith, 1998). 
Social sciences came under the influence of ‘objectivism’ during the nineteenth 
century, coinciding  with the establishment of scientific methods drawn from the 
natural sciences, with the term ‘positivism’ being coined by the French philosopher 
August Comte (Hacking, 1983).  Positivist traditions assumed a clear separation of 
objective facts from subjective values, believing it possible to discover objective and 
true accounts of both the natural and human social world (Smith, 1998). Social 
scientists adopted versions of the methods and assumptions of the natural sciences, 
in an attempt to provide scientific explanations for social relations and processes 
(Smith, 1998). Positivist approaches typically adopt quantitative approaches which 
aim to divorce a phenomenon from its context by seeking to minimise or control 
contextual influences, including subjective biases of the researcher (Crotty, 1998).  
The aim of this approach is to isolate the effects of a relatively small number of 




position, researchers select methods that will reveal a ‘true’, objective account of 
reality. 
A well-known critic of positivism, Popper (1959; 1963) believed that observation is 
always shaped by theory and considered the criterion of verifiability as too strong 
and proposed for it to replaced by a criterion of falsifiability (Smith, 1998; Popper, 
1959; 1963). Popper (1959; 1963) argued that it is impossible to verify that a belief is 
true and that scientists are called upon not to prove a theory, but to try to prove it 
wrong. Kant (1724 -1804) also had a major influence on the positivist position with 
his view that there was no absolute description of the world uncontaminated by the 
observer and that all knowledge is mediated by prior experience (Luchte, 2007; 
Smith, 1998)  
Kuhn (1970) proposed that it is not merely individual theories, but whole 
worldviews or paradigms involving sets of beliefs or conceptual constructs in which 
scientists make sense of the world, which must occasionally shift in response to 
evidence (Crotty, 1998; Kuhn 1970).  Kuhn’s ideas became the cornerstone of 
scepticism about scientific truth (Patton, 2002; Crotty, 1998). Rather than seeing 
scientific inquiry as progressing towards universal truths about nature, he 
suggested that science is best seen as a series of power struggles between advocates 
of different worldviews, which are embedded within a set of beliefs, values and 
techniques shared by that community (Patton, 2002). In the light of these arguments, 
science was no longer viewed as describing the world passively or objectively; 
rather it was seen as creating knowledge of the world (Kellner & Lewis, 2007). 
Over time ‘positivism’ and the assumptions about the knowledge associated with it 




Today’s more circumspect form of positivism, known as post-positivism refers to 
probability rather than certainty and claims a degree of objectivity, rather than 
absolute objectivity (Crotty, 1998). However, due to the complex history 
underpinning positivism, the term itself and many related terms have attracted 
some negative connotations and disputed definitions (Patton, 2002). Despite being 
criticised for being reductionist and failing to consider the influences of context, 
versions of positivism have been hugely influential in the progression of science and 
medicine (Smith, 1998). It is no longer considered necessary to go to great lengths to 
criticise post-positivist assumptions or to set qualitative methodologies against 
quantitative methods or vice versa.  
Few, if any, scientists or researchers today would regard themselves as unreformed 
positivists, and evolving forms of post-positivism continue to inform much 
contemporary social science research. Nevertheless, post-positivist assumptions are 
most typically associated with quantitative methods of enquiry and interpretive 
assumptions linked to qualitative methods. For instance, within the field of trial 
recruitment, researchers influenced by post-positivism are more likely to adopt a 
survey approach to measure dimensions of satisfaction or understanding during 
recruitment, employing quantitative methods and statistical analysis. However 
qualitative research may also be informed or directed by post-positivist 
assumptions (Creswell, 2007 ; Patton, 2002). In practice, for qualitative inquiry, this 
would mean the incorporation of the language and principles of science into 
naturalistic inquiry; striving to minimise bias through the adoption of a neutral 
stance and a belief in an objective truth and concern about validity, reliability and 
generalisability (Patton, 2002). From this position, interview data may be collected 
using standard procedures, and the researcher may assume the data will provide 




can be criticised for not acknowledging the social and cultural contexts in which the 
accounts are created and understood. 
2.1.2 Interpretive paradigms 
Comparable to the complex history underpinning positivist traditions is an equally 
complex history underpinning interpretive traditions. The terms constructionism, 
constructivism, social constructionism and interpretivism occur in the literature 
reflecting a range of interrelated concepts and positions underpinning non-positivist 
paradigms (Ritchie et al., 2014; Merriam, 2009; Crotty, 1998).  Nonetheless, a central 
assumption underpinning these positions is that human beings have evolved the 
capacity to interpret and construct reality. Therefore the world of human 
perception, unlike the physical world, is not real in the absolute sense, but meanings 
and knowledge are constructed by human beings as they engage with the world 
they are interpreting (Patton, 2002). Interpretation is therefore considered integral to 
how humans, relate to others and our social existence.   
Unlike positivist positions which seek to apply the same rules of knowledge 
production used to understand the physical word to the social world, interpretivism 
views the human social world as different from the natural physical world. 
Therefore the reality and knowledge of this world must be situated differently 
(Guba & Lincoln, 1994). Consequently, from this theoretical position, the best way to 
understand or acquire knowledge about the social world of humans is to perceive 
all knowledge about this world as being socially constructed, as opposed to there 
being an objective truth, waiting to be discovered (Merriam, 2009; Patton, 2002).  
Kuhn (1970) applied this assumption of constructed knowledge to every way of 




context of this thesis, I am focusing on the constructed knowledge only in the 
context of social sciences, that is, how knowledge of the social world rather than the 
material world is situated.   
The roots of interpretivism as an academic activity predate social constructionism, 
with two centuries of philosophical dialogue providing a foundation for 
‘understanding,’ which lies at the heart of interpretivism (Patton, 2002). Today’s 
interpretivists have been influenced by many historical and theoretical streams 
including; hermeneutics, phenomenology and symbolic interaction (Merriam, 2009;  
Crotty, 1998). Hermeneutics has origins in theology, philosophy and linguistics, and 
is defined as the theory of interpretation; the hermeneutics introduced the 
significance of studying the ‘lived experiences’ of individuals (Smith, 1998).  ‘Lived 
experience’ refers to meaning that is interpreted and constructed by people in their 
social and historical context, with the underpinning view that experiences cannot 
make sense without reference to the context in which they occur (Smith, 1998). The 
idea here is that the whole can only be understood in terms of the sum of its parts, 
with the whole being an individual’s perception of reality and the parts being the 
situated or lived experience.  
Interpretivism has also been influenced by phenomenology, which originated with 
Husserl's (1859-1938) attempts to construct a philosophical science of consciousness.  
Phenomenology involves the study of the social world and the nature of experience 
(Patton, 2002). This position requires a suspension of presuppositions to allow 
access to the nature or ‘essence’ of the so-called lived experience i.e. the objects of 
our experience before we start thinking about them, interpreting them or attributing 
meaning to them  (Crotty, 1998). Phenomenology, therefore, assumes there is an 




Symbolic interactionism, another important theoretical movement informing 
interpretivism, is a social-psychological approach which sees interactions between 
people and the symbolic meaning and interpretations people attach to their social 
actions and environments as a means of understanding human behaviour (Blumer, 
1969).The process of symbolic interaction embedded within societies is assumed to 
give rise to our very ‘being’ - a ‘being’ that defines us as conscious and self-
conscious human beings, where the self is an ever changing ‘product’ of ongoing 
interactions (Smith, 1998; Blumer, 1969).  
Unlike other philosophical positions, social constructionism cannot be traced back 
to a single source and has emerged from the combined influence of various 
philosophical developments (Burr, 2003).  The concept of socially constructed 
knowledge is embedded within all the early interpretive positions, which asserts 
that there are useful interpretations of the social world, but there is no ‘true’ or 
‘valid’ interpretation (Crotty, 1998).  Even so, it wasn’t until Kuhn’s (1970) radical 
notion that socially constructed knowledge could be applied to science, that social 
constructionism became a highly influential methodological paradigm (Patton, 
2002). 
 A significant contribution to social constructionism is the work of Berger and 
Luckmann (1966), in which knowledge is viewed as the effect of social processes 
and practices with individuals experiencing these as if the nature of the world is 
pre-given or fixed (Burr, 2003; Burger & Luckman, 1966). That is, ‘the way things 
are’ is really just ‘the sense we make of them’. Social reality is seen as socially 
constructed, through persons and groups interacting together in a social system 
over time, with knowledge and meaning becoming embedded in the institutional 




to identify a social constructionist position (Burr, 2003). However, this position 
usually has one of the following key assumptions: a critical stance toward taken-for-
granted knowledge; recognition of the historical and cultural specificity of 
knowledge; recognition that knowledge is sustained by social processes and that 
knowledge and social actions go together (Gergen, 1985).  
More extreme constructionist positions, which argue that true representation is 
unattainable and everything is socially constructed (Waszak & Sines, 2003), are of 
limited value if taken too literally. From such an extreme viewpoint, where 
everything is ‘relative’ and nothing is known, all concepts and theorising that form 
the basis of the research question, become social constructs and matters of analytic 
interest. Therefore, no moral or cultural consensus can ever be reached, and nothing 
can ever be known (Burr, 2003; Crotty, 1998). 
More moderate versions of constructionism embrace a form of realism which 
acknowledges that human perceptions do provide some kind of knowledge about 
the world, even if this knowledge is mediated through our senses and we cannot be 
directly aware of it (Ritchie et al., 2014; Burr, 2003). From this view all forms of 
knowledge are partial, and a certain degree of relativism is unavoidable. Social 
constructionism can, therefore, be considered as both realist and relativist, in the 
sense that even if we accept that reality is a socially constructed reality, this is not to 
say that reality is not real (Crotty, 1998). We cannot make sense of this world 
without our perceptions of the world, but these perceptions are informed and most 
likely originated in our understanding of the social world. Therefore an individual’s 
interpretation of the social world is dependent on the cultural and social context in 
which they exist, fused with individual variability as to what each of us makes of 





Pragmatism does not assume a unifying position or methodology which 
underscores all scientific activities.  Rather, it recognises that criteria for ‘ways of 
doing’ research change over time and strategies are in place dependent on the 
objectives that guide research and what is to be achieved (Rorty, 1991). 
Consequently, providing a precise definition of pragmatism is challenging, 
reflecting the diverse, evolving range of philosophical positions and rival factions 
that are characterised as pragmatic (Talisse & Aikin, 2008; Baert; 2005; Crotty, 1998).  
 Typically referred to as the initiator of pragmatism, Peirce (1931-58) insisted 
‘pragmatism is not a worldview but a method of reflexion, having for its purpose to 
render ideas clear’ (Crotty, 1998). In essence, Peirce proposed that to survive, 
humans develop habits of thought and action to comply with their individual needs 
(Maxcy, 2003). Pragmatists regard their meta-methodology as neither a ‘system’ nor 
a fully formed ‘philosophy’. Indeed, they tend to only regard a method as 
appropriate if it achieves its purpose (Maxcy, 2003). The influence of pragmatism 
can be seen in the increasing tendency for researchers to use pragmatic criteria for 
deciding method acceptability rather than epistemological assumptions and 
associated traditions. With the best method or mix of methods considered to be the 
one that is most effective (Tashakkori & Teddlie, 2003).  
Pragmatism acknowledges the plurality of knowledge and views the social world as 
a matter of practice, offering justification for the use of research method pluralism, 
by moving outside of the methodological confines of particular orientation or 
discipline (Tashakkori and Teddlie, 2003). The influence of pragmatism on social 




identification of what is ‘true’ or ‘valid’, allowing researchers to broaden their lens 
and practicalize (to make practical) their research goals (Maxcy, 2003).  
Despite their diversity, all pragmatic approaches share an emphasis on that ‘which 
works out most effectively’ (Rescher, 1995).  Rorty suggests that philosophical 
debates should be relinquished if they do not have visible consequences (Rorty, 
1990; 1999). Nonetheless pragmatism’s reluctance to define itself as a ‘school of 
thought’ means that it is open to criticism for its lack of critical rhetoric and 
theoretical ambivalence (Proctor, 1998). Baert (2005) suggests that abandoning 
theory altogether is untenable as pragmatists themselves have pointed out that our 
presuppositions are an essential element of any knowledge. Baert (2005) proposes a 
version of pragmatism that remains open-minded to presuppositions, recognising 
that it is better to be aware of our theoretical perspectives rather than deny what 
cannot be denied. 
 There is also a reluctance among advocates to label pragmatism as an epistemology, 
as this way of knowing can provide a useful perspective to navigate through the 
theoretical complexity which underpins  social science research. A pragmatic 
perspective can also be particularly effective in the field of health care where 
applied research is necessary, and the need for practical research goals is pressing. 
Moreover, the adoption of a pragmatic position does not necessarily equate to the 
relinquishing of schools of thought. Rather, pragmatism can be viewed as a way of 
ensuring that methodological considerations are rooted in what is most effective for 
achieving the aims of the research and avoiding what Mason (2002), describes as ‘ 





2.2 Positioning my case study 
A key assumption underpinning the theoretical positioning of this case study was 
how I chose to define or perceive clinical trial recruitment and how trial recruitment 
could be best understood in terms of the aims of my thesis. My thesis was 
positioned in the context of a grant-funded PhD studentship which formed part the 
patients’ perspective theme of the MRC Hub for Trials Methodology Research. This 
theme focuses on ensuring the views and experiences of patients are drawn upon to 
inform the design and conduct of clinical trials. Consequently, my broad objective 
was to gather empirical evidence in an unexplored area of recruitment to contribute 
to the existing literature, both conceptually and empirically.  
 In addition to considering trial recruitment from the perspective of a member of the 
HUB, I also considered my own assumptions about trial recruitment as a member of 
society and a user of the health service. I have been approached about two separate 
clinical studies: an observational study involving the monitoring of my daughter’s 
oxygen levels shortly after birth; and a second involving an RCT of a foetal 
monitoring system used during labour with my son. From these personal 
experiences of recruitment, I recognised the significance of the socio-medical context 
in which recruitment occurs. Moreover, insights gained into the process of 
recruitment acquired while working on a qualitative study which examined 
experiences of recruitment in the paediatric context, also influenced my 
interpretation of the process of recruitment (Shilling et al., 2011). Conducting multi-
perspective interviews with individuals with direct experience of recruitment made 
me aware of the strengths of qualitative inquiry when examining a phenomenon 




In light of these critical reflections, I adopted a moderate position of 
constructionism, influenced by pragmatism. Aligned with this qualitative tradition 
of a case study methodology, I viewed this study as an interpretive endeavour with 
the most important role of the researcher being not to discover an external reality 
but to construct a clearer picture of the phenomenon under study through 
integrating interpretations of situation and context (Stake, 1995). From this position, 
I considered trial recruitment not as something that can be known in an absolute 
objective sense, but as something that could be known about in the ways ‘most of us 
live our everyday lives, as though reality exists and can be known about’ (Oakley, 
1999).  
Due to case study’s focus on a particular situation, context or event, a common 
criticism of this methodology is its inability to achieve empirical generalisation from 
sample to population typical of positivist positions. Nonetheless, advocates propose 
that case study can produce generalisation that is conceptual, therefore having 
relevance in theoretical development (Merriam, 2009; Yin, 2003). However, in 
contrast to quantitative research which aims to eliminate or balance out contextual 
effects, a focus on the  ‘uniqueness’ of individual cases and context are considered 
essential for the refinement of understanding in case study methodology (Stake, 
2003; 1995).  Furthermore consistent with a qualitative methodology,  in-depth 
engagement with the complexity of phenomena has the potential to provide new 
insights enabling the researcher to develop models, typologies and theories as ways 
of describing and explaining the social world (Flick, 2007; Seale et al., 2004). Due to 
the lack of robust theory underpinning recruitment research I was interested in the 
refinement of understanding and conceptual development that can arise from a 




From a position of a qualitative researcher, researching a fundamental component of 
a principal quantitative methodology underpinning evidence-based medicine, I was 
aware of the inherent tension between adequate recruitment and the ethical conduct 
of clinical trials. My epistemological awareness enabled me to position myself 
outside of this tension. I did not perceive my role as necessarily to directly inform 
practice to improve recruitment in the sense of the numbers recruited, or to improve 
the ethical conduct of research. I regarded the purpose of my research to provide a 
detailed examination of how individuals construct the process of recruitment, 
providing insights that would help to inform those who are involved in developing, 
recruitment research, recruitment strategies and practices. A stance influenced by 
pragmatism allowed me to view my interpretive position as a qualitative researcher 
as not in opposition or antithetical to the quantitative methodology intrinsic of 
clinical trials, but as the most effective position to enable me to address my research 
objective. Pragmatism provided a paradigm that enabled this complexity to be 
navigated efficiently, avoiding opposition and remaining aware of the need for a 
multiplicity of forms of health related knowledge. 
I considered a case study methodology an important research design applicable to 
health and social sciences as it can answer complex research questions in which the 
phenomenon of interest is very closely embedded within the context while 
addressing the holistic nature of care and treatment (Simmons, 2009; Luck et al., 
2006). I, therefore, chose an exploratory qualitative case study methodology, 
considering this open, flexible methodology as the most appropriate design for the 
purposes of the study. I believed this methodology would provide meaningful 
insights into personal experiences of recruitment while acknowledging that human 
experience is mediated, historically, culturally and linguistically and that multiple 




into factors that were significant to individuals’ construction of trial recruitment and 
what factors they viewed as influential to both their satisfaction with this process 
and their subsequent participation decision.  
2.2.1 The ‘case’ of cystic fibrosis  
The clinical context of cystic fibrosis provided the parameter of the ‘case’, which was 
jointly agreed between the HUB management team, the local Clinical Trial Research 
Centre (CTRC), CF experts in the field, my PhD supervisors and myself. 
Comparison was an important design aspect of this qualitative case study both due 
to lack of research comparing recruitment experiences across child and adult 
settings, combined with the recognition that comparison within qualitative 
methodology forms an important analytical tool used to develop, insight into 
complex social phenomena (Bradley et al., 2007). CF presented both an 
underrepresented population in the recruitment literature and an ideal case in 
which to examine recruitment experiences across child and adult settings, with 
specialist paediatric and adult CF centres in operation across the UK. Consequently, 
it was anticipated that this healthcare context would enable me to gain insights into 
a diverse range of trial experiences including novel and earlier phase trials, older 
individuals and parents of infants. Furthermore corresponding with my period of 
data collection a phase IV CF clinical trial was currently recruiting. This trial 
provided the opportunity to examine recent trial recruitment experiences, 
particularly in the paediatric context where the majority of this trial eligibility was 





2.2.2 A qualitative methodology 
Case study, located within a broadly constructionist position, consistent with other 
forms of qualitative methodology, is concerned with specifying and studying 
individual phenomena in detail, focusing on personal views and circumstances 
(Thomas, 2011b; Merriam, 2009; Willig, 2008). As I was concerned with how trial 
recruitment is interpreted, experienced, or constituted, I considered a qualitative 
methodology as essential to achieving this aim (Merriam, 2009 ; Flick, 2007; Mason, 
2002).  I sought to understand and unpick how people construct trial recruitment in 
terms that are meaningful and that offer in-depth insight into this challenging 
phenomenon. 
Case studies do not claim any specific data collection methods but, rather, focuses 
on achieving holistic explanations of the issue or phenomena under investigation 
(Merriam, 2009; Stake, 2003, 1995). Nonetheless interviewing is perhaps the most 
widely used method in qualitative research and is frequently used in case studies 
(Merriam, 2009; Seale et al., 2004). While single perspective interviewing is 
commonly employed in qualitative studies, multiple perspective interviewing has 
the potential to generate a richer understanding and to provide additional insights 
through studying the discrepancies and convergences in the views of different 
parties (Kendall et al., 2009). Furthermore, previous studies on recruitment, which 
have tended to rely on one−dimensional accounts of recruitment (e.g. Quinn et al, 
2011; Henzlova et al., 1994), offer limited insights into the relationships between 
parties and the wider context of recruitment. Multi-perspective qualitative 
interviews are particularly valuable when seeking to understand the relationships 
and dynamics among patients with long-term conditions, families and practitioners, 
and similarities and differences across the needs and concerns of these different 




I recognised that alternative methods were available, for example, observational 
techniques, narrative or fully structured interviews. Observational methods may be 
favoured as a way of examining recruitment as it is ‘naturally occurring’ avoiding 
the use of ‘contrivances’ such as interviewing (Potter, 2002).  Nonetheless, 
distinctions made between natural and contrived methods are considered over 
simplistic and observational data is still mediated by factors such as the presence or 
the position of the researcher and recording equipment and the knowledge that the 
observation is being conducted (Silverman, 2006). Also, within the context of this 
study, observational data would have provided little insight into how an individual 
constructs or makes sense of this process, which was the purpose of this study.  
A more open narrative method to interviewing could have been selected as an 
alternative to semi-structured. This style of interviewing is designed to provide an 
opportunity for the informant to give a detailed narrative account of a particular 
experience with minimal prompting (Murray, 2015). Narrative methods appear 
more relevant for gaining insights into personal existential life events or processes 
which are temporally structured, such as living with illness or the experience of 
ageing (e.g. Becker, 1999; Pejlert et al., 1999; Reissman, 1990). Recruitment, in 
contrast, is not existential, but a form of clinical communication embedded in 
particular institutional discourse. Therefore, very open narrative methods may not 
produce the most insightful accounts. In contrast, highly structured interview 
methods involving fixed-choice answers would not enable informants to take the 
lead regarding what is important to them. Influenced by pragmatism balancing 
ethical, methodological and practical considerations the most effective choice of 
design was considered to be multi-perspective, in-depth semi-structured interview. 
From a constructionist position, I viewed interviews not as accounts that are true or 




and inner psychological worlds produced in discourse (Sliverman, 2006; Potter & 
Wetherall, 1987). 
 
2.3 Quality in qualitative research 
The debate on quality in qualitative research is diverse and unresolved and parallels 
the diverse, evolving historical epistemology underpinning social science research, 
discussed previously in this chapter. Assumptions about what an individual 
considers as knowledge are embroiled with conceptualisations of quality. How we 
know and perceive quality depends on our epistemological position and many of 
the debates around perceptions’ of quality map onto individual debates about the 
nature of knowledge. In contrast in the domain of quantitative social science 
research unified standardised procedures have evolved to provide quality 
assurance procedures which are mostly rooted in positivist epistemology (Reynolds 
et al., 2011). Concepts of reliability, validity, (statistical) generalizability and 
objectivity, developed in the natural sciences as criteria with which to judge quality, 
have been extended for use in quantitative social sciences (Ritchie et al., 2014; 
Winter, 2000). However, this criterion used in quantitative methods are not 
considered appropriate for most qualitative research (Yardley, 2000; 2015) although 
debate still exists around this issue and there is no unified approach for assessing 
the quality of qualitative research (Reynolds et al., 2011). 
However, many qualitative researchers have accepted the need for some criteria for 
judging the quality of qualitative research (Reynolds et al., 2011). Dixon-Woods et 
al. (2004) identified over 100 sets of proposals on this topic with many of these 
adopting conflicting ideologies. On reviewing this literature, Reynolds et al. (2011) 




as being linked to specific sets of criteria or checklist detailing specific methods or 
techniques deemed as indicators of quality. This approach appears to have been 
shaped by post-positivist requirements embraced with the social movement of 
evidence-based medicine, with the introduction of Lincoln and Guba’s (1985) 
criteria for establishing trustworthiness in qualitative inquiry (Reynolds., 2011; 
Barbour, 2003; Mays & Pope). Typical criteria include respondent validation, 
multiple coders, and deviant case analysis. The second discourse identifies quality 
in terms of the research process reflecting an internal set of values inherent in 
qualitative inquiry. Common values included: reflexivity, transparency, 
comprehensiveness, and a systematic approach. This approach advocates 
researcher-led principles of good practice and questions how far externally 
determined constructs of quality and predetermined techniques can assure quality 
(Reynolds et al, 2011;Tracy, 2010). 
Advocates of case studies adopting a post-positivist position are drawn to the first 
discourse on quality, influenced by the criteria originating from the natural sciences 
(Brown, 2008; Yin; 2009). In contrast, supporters of an interpretive approach to case 
studies are drawn to the second discourse, acknowledging the centrality of the 
researcher’s role in building a clearer view of the phenomenon under investigation 
(Merriam, 2009; Brown, 2008, Stake, 1995). The latter position accepts that a 
researcher cannot be neutral, or objective, or detached from the evidence they are 
generating, and requires that they seek to understand and make transparent their 
role in the research process (Thomas, 2011a; Merriam, 2009; Mason, 2002). 
Consequently striving to remain critically aware of personal values, preconceptions 
and socially derived frames of reference in this way has been termed reflexivity or 
reflective practice and is considered central to meaningful interpretive inquiry 




as an interpretive activity, with the researcher playing the role of interpreter and 
constructor of knowledge. Qualitative research acknowledges that the orientations 
of the researcher are shaped by their socio-historical locations and that social 
research cannot be unaffected by social processes and personal characteristics 
(Ritchie et al., 2014; Stake, 1995). Researchers are therefore perceived as active 
participants’ in the research process and in this way the researcher is someone who, 
like research participants, is actively making sense of the world (Charmaz, 2004; 
1996). Similarly, far from regarding experiential data as a potential bias to be 
removed, Strauss (1987) saw various kinds of personal experience as central to 
different stages of analysis and maintained that personal experience was integral to 
researchers being able to generate relevant research questions and uncover valuable 
insights.  
I positioned my judgement of quality from an interpretive framework in which I 
sought to understand and make transparent my role in the research process (Mason, 
2002). I accepted as a qualitative researcher that I was both the subject and object of 
the research process. I viewed the process of research as an interpretive activity, 
with the researcher playing the role of interpreter and constructor of knowledge. I, 
therefore, ensured I maintained a process of reflexivity or critical engagement 
throughout the research process while recognising the value of my own experiential 
data (Mason, 2002). Rather than viewing my own experiences as a potential bias to 
be removed I viewed these experiences as an important methodological tool 
(Strauss, 1987).  
My overall aim was to represent this ‘case’ of recruitment with a narrative, 
reflective, tone while complying with the necessary methodological conventions of 




constructionist position, I viewed the criteria for judging either reality or validity as 
not absolutist but derived from community consensus about what is useful and has 
meaning (Guba & Lincoln, 2008). Moreover, from a constructionist position, it may 
be assumed that it is the reader of the research, not the researcher who ultimately 
determines what applies to his or her context.  
2.4 Sampling  
Like much qualitative research, qualitative variants of case studies usually draw a 
purposive sample aimed at capturing the character and diversity of the 
phenomenon in question (Stake, 2003). In contrast to probability sampling, 
purposive sampling aims to discover, understand and gain insights into the area of 
interest (Merriam, 2009). The sampling of cases which are ‘information rich’ with 
regards to the focus of the study is considered to be of central importance to 
purposeful sampling (Patton, 2002). Nonetheless, sampling remains one of the 
complex dilemmas in research design that qualitative researchers face, and there is 
no ‘one size fits all’ solution to the problem (Barbour, 2001). 
Also similar to qualitative research within qualitative variants of case study a 
predefined sample is not always appropriate or meaningful.  Advocates of the case 
study acknowledge that how much and how long the complexities of the case 
should be explored involves a strategic decision and that the researcher must 
acknowledge that not everything about the case can be understood (Stake, 2003). 
Within much qualitative research ‘theoretical saturation’ or the point when no new 
insights would be obtained from further sampling (Charmaz, 2006; Glaser & 
Strauss, 1967), is used to guide when data collection should cease. Nonetheless, 




be achieved in practice (Charmaz, 2006; 1990). To pragmatically address the 
difficulty of achieving theoretical saturation or knowing everything about the case I 
considered an appropriate sample size for this study to be one that enabled me to 
adequately answer the research question and put my case forwards (Marshall, 
1996).   
2.5 Analysis  
An important difference between case study and other qualitative methodologies is 
that the case study can be both inductive and deductive, and as such, can be useful 
to test and extend existing theories (Thomas, 2011; Yin, 2009). Equally, it can be a 
useful strategy where there is no strong theory on which to base a study. Initial 
questions can be developed, changed, refined or deleted as the study progresses, 
and in the light of new findings from the data. A comparative focus is a powerful 
conceptual, analytical mechanism often adopted within a case study methodology 
and indeed in qualitative research in general. Nevertheless, a strong comparative 
focus within case study research may at times compete with learning about a 
particular case (Stake, 2003). 
A case study is not strictly attached to a specific paradigm and multiple methods of 
data analysis are characteristic. Consequently this approach draws on the range of 
analytical strategies which have evolved from the diverse range of disciplines 
underpinning qualitative inquiry. Analysis is primarily led by the nature of the case 
and the purpose of the research. Multiple methods of data analysis are characteristic 




Pluralistic approaches to qualitative analysis aim to address the difficulty of 
balancing meaningful interpretations of personal ‘narrative life world’ accounts 
with broader ‘sociological world’ accounts (Frost, 2011; Thomas, 2011b; Conrad, 
1990). With a concern that focusing on border patterns in which the data are only 
coded conceptually has the potential to ‘disembody’ the data from the context in 
which it was co-constructed with the interviewer (Frost, 2011; Conrad, 1990). 
Conversely, there is a concern that focusing on the finer details of individual 
perspectives may be at the expense of losing conceptual or theoretical strength of 
the analysis (Thomas, 2011; Conrad, 1990). By examining data from different 
analytical positions, the impact of assumptions and limitations associated with 
viewing the data from one perspective is reduced (Frost, 2011).  
Analysis of qualitative data  has been described as a blend of art and science, 
involving a process of breaking down the corpus of data into its constituents parts, 
and through the reassembly, one gains a detailed understanding of the integrity of 
the whole (Schwandt,2001). The exact balance of art and science and the distinction 
made between analysis and interpretations varies according to differing 
epistemologies. Although ‘the art of understanding’ is not fully definable in terms of 
procedural steps, what is common across approaches is the recursive practice of 
sorting, organising and reducing data into something manageable, combined with 
the exploration of ways to reassemble the data to assist in the process of 
interpretation and ‘the art of understanding’ (Schwandt, 2001). 
Grounded theory is one of the most cited methodologies in qualitative inquiry in 
medical research  and the ‘constant comparative’ method, a fundamental part of this 
approach, has become a central method of many interpretive, analytical processes 




grounded theory work being criticised for not adhering to all the principles laid 
down by its founders (Dixon-Woods et al., 2007; Barbour, 2001), much research from 
an interpretive position adopts components or different combinations of these 
elements without claiming to adopt a grounded theory methodology. While it is 
beyond the scope of my thesis to provide a full critique of grounded theory, it is 
important to recognise the significance of this approach in informing much 
contemporary forms of qualitative analysis today. Since its inception (Glaser & 
Strauss, 1967), grounded theory methodology has evolved into diverse forms (e.g. 
Charmaz, 2006; Strauss & Corbin 1998) with the original authors diverging in their 
interpretations of the methodology, they jointly created. Within earlier versions of 
grounded theory, the influence of post- positivism is more notable  (Glaser & 
Strauss, 1967), with later versions more in keeping with constructionist principles 
(Charmaz, 2006; Strauss & Corbin 1998). 
Grounded theory emphasises inductive analysis, with analysis and data collection 
coinciding, involving an iterative process designed to advance the developing 
theory (Charmaz, 2006; Glaser & Strauss, 1967). Data analysis involves breaking the 
data down into labeled components or ‘codes’ that are continually compared within 
and across interviews (constant comparative method). The process of coding is 
central to most qualitative analysis, and it is during this process of coding and 
comparing that the researcher begins to define what is happening in the data, and 
‘to grapple with what it means’ (Charmaz, 2006). This grappling appears to be 
synonymous with the delicate balance of art and science, the intuitive and 





While I recognized the value of breaking the data down to gain a detailed 
conceptual understanding, from a constructionist position I also the recognized the 
value of discursive approaches to analysis which aim to highlight the ways in which 
‘knowledge’ is ‘socially constructed’ (Holt, 2011, Potter & Wetherell, 1987). 
Discursive approaches are underpinned by a constructionist ontology which aims to 
address hidden assumptions and taken-for granted knowledge (Holt, 2011; Burr, 
2003). This approach emphasises the consequential nature of accounts in which 
meaning is viewed as being constructed from our engagement in the world rather 
than discovered (Potter & Wetherell, 1987). Rather than viewing language as a 
means to access ‘the truth’ constructionist approaches recognize that it is through 
language that meanings are negotiated and ‘realities’ are produced (Holt, 2011). 
Charmaz (2006) has developed a grounded theory approach aligned with 
constructionist principles which are considered compatible with discourse analysis 
methods and it is from this position I aimed to approach my analysis. In line with 
key assumptions of a position of social constructionism and a qualitative case study 
methodology my approach to analysis was interpretive, flexible and pluralistic 
(Frost, 2011; Thomas, 2011). I avoided imposing a particular strategy of 
interpretation on the data that risked losing important facets or components of the 
data.  Instead, I drew on analytical methods that were most suited to the type of 
data generated and most able to address the research aim.  
I aimed to examine the data conceptually, drawing on elements of grounded theory 
without claiming to adopt a formal grounded theory methodology (Charmaz, 2008; 
2006). From a constructionist position, I did not view analysis as a passive process 
with themes or concepts simply ‘emerging’ from the data.  Rather I recognised that 




meanings in the data and construct a comprehensive account of the ‘case’.  In 
addition I aimed to draw on aspects of discursive forms of analysis to ensure that 
the contexts of themes occurring in the data were not lost and any contradictions, 
ambiguities and tensions within individual accounts were captured (Holt, 2011; 
Potter & Wetherell, 1987). I therefore aimed to adopt a pluralistic approach to 
increase the integrity of the interpretation and to help reduce the likelihood of my 
assumptions dominating interpretations, rather than the participant’s construction 
leading the story (Frost, 2011). I aimed to capture the integrity of the data by 
capturing the context in which it was produced, whilst also interpreting the data 
conceptually (Charmaz, 2006) 
2.6 Summary 
Within this chapter, I have discussed the choice of a qualitative case study 
methodology which was adopted from a moderate constructionist position 
influenced by pragmatism. Central to my research focus was the importance of the 
individual perspective, both as ‘potential participant’ ‘parent of potential 
participant’ and ‘recruiter’. However rather than defining these roles according to 
the legislative and ethical guidelines I aimed to make the concept of recruitment 
connect to the accounts of people with direct experience of the process. Within the 
next chapter, I will outline in detail the methods that were chosen in order to 




CHAPTER 3: METHODS 
3.0 Introduction 
A qualitative case study in cystic fibrosis was carried out to examine recruitment 
experiences across adult and child settings, involving perspectives from both sides 
of the exchange-those being recruited and those doing the recruiting. In this section 
I describe the design of the study where methods were selected and adapted within 
the framework of the qualitative case study.  
3.1 Research aim and objectives 
Aim  
To conduct an exploratory qualitative case study, with a comparative focus across 
adult and child settings, to further empirical and conceptual understanding of the 
process of trial recruitment  
Objectives  
 To use in-depth, semi-structured interviews to explore perspectives on trial 
recruitment for children (and their parents), adults and practitioners. 
 To examine divergences and convergences across accounts from within the 
subgroups: children (and their parents), adults and practitioners. 
 To explore issues contributing to positive and negative recruitment 
experiences. 






3.2 The research setting  
In order to achieve the research aim of this study, I needed to engage with patients 
and practitioners working within the context of CF care in the UK. People with CF 
are treated within tertiary centres which comprise part of the ‘specialist services’3 
within the NHS.  These specialist services are defined nationally according to the 
Specialised Services National Definition Set (SSNDS), which has been drawn up to 
identify and ensure provision of care within the NHS for children and adults with 
rare diseases or disorders (NSCG, 2010). According to this definition, a service is 
considered specialised if the catchment area for that service is greater than one 
million, which means that CF specialised care is not provided by every hospital in 
the UK. Therefore specialist CF centres usually have an active caseload of over 100 
patients, with adult centres often exceeding 150.  
At the time of this study, there were 24 adult and 24 paediatric specialist CF centres 
in the UK. These centres provide and oversee care to people with CF depending on 
the individual’s needs and circumstances. For instance, this care may be provided in 
the form of ‘shared-care’ between the local hospital and the nearest specialist CF 
centre, where the individual does not live a convenient distance from the specialist 
centre. Consequently, early sampling decisions involved the selection of specialist 
CF centres from which to recruit adults, families and practitioners.  
                                                     
3 Specialist services are services which have been designed and commissioned to improve the lives of 
children and adults with rare health conditions, which include 34 definitions of relevant conditions 





 As these CF centres were part of the health care provision of NHS England, I 
required informal approval from the centre CF teams and local formal Research and 
Development (R&D) approval.  Initial concern was expressed from the MCRN 
Study Assessments Committee that CF patients were already “heavily researched”, 
so the committee needed to be assured of both the sensitive management of the 
study and the potential value of findings for practitioners and patients. The 
sampling of CF centres was therefore guided closely by experts in the field which 
included; CF specialists, the local clinical trial team, involved in setting up a national 
CF trial (TORPEDO-CF), the NIHR Comprehensive Research Network and the 
MCRN Local Research Networks (LRNs). 
Through collaboration with these experts, the number of informants recruited from 
each centre was kept low, to reduce the research burden on participating centres, 
with the additional advantage of introducing variability of CF centres across the 
overall sample. It was therefore proposed that the study would run at four adult 
and four paediatric CF centres across four regions in England. Where possible, I 
approached adult and paediatric CF centres within the same geographical 
location/city in the first instance. I considered the study to be a multi-sited or a 
collective case, as opposed to a multiple case study, where  the intention was not to 
compare recruitment experiences across different CF centres (Baxter & Jack, 2008).  
At each CF centre, a senior CF clinician was invited to act as the clinical lead for the 
study. Once this had been agreed, further negotiations began with the CF team and 
associated researchers about the details of the study including aims, objectives and 
centre requirements regarding informant identification. Practitioners at each CF 
centre were invited to attend a presentation about the study. This enabled them to 




provided me with a first-hand opportunity to describe the study in detail, distribute 
necessary study documentation and where appropriate, provide reassurance and 
guidance regarding the focus of the research. 
These access negotiations with practitioners involved a protracted process of 
mediation. I maintained an honest, open position, drawing on my professional and 
personal skills and experience, to establish rapport and trust with practitioners.  I 
strove to maintain this trust throughout the study and beyond. Initial negotiations 
were the most difficult, as practitioners were most likely to potentially feel under 
scrutiny in relation to their recruitment practices, and protective of ‘their’ client 
group, acting as ‘gatekeepers’ to potentially vulnerable informants.  
3.3 Sampling for semi-structured interviews  
For the patient and parent sample a combination of consecutive and purposive 
sampling was used. Consecutive sampling aimed to avoid practitioners selecting 
patients or families who they thought would agree and purposive sampling was 
used to encompass diversity.  This strategy involved actively selecting the most 
productive sample by its relevance to the research question (Mason, 2002; Marshall, 
1996). The aim was not to generate a representative sample (often the aim of 
quantitative research pursuing ‘generalisation’), but rather to capture variability to 
support analytical generalisation or theoretical elaboration. This type of 
generalisation attempts to link findings from a particular ‘case’ to develop or 
elaborate theoretical concepts that may have relevance to settings beyond that 
studied (Scwhandt, 2007). Practitioners were sampled purposively to capture 




participate by myself during site visits or via the Principle Investigator (PI) at each 
CF centre. 
The sampling strategy was stratified according to 6 respondent groups. 
 Adults with CF 
 Parents of children with CF  <7 years  
 Parents of children with CF ≥ 7 years   
 Children with CF aged ≥ 7 years   
 Paediatric practitioners 
 Adult practitioners  
Within each of these sub-groups, I aimed to sample informants with a broad 
spectrum of views and experiences. For the patient sub-sample, I sought to include 
individuals with different clinical research experiences including those who had 
declined participation; those who had accepted; those who were found to be 
ineligible; those who had withdrawn from a trial or study, and; those who were 
non-eligible.  I also aimed to sample patients of a range of ages including young and 
older adults, parents of infants and children (too young to be interviewed) and 
children of diverse ages. It was felt that only children aged 7 and older could 
reasonably be approached about the study, due to the nature of the research and the 
complex concepts involved. 
 For the practitioner sample, I aimed to sample practitioners with a range of 
recruitment experiences including those with direct trial experiences in the CF 
context, including both nurses and clinicians. By selecting a diverse sample both 
within and across these sub-groups, the aim was to identify central concepts which 




and in part developed iteratively in the light of findings in the data and the 
provisional analysis and interpretation of the data. For example, during my analysis 
of the early interviews, I found that some informants appeared to speak of 
intrinsically valuing being offered research, describing how they had felt glad to 
have been asked to consider participation, despite declining. Based on some 
practitioners’ perceptions of the CF patient group as being ‘heavily researched’, I 
had anticipated that it would be more likely for patients to construct being 
approached about trials as a potential burden. To explore the concept of research as 
both a potential burden and the value of being asked I was keen to sample patients 
who had not recently been invited to participate in a clinical trial or who had never 
been asked, to gain insights into the circumstances that might influence how 
individuals experienced the invitation. This sampling criterion was not part of my 
initial sampling strategy, which was to focus on patients who had been recently 
approached about a clinical trial. This refinement of the sampling criteria during the 
study was in line with the goal to sample respondents with a broad and diverse 
range of experiences.  
3.3.1 Sample size 
In collaboration with my supervisors, based on their prior experience and the 
comparative focus of this study, it was anticipated that a minimum sample of N=48 
(16 adult patients, 16 patient families and 16 practitioners) would be both achievable 
within the time constraints and adequate to address the research aim. To address 
the comparative aims of the study, I aimed to recruit patients and practitioners from 





3.4 Recruitment to this study 
Recruitment to this study was dependent on participating CF centres acting as 
patient identification centers (PICs) which required a continuous process of 
collaboration with each participating centre throughout the data collection phase. 
Patients and parents of child patients were invited to consider participation in this 
study either by members of the CF team or members of the local research network 
(LRN), depending on the resources available and procedures in place at each centre. 
I collaborated closely with the CF clinical team or the LRN team at each 
participating centre to develop a suggested guideline for introducing CACE.  
A practitioner introduced this study as a separate interview study, which is entirely 
independent from the CF centre and clinical research conducted at the centre. A 
recruitment log was also provided to enable centres to keep a record of the number 
of patients that were approached which would provide insights into the sample 
characteristics and the acceptability of this qualitative study. 
If the patient/parent was interested in the study, the practitioner gave them a CACE 
recruitment pack (containing an introductory letter, a CACE informant information 
leaflet, consent form, a reply slip and a Stamped Addressed Envelope). Personal 
contact details were passed onto me only after potential informants had expressed 
an interest in the study and given permission for me to contact them. Alternatively, 
the family completed the reply slip containing their contact details and returned in a 
stamped addressed envelope. These alternative methods provided practitioners 
with flexibility in their approach, according to individual patients and parents’ 




I liaised closely with CF teams at each centre regarding the most appropriate time to 
contact patients and their families according to the team’s judgement, allowing me 
to be sensitive in timing my approach to patients and families. Practitioners were 
invited to participate in the study either by myself during site visits or via the 
Principal Investigator (PI) at each participating CF centre. 
3.5 Ethical considerations 
3.5.1 Approval requirements 
This study required contact with NHS patients and practitioners, hence approval 
was sought via the National Research Ethics Service (NRES), through the Integrated 
Research Application Process (IRAS) and approval was given 20th August 2010 by 
the North West 9 Research Ethics Committee (REC) (ref.10/H1014/41) In addition, 
Management permission (“R&D approval”) was obtained from each participating 
NHS Hospital Trust. To assist in the R&D approval process and ensure adequate 
support and management of the study, the study gained (NIHR) portfolio adoption 
(NIHR CSP Ref. 53231) and MCRN adoption. 
The study was carried out within the guidelines of the NHS Research Governance 
Framework HRA, 2015; DOH, 2005). The study also complied with the Data 
Protection Act of 1998 concerning the handling, processing and storage of the study 
data (Legislation.gov.uk. 2015). Rigorous steps were undertaken to avoid any 
breach of confidentiality including anonymisation of data, secure transfer and 
storage of audio−recordings, removal of personal details from transcripts and secure 




3.5.2 Service user involvement 
In the context of this study service users were the children, their parents and adult 
patients attending CF centres in the UK. To ensure that the views of these groups 
informed the study design, service user involvement was sought throughout the 
study duration. This engagement was achieved through liaison with a CF Trust 
Expert Patient Adviser and a local Young Person Advisory Group with the support 
of the MCRN Consumer Liaison Officer. The Clinical Director of a local Paediatric 
CF Networks also acted as a co-investigator for the study, providing important 
practitioner involvement along with clinical expertise and knowledge in the area of 
CF. I also liaised closely with and received important feedback from the local 
clinical trial team involved in setting up a national CF trial (TORPEDO-CF) and each 
local participating CF centre throughout the duration of the study.  
This liaison focused on: 
i) the study design, including views on Patient Information Leaflets 
ii) data collection and conduct of the research, including ongoing feedback 
on  interview guide  
iii) assistance and guidance on the dissemination  
Together this extended period of collaboration with service users and experts in the 
field helped ensure the study’s design and conduct were sensitive to the needs of 





3.5.3 Risks, burdens and benefits  
Throughout the study, the needs of potential informants, both patients and 
practitioners, were always put first before the needs of the study. I regarded an 
empathetic stance as ethically essential and also important in gaining and 
maintaining trust and rapport with patients and practitioners, which was critical to 
the success of the study. I remained sensitive to the possibility that the time and 
energy of all informants, particularly patients’, would be limited. Therefore I always 
ensured that there was considerable flexibility regarding the time and place of our 
meetings, to help minimise any potential burden of the study on informants.  
Interviews with patients and parents either took place in their homes or at a place of 
their choosing and at a time and date that was most convenient for them.  
The aim of this study was to provide insights into how individuals made sense of 
the process of recruitment and though this study did not claim that there would be a 
direct benefit for informants, it did allow imformants  opportunity to air their views 
and to reflect on their experiences (Scott et al., 2002). Also as part of the study 
design, all informants were offered summaries of the main findings. While I 
recognised that taking part in an interview may bring some quite strong emotions to 
the surface for some informants, I also anticipated this risk was minimised due to 
the focus of the interview. In addition, I always signalled to informants that they 
had control over the interview and could decline to answer any questions if they 
wished, or stop the interview at any point. Guidelines adopted by the RECRUIT 
study (Shilling et al. 2011) were also in place for managing informants whose level 




 I had prior experience of conducting qualitative research in trial recruitment, 
having worked on the RECRUIT methodology study (Shilling et al., 2011) (in the 
context of four paediatric trials in both chronic and acute specialities) for over 12 
months. I am also a qualified mental health nurse with nine years’ post qualification 
experience of working in highly sensitive and challenging clinical and research 
situations. I also received regular supervision and support from my supervisors 
who have extensive knowledge and expertise in health related studies and 
qualitative research.   
3.5.4 Informed consent 
Key ethical requirements within this project were the maintenance of the rights and 
safety of all informants, including the preservation of freely given consent.  All 
potential informants were provided with a study Information leaflet (see Appendix 
2 for an example of a study information leaflet) which was designed according to 
the different requirements of the participating parties (i.e. children, young persons, 
parents, adults and practitioners). Before informants were asked to complete the 
consent form, I ensured that they were aware of: the voluntary nature of 
participation; and the study’s independence from their CF team and any clinical 
trial or studies they may have participated in, what the study would involve and 
what would happen to the information they provided (including audio recordings 
of the interview and anonymisation of data). 
Maintaining independence from the CF centres was important to ensure informants 
did not feel under any obligation to participate and that they felt they could speak 
freely about any CF trials they had been approached about. Consent was obtained 




on the abilities) of the child/young person involved. Separate Information leaflets, 
assent and consent forms were designed for younger (7-10 years) and older children 
(11-15 years).  The groups mapped onto the primary and secondary school division, 
but I used the age brackets flexibly and always took along all sets of information 
leaflets, and the child/young person then selected the leaflet they decided was most 
appropriate for them. This process was particularly important for older children, as 
some teenagers preferred the adult information leaflet.  
3.6 Data collection 
3.6.1 Multi-perspective qualitative interviewing 
In -depth, semi-structured interviews were used to explore perspectives on trial 
recruitment for children (and their parents), adults and practitioners. I recognised 
the need for some structure in order to be able to address my research aims 
(Silverman, 2006; Rapley, 2007).  Consequently, the trajectory that each interview 
took was based on an interview guide (discussed further in section 3.6.2) that was 
developed for each group of informants. 
Despite some structure, my interviews aimed to elicit where possible a narrative 
account of recruitment experiences, as well as informants’ specific views about 
certain aspects of clinical trials and clinical research (depending on individual 
experience). Flick (2014) has termed this approach, the episodic interview, in which 
individuals are encouraged to tell stories about particular experiences in question 
and answer sequences. This method enabled informants to pursue what they felt 
was most relevant, while ensuring that specific topic areas were explored. Due to 
the semi-structured quality of the interviews, it was not considered appropriate to 




Willmott, 2002). Instead I was interested in informants’ qualitative experiences of 
trial recruitment and in the issues’ they raised in relation to this process.  
Basic demographic details were also collected for each informant and audio-
recording of the interviews was necessary to ensure adequate capture of 
informants’’ accounts. These recordings were made digitally and were encrypted 
and transferred from local sites on laptop computers while awaiting transcription. 
3.6.2 Development of interview guides  
I viewed the research interview for this study as an extended conversation in which 
I aimed to establish rapport with informants’ so they felt  comfortable and able to 
share  their perspectives on trial recruitment. I also recognised that within the 
research context this extended conversation also had distinct qualities which 
included: 
 To maintain an awareness of my effect on the interview (reflexivity) 
 To elicit experiences of informants view and experiences. 
 To maintain continuity and  clarify meaning  
 To  keep on topic while maintaining  depth and clarity  (Rubin & Rubin, 
2005) 
To help ensure the interviews covered the topics necessary to meet my research 
objectives, I developed a set  of interview  guides (Mason, 2002) by reviewing the 
literature, my past experiences in qualitative interviewing in the field of trial 
recruitment (Shilling et al., 2011), collaboration with experts in the field, including 
my supervisors, CF specialists, and expert patient advisors. I developed a separate 




children, parents and practitioners (see Appendix 3 for an example of an interview 
guide). The latter guide was adapted according to whether the informant was based 
in an adult or paediatric setting.  
These guides were semi-structured to help me to keep on topic while ensuring 
enough flexibility to achieve a comprehensive, authentic account of informants’ 
experiences. The interview guide comprised mainly open questions and included 
suggested wording of questions and potential prompts. At the beginning of each 
interview, I aimed to elicit informants’ broad conceptions, prior knowledge and 
experience of clinical research.  From here, I was able to adapt the questioning 
according to their research and trial experiences. For individuals who had been 
approached about a specific clinical trial or trial(s), I also elicited their narrative 
descriptions of the trial and their construction of the recruitment process, allowing 
them to voice their concerns and priorities. I also explored what individuals 
expected of the recruitment consultation, how they constructed these consultations, 
and how they described the decision-making process involved.  For individuals 
who had been involved in more than one clinical trial or study the informant chose 
which instance they would like to focus on initially. They then typically discussed 
other trials or clinical research experiences according to their priorities or concerns. 
For parents of child patients, I explored how the parents negotiated the child’s 
involvement and how they viewed their responsibilities in this context.  For 
children, I explored their feelings about particular aspects of the trial and how they 
made sense of the process and what factors they viewed as notable (for more details 
on interviewing children and young people see below). Interviews with 
practitioners followed a similar course to the patient interviews, exploring their 




3.6.3 Interviewing children and young people 
It was intended that where possible parents and children would be interviewed 
separately, ideally with parents being close but not actively involved (Irwin & 
Johnson, 2005). This was to avoid the difficulties of interpreting individual 
experiences from data collected at joint interviews and to ensure each informant’s 
views were accessed. However, during initial data collection I recognised the value 
of allowing families to negotiate the structure of interviews according to their own 
needs and preferences. Often parents did encourage their child to be interviewed 
separately, while they remained nearby and available. However, at other times 
parents and children indicated a preference for joint interviews. Both the 
negotiation process prior to the interview, and how the interview process was 
navigated between parents and child, provided valuable additional insights into 
family relationships (Kendall et al., 2009). Furthermore, these joint interviews 
enabled parents to help prompt children to expand on specific issues or experiences. 
I recognised that building rapport with young children takes time and that being 
able to meet a child on more than one occasions is conducive to the establishment of 
rapport (Irwin & Johnson, 2005; Balen et al., 2000/2001). Unfortunately this was not 
logistically possible due to time constraints. Alternatives include forms of play-
drawing, role-playing, and using props to assist in the establishment of rapport 
(Irwin & Johnson, 2005).  Therefore before interviewing, I liaised with parents with 
regards to what might help enhance their child’s involvement and ease during the 
interview, for example, if their child liked drawing. The approach to interviewing 
was also always negotiated directly with the child and adapted to their specific 




For younger children, I used a task-based ‘getting to know you’ activity to help 
reassure children that taking part in the interview was about their views and 
thoughts, not a matter of right or wrong answers (Punch, 2002; Hill, et al., 1996). I 
invited younger children to write down four likes and dislikes on a spidergram4   
shaped like a friendly spider with “googly”’ craft eyes, which children appeared to 
find amusing and reassuring.  I found it helpful in establishing rapport if I also 
completed a spidergram listing some of my likes and dislikes. I also invited children 
to ask questions about the study or myself which helped to put them at ease. In 
addition, before the interview I also encouraged younger children to try-out out the 
digital recorder, and used this act of recording and listening to their voice to help 
establish rapport (Ross et al., 1984). I also invited children to take charge of turning 
the recorder on and off, which gave them a sense of some control over the situation 
(Mahon et al., 1996).  
I developed two prompt guides; a simplified version of the parent prompt guide 
(aimed at older children) and a set of question cards (aimed at younger children). I 
invited the child to decide which format they would prefer and children aged below 
ten years opted for the card format.  The set of question cards had a simple, self-
contained question relating to taking part in research on one side and a familiar 
picture of an everyday object or animal and on the other. The sight of these pictures 
usually made the children laugh or smile, and their familiarity and simplicity 
appeared reassuring. The cards were laid on the floor, picture side up, and the child 
was asked to pick up the card with a certain picture and was invited to either read 
the question or request that I read it. The advantage of this approach was that it 
                                                     
A spidergram (or spider diagram) is a drawing similar to a mind map, showing a summary of facts or 




provided the child with a guaranteed degree of control and a sense of involvement 
and ownership in the research process from the beginning.  A one-to-one interview 
with an unfamiliar adult activity is an unusual activity for younger children (Balen 
et al., 2000/2001), so this method helped move away from a more formal interview 
style and engaged the child quickly with the identification of familiar objects.  The 
child was also able to see clearly what was expected of them. 
3.6.4 Transcription 
Various conventions exist for transforming spoken text into written words, and 
these conventions are associated with specific forms of analysis, influenced by 
different methodological and theoretical positions (Lapadat & Lindsay, 1999; Braun 
& Clarke, 2006). Therefore the choice a researcher makes about transcription in part 
determines what interpretations can be drawn from the text. Consequently, it is 
important the transcription process suits the purpose of the analysis (Lapadat & 
Lindsay, 1999). From a social constructionist position, I did not assume that any 
transcription convention would directly reflect the true ‘real’ account of the actual 
interaction. I recognised that the process of recording and the process of 
transcribing, both structure the data in some way and that the perfect transcript is 
‘illusory and time-consuming’ (Silverman, 2006). From a pragmatic position, I 
adopted a transcription process, which included a level of detail that suited the 
purpose of my analysis and reduced the possibility of altering the meaning of 
informants’ accounts. For clarity non-word sounds or words and phrases that were 
immediately self-corrected or repeated were not included in the findings unless they 
indicated an intentional change in meaning 
I ensured that the same methods of transcription were used across all interviews, 




same time as being aware of the value of transcribing the material myself, I accepted 
that due to my lack of transcription experience combined with time constraints the 
most feasible option was to have the interviews professionally transcribed.  I 
nevertheless still regarded myself as having a role to play in the transcription 
process, since I carefully reviewed the transcription against the original audio 
recording correcting any errors and ensuring the meaning was consistent across 
audio and transcription.  Also at this time, I anonymised the entire interview 
transcripts by removing all material that might support identification.   
3.7 Data Analysis  
During the analytical process, I drew on elements of both grounded theory and 
discourse analysis. This pluralistic approach facilitated a deeper understanding of 
contradictions and ambiguities within the data and stimulated and extended the 
way I thought about the data and to challenge any initial assumptions. Within this 
case study, the comparative aspect of my analysis formed an important analytical 
tool rather than overarching component. I used the comparative element to inform 
theoretical understanding of recruitment, as well as to detail important divergences 
and convergences across the adult and child setting. A core principle underlying the 
analytical process was the ongoing, iterative nature of my analysis which began 
during my data collection and continued throughout the writing process to the 
point my final draft was completed. Despite my analytical process being essentially 






TABLE 3.1: The analytic process  
 
Definition Purpose Process 
 
Stage 1  
Familiarisation 
 
To become fully acquainted with the 
data and to understand its meaning 
in entirety (Charmaz, 2004) 
 
To identify what people are saying 
that is relevant to the research 
objective (Ritchie et al., 2014) 
 
Reading transcripts & listening to audio files 
making handwritten notes on transcripts, 
checking ambiguities.  
Reading field notes and making case 
summaries.  
Identifying key ideas within individual 
accounts. Discussion with supervisors 
 
Stage 2  
Initial coding  
 
A formal system to manage and 
organise the data (Bradley et al., 
2007).  
To allow systematic and 
comprehensive coverage and 
comparison of the data-set  (Ritchie et 
al., 2014) 
To begin to identify key experiences 
described/grounded in the data and 
to begin to uncover links between 
these experiences across and within 
accounts  (Bradley et al., 2007) 
 
Uploading of transcripts to qualitative data 
analysis software QSR NVivo 10. 
Using this software to assist in grouping of 
data according to descriptive codes derived 
from the data.  
Supervisor feedback and group coding of 
selected data  
Returning to stage 1 where necessary. 
 
Stage 3 
To interpret the 
data conceptually 
while remaining 
sensitive to the 
context 
 
To identify dominant recurrent 
unifying ideas or concepts occurring 
across the data concerning the 
research objective (Bradley et al., 
2007; Charmaz, 2006). 
To address hidden assumptions and 
taken-for granted knowledge (Holt, 
2011; Burr, 2003).  
Examine data discursively 
identifying significant scripts 
contradictions, ambiguities and 
tensions (Potter & Wetherell, 1987) 
 
Analytical memo writing of key ideas to 
assist in moving from descriptive to 
conceptual interpretation. To complete case 
based summaries for each informant to 
highlight variation within accounts.  
Compare and contrast coding between cases, 
across cases and sub-sets of data. 
Recode or refine dimensions of existing 
codes, using insights gained from analytical 
from memos.  
Supervisor feedback, continued group coding 
of selected data. Returning to stage 1 and 2 
where necessary.  
 








To actively look for meaning in the 
data to explain features and patterns 
found across the data set (Frost; 
Ritchie et al., 2014). To develop a 
central key analytical concept 
grounded in the data. To use theory 
as an interpretive device to develop 
my understanding of the data further 
(Bowen, 2006; Charmaz 2006).  
 
Continue cross-examination of the data 
described in stage 1-3 
Primary analytical tool active writing 
(Liebenberg, 2016) 
To examine how the literature defines 
fairness as a theoretic concept. To use this 




In the first instance, I kept field notes (Appendix 5) which I completed after each 
interview. Initial thoughts, feelings, regarding the course of the interview, how the 
interviews were negotiated and any significant discussions which occurred outside 
the recordings were included. I viewed these field notes as an important 
supplementary device which helped to enrich and contextualise the interpretation 
process (Wolfinger, 2002). In addition, once the interview had been transcribed I 
also wrote an initial narrative case summary (Appendix 6) related to my initial 
reflection on my interpretation of the content/co-construction of the interview. 
My focus for the summary was to capture the main discourse and familiarise myself 
with each interview capturing key features of interest to the research aim, while 
paying attention to any inconsistencies or ambiguities. As the analysis progressed, I 
began to compare across different narrative summaries, which enabled me to get an 
idea of the main issues being raised.  
A core tenet of all grounded theory and indeed much qualitative analysis which also 
formed another central component of my analysis involved the ‘constant 
comparative method’ first described and formalised by Glaser & Strauss (1967) 
(Strauss & Corbin, 1998; Charmaz, 2006). This process began once I had received 
several transcribed interviews, anonymised and checked for accuracy. They were 
then entered into the qualitative analysis software QSR NVivo Qualitative analysis 
software (QSR NVivo 10).  During the constant comparative method, I continued to 
listen to the recorded interviews in conjunction with the written text throughout the 
analytical process, to address any ambiguity and add context and authenticity to the 




This process involved breaking the data down into meaningful components or 
‘codes’ to facilitate the comparison of ideas within and across transcripts,  to 
identify recurring or unifying features within the data. From a constructionist 
position, I did not view the analytical process as passive in which themes or 
concepts simply ‘emerged’ from the data.  Rather I recognised that I, in effect, 
created themes or conceptual categories to help make sense of the meanings in the 
data and construct a comprehensive account of the ‘case’. The purpose of my 
analysis was not to measure the prevalence of ideas or views but rather to map the 
range and diversity of how people made sense of recruitment and to explore and 
explain the links between unifying concepts identified within the data.   
The way I initially grouped the data in the first instance was primarily descriptive, 
with the aim to keep the codes as similar to the data as possible. This coding then 
became more focused through continual comparison within and across individual 
transcripts. Writing analytical memos to record my reflection on concepts and 
patterns identified with the data, in combination with a recursive analytical process 
(Table3.1 ) facilitated this process. Also, contradictions or tensions occurring within 
narrative summaries alerted me to test and examine these tensions conceptually 
across broader patterns identified within the data. Continually returning to the 
individual narrative helped avoid the conceptually focused analysis becoming de-
contextualised or ‘disembodied’.  Furthermore, the analytical process was guided by 
my supervisors, who co-coded a selection of transcripts and continually checked the 
analytical process. Sections of my findings were also presented at methodology 
conferences as part of the North West Hub and within the regional paediatric 





While my approach was principally data-driven, to avoid introducing preconceived 
outcomes, I nonetheless recognised the value of adopting an integrative approach to 
facilitate the comparative focus of my analysis. I therefore used both inductive 
(ground -up) and deductive (start list) organising structures to the data (Thomas, 
2011; Bradley et al., 2007). The start list I initially used to structure my analysis was 
around an informant’s role and responsibility in the recruitment context  
i) The voice of adults: the autonomous individual 
ii) The voice of parents of children: the family context  
iv) The voice of children and teenagers: emerging autonomy  
v) The voice of  adult and paediatric practitioners: the recruiters  
 
I did not treat these social roles as discrete categories but rather as a feature of the 
social landscape which facilitated the emergence of different patterns (Ritchie et al., 
2014). Comparison across these informant groups enabled me to assess whether the 
same elements were more apparent or were described differently in one group than 
another, providing an important analytical mechanism to develop insights into how 
the process of recruitment was understood (Bradley et al., 2007; Stake, 1995). Data 
was initially coded within each sub-group to avoid forcing unifying features across 
these different groups and to ensure divergences were identified. The analytical 
process involved a continuous process up until my final conceptual framework was 






TABLE 3.2: Identifying common elements: When is a research offer fair? 
 
A rational discourse Weighing things up 
Information disclosure 
Judgements of risk/ safety 
Does trial/study make sense  
Burden/inconvenience 
 
A psycho- moral discourse A progress narrative 
 A moral/social responsibility/duty/obligation 
A moral education 
Intrinsic value pro-social/inner glow 
Optimism and hoping for the best 
Balancing hope and duty 
Hope as coping  
Hope for  a cure  
The morality of marketing  
 




Centrality of trust 
Trust and acquiescence 
 
Factors influencing  informants’ views of a fair offer 





Personal resources  
 






During the final stages of my analysis, I moved away from the software to a period 
of active writing, which became my primary analytical tool (Charmaz, 2006; 
Liebenberg, 2016). This extended period of writing and thinking enabled me to 
examine ideas more closely, refining the focus my interpretation. By taking a 
qualitative case study approach involving multiple perspectives an extensive 




concerning many different viewpoints resulted in inevitable inconsistencies and 
intricacies. While I addressed some of these intricacies, my overarching aim was the 
identification of commonalities or unifying concepts’ which could account for both 
convergences and divergence across these sub-groups, providing a cohesive account 
across this multiplicity. I aimed to characterise common elements which contributed 
to how a child, parent, adult or practitioner viewed the process of trial recruitment. 
When and how I engaged with existing empirical and theoretical knowledge 
involved several distinct decisions. Engaging with the extant literature before 
undertaking my primary research was essential, to position my study within the 
wider literature and to support my rationale. For example, it was necessary to 
establish that the aims were novel and that the study would not be simply 
replicating a previous one.  Towards the end of the analytical process, I also began 
to draw upon relevant themes within the literature to help interpret my findings. 
However, I  delayed an in-depth critical engagement with the empirical qualitative 
recruitment literature until after the analysis of my interview data was complete. 
This would avoid imposing preconceptions and assumptions on to my findings and 
enable me to repond better to the data with original insights (Charmaz, 2008). 
Therefore full engagement with the extant recruitment literature took place in the 
discussion section, following the presentation of my findings. 
I identified three patterns or common discourses centred on perceptions of 
‘fairness’. I chose the term fairness, as a simple term to convey how informants 
made sense of the process of recruitment. The term is also relevant to childhood, 
where many things may seem unfair and yet it remains an overarching ideal of 
relevance well beyond childhood. Nevertheless, rather than a universal ethical 




conveyed personal judgements  in relation to the  fairness  of the offer being made 
and their chosen course of action. These perceptions of fairness were personally 
orientated and coincided with, for example, what a mother judged as fair for her 
family and her child, or what trial a practitioner considered to be fair for their 
patients. Personal perceptions of the fairness of trial related costs and the benefits of 
a particular trial were ‘weighed up’ using a ‘logical head’ in which risks were 
prioritised. The fairness of an offer was also constructed according to the social 
context in which recruitment occurred and whether informants felt comfortable and 
at ease during the social exchange, in which a concept of trust was pivotal. 
Informants also constructed the fairness of a research invitation in terms of the 
psychological and moral value of participating in clinical research.  
Fairness was sometimes explicit and sometimes implicit in informants’ talk and 
while it could not be applied to every aspect of my findings, the meaning and 
implications of fairness provided important ‘theoretical rendering’ and conceptual 
development of my findings (Charmaz, 2006; 1990). From this position, I was able to 
distinguish three distinct yet interdependent discourses - a rational, a social and a 
psycho-moral – which influenced and shaped how informants made sense of trial 
recruitment. These findings illustrated a labile interpretive context relating to how 
informants worked to construct an account of recruitment according to these three 
discourses which were influenced by several key mediating factors. These 
mediating factors included personal circumstance, health status and the particular 
costs-benefits and trials or study design. Within this comparative design, personal 
perceptions of fairness took on different forms depending on an individual’s sense 
of responsibility, whether they were parents acting on behalf of their child, or adults 
acting autonomously, or children within the family context or practitioners 




The findings of this study will be presented over four related chapters. Chapter four 
will provide the contextual details concerning participating CF centres and 
individuals who participated in the study. I will then introduce the conceptual 
framework in more detail at the beginning of chapter five around which the 
subsequent three chapters will be structured. Thus chapters Five, Six and Seven will 
present findings which illustrate a rational,  a social and a psycho-moral discourse 
characterised by how informants made sense of the recruitment process. 
3.7 Ensuring quality 
I considered quality from an interpretive position, as part of the research process, 
reflecting an internal set of values inherent in qualitative inquiry (Ritchie et al., 2014, 
Thomas, 2011a; Mason 2002). Rather than reducing it to specific criteria or checklists 
of techniques deemed as indicators of quality (Reynolds, 2011). I perceived myself 
as an active agent who, like the informants’, was actively making sense of the world 
(Charmaz, 2004) with the interview data representing meaningful accounts of 
informants’ perspectives and experiences of trial recruitment. I accepted that there is 
no final answer to questions about the extent to which “our co-created constructions 
are trusted to provide some purchase on some important human phenomenon” 
(Guba & Lincoln, 2008). However, I also recognised the value of an ethical, 
systematic, comprehensive, reflexive approach towards enhancing the credibility of 
qualitative findings, which must ultimately, be judged by the reader (Tracy, 2010; 
Charmaz, 2006). 
This qualitative case study was developed with the input from experts in the field of 
trial methodology, qualitative research and cystic fibrosis. Guidance was also 




by these groups to ensure coherence and authenticity for both informants taking 
part in this study and recruiters within the clinical setting. This input helped to 
ensure that the interviewing was ‘fit for purpose’. Sampling across multiple CF 
centres within the UK enabled the research burden to be kept to a minimum while 
accessing a diversity of experience and improving the scope for wider inferences to 
be made about the findings. The use of field notes and a repeatedly returning to the 
recorded interviews, rather than just re-reading transcripts, added valuable context 
to the interpretive process, supporting the authenticity and coherence of the 
findings. Systematic scrutiny, by my supervisors of my ongoing data analysis 
provided critical feedback and was invaluable in refining my interpretation of the 
data, enabling me to broaden my focus and avoid becoming submerged in the 
richness of the dataset. Further interim feedback of my analysis from members of 
the North West Hub and practitioners within the clinical setting enabled me to 
clarify my ideas further while ensuring I remained focused on findings that would 
be most meaningful for the clinical setting. 
Data analysis was based on the entire dataset, and illustrative quotes were used 
from across all interviews. My aim throughout this case study was to deliver a 
meaningful account, which adequately captured and represented the informant 
voice while achieving my overall research aim - to further understanding of the 
process of trial recruitment and contribute to practice. Within the findings chapter, I 
sought to provide adequate description and coverage of the data, while ensuring 
that interpretations were transparent. In the discussion, I further examine the 
findings in the light of existing evidence, so that the reader can decide the coherence 




My work to make sense of informants’ accounts is an interpretive activity. Therefore 
it was critical that I was continually involved in the process of self-questioning or 
‘reflexivity’ - ‘the process of reflecting critically on the self as the researcher, the 
‘human instrument’ (Lincoln, & Guba, 2000). Thus, I continually questioned my 
assumptions and interpretations throughout the research process (Thomas, 2011a; 
Merriam, 2009; Mason, 2002). Keeping a reflexive journal facilitated this process and 
provided a vehicle for me to critically appraise my perspective and those of the 
informants, and examine how these influenced the collection and interpretation of 
the data (Emerson et al., 1995). 
Striving to remain aware of my own and other influences provided me with 
valuable insights into the subject under investigation. I also endeavoured to use my 
personal experience of parenthood, as a person accessing the health service (both as 
a parent and a patient), as a former health care provider and as a health care 
researcher, to facilitate and focus the research so it was meaningful and relevant to 
other parents,  individuals, practitioners  and to the broader research context.  This 
subjectivity assisted in the establishment of rapport and trust with informants - both 
with practitioners, to allay fears of being assessed about their recruiting abilities; 
and by bringing an understanding attitude towards the family dynamics and 
individuals living with a long-term health condition. Throughout the research 
process, I aimed to remain aware of the importance of finding the right balance 
between drawing on my experiences while staying critically aware of my own 







Within this chapter, I have provided a detailed account of the research process 
adopted for this case study. In-depth semi-structured interviews comprised the 
main data collection method, which was supplemented by field notes. The analysis 
involved an iterative process which continued up until the latter stages of my final 
write-up. In the next chapter, I will provide contextual details of the data that was 




 CHAPTER 4: CONTEXT FOR STUDY FINDINGS  
4.0 Introduction  
The findings of this study will be presented over four interrelated chapters. This 
first chapter provides details of study setting, sampling and the characteristics of the 
participating CF centres and informants. This chapter therefore provides an 
essential context and detail for the reporting of the case study findings in the 
subsequent three chapters. I will then introduce the conceptual framework in more 
detail at the beginning of chapter five, around which the subsequent three chapters 
will be structured. 
4.1 Details of research setting 
My original sampling strategy was to include four regions (Region A-D, Table 4.1) 
within the UK. Each region containing an adult and a paediatric specialist CF 
centre.This strategy was adopted to reduce the research burden on participating 
centres, while maximising the variability of the sample and enabling the most 
efficient use of resources regarding travel and administration. As initial engagement 
with CF centres, in particular, adult centres, proved protracted and uncertain I 
decided to extend recruitment to include additional UK regions (Region E-G Table 
4.1) to ensure an adequate sample was achieved within the time constraints of the 
study. This sampling of CF centres was guided by CF experts in the field, the Local 
Clinical Trials Research Centre (CTRC) and the managerial team of my PhD and 
involved inviting five paediatric CF centres and eight adult CF centres to act as 
Patient Identification Centres (PICs) for this study (Table 4.1). In addition, due to the 




expert patient advisor (EPA), a number of adult informants were invited to take part 
in this study through the CF Trust (Table 4.1). 
TABLE 4.1 Sampling of specialist CF centres  
UK Region  Paediatric centre 
 
Adult  centre  
A agreed agreed 
B(ba) agreed declined 
C agreed agreed 
D agreed agreed 
E agreed declined 
F N/A agreed 
G N/A agreed 
CF Trust N/A 
 
agreed 
Total  5  centres 5  centres (+ CF Trust)  




The sample comprised five paediatric specialist CF centres and five specialist adult 
CF centres who agreed to take part in this study (Table 4.1). Out of the eight adult CF 
centres contacted, three declined to take part. One stated lack of resources, one 
implied concern about research burden. For the third centre, their reason for 
declining remained unclear, as the hospital research committee had approved the 
study and some practitioners had expressed a keen interest. 
There was some variability between the ten participating CF centres with regards to 
the demographic areas covered, the size of the CF population and the facilities 
available. For example, for paediatric centres, the mean number of active patients 
registered with the centre at the time of data collection was 153 (range 58-293) which 
included shared care patients. For the adult centre, the mean number of active 
patients registered at the time of data collection was 264 (range 63-638). All 




UK cities. At the time of the interviews, all the participating paediatric CF centres 
and one adult centre were involved in the CF trial TORPEDO-CF, which was open 
to recruitment at that time. All sites were also either currently involved in or had 
recently been involved in recruiting to other CF trials or clinical research, involving 
both publically funded ‘in-house’ and commercial drug trials. 
4.2 Sampling of study informants  
The patient and parent sample for this study was recruited across 10 CF sites (5 
child and 5 adult), using a combination of consecutive and purposive sampling to 
encompass diversity. Individuals were invited to consider participation in this 
interview study by a member of the CF team and/or researcher from the Local 
Clinical Research Network (LRN). Families at child centres B and C were invited by 
a member of the CF team which typically involved a CF nurse specialist or a CF 
consultant. At the remaining child centres families were approached by either a 
research nurse or a member of the CF clinical team (described as Recruitment point 
A, Table 4.2). In contrast, in the adult setting, all potential informants were 
approached by a member of the CF team as no research nurses were available and 
CF practitioners appeared to prefer to take on this role themselves.  
The sub-sample of adults recruited though the CF trust, comprised either CF 
Trust EPAs (who were invited to take part by the EPA supporting this study) or 
were individuals who responded to an advertisement on the CACE Trust 
website (developed with the support of the study EPA).  
Practitioners were invited to participate in the study either by myself during site 




Practitioners who were interested in participating in the study contacted me via e-
mail and a date and time for the interview would then be arranged. All practitioners 
who contacted me via e-mail agreed to take part (Table 4.3) 
TABLE 4.2:  Recruitment of patients and families 
CF Centre Child CF :        Patient families Adult CF centre: adult patients 
 Point A: 
approached by 
a practitioner 
at CF centre 
Point B: 








CF centre or 
Trust 
Point B: 





A 14 12 8  4 1 1 
B 6 5 5 N/A N/A N/A 
C 7 6 4 7 6 6 
D 14 5 3 5 4 1 
E 5 4 3 N/A N/A N/A 
F N/A N/A N/A 4 4 4 
G N/A N/A N/A 4 3 3 
CF Trust N/A N/A N/A 6 5 5 
Total 46 32(69) 23(50)  30 23(73) 20(67) 
Data are presented as n (%) 
The final data set comprised 82 informants; 20 adult patients, 23 families (22 
mothers, eight fathers, and 12 children) and 20 practitioners, across five paediatric 
and five adult CF centres (Table 4.2; Table 4.3).  
TABLE 4.3:  Recruitment of practitioners 
CF centre                                Child specialty                  Adult specialty 
 Point A: 
approached by 
myself or PI 
Point B: 
Received 
 e-mail  









Point  C: 
Consented to 
interview 
A 5 2 2 1 0 0 
B 7 3 3 N/A N/A N/A 
C 2 2 2 3 3 3 
D 2 2 2 2 2 2 
F 3 3 3 3 2 2 



















4.3 Patient and parent sample characteristics   
Within the section that follows, I give an overview of the socio-demographic, 
clinical and research characteristics of the patient and parent sample. 
4.3.1 Socio-demographic and clinical characteristics  
Most parents commented on a lack of family history or prior in-depth knowledge of 
CF and the ‘shock’ associated with their child’s diagnosis. Parents of infants 
described themselves as still in the process of coming to terms with their child’s 
condition. Many spoke of how their child had been diagnosed through the newborn 
screening which was brought in as a standard programme in 2007 (CF Trust, 2015). 
The parents valued this early diagnosis while parents of older children, whose 
condition was often diagnosed later in childhood, appeared to find the diagnosis 
process more complicated and drawn out, and hence, more difficult. 
A family’s main concerns were related to lung complications although several spoke 
of the liver and digestive system being more severely affected, with one teenager 
requiring a referral for a possible liver transplant. Many children had undergone 
surgery during early childhood spending periods in hospital. Some of the children 
were described by parents as being lucky and not displaying many symptoms. 
Other families of older children spoke of their child’s health as relatively stable 
while also describing many defined periods of ill-health and instability. Several 
children and parents talked about being fitted with a porta-cath (an implantable 
venous access device) to reduce the stress caused by repeated blood extraction or 




The typical age of diagnosis for the adult sample was much later than the paediatric 
sample. Only one informant described being diagnosed at birth due to the bowel 
complication- meconium ileus characteristic of CF. How adult patients described 
their health status varied in severity, intensity and range of physiological 
symptoms. However, most adult patients acknowledged that their health was 
fluctuating and deteriorating. Many adult patients spoke of their parents being told 
that they may not live until adulthood. Three had siblings who had died of CF, one 
adult patient had a sibling living with CF, and three of the adult patients were 
themselves, parents. One informant was post lung transplant, one was post liver 
transplant, and a further adult patient was on the liver transplant waiting list. 
Another was on oxygen supplementation therapy5, and several had developed CF 
related diabetes. At the time of the study, six individuals were currently 
unemployed due to a deteriorating health status, and the remaining participants 
were either in full or part-time employment or full-time education (Table 4.4). 
Socio-demographic characteristics of the patients and parents who took part in this 
study are detailed in Table 4.4 below. For children aged seven years and older, both 
the child and their parents were invited to participate in this study; otherwise only 
the parent was invited. Ten of the patient families had infants aged less than seven 
years of age, with six of these children aged <2 years (median age = 1 year; range <1-
5years)  
  
                                                     
5 The most serious complication of CF relates to respiratory insufficiency and oxygen supplementation 
therapy has long been a standard care for individuals with chronic lung disease associated with 




TABLE 4.4 Socio-demographic characteristics of the patient/parent informants 
 Child patients 
 
Parents of child 
patients  
Adult patients  
No. of informants 12 30 20 
Median age (range) 
years 
13(8-17) 37(24-50)  29(19-63) 
Gender    
Male  5 (42) 8 (27) b 11(55) 
Female  7(58) 22(73) 9(45) 
Ethnic group b     
White  N/A 28 (97) 19(95) 
Asian or Asian British  1 (3) 1(5) 
Employment status N/A   
Full-time  12 (40) 7(35) 
Part-time  9(30) 5(25) 
Not employed  8 (27) 6(30) 
Further education  1(3) 2 (10) 
a - Ethnic group data was classified according to those recommended by the 2001 census in England and Wales 
developed by the Office for National Statistics (ONS,2001) 
b - Data are presented as n (%) unless otherwise stated 
During my analysis, I decided to exchange my original numerical coding system for 
pseudonyms for all ‘patient’ informants. This was prompted by the comments made 
by informants during interviews, about the importance of being treated as ‘a person 
rather than a number’ in the context of research.  For clarity parent informants were 
referred to as mother or father of the child rather than being given a pseudonym of 
their own e.g.  Mother (Alice 3y).  
4.3.2 Research experience  
With regards to the clinical experience discussed in the interviews, I defined any 
direct approach or invitation about clinical research to an eligible family or adult 
patient as ‘research experience’ regardless of whether the child or adult enrolled or 
participated in the trial or study. The extent to which informants differentiated 
clinical trials from other types of clinical research was variable and dependent on 
experience and knowledge. Consequently, many informants referred to clinical 




as a ‘research study’. For clarity throughout my findings I refer to research that does 
not involve a clinical trial as a clinical study.  
Informants’ clinical research experiences were variable. However, due to the nature 
of CF and the significance of maintaining lung health, much of the research 
described by informants focused on treatments for improving or maintaining lung 
function (Table 4.5). Therefore, many patients and families described being 
approached about nebulised drug trials intended to improve or preserve lung 
function or antibiotic drug trials designed to treat respiratory infections. In the 
main, for parents of infants and younger children, their research experience 
consisted of an invitation to participate in a current antibiotic trial, TORPEDO-CF.  
 
TABLE 4.5:  Research experience 
Research experience  
 
Child (no. of approaches)  
 
Adult (no of approaches)  
 
Current/ongoing 
Clinical trials  
Antibiotic trial  (TORPEDO-CF trial) 10 1 
Nebulised drug trial  3 0 









Previous two years  
Clinical trials  
Antibiotic trial 0 1 
Nebulised drug trial  3 6 




Clinical studies  5 11 
The TORPEDO trial compared two types of eradication therapy to treat a lung 
infection-pseudomonas infection (Pseudomonas aeruginosa) and involved 




oral antibiotic therapy. Pseudomonas aeruginosa is a commonly occurring bacterium 
infecting 80% of people with CF by age 18. The infection is linked with a more rapid 
decline in lung function and is a significant predictor of mortality (Balfour-Lynn, 
2008). Six informants described being approached about trials of new drugs 
involving gene therapy or mutation specific therapies aimed at correcting 
underlying cellular dysfunction linked to CF.  Informants also described being 
approached about clinical trials which did not involve lung focused medicinal 
products, including trials aimed at treatment and prevention of drug related 
osteoporosis, physiotherapy trials and nebuliser ‘device’ trials. Many informants, 
particularly adults described other clinical research experience which included 
observational studies involving kidney function, glucose monitoring, viral 
monitoring, nasal tests, mental health questionnaires, and sleep and dietary 
monitoring.  
In the first instance during interviews, I tended to begin each interview by exploring 
the most recent trial and research experiences, and from here informants chose to 
pursue issues they felt were most relevant. As noted above within Table 4.5 I have 
detailed informants’ most recent research experiences, within the two years 
preceding their interviews. However, some informants chose to talk about earlier 
experiences of research; particularly ones they felt had been especially salient. 
Where these were informative, I have included them in the analysis. Several patients 
and families (n=5) had no direct research experience, and their views on clinical 
research were used to supplement issues raised by those with direct experience.  
Of families with children, 75% reported having been approached to take part in a 
clinical trial on at least one occasion. Furthermore, 39% described being invited to 




they had been approached about clinical research while attending a paediatric CF 
centre. Of the adult patients, 75% reported having been approached to take part in a 
clinical trial on at least one occasion, and 55% indicated they had been approached 
on more than one occasion. With regards to clinical research in general, 90% of the 
adult patients reported having been invited to take part in clinical research. 
Moreover, several adult patients indicated that they had been approached on 
numerous occasions about clinical research including clinical trials, but they did not 
remember the details of many earlier studies as the approach had typically occurred 
some time ago.  
4.4 Practitioner sample characteristics   
Many of the practitioners (60%) interviewed were specialist respiratory consultants 
or registrars (60%) (Table 4.6).  
TABLE 4.6: Characteristics of practitioner sample  
 Paediatric specialty  
 
Adult specialty 
No. of practitioners  12 8 
Gender   
Male  7 3 
Female  5 5 
Professional status   
Consultant  5 3 
Registrar 3 1 
Allied Health Profession (AHP) - 1 
CF Nurse Specialist 2 3 
Research Nurse 2 - 
Length of practice, years    
<10 - 1 
>10 2 - 
>15 2 2 
>20 5 5 
>30 2 - 





The remaining practitioners included specialist CF and research nurses and one 
allied health professional (AHP). Eight of the practitioners worked solely in the sub-
specialty of CF, and the remaining practitioners worked in respiratory or general 
medicine, which incorporated the sub-specialty of CF. Practitioners had levels of 
experience ranging from six to over forty years of experience since qualifying, with 
most (74%) having over 15 years of experience. 
For clarity and to preserve anonymity I referred to practitioners who agreed to 
participate by their generic job title such as nurse or doctor combined with a unique 
identification number e.g. Nurse 1. As the majority of doctors in the sample were 
male (n=10), I decided to refer to all doctors using the masculine gender, to protect 
the anonymity of the participating female doctors. Practitioners’ research experience 
was varied although all had experience of approaching patients about clinical trials 
and all but one practitioner had direct experience of approaching patients with CF 
about clinical research.  
4.5 Details on interview data 
The child sample resulted in 31 interviews (19 parent interviews; 9 child interviews, 
three family interviews) producing over 28 hours of audio- recorded dialogue. 
Three interviews were conducted in the hospital while the patient was an inpatient 
and the remaining interviews (n=28) were carried out at the informant’s home. As 
indicated above, where children were aged seven years and over both parents the 
child and were invited to take part in the study. For eight families both the child’s 
mother and father agreed to take part in the study, and in each case, these parents 
opted for a joint interview. Of the children who chose to be interviewed three 




were interviewed separately although their parents were present for at least part of 
the interview and on most occasions parents contributed to some degree. Parents of 
younger informants remained present throughout the interview.  One teenager 
declined to be interviewed, although his parent took part in an interview, and the 
parents of another teenager declined to be interviewed. The length of parents’ and 
joint family interviews ranged from 26 minutes to 113 minutes; the mean duration 
was 66 minutes. Children’s interviews ranged from 10 minutes to 38 minutes; the 
mean duration was 26 minutes. 
Twenty adult patients were interviewed producing over 22 hours of audio-recorded 
dialogue. Within the adult sample, only the patient themselves took part in an 
interview, although other family members were occasionally present at the 
informants’ request. Two adult patients were interviewed at the CF centre, 17 were 
interviewed in their homes, and one was interviewed at another place of the 
informants’ choosing. Adult patient interviews ranged from 28 to 116 minutes; the 
mean duration was 67 minutes. 
I interviewed twenty practitioners, 12 based in a child setting and eight within an 
adult setting, producing over 22 hours of audio-recorded dialogue. All practitioner 
interviews took place at the hospital in which they worked. Practitioner interviews 
ranged from 40-92 minutes; the mean duration was 67 minutes.  
4.6 Summary  
This chapter has detailed the contextual information for this study sample upon 
which the next three findings chapters are based. Within the subsequent three 
chapters, the substantive findings in relation to informants’ views and experiences 




CHAPTER 5: FINDINGS 
WHEN IS A RESEARCH OFFER FAIR? - A RATIONAL DISCOURSE  
5.0 Introduction 
This case study of how informants made sense of research invitations illustrated an 
intricate and diverse picture involving many inter-related factors. In responding to 
this richness of the data, this analysis sought to identify key concepts that could 
explain divergences and convergences across informants’ experiences and 
expectations, providing a broader description and understanding of the process of 
trial recruitment. My analysis indicates that informants were able to negotiate the 
uncertainty inherent in clinical trials, in terms of personal perceptions of fairness 
that centred around three prominent discourses, a rational, social and psycho-
ethical discourse.  
Even though the three discourses were typically interwoven and interdependent 
within accounts, for the purpose of analysis, I have aimed to present each discourse 
separately. Therefore, analysis of the data within the framework of these three 
discourses is presented in this and the following chapters. Within this first chapter, I 
examine the data from the view of a rational discourse. I examine informants’ 
accounts of how they rationalised the choice they faced and their actions and the 
extent to which their accounts corresponded with normative assumptions of 
decision-making. I will also examine to what extent medico-legal requirements of 





5.1 A rational discourse: Weighing things up 
A central feature of this rational discourse was informants’ construction of a process 
in terms of balancing factors that typically corresponded with their perceptions of 
the costs and benefits of participating in a particular trial or study. Consistent with 
normative models of decision-making, patients and parents spoke of a process of  
‘weighing up of options’ or a ‘weighing up of pros and cons’ to ‘try and do what is best'. 
I suppose you always worry you don’t know whether you’re doing the right thing or 
not, you just, you know you’ve got to I suppose weigh up the options and try and do 
what’s best, and then you’ve just got to get on with it really, yes. Mother 
 (Dylan 2y) 
 
Looking at the pros and cons, would it have any effect on her health, detrimental 
effect, so making sure that it’s not going to do her more harm than good I think was 
a massive decision[...] Mother (Rachael 10y) 
Megan had been invited to take part in various clinical trials on numerous 
occasions, some of which she had agreed to and others she had declined. Her quote 
below captures the predominant features of the ‘weighing up process’ Megan 
engaged in, which characterised this rational discourse.  
If they wanted me to come back say twice a week for a blood test often I would just 
say I am really sorry no because I am here a lot already and it's quite a long way 
away, and I don't want to commit that amount of time especially if you are feeling 
unwell and quite tired it's just, you think I can't really do that. The second thing is 
how invasive the trial is so if it's just part of your clinical routine they want to take 
an extra vial of blood or get you to do an extra test it's not too bad but if they want 




painful as well that used to kind of influence me if I wasn't really feeling up to that, 
I would say no to that. And then finally often if I thought oh this sounds like it could 
be a good new treatment or this sounds actually like it could be really beneficial then 
I would think I want to give my time to that so that this can come to fruition so 
those are the three main things that kind of would go through my head when being 
approached for a trial .  Megan (26y) 
Within the accounts of very young informants, a ‘weighing-up process’ was either 
less evident or not present.  However, some child informants, in particular 
teenagers, did describe a weighing-up process comparable to that of adults’ and 
parents’ accounts. For example, Rachael’s account illustrates which factors she 
considered before agreeing to participate in an on-going clinical trial involving a 
nebulised drug. 
Important was should I do it because of the needles, but I have had so many I 
thought should I do it because maybe I might enjoy it, or should I do it maybe 
because should I try a new inhaler, maybe it might be nasty, but I ended up doing it 
because they said to me. Afterwards, he said you can do it because they are thinking 
it might… because we take bloods, it might help you because you have bloods at the 
start and then afterwards, to see if it could help every CF[…] Rachael (10y) 
Rachael considered the possible invasiveness of the trial relative to the invasiveness 
of her routine treatments. Furthermore, her acceptance that the inhaled drug ‘might 
be nasty’ indicated an awareness of potential risks and side-effects.  Her account also 
indicated awareness of personal benefits, in that she considered whether she ‘might 
enjoy’ the experience. Consistent with many of her adult counterparts, Rachael’s 
assessment of direct costs and benefits were influenced by her personal disposition 




Despite many accounts of the weighing process being variable and personally 
orientated and often extending beyond standard tangible trial costs and benefits, an 
informant’s endeavour to rationalise their actions was a predominant feature. 
Whether informants described making a ‘snap decision’ or a period of prolonged 
deliberation, they emphasised how they had engaged in a rational process of 
‘weighing up the pros and cons’ in which they used their ‘logical head’  to reach a 
reasonable decision. In this respect, their discourse mirrored a particular normative 
model of decision-making which assumes people are ‘rational’ and deliberative in 
how they approach decisions. 
5.2 The weighing up process: autonomy, responsibility and dependency 
The characteristics of the weighing -up process were broadly comparable for adult, 
parent and some child informants, each group portraying a careful balancing of 
issues relating to perceptions of benefits and burdens. Nonetheless, noticeable 
divergences were also evident across the groups. 
5.2.1 Autonomy: ‘is it worth the risk’ 
An adult’s capacity to act autonomously within the research context was conveyed 
as involving both expectation and responsibility. Many individuals had been 
approached about clinical research on numerous occasions; and their accounts 
illustrated how they had become accustomed to deciding for themselves what 
treatments to accept or decline based on their personal clinical and research 
experiences. Consequently, for many adults, decision-making in the context of 
research was frequently perceived as relatively ‘straightforward’ compared to 
decisions they have had to make in the clinical context. For Instance, John who had 




to trial participation, ‘considering what I’ve been through, easy, easy, a drop in the ocean 
really’. 
Nevertheless, most informants recognised how the ease of the decision-making 
process changed with the varying cost-benefit trade-offs of different trials. 
I think it varies from study to study  like some things are really easy decisions so 
when you are an in-patient, I remember sometimes when they are testing what the 
best combination of drugs to give to you, so some people will be on 3 times a day, 
and some people will be on twice a day, and it’s like well if I can go on them twice a 
day then yes, why I would be silly not to as long as you don’t think that it’s going to 
affect my health[...]  Kate (28y) 
Safer more straightforward later phase trials were viewed as easier decisions 
compared to potentially riskier early phase trials involving higher stakes, which 
were typically perceived as more difficult decisions.  
Unlike children and parents, adults emphasised ‘where you are with your stage of 
health’ as a central feature in their weighing up of whether the trial was ‘worth the 
risk’. Comments indicated that diminishing health often resulted in heightened 
concerns about potential risks because they felt they, ‘haven’t got that spare to play 
with, so to speak’. For individuals who viewed themselves as having unstable or 
problematic health status at the time of a trial invitation, this factor was most 
influential in their decision to decline. Helen, who had taken part in several clinical 
studies, commented that due to her deteriorating physical health and the intensity 
of her treatment regime, she would only consider participating in a trial if it 




Unless all of a sudden it's going to be a miracle drug and I'm going to feel 
wonderful, I would never sign up because I just think back to that thinking, how 
much time is it going to take?  You know, the impact on my life generally, you 
know, the extra needles, you know the inconvenience of things like that, but at that 
age, no not really a problem, because I was quite okay and fine, and it was almost a 
novelty, really.  Helen (34y) 
Helen reflected on how research participation during a period of relatively stable 
health was ‘almost a novelty’ and something she could cope with. Nonetheless, she 
also recalled the burden and ‘inconvenience’, something all the more burdensome 
from a position of more fragile health. 
5.2.2 Responsibility:  ‘wanting what’s best’ 
A parent’s role in the research context was viewed as the responsibility to act in 
their child’s ‘best interests’ and do the ‘right thing’. 
 
She is my child, and I am going to do what is best for Lily [...] Mother (Lily <1y) 
 
I think when it comes down to your child, no matter who it is, you have this inbuilt 
I’m going to protect my child; I’m going to do what’s right for her no matter what 
[...] Mother (Emily 9y) 
 
We, me and her dad just want to do what’s best for her, and if the research is going 
to help at the end of the day to help keep her healthy for as long as possible then, then 
we are happy to do whatever we can to help her. Mother (Zoe 1y) 
Parents perceived that ‘there is a lot more responsibility because it’s somebody else’s 




drive to ‘do what’s best’ for their child’s health, viewing it as part and parcel of their 
role of parent. They presented the everyday task ‘to care for your children’ as ‘a lot of 
pressure’ but also emphasised that this was heightened within the context of caring 
for a child with CF, where both  day-to-day and clinical decisions were viewed as 
having the potential to shorten a child’s life.  
You are under a lot of pressure anyway to care for your children, but having to make 
decisions which could really shorten her life, because when you are talking about 
chest infections and things, it can affect their life expectancy [...] Even decisions like 
should I take her swimming because she has got a bit of a cough [....] it is still a 
decision you have got to make which could impact on her health […]  
Mother (Alice 3y) 
Accordingly some parents positioned their responsibility in the research context as 
comparable to their role in other contexts; nonetheless, some viewed this task as 
distinct from other types of parental responsibility and a task which they regarded 
as ‘a lot of weight on your shoulders’. 
Nathan’s mother described in detail the emotional strain she experienced in 
deciding on behalf of her son to participate in a trial which she believed had had a 
potentially serious side-effect – a cost which she countered through her belief in the 
value of the trial, research per se and her trust in the CF team. 
The first trial which he did, was the tobramycin, his antibiotic once a day, they were 
giving it 3 times a day and they wanted to know whether just giving it once a day 
would make much difference [...] but it was a bit scary, because it can cause deafness, 
if it’s at such a high level of, in the blood [...] it was in the back of my mind worrying 




the lines again if nobody does anything, nothing will change, and treatment will 
always be the same, and nothing will get advanced. Mother (Nathan 16y) 
This responsibility seemed to weigh particularly heavily on parents when they felt 
their child was too young to voice their own perspective.  Parents saw it as 
‘something that plays on your mind’, anticipating feelings of ‘blame’ should the decision 
they made result in a negative outcome.  
It’s living with the guilt if anything does happen, isn't it?  Father (Joseph 5y) 
 
As a parent making the decision on a trial, and whether to take part or not, obviously 
I think you worry, you know you have reservations, and you worry.  You do worry if 
maybe by doing it are you causing any harm [...] Mother (Dylan 2y) 
In leaving parents feeling personally and directly accountable for their child’s 
outcome in the trial, the goal of ensuring the decision about the trial was ‘what’s best’ 
appeared more burdensome. Moreover, some parents of infants less than a year old,  
who had either declined a trial or had not yet been approached,  displayed 
considerable reluctance and discomfort about acting on behalf of their child while 
they were ‘still little’. It was notable that these parents were comparatively less 
favourably inclined to medical research, their descriptions of clinical trials including 
terms such as ‘a gamble’ or a ‘lottery’ or ‘being used like a guinea pig’. They also viewed 
themselves as being in a period of adjustment with regard to their child’s diagnosis 
and, for first-time parents, parenthood. 
If I am honest I would probably not want Lily to do it while she was so young, only 




mean.  I suppose because any test there is a chance it could have a side effect [...] 
Father (Lily <1y) 
These parents anticipated that with increasing age, their child would take a share of 
the decision making responsibility and therefore reduce the psychological unease 
related to this role. One parent reflected on ‘the pressure being taken off her’ - a 
sentiment echoed by other parents - as her son became more involved, describing a 
sense of relief when her son reached the legal milestone of 16. This parent 
contrasted the ‘hard’ ‘scary’ ‘frightening’ ‘difficult ‘ decision to allow her son  to 
participate in a  trial with potentially high risks when he was younger, with the 
‘easy’  decisions  she had been involved in more recently,  concerning lower risk 
nebuliser trials, for which her son had taken the lead role.  
 In the main, parents indicated that from the point they viewed their child as having 
their own ‘wishes’, they negotiated the nature of the child’s input, while ensuring 
they upheld their personal and parental expectations of the ‘right decision’. 
Overall you try and do what’s [best] you know your child has her wishes, and you 
want to respect those because I want her to feel that she does have an input, but at 
the end of the day the responsibility was with me to actually make the right decision 
for her [...]  Mother (Emily  9y) 
How parents negotiated a child’s ‘wishes’ was in part determined by how they 
negotiated their child’s involvement in other areas of their life - what one parent 
described as your ‘family-set up.’  Existing family dynamics were instrumental in 
shaping broad patterns of involvement, particularly for children who were not yet 




information and terms of the negotiation according to existing family dynamics, the 
age and developmental stage of their child and their perceived value of the trial. 
I think it’s your family setup as well because some mums I know are very controlling 
even if the child is like Ellie’s age 14, I do know of some mums that the child doesn’t 
go out, doesn’t have many friends and just goes everywhere with mum.  
Mother Ellie (14y) 
 
I suppose it’s what kind of house you grow up in and what rules you have.  
Mother (Daniel 11Y) 
Despite some parents expressing unease and discomfort in this role, many parents 
accepted this responsibility as a natural extension of their parental role and most 
parents had agreed to allow their child to participate in a clinical trial or study.  
5.2.3 Dependency:  I can decide but my parents’ know best  
Consistent with parents’ accounts, how children negotiated their involvement in 
trial discussions was influenced primarily by their own family’s model for 
managing roles and responsibilities. Moreover, the influence of a child’s family set-
up on the nature of her/his involvement in the research context was inextricably 
linked to their developmental stage, personal experiences of research and existing 
level of involvement in the clinical context.  
At times children’s reasoning, particularly in teenagers, appeared qualitatively 




For instance, Clare’s account below is more consistent with other adults’ accounts 
(as opposed to parents), in that she framed the decision around the practical aspects 
of the trial. Parents, in contrast, were more inclined to view the decision in terms of 
whether it was in their child’s best interests or the right thing to do.  
I was just worried about whether it was actually going to work or not and I just 
thought well if I come out of it at the end and find that it hasn’t worked I will feel a 
bit like Oh well  that was a bit pointless.  I didn’t really want to feel like the whole 
thing was just a waste of time. Which I still feel the same way, really I don’t, I 
wouldn’t want to do it if I thought that it was just going to be a waste of time for a 
drug that doesn’t really do anything. Clare (17y) 
However, significant to many children’s’ accounts, especially children who had not 
reached their teenage years, was an implicit reliance and trust in their parents’ 
direction.  While most of these children described being involved in trial discussions 
and some viewed the decision as being theirs to make, their accounts often indicated 
that their parents had engaged in the weighing up process on their behalf. 
In contrast one informant chose to emphasise the carefree indifference of a ‘not 
bothered’ teenager.  
My initial thoughts were yes, a day off college, I didn’t think… oh yes, find out how 
well my kidneys are doing, no it was more all right then, a day off college, not bad. 
Kirsty (16y) 
This teenager viewed her decision as something she made ‘straightaway’. However, 




an awareness of the objectives of the study and a potential personal benefit of 
participating. Furthermore dispersed throughout her narrative, akin to those within 
adult and parent accounts, were conceptions of costs and benefits. Though her 
account alternated between that of a ‘not bothered’ teenager and an autonomous 
decision-maker, Kristy chose to place emphasis on the discourse of a ‘not bothered’ 
teenager, perhaps as preferable to that of a teenager that has to manage a serious 
lifelong condition. 
 All children expressed awareness that trial or study participation involved making 
a choice and that they didn’t have to take part. No child indicated they felt under 
any pressure from either practitioners or their parents and all but the youngest 
positioned themselves as having an active share in the decision-making. This 
finding was corroborated further by all parents acknowledging their child ‘has to 
have a choice whether he wants to take part or not’.  However, some younger children 
indicated that they would feel comfortable accepting the decision their parents 
advocated, whether this was to say yes or no. Moreover, children’s references to a 
weighing-up process were much less apparent. One plausible interpretation is that 
the shared decision-making responsibility typically described in child and parent 
accounts lessened the choice burden and pressure for these young people. While 
parents ensured they were included and had a share in the decision-making 
process, they took the ultimate responsibility of balancing the costs and burdens 
and the authority to consent or decline from their shoulders. Most child informants 
illustrated some awareness of conceptions of cost and benefits, albeit at times 






5.3 Information disclosure 
In this section, I will examine to what extent the formal trial information featured in 
informants’ accounts of the weighing up process. In the first section I examine how 
trial information figured in patients and parents view of a fair research offer. I then 
examine practitioners’ experiences of disclosing trial related information to potential 
‘participants’. 
5.3.1 Patients’ and parents’ perspectives  
All except the youngest informants spoke of being given explanation and written 
details about the trial or study they had been invited to consider. For the most part 
parents and adult informants spoke about the content of the formal study 
information in quite generalised ways as ‘fine’, ‘self-explanatory’ and ‘really good’, the 
‘right level’, ‘it told you everything you needed to know’.   
Some informants made a distinction between the trial related information aimed at 
ensuring you ‘understand what the trial is about ‘ and then all ‘the boring information ‘, 
‘your kind of standard stuff’ that has to be included ‘due to certain rules and regulations’. 
For some parents, the ‘legalities’ and ‘legal jargon’ in the leaflet were ‘rather a strain to 
read’, and  ‘unnerving’ and something which ‘maybe could be put aside until later’.  In 
fact, several informants suggested they were only interested in reading the ‘basic 
information’ concerning what the trial involved and why it was being done; and 
were not interested in going into all the written details. In contrast, others spoke of 
needing to know the trial information ‘inside out’ before making a decision. 
Informants viewed verbal and written information ‘both together’ as necessary in 




discussion. Several adults, particularly those who were more reserved about trial 
participation, stressed the importance of being introduced to the trial outline 
verbally initially, rather than being ‘just handed a leaflet’. 
I think certainly you are going to be more engaged if it's verbal, on a one-to-one than 
if you are just handed a leaflet told to go away and read it, a lot of people probably 
stuff it down the side of the chair to be fair but, I think certainly if they can, if they 
can talk to you about it, and you can ask questions at the time, then it's, it's a lot 
more engaging.  Phil (35y) 
However, informants who had consented to trials valued the written trial 
information as a necessary ‘point of reference’ to ensure they were clear about all the 
stages and details of the trial.  
That's the point where if you think oh I haven't understood that properly you can go 
back to it, and you can refer to it as you go through the trial and I suppose if 
anything crops up in the trial that you didn't read in the leaflet you have then got 
the leaflet to say well you didn't say this in the leaflet, so it is good to have that point 
of reference for yourself.  Megan (26y) 
Most children recounted receiving a separate leaflet to their parents. However, in 
the main they did not comment specifically on the quality or nature of the written 
information, but rather whether they had read it or not. Consistent with many of the 
child informants, Clare described being given a trial information leaflet but viewed 
her discussions with her parents as being the more influential on her decision to 
participate. While children did not regard the written information as central to their 




such information. Younger informants too sometimes spoke of value they attached 
to having received a leaflet.  
All informants viewed a combination of verbal and written information as an 
integral component to establishing when they perceived an offer to be fair and one, 
they were comfortable accepting. However, there was no case in which an 
informant based their decision solely on assessments of the written trial 
information.  Moreover, there was some variability as to what extent deliberation of 
written trial information influenced actual decisions. Francis, who had been 
approached to take part in two clinical trials, one ongoing, and various clinical 
studies, all of which he had consented to, at times conveyed his decision-making as 
centred  on the provision and assessment of ‘accurate’ information  
I just read the blurb and sort of see if anything leaps out at me […] So long as the 
information is as accurate as it can be and you feel that they’ve presented the pros 
and cons fairly and you can assess it.  Francis (63y) 
Francis indicated that the decisions he had made so far had largely been ‘snap 
decisions’. Though this might appear inconsistent with his earlier more rational 
account, Francis spoke about his personal disposition to clinical research and 
‘subconscious’ assurance about the value and integrity of the research introduced in a 
familiar context. This viewpoint seems to represent a more intuitive decision-
making process, a sentiment which was echoed in other accounts. Many informants 
attributed their motivation to take part as due more to the endorsement provided by 
a known trusted practitioner than to any written trial information.  Furthermore, 
some informants indicated how they viewed their decision as being made in 




They give you the information to take home and read, but I would make the decision 
unless it was harmful, other than it being harmful for Peter, I would never, I would 
say yes straight away.  Mother (Peter 12y) 
Consistent with parent and adult accounts, children sometimes indicated they had 
made their decision before reading or receiving the information leaflet, and some 
stated that they ‘didn’t bother reading’ the information leaflet at all.  
However, children who didn’t read the information leaflet but who agreed to take 
part in the trial were aware that their parents had vetted the information on their 
behalf. 
Conversely, some informants spoke of their decision to decline as being made 
almost straight away before they had received all the information regarding the 
trial.  
It was just such an instant decision, they would have given her longer to think about 
it, but she just didn’t need it because she, there was no way she was not going to 
have IVs. Mother (Amy 16y) 
 
I think Emily and we had kind of made our mind up that if there was any chance not 
to go for IV and the stay in hospital […] If there was any way that we could avoid 
that really because she had a lot of time off school during the trial, over four months 
last year, and we felt personally that if Emily really didn’t want to have the IV […]  
Mother Emily (9y)  
Each of the parents above referred to a treatment preference as the primary 




approached to take part in, which in each of these instances involved the 
TORPEDO-CF trial. 
One family who declined before engaging with the trial information appeared 
confused about the TORPEDO-CF design and they spoke of being ‘scared’ and 
‘stunned’ about their daughter’s diagnosis of pseudomonas. 
I can’t remember which way round it was, you’ve got the antibiotics first and then 
something else after and then the other one is the blowing  and the antibiotics  later 
[…] Mother (Mia 8y) 
In some cases, informants implied they had made the decision to take part in 
research long before the trial had been offered to them. These parents did not 
dismiss the importance of pragmatic considerations in their decisions. However, 
their accounts suggested these were something of a formality, compared to how 
they viewed the influence of their values and beliefs. While they spoke of checking 
through the information to satisfy themselves that the trial would not be 
detrimental to their child and that it made sense, ultimately they felt they had 
already taken the decision.   
 When cystic fibrosis was first diagnosed in October 2010 when the baby was born, 
at the time we heard about cystic fibrosis, from that point, I decided to help with the 
research because I know that my daughter has it so I would be going through that 
feeling how  other parents feel when their daughter, when their child has got this 
kind of a disease.  So I decided okay, I will do kind of charity; I will try to participate 
in any, help or anything that can support the cystic fibrosis research.  




 I’ve always said that I think research is a good thing and we’ve always discussed it 
and said if we were ever approached, we, you know, if it could mean a difference to 
Dylan’s life or even Adams [Dylan’s brother] then we would more than likely say 
yes, so I think in a way we kind of knew anyway[...]because we’d had those 
conversations before it made it a lot easier for us to decide, so that made it a lot easier 
[...] Mother (Dylan 2y) 
5.3.2   Practitioners’ perspectives  
Practitioners’ accounts illustrated how they had adapted their approach to 
information disclosure according to research regulation and their personal 
experience, so as to achieve what they perceived to be an ‘unbiased’   presentation of 
the facts.  Some stressed the need to ‘stick to the book’ or ‘remain neutral’. One 
practitioner emphasised the need to balance information regarding tone and 
content, remaining neutral but positive, while ensuring adherence to necessary legal 
and ethical requirements without causing any undue concern. Others similarly 
highlighted the delicate balance between the importance of being frank with 
patients while remaining within the limits of what they ‘can take’. 
It’s good, to be frank with parents and tell them, rather than trying to, I mean 
normally we don’t try to keep information from them, but it all depends on the 
individual parents how much they can take, because some parents can pick up on 
certain words and then that sort of stays in their mind all along and it will affect the 
whole picture  Doctor 11 (child) 
One practitioner whose role was purely research based was the only one to 
emphasise the legal and procedural requirements of the research discussion by 
indicating her use of the formal trial regulation guidelines (ICH  (E6) Guidelines for 




described how she would always read the information sheet to prospective families 
and work through the ‘20 rules of consent’. In contrast, other practitioners, while 
recognising the need to cover ‘important points’ necessary to conform to the ethical 
and legal requirements of informed consent, emphasised the significance of 
tailoring information in a way that was the most meaningful for each individual or 
family. These practitioners implied that what might be perceived as ‘dumbing down’ 
to an individual who ‘wants every last detail about how many rats got the treatment 
before they did’ might look ‘like a court order’  or ‘intellectual jargon’  to another. Their 
accounts conveyed a sense of the delicate balance required to uphold the ethical and 
legal requirements of informed consent while ensuring information is tailored, so 
individuals do not feel overwhelmed or deterred. 
Within the context of existing clinical relationships practitioners remarked on the 
tendency for patients to ‘rely’ on ‘what you are telling them’ rather that examining the 
trial information in detail. 
I think they rely on what you are telling them to do. Some of them will read 
everything you know even the small print, but I think the majority, will you tell me 
about it. Well take this away and read it at home and you think you are not going to 
read it at home.  Nurse 1(child) 
 
I'm not going to read that, is a common comment. ‘I trust you’, I say no, no, you're 
supposed to read it, ‘I trust you’.  The big commercial ones are the worst, American 
companies. So there can be pages and pages and pages, and the parents just throw 
that straight in the bin. [...] You tell them what it's about and say you can take this 
away with you and read it and if they choose to throw it away, that's their choice, 




Practitioners described how some patients displayed a reluctance to read the trial 
information leaflets, particularly the denser documentation typical of commercial 
trials, instead expecting a trusted practitioner to summarise key points. 
5.4 Perspectives on the gold standard  
Within this section I will examine informants’ views on the highly structured design 
which characterises a conventional  randomised controlled trial or related trial 
designs (Kerr et al., 2006; Jadad 1998).As in the previous section I will examine the 
patients’ and parents perspectives first,  followed by those of  practitioners. 
5.4.1 Patients’ and parents’ perspectives  
Informants varied in the detail and emphasis they gave to trial design and the 
process of randomisation. However, in the main, they viewed this design aspect as 
‘fair enough’.  Informants with less familiarity with the procedure described 
‘accepting it as part of the trial’. Those with more familiarity indicated that it was a 
necessary feature of the trial design to enable comparison of treatments to produce 
meaningful results.   
That is how things have got to be done, because… you can’t pick certain people for 
things because that’s not what trials are about, it’s to see how everybody reacts to 
different things. Mother (Isabel 2yr) 
 
To me it’s very simple we are doing a trial to see if this drug works, the only way we 





Some recognised the scientific value of randomisation as necessary for producing ‘a 
true reflection’ of efficacy.  
 If you want to prove something is statistically significant then you have to have a 
way of doing it, you have to like, you have to have a control [...] Alex (29y) 
The detail and emphasis children gave with regard to the trial design was variable, 
according to experience and developmental level. Older teenagers who had direct 
trial experience were aware of the need for and the nature of randomisation and 
placebo, and their accounts were indistinguishable from adults and parents. 
Younger children with direct trial experience had some awareness of design aspects 
of a clinical trial, but their accounts varied in detail. 
Well, my mum has told me that there’s some real ones and some fake ones, but 
they’re asking everyone if they know which if there are any differences since they’ve 
had it.  Daniel (11y) 
 
Say someone has an infection, and the doctors never knew what it was, they would 
have like trials, to see if it’s in anybody else. Peter (12yr) 
Some informants, while accepting the procedure, also expressed some ambivalence 
about the reality of accepting uncertainty and lack of choice for themselves or their 
child. One teenage informant understood and accepted that randomisation was part 
of the ‘whole point of the trial’ but nevertheless described how the experience felt ‘a bit 
weird’ in reality. 
Obviously, it’s ok that it’s chosen at random it’s better that way, but I still thought 




else might, or I might get it and someone else, wouldn’t. I thought that was a bit 
weird.  Clare (17y) 
Several parents’ perceptions of randomisation were complicated by comments made 
by the recruiting practitioners post-randomisation. In the context of the TORPEDO-
CF trial, Dylan’s mother had struggled to balance equipoise on the part of the 
clinician with her motivation to do ‘what is best’ for her son.  She described how she 
would have been guided by the consultant, but because he wouldn’t tell her what 
was best and chose to talk most about the trial, she interpreted this as an indication 
she should opt for it.   
I would have gone on the information of the doctor, what he thought was best, but 
because he wouldn’t tell us, because obviously, I think he was obviously trying to get 
us to opt for the trial, so he wouldn’t give us a clear indication of what he thought 
was best and what everyone else thought was best [...]he was trying to kind of push 
us into going into the trial, not in a forceful way but that’s where his information 
was leading, you know and that’s kind of what he talked about most.   Mother 
(Dylan 2y) 
However, this parent’s ambivalence in relation to the issue of equipoise and 
randomisation appeared to have been confounded by comments her clinician made 
once her son had been randomised to a treatment arm. 
After they did the randomisation and it came up with two weeks of IV’s in hospital, 
the doctor said, I’m glad that’s what I would’ve chosen myself.  So then I was a little 
bit worried because then I thought, well if we had home treatment, you know, it 
wouldn’t have been getting the best, but then in the long term obviously you know 




Several other parents described similar comments being made by clinicians 
following randomisation. It is conceivable that these practitioners’ comments were 
aimed at helping to reduce any choice conflict or ambivalence in relation to the issue 
of equipoise. Conversely, these comments appear to have had a counterproductive 
effect, leading to more ‘concerns’ and potentially impairing informants’ belief in the 
integrity of the research.  
Some informants who had previously declined participation or had not yet been 
approached about a clinical trial remained ambivalent or concerned about the 
fairness of the randomisation process. These informants, while recognising the 
necessity for randomisation, indicated a preference for the ‘newer drug’, viewing the 
situation as ‘a hard one’ to reconcile. Mia, who had declined several clinical trials she 
had been offered, captured this tension within her account. Her reflection on 
randomisation design illustrated the tenets of a ‘patient preference trial', a design 
advocated by some trialists. 
I suppose it's the only fair way to do it, but, then again, I do think in these things, 
that there would be a group of people who would prefer one, prefer the other and then 
there would be some in the middle, who wouldn't really be that bothered, that they'd 
do either. So I think in some ways it would be nice if there was an option, you might 
be more inclined to take part if you got the option that you wanted.  
 Mia (25y) 
Another adult informant, Sara, who had declined two clinical trials, after reading a 





So it would be a group of people in group A trying that drug and group B. I think 
well everyone’s body works differently, so the people, the treatment that is group A 
doesn’t work, it might work with group B and vice versa. So if anything, if I was to 
do that, I’d try A treatment for so long and see if there’s any difference and then go 
on to B and see if there’s any difference, if anything. I wouldn’t mind trying it, yes.  
But again if there’s no side effects I probably would try it, but there’s no guarantee.  
But again I’d like to try the two things because something that might not work with 
someone else might work with me [...] Sara (30y) 
Despite Sara’s lack of familiarity with a trial design, she conveyed a legitimate 
concern about being excluded from potential benefits of a trial drug and her account 
reflected the principles of a ‘crossover trial6’. Several informants who had agreed to 
take part in a crossover trial viewed this design as a ‘win-win situation’ and a way of 
‘attempting to please everyone’. While the cross-over design appears to be primarily 
advocated by trialists as a strategy to increase the safety profile of trial drugs, 
informants who had direct experience viewed this and similar designs as intuitively 
fairer and as ensuring they were not missing out on something potentially 
beneficial. 
While informants accepted the necessity for placebo trials, they expressed varying 
concerns about the ethics of such trials and some were more inclined to perceive 
them as a potential ‘waste of time’.  
                                                     
6 A crossover trial involves a trial in which participants receive a sequence of different treatments. For 
example in a design which involves 2 treatment arms  all participants will  receive a period on both 




 It’s always difficult  with placebo trials and in the past I know my parents have sort 
of said no we aren’t  doing it because you do have to sort of take the additional 
treatments but it might not be doing anything, or you could be on the other half of 
the trial where it's a massive benefit, and I have always wondered about the ethics of 
those kind of trials[...] Megan (26y) 
5.4.2 Practitioners’ perspectives 
For some practitioners, optimal recruitment necessitated a personal position of 
equipoise, clearly communicated to potential participants. 
As an investigator, you should be in equipoise, and actually, you should convey that 
to the parents. Doctor 9 (child) 
In the context of somewhat ‘straightforward trials’ such as TORPEDO-CF involving 
two standard treatments, practitioners indicated that they found the concept of 
equipoise ‘reasonably easy to explain’. 
I really genuinely don’t know which one is better and the reason behind the research 
study is to try and find out if one is better than the other one.  Doctor 10 (child) 
Connected to the concept of equipoise was the need for practitioners to explain the 
process of randomisation which they generally didn’t find ‘a problem’. However, 
some practitioners recognised potential difficulties in explaining this term and 
helping patients to understand it.  
Very much depends on the patient and their level of education, their level of 




generally… or a lot of the time overestimate people’s literacy and numeracy, and 
there is … I am sure that a lot of the time we… pitch things at the wrong level for 
people, whether that’s making things too complicated or, or dumbing down too 
much, it’s very hard to get that right because everybody is different.  
Doctor 12 (adult) 
Practitioners often drew parallels with how tailoring the information concerning 
trial design was comparable to the difficulties practitioners face when adapting any 
medical terminology, which needs to be in accordance with a family’s ‘level’ and 
needs. In the main, practitioners viewed most individuals, including children, as 
able to understand that the allocation to particular arms of the trial would be made 
by chance or at the very least children could understand that their doctor would not 
be responsible for making that decision. Practitioners also reported that explaining 
the concept of placebo trials is largely unproblematic. 
The easiest way to explain it is that there's a tendency for children to get better 
without doing anything […] quite a number of children will get better if we do 
nothing at all, so what we want to do is work out how many would have got better, if 
we hadn't done anything and see how many more than...would have got better just 
on their own?  And try to explain it that way, but again, that's never an issue. 
Doctor 3 (child) 
However, some practitioners pointed to concerns about ‘fairness’ in relation to 
placebos, particularly that they might be regarded by some patients as ‘unfair’ or at 
least less attractive than a trial comparing active treatments. 
People have tried to organise studies in CF looking at chest physiotherapy and 




Now although there is no evidence for chest physio, intuitively it makes sense if you 
have got someone with thick sputum and you bash their chest they will cough it up.  
And, they couldn’t recruit people, because people would say how we cannot do chest 
physio, no. Doctor 5 (child) 
Some practitioners implied they would try and ‘sell’ the placebo design as 
something positive in relation to increased monitoring and a ‘regression to the mean’. 
If you get the placebo, well it won't make you better, but actually being in a trial 
sometimes, gives us a closer view of your CF disease and that in itself can be helpful. 
Doctor 6 (adult) 
 
We try and sell it as something positive, I am not sure anyone has bought that [...] 
the study is quite clear that if you are in the placebo, you know placebo arm of a trial, 
you do better than the historical norms, and the presumption is because you know 
you will be having increased monitoring but not sure that patients buy into that. I 
wouldn’t say it to everyone, but I do say that quite regularly to patients.  Doctor 7 
(adult) 
Other practitioners implied that the concept of fairness and unfairness in the context 
of placebo trials was becoming more of a ‘concern’ in the wake of the recent ‘wonder 
drug trials’. 
Placebo is a concern, and probably more so recently, there's often this discussion of 
fairness and unfairness [...] it's harder and harder to justify placebo versus drug A if 
drug A is perceived as the marvelous new treatment already, in a build up that's 
gone on the internet.  So having the ability to swap onto drug A at the end makes 




One practitioner indicated that there had been a ‘deliberate buy-in’ to trials which 
finish with an open-label period in which all participants receive the active drug, as 
a solution to concerns surrounding fairness. Practitioners viewed this design as 
providing a way of assuring that all participants have a ‘chance’ to access the trial 
drug. Practitioners implied that the design removed some of the uncertainty 
inherent in more conventional RCTs, where patients might be left wondering 
whether they were on the active drug or whether the treatment had any effect. 
Practitioners indicated that this design had both a moral and scientific appeal, 
which in turn, had the potential to improve recruitment rates. One practitioner, who 
was the most enthusiastic about this trial design, viewed the traditional RCT design 
as a ‘lottery’, which was something he didn’t want for his patients. 
The company have said, the first so many finishing the study will get access, and 
I've said, can we make it clear whether our patients will or won't because I don't 
want them to be in a lottery[…]So having the ability to swap onto drug A at the end 
makes recruitment easier. Doctor 6 (adult) 
While practitioners spoke of explaining the principle and procedural aspects of 
clinical trials as largely unproblematic, they recognised the underpinning 
uncertainty about not knowing ‘what is best’ as something that some patients had 
difficulty accepting in a health professional who had  ‘umpteen years of treating CF’. 
Some also reflected on doubts they had about their personal position of ‘genuine 
equipoise’. One accepted that her experience of treating pseudomonas infection a 
certain way had left her struggling with equipoise in the TORPEDO-CF trial. While 
this practitioner recognised that the treatment standard for pseudomonas at her 
centre might not be ‘right’, she was concerned about deviating from ‘aggressive’ 




We have got a very healthy population, we do very well, so we’re obviously doing 
something right, so then to change it, you don't know what you are changing and 
you know somebody who is a bit iffy with treatment, who you then think well you 
can't get away with your IVs because you are in, you know you just give them that 
head start I don't know but, but I do appreciate that you know, part of antibiotics 
especially nephrotoxic drugs and stuff in the long term is not good, so you do have to 
weigh that up and actually is their alternatives it's just, I don’t want you to use my 
population to find that out. Nurse 7 (child) 
Some practitioners appeared to contend with the uncertainty presented in trials, by 
positioning it as comparable to or on a continuum with the uncertainty inherent in 
all medical care. 
When you are dealing with clinical interventions even if it’s not a research project 
you still have to sort of give some kind of ownership and empowerment to the people 
that you are talking to […]Rather than just saying well I am going to give you this 
and it’s going to work, I would say look there is this other treatment this is the 
evidence behind it,  these are the good things, these are the potential side effects, but 
in my opinion I think this is the right thing to do, what do you think? I think that 
it’s a similar approach to recruiting for a research study, it’s kind of well actually in 
this condition we know there is this drug, but we also know that there is this other 
drug and we don’t know which is better, or we don’t know whether giving nothing 
or giving this drug is better. Doctor 8 (child) 
From this position, practitioners drew parallels between discussions required when 
changing treatments in the clinical context and introducing the possibility of 
entering a clinical trial. They positioned both situations as informed by evidence 
and with associated risks and benefits.  However, the ability to provide an opinion 




consultation context, was no longer available to practitioners within the context of a 
clinical trial. 
5.5 Rationalising the costs and benefits 
In this section I examine how informants’ perceptions of costs and benefits relating 
to different research invitations featured in their view of a research fair offer.  
5.5.1 Patients’ perspectives. 
Informants’ perceptions of costs and benefits of trial participation were typically 
multi-dimensional, extending beyond the standard ones detailed in trial 
documentation. For the most part, adults and parents prioritised assessments of 
physical risk, which formed a critical ‘cost’ in the weighing-up process. Generally 
teenagers, and occasionally children, also prioritised a concern about potential risks 
to their health. For example, Ellie who had not yet been approached about clinical 
trials spoke about her reservations about participating and anticipated that she 
wouldn’t be able to accept the element of risk inherent in many trials.  
I just don’t like testing because I just, I don’t know really. I don’t know I just feel 
like I wouldn’t be able to trust it or like if it went wrong.  Because I don’t want to 
take the risks [...] I would like to help, but I just wouldn’t want to, no. Ellie (14y) 
Clare indicated how her first concern was regarding a potential contraindication 
about her current medication and the trial drug.   
Originally I was a bit confused about steroids and things because … I was like well 




For children who had not yet reached their teenage years, judgements of risk were 
less prominent or absent from their accounts generally and overall their conceptions 
of cost and benefit were less detailed. It is unclear to what extent these children 
were shielded from some clinical risks or the task of the weighing up process, or 
were unconcerned or were happy to defer judgements of risk to their parents 
For children who did not discuss clinical risks, parent data indicated that the 
possibility of requiring extra blood tests was an important consideration. These 
younger children appeared reluctant to talk about the family’s decision to decline a 
trial or study, despite their parents’ encouragement. For instance Emily, who was 
happy to talk about her involvement in novel drug trial, also conveyed a reluctance 
to talk about the family’s decision to decline the TORPEDO-CF trial. Whether 
children’s concerns were dissipated through a positive participation experience or 
declining, or they were reticent about disclosing this fact, is unclear.  
Parents who had involved their child in decisions about trials involving extra 
invasive procedures, for which they had consented, decribed how they had to ‘play 
it really quite cool and calm and collected’ to explain the trial in nice simple terms. They 
suggested that if these negotiations were not carefully considered the child might 
‘latch on’ to a particular aspect of the study such as a blood test and then ‘decide they 
are not doing that’. 
In contrast to children, in the accounts of adults and particularly parents their 
judgements of risk were keenly expressed as the ‘first thing’ that came to their mind. 





The first thing I thought was what if something goes wrong, what if he is allergic to 
it and they can’t resuscitate him. I just spent six years of my life trying to keep this 
boy as well as I can, and within 10 minutes they have wiped it all out and initially I 
was a bit guarded […] Mother (Jack 8y) 
Risks had to be offset or countered by benefits in order for informants to judge a 
research offer as fair. Characteristically the first benefit to be weighed in relation to 
potential risks was the possibility of an improvement in health from participating.  
On the whole, informants did not position the possibility of a therapeutic benefit as 
an expectation, but rather as a hope.  They hoped they would receive some benefit 
or they hoped for a more general best personal outcome which was typically set 
towards the future. Interrelated with this was confidence that ‘the trial made sense’. 
Rather than an exhaustive understanding of all the trial details, informants initially 
emphasised how the ‘worth’ of the trial needed to be established before they would 
consider giving up their time or incurring any related costs. 
If you are being asked to give up your time you want to know exactly what for, and 
what they are hoping to achieve […] you really want to know that it's worth it and 
that you want to know clearly what they are hoping to achieve. Megan (26y) 
In the case of Jack’s mother, the trial she was considering was fairly invasive, 
requiring regular additional blood tests. This risk was offset by the fact that the trial 
objective matched her concerns and was something she hoped would be beneficial 
for Jack in the future. 
The impression I got was this drug would drastically, if it was ok, in the future, 
potentially make Jack’s lung function, brilliant or a lot, lot better or stop it from 




around but lung function, is massive to me and so I believed that if this drug was 
going to be ok for him in 3 or 4 years time, I wanted him to have that. I really, really 
wanted him to have that […] Mother (Jack 8y) 
An informant’s typical, immediate hope for the best personal outcome remained 
fairly stable across accounts and trials, yet how individuals rationalised physical 
risk was more variable. Some adults described a systematic risk-based assessment 
based on the formal trial-related information. For instance, Alex described how he 
used safety profile data from earlier phase gene therapy trials to judge the potential 
risk of participating in a later phase one. 
This was right towards the end of the trial, they had done it on I don't know, tens of  
maybe hundreds of people so if there was anything that they had found that went 
really badly wrong with it then you know they had been through quite a few 
iterations before it got to me [...] Alex (29y) 
Other informants rationalised perceptions of trial related risks relative to risks they 
had encountered within the clinical context or indeed risks they encountered in 
their daily life.  
There’s always a chance of something going wrong; you could get run over by a bus.  
It’s I don’t have any strong feelings about that. Frances (63y) 
Initial judgements of risk were capable of influencing an individual’s receptivity to a 
trial, determining whether they would ‘want to open themselves up’ to the idea of 




The actual thing [study] itself, I can’t remember what it was trying to find out, but 
it would involve something like, they’d want to shove a line into the vein in your 
neck and send that into your lungs to check something.  They’d want to do a liver 
biopsy, a few other invasive things [...] I thought, it ain’t worth doing you know. 
Adam (19y) 
Adam was invited via letter to take part in an observational study alongside his 
upcoming transplant surgery. However, his unease about the invasive nature of the 
study overshadowed his engagement with the aims and objectives of the trial or 
study. Furthermore Adam’s pressing concerns about safety could not be allayed in 
the first instance due to the nature of the initial approach, which was via a letter 
from an unfamiliar hospital. In a situation where an individual had declined, 
potential risk was often the hurdle they could not get past.  For instance, Phil 
described how despite a nebuliser trial being sold as ‘the new big thing’ a safety 
profile of ‘0.01% chance risk’ would still constitute a ‘nagging’ level of uncertainty for 
him. He viewed his concern ‘that he might just be the one in a million’ to experience an 
adverse reaction, as both ‘stupid’ and ‘human nature'. Phil related his heightened 
sense of risk to his deteriorating physical health and a lack of adequate reassurances 
about safety provided by the recruiting practitioner. 
In contrast to Phil’s heightened sense of risk one parent, whose daughter had 
experienced a life-threatening anaphylactic reaction from a widely used antibiotic, 
recognised that things could equally ‘go wrong’ within the normal clinical context. 
This parent talked about how any drug, taken for the first time, equated to a ‘bit of 




Things can go wrong, but things can go wrong on drugs that have been tested and 
used for years, so, I mean Becky’s had one anaphylactic reaction to an antibiotic, I 
could then argue that well clearly that's not a safe drug if that's what it's going to 
do to her, but it saves millions and millions of other people [...]  Mother (Becky 4y) 
Many parents who had consented to the TORPEDO-CF trial recognised the relative 
safety of this phase IV trial which was comparing two ‘tried and tested’ standard 
treatments. A decision which was viewed as being equivalent to treatment decisions 
they had to make on behalf of their child.  
Last winter we had to decide whether to try a last-ditch antibiotic or send him 
straight in for his bronchoscopy. Which was scary for us because he was only 10 
months old, and we went with the medicine rather than sending him for that [...] Yes 
it’s the only sort of decision I suppose I can compare it [TORPEDO-CF ] to [...] 
Mother (Dylan 2y) 
In fact, for one parent in this situation indicated that the process of randomisation 
provided a welcome relief from the usual burden of decision-making in the clinical 
context. This parent described “how it was much better that (the decision) was taken out 
of her hands” and “it made more sense to leave it up to fate”.  
For parents with no prior trial experience, recent clinical experiences often informed 
judgements of risk and benefit. The most prominent example was a parent who 
drew on a recent ‘traumatic’ clinical experience involving her son’s first blood test, to 
inform her decision to decline the TORPEDO-CF trial and thus avoid the IV arm of 




When he started going on about needles and stuff, he had a bit of a bad time getting 
bloods out of him, so I didn't want to put him through it again [...] it was just 
traumatic for him[...]  Mother (Tom <1y) 
This parent described herself as still coming to terms with her son’s condition and 
she did not identify any immediate or future benefits for herself or her son through 
participating in the trial. Also, she used the term ‘guinea pig’ to depict the invitation, 
conveying a feeling of distrust; and was concerned about making a decision on her 
son’s behalf. Moreover, her invitation to take part in the trial was the only approach 
which involved a telephone invitation by an unfamiliar practitioner whom she 
never met face- to face.  
Adults also discussed how the intensity of their recent clinical experiences, 
including the number of blood tests or hospital admissions they have to cope with 
combined the ‘additional poking and prodding’ required for trial participation, was 
influential to their willingness to participate. Mia described how she had declined 
all the trials she had been approached about primarily due to the significant costs of 
trial participation including additional invasive procedures and extra trips to the 
hospital to her usual treatment regime. 
I've been approached about a lot, there was one where it involved, it was a new 
nebuliser for like so many weeks, and every week you'd have had to get, I think every 
couple of days at the beginning, and then every week it was different breathing tests 
you'd have to go up to the hospital and have done, and there were bloods, and there 
were all sorts [..]my veins aren't good and it's quite, it's not that easy having a 




For some, the potential change in a current treatment regime which may impact on 
health status, rather than the risk associated with the trial drug and procedures, 
constituted a risk not worth taking. 
What I would have had to stop was really working, still really works now so I 
wouldn’t have liked to have chanced and take a chance and not do it and then get ill 
again so[...]I felt a bit bad like I would like to have done it, but at the same time it is 
not worth risking it. Luke (22y) 
Informants’ acknowledged that risk varied from ‘study to study’ and low-risk trials 
were generally considered easier to decide on. However, higher risk novel trials 
with great promise were often prioritised by informants over more run-of-the-mill 
trials. Accordingly, adults’ and parents’ accounts illustrated how they were 
prepared to ‘stretch’ their child or themselves and negotiate higher levels of risk 
than they would normally accept for trials which offered great promise.  For 
example, for one family in the context of a novel trial relating to a potentially 
revolutionary new drug, which they believed ‘could be huge’ or possibly ‘life-
changing’ for  their child, they were prepared to accept their daughter having to 
‘overcome a real phobia’ related to venipuncture .  
With the blood tests, the two visits because she was screaming and crying, they 
could not force her to do it.  And we nearly, very, very nearly weren’t able, and I had 
to say to Emily, “Look, you’re going to have to calm down, if you want to do this 
trial and be part of it you need to calm down because the minute the consultant says 
we can’t continue, there’s no going, “No, no, I want to do it now, once she’s gone we 
get on that train we go home,” and she was old enough, mature enough to calm 
down.  And even though she still cried, she let them do it.  So I said, for an eight-




Similarly in the adult context Kate explained how she had some initial ‘reservations’ 
concerning the degree of risk and burden connected with a gene therapy trial, but 
was prepared to raise the stakes on this occasion due to its potential significance. In 
spite of this, the trial costs had proved greater than she had anticipated and with 
hindsight she probably would not have accepted the invitation. 
It was really exhausting there were so many tests, and up and down to London all 
the time, I don’t think I had fully appreciated it [...]There was so much work to do 
and you had to through lots of really quite not very pleasant tests and I don’t think if 
somebody asked me again to do the same thing I don’t think I would do it, because I 
found it really hard. Kate (29y) 
This sentiment was echoed within other informant’s accounts, in which the actual 
trial burden had exceeded their expectation. For some informants the unanticipated 
costs of a trial had lead to their subsequent withdrawal. For instance, Tim had 
agreed to take part in a Mannitol7 trial, perceiving it as a fairly low-risk. However 
the trial had turned out to involve intricate, time-taking procedures requiring Tim to 
carry large volumes of medication (a sentiment echoed by another informant who 
had dropped out of the same trial). 
I did a Mannitol sugar trial; yeah that was a pain in the backside.  It took me an 
hour in the morning to do and an hour at night to do.  I had 30 capsules I had to 
empty and breathe in, and it just took so much time. [...]I did it for six months and I 
then said to the CF centre look, I know it was a nine month trial, I said I done six 
                                                     
7 Mannitol is an osmotic agent available as a dry powder to be used as an inhaled drug for treating 




month, I really can’t do anymore, you know  I just cannot afford the time to do it [...] 
Tim (49y) 
Patients and families had often been asked about trial participation more than once 
and sometimes, particularly in the adult setting, on numerous occasions. Thus, in 
addition to assessing the costs and benefits for each trial or study it was not 
uncommon for informants’ to refer to a broader weighing-up process in relation to a 
cumulative research responsibility and a perception of ‘doing their bit’ and not being 
overburdened. Megan, who had been approached many times both at the paediatric 
centre and adult CF centres, spoke of attempting to ‘balance out’ the distribution of 
research burden or responsibility.  
I have always tried to balance it out if I have said no to one or two I have said yes to 
another one […] Megan (26y) 
5.5.2 Rationalising costs and benefits: practitioners’ perspectives 
Consistent with patients and families, practitioners’ judgements concerning safety 
were central to their views of the ethical acceptability of trials and their personal 
commitment to them. Assuring patients of safety was a priority for the positive 
marketing of a trial. The research regulatory system provided an important ‘selling 
point’ for potential participants and ‘protection’ for practitioners themselves. 
However, practitioners indicated that the research system was not infallible and one 
practitioner recalled how a trial their centre had been involved in had actually done 
‘more harm than good’ and had failed an ‘interim safety review’.  
Consequently, while all practitioners accepted the need for a research regulation, 




judgements of safety. Practitioners recalled occasions when the CF team had 
declined to take part in some trials ‘sponsored by pharmaceutical companies’ as they felt 
the potential risks and burdens were ‘too onerous’ for their patients. One practitioner 
spoke of how she would only feel comfortable approaching families about trials or 
studies that she would feel comfortable recruiting her own children to, and indeed, 
she had recruited her own children to clinical studies and trials within the hospital. 
This practitioner drew on her experience as a parent to consider the fairness of the 
research offer.  
There are studies that I've had that I wouldn't have recruited my babies or children 
to and I think that's a big thing if, the studies I've worked on I would recruit my 
children to all of them […] I think the biggest selling point is, if you wouldn't 
recruit your own child to it, I wouldn't expect anybody else to [...] Nurse 3 (child) 
She also explained how she had identified trials that had not met her personal 
benchmark of acceptability, and she recalled that one of the trials failed to recruit 
any families.  
At times practitioners’ assurances of safety or being free from doubt appeared 
somewhat at odds with the inherent uncertainty within clinical trials. 
I wouldn't ever start a treatment where I really didn't think it was safe.  
Doctor 3 (child) 
 
If I have got doubt, then I should not do this for my patient, so you need to know this 
study very well, you need to be very, very clear, if I have any doubts I will not do it 
for my patients [...] I do not want my patient to be exposed to an unnecessary trial, 




Nonetheless, their accounts were consistent with patients’ expectations that 
practitioners would not suggest a trial that they really didn't ‘think was safe’. As well 
as assurances of safety, practitioners drew attention to parents’ inclination to want 
or hope for the ‘best return’, which they saw as being part of ‘human nature’. 
It’s human nature that if you are entering a trial, you would hope that you were 
getting that drug that may well make you better, wouldn’t you really, but then by 
the very nature of consenting to it, you run the risk that you are not going to don’t 
you.  Nurse 2 (adult) 
Some practitioners indicated that where they believed there was a potential for 
personal benefit, this would be positioned as an individual ‘selling point’. 
You have got to find the selling point for each individual patient. Now sometimes 
there isn’t, and I am honest enough to say to them look, for you, it might not make 
any difference at all, but in the long run, you know in the future. Doctor 5 (child) 
Nonetheless, they acknowledged that trials could not guarantee personal benefit 
and even in those trials which had more potential of personal benefit, this might 
only constitute ‘minor benefits’. One practitioner spoke candidly about how trials are 
‘rarely a great’ opportunity’ in terms of clinical benefit as ‘most of the pharma stuff is a 
bit of me-too’8. This practitioner believed that for a trial to represent something he 
could view as a great opportunity, it would need to involve ‘new revolutionary drugs’ 
that could potentially ‘transform people’s lives’. In contrast some  practitioners viewed 
                                                     
8 ‘Me-too’ drugs also referred to as ‘follow-on’ drugs, comprise pharmaceutical products which largely 
replicate the action of existing products, contrasting with potentially ‘pioneering’ or ‘revolutionary’ 




their belief in the potential of the trial drug  as intergral to their construction of a fair 
research offer and a way of balancing their duty of care’ and the inherent uncertainty 
in a clinical trial.  
I've been the person that's been saying, “Here's this treatment, I think that will be 
good for you”, so when I'm doing a, putting a study forward, they look at me, and 
they say, “Do you think this drug is worth it?” Now clearly, ethically and on the 
information sheet you know, so I say things like, look I wouldn't have agreed to do 
this study if I didn't think it would pass muster on the safety so far, but we are 
doing a trial and on the potential for it to work because I have a duty of care […]   
Doctor 6 (adult) 
I viewed this practitioner’s comments, that the trial drug had the ‘potential ‘to work 
as the counterpart to an individual’s hope for the best personal outcome. 
While equipoise is considered to be the ethical professional response to the 
uncertainty of a novel clinical intervention, practitioners’ accounts reflected the 
delicate balance between the principle of equipoise and the pervasive psychology of 
hope. Which was captured by a practitioner’s quote below, when asked about the 
importance of equipoise in relation to his commitment to a trial. 
I wouldn’t want to be involved in a study where I didn’t believe that one of the 
medicines was better than the other [...].  Doctor 1(child) 
Given this practitioner’s extensive knowledge and experience, I was inclined to 
view this position as equivalent to a belief in the ‘potential for the trial drug to work’ 




that while the principle of equipoise is considered essential for the ethical conduct of 
a trial, a degree of hope in the therapeutic value of a new drug is equally necessary 
to embark on a trial or deem the study acceptable for their patients. Practitioners, 
like patients, rationalised inherent trial uncertainty with hope for the best personal 
outcome.  
5.6 Assessing trial burden 
In addition to assessing the direct physical risk associated with trial related 
procedures informants also considered trial related burdens when constructing their 
view of a fair research offer. 
5.6.1 Patients’ perspectives 
There were some notable divergences with regards to adult, parent and child 
perceptions of trial burden.  In the main, adults placed the most emphasis on 
potential trial burden, with a focus on time constraints. An adult typically 
positioned ‘time commitments’ as the most important consideration in determining 
whether to accept a research offer, once the issue of risk had been rationalised. Their 
accounts illustrated how they were not only managing typical activities of daily 
living but were also managing a life-limiting health condition requiring demanding 
daily treatments regime. Not only were objective time commitments important but 
also how these time constraints could be negotiated and how much the ‘big asks’ of 
trials were ‘taken into account’ in relation to individual circumstances and work 
commitments. 
I think what comes across and it's been my experience throughout actually is they 




nearly always worked full time, and they say oh well we would just like  you to come 
along for this, well that's a day off I have got to take [...]  Phil (35y) 
 
When you're approached about a study a lot of the time, they just see the CF side 
whereas you have got the life outside that as well, which it can affect and, you know, 
especially if you're working. A lot of them are big asks. Mia (25y) 
 Participants described being willing or more inclined to ‘find the time’ if the 
recruitment approach was ‘done right’.  For example, Gareth talked about how a trial 
involving a time commitment of ‘only 15 minutes a day’ was unlikely to be ever be 
perceived as that for someone with CF and suggested such requests needed to be  
handled sensitively.  
Yes this is only 15 minutes a day or whatever [...] it’s making it easy rather than 
saying right we have got this trial, it needs 15 minutes a day, you know you must be 
able to find 15 minutes, and you just sit there and think… go away, leave me alone 
don’t you tell me when I can find 15 minutes. Gareth (40y) 
Accounts also suggested that ‘the right trial’ had the potential to lead an individual 
to ‘find time’.  Studies involving minimal time requirements, that were viewed as 
being ‘rolled up into clinic’, and not requiring any ‘major commitment’, appeared to 
promote interest or accessibility, being seen as something which did not encroach 
on personal time.  
Some adults also talked about how ‘time is money’ and suggested that the 
expectation that someone should volunteer their body for testing free ran counter to 
societal expectations where few things are free. Consequently, for some a financial 




serving to ‘soften’ time lost. Other adults, however, while acknowledging the 
significance of time and economic constraints, expressed concern about the possible 
ethical tensions in relation to a financial incentive, which might encourage people to 
sign up for a trial for the ‘wrong reason’. For others, the combined potential personal 
costs, including economic, financial and time constraints constituted a too great 
burden to be offset by financial reimbursement alone. 
While some parents talked about the logistics of balancing the needs of the family 
unit including work and school commitments and caring for other children, their 
focus on issues of burden was much less prominent.  Furthermore, parents 
generally did not refer to the practical burdens typically detailed in patient 
information, including ‘added inconvenience of additional questions and extra clinical 
visits’ (TORPEDO-CF PIL, 2010). Indeed additional clinical monitoring was 
positioned as ‘a big plus point’. Trial procedures also offered to reduce responsibility 
for maintaining or improving their child’s health status, through the process of 
being ‘double watched’ and ‘checked’ throughout. 
Teenage accounts largely resembled adult’s accounts, with teenagers more inclined 
to frame their decisions around whether trial participation would be worth the time 
and effort. 
I was just worried about whether it was actually going to work or not and I just 
thought well if I come out of it at the end and find that it hasn’t worked I will feel a 
bit like Oh well  that was a bit pointless.  I didn’t really want to feel like the whole 




There were some obvious variations concerning children’s perception of trial related 
procedures or potential burden. Nonetheless, some of these issues appeared to 
impact on their receptivity to future research invitations’. For example, having to 
miss school was perceived as a burden for all the parents and some of the children, 
however for others ‘days off school’ were viewed as an ‘upside’ to trial participation. 
I would say yes because you get days off school and everything and you get to play. 
Daniel (11y) 
Several younger informants also viewed the trial experience as being ‘fun’. The 
source of children’s enjoyment in the trial experience appeared to be connected 
with: meeting ‘new people’ and the social relationship developed with the trial team; 
the novel element of trial participation; parents ensuring the trial experience was 
made ‘as good as they could’ with additional special treatment such as gifts or trips 
out; and facilities at the Clinical Research Facility 9(CRF).  For children who were 
able to have their ‘normal’ clinic visits at the CRF, this was described as an 
influential factor in their positive view of trial participation, with trial visits seen as 
more enjoyable than routine clinical visits. 
They’re better than just ordinary visits because ...you do a lot more fun stuff. You 
don’t need ... there’s lots more stuff to do, and it’s a bit more chilled out[...]And it’s 
fixed into the normal one, they do the stuff that you normally, like get weighed and 
stuff.  Daniel (11y) 
                                                     
9 CRF’s comprise part of the NIHR research infrastructure by providing dedicated purpose built 
clinical spaces in which expert staff can deliver high-intensity experimental research in the UK (NIHR 





Children spoke positively and enthusiastically about the resources available at the 
CRF which included a ‘DS’ (a popular dual-screen portable game system); a ‘Pool 
table’; ‘TV . . . and it’s got whatever you want on’; and ‘Wii’ (a home video game 
console). Rachael described a hospital admission and the restrictions required to 
stop cross-infection as a point of comparison to highlight the appeal of the clinical 
research facility. 
You don’t have to be in the same hospital and be in one room, a little room, you only 
have to be in a little room and just a TV and a bed and some colourings, but there 
you have got a pool table its massive, you can do what you like there, and there is no 
people that are separating you in the room.  Rachael (10y) 
Boredom was identified by both parents and young people as a potential burden or 
‘downside’ of research participation particularly at centres where no CRF were 
available.  
One time you could have been there for 3 hours, another time you were there for 5, 
another time you were there for 7, it was a long , the full day  basically and that was 
a long a long time, you were getting bored really, weren’t you, the length of time 
that some of it took,  that was only the downside really. Mother (Peter 12y) 
 
However, for the most part children like their parents perceived a number of 





5.6.2 Practitioners’ perspectives 
Practitioners’ judgements about patients’ vulnerabilities to trial risks and burdens 
varied across child and adult settings and influenced their view of who best to 
approach. Adult practitioners emphasised increasingly intense treatment regimes, 
deteriorating health and employment commitments as important vulnerabilities to 
trial burden. These practitioners were empathetic with regard to how research 
might be perceived by some adults as another burden and expressed ambivalence, 
reluctance and occasional avoidance of approaching some patients. 
There was a few that were probably eligible but we didn't approach because we 
didn't think they would either go for it or they wouldn't adhere to it or because there 
was a lot of work in it, or we didn't want to burden them even more than they were 
burdened already with their care. Nurse 5 (adult) 
Adult practitioners also highlighted potential ‘psychological barriers’ which they felt 
were more prevalent in the population of adult patients and which had the potential 
to exacerbate their concerns about research burden. 
Some of them do have psychological barriers because it’s usually that they are 
diagnosed as babies, and they have grown up with the CF, and they do get baggage 
and they do have psychological problems [...] anxiety and depression is very high as 
you can understand you know if you have got a life-limiting illness especially when 
they transition over from paediatrics to us because they don't really generally now 
lose children as in paediatrics but obviously they die in adult care, so there is a huge 




This practitioner draws attention to an important historical change in end of life care 
in CF, as this now occurs almost exclusively in the context of adult care rather than 
in paediatric settings, due to improving life expectancy for people with CF. By 
contrast, while paediatric practitioners considered the impact of trial burden on the 
patient and family they emphasised the physical risks and how ‘the little ones, they all 
hate blood tests’.  Indeed, the invasiveness of ‘needles’ was highly prominent in 
considering the burden of trials for very young children, compared to adults. 
I think paediatrics is different to adults because with an adult you would just say I 
am going to take some blood, and off you go but with children with a five year old 
there is a lot of preparation, that is needed before you just dive in with a needle. 
Nurse 4 (child) 
In cases where the child had a needle phobia or past traumatic clinical experiences, 
some practitioners spoke of trying to pre-emptively offset any burden from the trial 
by offering families ways of overcoming such difficulties. This might involve the 
use of Entonox (medical nitrous oxide and oxygen mixture) or play specialists to 
address needle phobia. 
In the context of commercially funded trials practising ‘competitive recruitment’10, 
practitioners described how investigator site target samples might often be small, 
and there may be more eligible patients than there are trial places. In this context, 
one practitioner commented that to suggest an invasive trial to the parents of a 
                                                     
10 Competitive recruitment works by pitting investigating sites against each other, to create an 
incentive for practitioners to recruit patients as fast as they can. In return for involvement in the 
protocol  and remuneration , investigators agree to recruit a specific number of patients(often within a 




‘needle-phobic six-year-old’ would be ‘totally unfair’. Consequently, this practitioner 
indicated she would use her knowledge of the patient and family to assess the 
degree of trial burden and the fairness of an approach.   
 I think you really then have to pick patients. There was once this trial where the kids 
had to have eight blood tests on day one and eight blood tests on day two because 
that was very well known that that was a very kind of invasive study, they got a lot 
of money for it [...] I have no problems suggesting that trial in particular to 14-year-
old boys where I know they can make their voice heard. And that’s fine, but I would 
have a problem approaching a mother of a 4-year-old boy for that trial because he 
will be totally traumatised afterwards and  you know why would they want to be in 
that study in the first place if you see what I mean?  I think you sometimes have to 
be a bit, what are we trying to get out of it?  And it’s really the patient benefit is 
paramount. Doctor 4 (child) 
In the context of large multi-centre trials, practitioners were more obligated to 
approach all eligible families. Nevertheless, one practitioner described how the team 
‘probably steered a family away’ from participating in a trial, at a time when they 
believed the trial burden was too great for them.  This ‘steering away’ rather than 
not approaching an eligible family at all seemed to reflect a situation where the 
practitioner made sure patients were fairly selected and their own obligations as a 
researcher were upheld, while still ensuring a duty of care. 
5.7 Summary 
When faced with the choice of participating in a trial, adults, parents, practitioners 
and some children engaged in a comparable ‘weighing up of options’ or a ‘weighing up 




balance of a trial or study. How individuals rationalised risk, made sense of a trial, 
evaluated its ‘worth’, and the adequacy of the information given, were prominent 
features of this discourse. Informants who had consented to a clinical trial typically 
viewed randomisation as something they tolerated, giving precedence to their 
perceived value of the trial and clinical research in general.  For the most part, 
informants prioritised risk and anything that may ‘jeopardise’ their own or their 
child’s current health status. It was also notable that informants, who were reticent 
about research or had declined research offers, were more risk averse. Furthermore, 
individuals with a deteriorating health status and extensive treatment burden, in 
general, emphasised judgements of burden and potential risks. 
There were also some parallels with normative ideas about decision making and 
risk in informants accounts,  which at times  mirrored a ‘rational’ and deliberative 
account of how they made sense of research invitations (Hardman, 2009). 
Informants indicated that they were prepared to negotiate higher levels of risk or 
burden for trials which offered greater promise or could even be potentially ‘life-
changing’. At face value, this model appeared to be an important element of 
informants’ construction of a fair research offer. However, it is uncertain to what 
extent individuals were complying with expectations of the informed consent 
process, which advises that ‘it is important for you to understand why the research is 
being done and what it will involve’ (e.g. TORPEDO-CF information leaflet, 2010). While 
many individuals framed their judgements of cost and benefits around the trial 
information, knowing the information was only one facet of how they made sense of 
the process and was not always necessary to establish what they viewed as a fair 
research offer. Moreover, expectations concerning cost – benefit ratios were not 
fixed and varied within individual accounts of the same trial, according to different 




on different forms and emphasis depending on an individual’s sense of 
responsibility and personal perceptions of fairness in relation to the costs and 
benefits of a particular trial.  Paralleling modern theories of cognitive psychology, 
these findings illustrated how informants’ rational and experiential systems 
appeared to operate in parallel with interplay between intuitive and more analytical 




CHAPTER 6: FINDINGS 
WHEN IS A RESEARCH OFFER FAIR? - A SOCIAL DISCOURSE 
6.0 Introduction   
This chapter focuses on the relational aspects of the encounter between the potential  
‘participant’ and recruiter and the social context of the research invitation, which 
together I define as a social discourse. For brevity, I refer to this initial invitation to 
take part in clinical research as the ‘approach’. The construct of trust featured 
prominently in this discourse. Taken at face value it provided little insight into the 
qualities necessary for the establishment of ‘trust’ or the processes involved, 
therefore the findings presented in this chapter sought to identify separate factors 
contributing to an individual’s  perception of trust. In the first section I consider  
patient and parent  perspectives concerning the social context of recruitment, which 
appeared to inform their conceptions of trust, followed by an examination of 
practitioner perspectives. Later in the chapter, I illustrate the centrality of trust with 
regard to the ease that patients/families  felt  at being approached and how trust 
featured in their subsequent participation decision. In the second section  I examine 
practitioners’ discourse relating to trust. 
6.1 Impact of relationships: patient and family perspectives 
Relational aspects were prominent in the accounts informants gave of how they 
viewed an initial invitation to consider participation in a clinical trial and their 





6.1.1 Familiarity  
Research invitations typically occurred within the routine clinical format across both 
adult and paediatric settings. Patients and families indicated that the regularity of 
clinic appointments, which took place at least every 6-8 weeks, had led to them feel 
accustomed to these interactions. For the most part, children, parents and adult 
informants who knew the practitioner before the approach, valued the relationship. 
Many accounts portrayed the ease, comfort and reassurance they experienced when 
recruitment occurred within a familiar clinical context.  
Some adult informants also recognised the clinic as a ‘convenient format’ in which to 
raise research, and that approaches made within the routine clinical context 
constituted the most effective and practical use of everybody’s time and resources.  
When you go to clinic you, you see a multitude of people. You see a dietician, you see 
a physiotherapist, and then you see doctors, and so it was in between the visits that I 
was approached. So it wasn’t infringing on my time, I was there anyway.  It was in 
between people coming in, so it didn’t seem like a, a nuisance or anything like that.  
It just seemed like you’re saving me from sitting around really […]  
John (33y) 
Many informants perceived members of the CF team, as ‘like a friend’, someone ‘who 
knows you really, really well’ and someone who they ‘trusted’.  Their accounts 
illustrated how they felt reassured  in their presence, portraying an encounter which 
they perceived as being ‘easier’ and requiring less effort than meeting someone new.  
Consequently, this familiar ‘model’ of recruitment was viewed as something that 




Amy’s consultant, he asked if we would be interested no pressure, they always give 
you the choice and a full explanation and freedom to choose [...] they have got it just 
right, I don’t see how you can improve on it. Mother (Amy 16y) 
For many patients and parents, this was the only ‘model’ that they had ever 
encountered when being approached about research and it was one that they 
described largely in positive terms, showing a preference for a context they were 
familiar and comfortable with. 
It’s nice that it’s the consultants that you know very well because the team do 
become like an extended part of the family because you do see them so often [...] 
They’re [the CF team] almost like my safety blanket, they make me feel secure and 
with them approaching me I feel more able to ask questions, talk to them, because 
they know you and they know Emily yeah, they know all of us [...] Mother (Emily 
9y) 
 
I would prefer to be approached by my CF team because I feel comfortable when they 
come and ask me. Because I don’t want like some  stranger coming up and saying ah, 
we have got this rah, rah, rah, would you like to do it, I would be like wow, who are 
you.  Ben (16y) 
The necessity for ‘specialists’ who they did not know, to approach them in the 
research context was also accepted. In this situation, individuals emphasised the 
importance of ‘someone you don’t know’ being introduced by ‘someone you know’, 
which they viewed as an endorsement for the trial and the researcher and a ‘matter 




Some individuals who only had experience of recruitment within this familiar 
clinical context formed preconceptions about how it would feel to be approached 
about research by a ‘stranger’ or a ‘random person’. In these accounts, which do not 
appear to relate to any actual research encounters, informants imagined what it 
would be like to be approached by a stranger about clinical research, and reflected 
on past clinical interactions with practitioners that they did not know. In doing so, 
they drew attention to communication styles, or interactional qualities, which they 
had come to value and expect during consultations, which may not be guaranteed 
in an unknown practitioner. 
Informants, who had experience of engaging with new researchers, also identified 
corresponding interactional qualities, to those they had come to value within 
existing successful clinical relationships, which they also valued in the research 
context. Together these accounts portrayed prominent socio-emotional qualities of 
the recruitment interaction which informants viewed as integral to an optimal 
approach. Furthermore, these accounts also conveyed an expectation that the 
clinician in the “inviting” situation should go the extra distance to ensure that these 
qualities were part of the research context to optimise their recruitment experience.  
6.1.2 ‘Feeling comfortable' 
Feeling ‘comfortable', at ease and able to ask questions were identified by informants 
as essential ingredients of a ‘reasonable’ approach.  Informants talked of ‘feeling 
comfortable’ as distinct to the establishment of ‘rapport’ in clinical communication, 
something which was already present in the routine clinical format. 
When meeting a new practitioner for the first time, several adult informants 




appreciation of an individual’s depth-of-knowledge about their condition as 
opposed to a ‘Dr knows best’ approach. 
The problem you get is that they've done their so many years of being a doctor, and 
they're a doctor, and they're better than you.  But, actually, they have no idea, they 
haven't got the depth of knowledge I have about CF, so they can get lost, really. So if 
they already come in with a bit of respect for me and give me a bit more, give me that 
rapport maybe, you know, to say, or acknowledgement [...] Helen (34y) 
Other informants spoke about the significance of a personable approach rather than 
just focusing on ‘the facts’ and clinical details.  
Just have a kind of more human approach, rather than the whole clinical doctor way 
of, well of some doctors, you know, the way they go about things, of just facts and, 
you know, “This is what it is, and this is …” You know, sometimes it’s nice to just 
soften it. John (33y) 
 
I think they've got to have a bit of personality, and I think they've got to be quite a 
people-person, not just, oh, this is this, and this is this, and any questions?  I think 
they've got to know how to approach it because I doubt that - with like dealing with 
a hell of a lot of medical people over my life, like it really makes a difference how 
you're approached[...] Mia (25y) 
These accounts conveyed the significance of interpersonal qualities of research 
invitations to avoid discussions seeming like a ritual involving the disclosure of ‘just 
the facts’.  
Some informants indicated that feeling ‘comfortable’ with a ‘softened’ approach was 




in the account of a teenager who emphasised how while she felt comfortable with 
some practitioners, there were others she knew who she did not feel comfortable 
with. Her account of a recent approach about a clinical study, conducted by an 
unfamiliar practitioner who had put her at ease and made her feel comfortable, 
illustrated that this informant placed a higher value on the ability of the recruiting 
practitioner to put the individual at ease, over familiarity. 
I felt comfortable with the [practitioner] who was talking about it I was like 
yes[...]He was a laugh, he was funny, you could have a laugh and a giggle with him 
about it […]  because he asked me what my thoughts were, and I said a day off 
college and he thought that was quite funny.  And he goes yes that’s what most 
people have probably said a day off college or a day off school[...] I think that is more 
important, if you can have a bit of a giggle with them, or if you feel comfortable to 
talk to them about it, then it’s, yes.  Kirsty (16y) 
Younger informants also echoed this sentiment and appeared particularly open to 
meeting new people. However this openness was in part conditional on ‘niceness’. 
Furthermore, this disposition seemed to be partly based on past successful 
engagements with new researchers. Younger informants described these new 
practitioners as ‘nice people’ who they had come to view as their ‘friends’ and people 
who they had enjoyed spending time with. These successful research engagements 
seemed to result in an open attitude to the prospect of meeting more new 
researchers in the future.   
[name of Dr ] asked me to do it and I agreed and then I met these nice people  [...]It 





Who would you like to ask you about studies in the future...have you got a 
preference who you’d like it to be?  
Lots of nice people.  Emily (9y) 
6.1.3 Feeling valued and being part of something of value 
Adult patients emphasised the significance of practitioners conveying a shared 
understanding of living with a ‘serious illness day in, day out’ on top of general day-
to-day demands. For the research exchange to be viewed as equitable their already 
constrained time needed to be sufficiently appreciated and employed in something 
worthwhile, to ensure they weren’t wasting their time. 
Informants perceived there was a ‘right way’ to approach people about research, 
which ensured people felt in control and understood. 
It has to be the selling aspect has to be done right and it… understanding you have 
got a lot on your plate if you work and your treatment, but there is a way of selling 
it to somebody that makes them want to do it.  Because, you sort of you are not 
saying we need you to do this, or we want you to do this or… or you are helping by 
doing this, it’s like well you know if I understand, the more understanding you show 
to somebody’s situation the more willing they are going to be to participate, or 
actually to find the time. And I think that’s it and it’s sort of putting them in a… 
almost in a position of control.  Gareth (40y) 
While many parents acknowledged practitioners’ consideration during approaches, 
parents tended to focus more on the value they placed on being able to be part of 
something worthwhile. Parents who viewed their invitations as trouble-free 




So that’s the first time we did it, but we were kind of… we didn’t feel privileged, but 
we felt like we were helping. Mother (Jack 8yr) 
 
I did feel quite honoured, yeah, when, and that was the first one we’d been 
approached about. Mother Emily (9y) 
Children’s illustrations of feeling valued were less explicit than those of adults and 
parents. However, child and teenage informants spoke of feeling ‘excited’ or ‘special 
‘at being invited to take part in a trial, conveying a sense that they understood they 
were engaging in something of importance. 
What did you think about being asked about that study?   
It felt quite fun because I was really excited to be one of the people that tested a 
tablet. Emily (9y) 
 
I think when he mentioned it was going to be a trial I was kind of, oh, kind of excited. 
Amy (16y) 
Rachael recalled how she was the first participant in Europe for one of the trials she 
had taken part in, conveying a feeling of special status. Also, some younger children 
spoke about undertaking special activities during trial visits, or being given treats 
by their parents during the research process, which also legitimised the value of 
their actions. 
Every morning before we went up to the hospital, we always went somewhere in the 





The good thing about it is when it’s dinner time they give you an hour or so and 
afterwards you can go to the museum or so for an hour, and I get an ice cream […] 
Rachael (10y) 
Adult and parent informants emphasised the significance of being approached face-
to-face, reading this as a sign of the value of the trial. 
 I feel if a doctor or a nurse hasn’t got time to come and ask you as an individual, 
then they shouldn’t be putting it out like that. So if somebody couldn’t come to me 
face to face and ask me, then I wouldn’t want to know.[...] I wouldn’t think it was 
worthy. Mother (Kirsty 16y). 
 
 I think this goes for quite a lot of people, I think generally life is quite a busy thing 
to do, especially now, everything’s getting faster, people have to be up longer, work 
longer, you know.  There are more things going on, so there’s less free time. So 
people are less inclined to take that time out of their daily routine and do something 
like a clinical trial, unless somebody approaches them because then they kind of feel 
special I think, and they feel like someone’s taking the time to ask me, so I’ll take the 
time to give it back. Adam (19y) 
By making the time to come and ask them individually, practitioners demonstrated 
not only the ‘worthiness’ of the trial itself but also that they the valued and 
respected the family or individual being approached.  Consequently, approaches 
that did not involve a carefully considered face-to-face approach did not reinforce a 
sense of being valued. Therefore postal methods or trial advertisements were 
conveyed as devaluing both the study and the individual, creating a situation that 




I thought it was bad that it came in a letter as well. Because I didn’t have, there 
wasn’t even a contact number. There was an email address, and that was it [...] there 
was no contact number to check, there was no-one even… you know, face to face or 
over the phone or anything.  I thought it ain’t worth doing you know.  
Adam (19y) 
Families and patients felt more reassured about the value of a trial that was 
introduced by a known practitioner, compared to actively responding to trial 
advertisements or trial websites even if these were displayed in a familiar setting. 
One parent anticipated she would feel more personally responsible for any negative 
outcomes of a trial that she had ‘gone out’ and found, compared to one that was 
introduced to her by a member of the CF team. Informants only spoke of being 
proactive about research in the context of revolutionary ‘wonder drug’ trials, such as 
gene therapy or comparable novel drugs, where the value of such trials had been 
widely reported in the media.  
6.1.4 Being provided with reassurance 
Informants highlighted the importance of the interactional nature of the encounter 
in which individual fears, or worries, could be identified and addressed by 
practitioners. This quality was distinct from feeling comfortable and at ease and was 
directly related to a practitioner’s ability to identify anxieties and provide necessary 
reassurances and was viewed as having the potential to influence their receptivity to 
research offers. 
When meeting a new researcher for the first time, a practitioner’s manner and 
expertise provided informants with ‘peace of mind’ regarding the practitioner's 




I think it's important that the people that are asking are kind of very approachable 
people, someone that can explain things and able to answer questions well, and sort 
of able to listen you know and actually say have you got any problems or have you 
got any questions and just be very knowledgeable really but in a sort of friendly way. 
Megan (26y) 
For some individuals, the seniority of the recruiting practitioner instilled confidence 
in the quality of the trial. 
Having him telling you, because he’s the most senior I don’t know I think we felt a 
bit - I don’t know if safer is the right word - but you know you’ve kind of got the top 
man for the job advising you and talking to you, so yes you feel like it’s safe to kind 
of make those decisions.  I think if it was just a nurse or you know, it’d be different, I 
would sort of demand to see someone of his stature to talk about it really. 
Mother Dylan (2y) 
Being approached in person by a practitioner, who was aware of their medical 
history, was also viewed as reassuring with regards to the relevance of the trial, 
something which could not be guaranteed when responding to a trial database or 
website.  
I recently had a look at the CF Trust website I was like well I don’t know if I fit into 
any of these categories you know sometimes it was a bit vague as to what sort of 
person they wanted for the trial, so although I had a look I didn’t really like respond 
to any of the you know… there was none that really caught my interest, whereas if 
your doctor recommends it to you then you know he has already thought  about it, so 




Children’s accounts’ illustrated how they felt unconcerned or supported during 
research invitations. This lack of concern appeared to be due to the reassurance 
derived from the usual format and setting of the invitations, which included the 
presence of their parents and typically a familiar practitioner.  
Mother (Rachael 10y): The other main Doctor who you see quite a lot broached this 
one. 
Rachael: She is supportive to me.  
Some older teenagers had begun attending clinic appointments without their 
parents, or the idea had been raised as something that would be introduced in the 
near future. However they spoke of valuing the reassurance they derived from their 
parents’ presence and most teenagers indicated a preference for them to be present 
during clinic appointments and when being approached about research. 
Mother (Amy 16y): They ask Amy now rather than ask me, ask Amy through me, 
they ask Amy directly now.   
Amy: I still rely on you. I always prefer mum there. If I get stuck, I just look 
at mum, and she just knows what I am thinking [...] 
Mother: But I also don’t want people to think that I am butting in and I am talking  
Furthermore, some adults and occasionally parents described seeking additional 
reassurance and support from their own parents when approached about research, 
with some parents of adult informants regularly attending clinic appointments. 
The significance of sufficient reassurance in an emotional context was highlighted in 
parents of infants’ accounts of their invitations to participate in the TORPEDO-CF 




about. The clinical eligibility for TORPEDO-CF trial involved an individual testing 
positive for a serious bacterial infection of the lungs - pseudomonas, which can lead to 
permanent lung damage if not eradicated successfully. Consequently, the emotional 
context of the approach was one of concern for all parents as they were aware of 
‘how horrible pseudomonas is’. Parents described being ‘shocked’ and ‘worried sick’ 
which was especially intense for parents for whom this was their child’s first 
episode of pseudomonas.  Nonetheless, being approached face-to-face within the 
context of an existing clinical relationship was viewed as providing the necessary 
reassurance for these parents, to the extent that the experience was relatively 
unproblematic for them.  
Alice’s mother described how a practitioner who knew the family well, was able to 
support the family and address their particular needs and concerns, enabling an 
unguarded interaction, which may not have been achievable with a ‘complete 
stranger’.   
It was reassuring, the nurse that was there to meet us is one of the CF nurses that 
we know really well, and she understood our kind of anxiety and was very 
reassuring [...] it can get a bit much when you see new faces all the time [...] you can 
ask questions that you wouldn’t necessarily ask  somebody that is doing the trial, 
because  you know them and you know that they are going, to be honest and give 
you truthful answers, and they also know what sort of people we are, so they knew 
how we would react to being asked about the trial and they knew what Alice’s’ dad’s  
main concern would be [...] because I think if it had been a complete stranger they 
wouldn’t have known our situation, or  how you know because Alice’s dad and I are 
very different with how we deal with the whole CF, so they know that  he gets quite 




For some parents, the knowledge of the trial appeared to act as an emotional buffer, 
something that helped to counter the emotional ‘shock’ of finding out about their 
child’s infection, resulting in her feeling ‘more determined to be part of it.'  
I was still reeling from finding out about the pseudomonas, to be honest but yes, I 
think it kind of made me more determined to be part of it [TORPEDO-CF trial] [...] 
So I think it does help to be honest. If you are faced with that situation and you know 
there are drugs available that can help, and that there are people researching this to 
see if they can get rid of this altogether [...]  Mother (Isabel 2y) 
In contrast, several parents of infants described being approached initially about the 
TORPEDO-CF trial via telephone by an unfamiliar practitioner as something that 
‘could have been handled better’. 
It came as a shock to find out about the pseudomonas, so that first phone call was a 
little bit of a information overload, you know [...], so it seemed very rushed. I think 
maybe, not so rushed would’ve been a bit better or you know if he’d just said that, 
this has been raised, could you come in, you know pop in and see me, have a coffee, 
chat about it [...] Mother Dylan 2yr 
 
Someone rang me and just asked me about it [...] They sent like booklets out and 
stuff, on It [...] I would have liked someone to come out and speak to me one of the 
CF team probably, someone that I know from there. Mother (Tom<1yr) 
 
If it's a total stranger, you know, you just think first of all you're taken a aback by, 
oh, someone's phoned me up about a trial and, you know, it's a lot to take in […] I 
think it would have been better for us if  our CF nurse had as I say, because we've 
got a bit of a relationship with her and, you know, it would have  just reassured us.  




The reassurance and comfort provided in person, or by someone known and trusted 
from the CF team, appeared to be the qualities that were absent from these 
approaches. Consequently, these parent accounts portrayed how in this context they 
felt ‘taken aback’  and found it difficult to raise concerns, perceiving the information 
about the trial and the infection as ‘a lot to take in’.  
This was offset by their belief in the importance of clinical research as the overriding 
factor in their decision to take part. Nevertheless, the deliverance of an optimal 
approach was more likely to be critical to the construction of a fair offer for 
individuals who were ambivalent, unsure, or comparatively less favourably inclined 
to clinical research.   
For instance, Tom’s mum who declined to allow her child to participate in the 
TORPEDO-CF trial was the only informant in the sample whose recruitment 
experience consisted of two telephone calls with no face-to-face discussion. While 
this parent cited the most influential factor as her preference for the oral arm of the 
trial, due to a recent ‘traumatic experience’ involving her son’s first venipuncture, she 
also spoke of not wanting her son ‘being used like a guinea pig’. This parent’s use of 
the term ‘guinea pig’ appeared to reflect her misgivings and unease about the 
unfamiliar research context. It is plausible that with a more conducive encounter, 
involving a face-to-face meeting with a known CF practitioner, an improvement she 
suggested, her trust may have been gained and some of her concerns may have been 
allayed. 
6.1.5 Downsides to familiarity 
Depite the clinic being a convenient format for research invitations, patients and 




not be as likely to take the time to think about research, or show an interest. Some 
adults also described how approaches made directly in the clinical context could 
feel slightly pressurised.  Staged approaches involving being forewarned about a 
study in advance, before being directly approached, for example by receiving a brief 
introduction and patient information leaflets at the end of the clinic, or with clinic 
appointment reminder letters, were suggested as strategies to allay any sense of 
pressure felt with direct approaches. 
I like the fact that you got the letter you know and it provides a lot of information 
and you know you can think about it before you go to clinic rather than… sometimes 
in clinic, you could feel like you have been put on the spot. Kate (29y) 
Research invitations within this routine setting, when the conditions were right 
were often portrayed as being relatively insignificant as almost a ‘non-event.'  
'When you're approached, and you're fine with it, it doesn't feel like anything  
John (33y) 
The familiarity of the clinical context appeared to have lessened the significance of 
the approach and the distinction between research and clinical encounters, resulting 
in the approach becoming a ‘non-event’. This view was noticeable across all sub-
groups but emphasised in adult accounts. Adults had the most long-standing 
clinical relationships with members of the permanent CF team and typically had 
received more invitations to participate in clinical research compared to parents of 
younger children. It is therefore plausible that these individuals had become more 




Some adult accounts appeared to reflect the tension between wanting the approach 
to be the unpressured and non-intrusive usual ‘model’, and also wanting an 
approach that conveyed both the worth of the study, and the value of themselves as 
potential participants. One informant described repeated occasions on which he had 
been approached about research ‘on the fly, on the day’, a circumstance he indicated 
was not well considered or thought out.  While he felt comfortable saying no ‘as they 
were never precious about it in that sense’, this approach appeared to have influenced 
his receptivity to the idea. 
Similarly, Sara another informant implied that due to the familiarity of the clinical 
context, despite feeling at ease with the circumstances of the approach, which 
involved a CF nurse who she described as ‘like a friend’,  she didn’t feel she had 
‘actually’ been approached. For this informant, being given leaflets via her CF nurse, 
rather than by someone she perceived as a member of a research team, did not in 
itself appear to constitute an approach about research. 
I haven’t been really approached.  I’ve been given leaflets, but I didn’t really read 
them if I’m honest [...] There’s probably just been one or two, and again I think, I’m 
sure that was through the CF nurse, so no one physically approaching me.  
Sara (30y) 
Children who commented directly on their experiences of trial or research 
discussions typically described approaches about research in quite neutral terms as 
something that ‘doesn’t really bother me’. To a certain extent, these findings resonated 
with adults’ accounts of the approach as a ‘non-event’. Nonetheless, children, 
particularly younger children, provided the fewest details with regards to the 




several explanations for this finding. Firstly it could be that these children had little 
involvement in the initial approach and subsequent discussions. Consequently, the 
approach was not salient to them. This assertion seemed the least probable, as all 
parents went into detail regarding the extent both recruiting practitioners and they 
themselves had involved their child in research discussions. Also, parents spoke of 
encouraging their children to participate in this study about trial recruitment, which 
would seem counter-intuitive if these young people had been excluded or given 
little involvement in the recruitment process. What seems the most probable 
explanation is that from the child’s perspective, research invitations made in a 
familiar context lessened the significance and the distinction between research and 
clinical encounters, combined with a child’s preference to delegate decisions about 
their CF to their parents. Added to this, some approaches were made sometime 
before the interviews took place, so some younger children may have struggled to 
remember the event. 
Problematic existing clinical relationships also led to some ambivalence about this 
familiarity ‘model’ of recruitment. For instance, one adult informant described how 
he had been reluctant to accept a research invitation from a known clinician whose 
communication skills he viewed as inadequate. For this individual despite having 
known the recruiting practitioner for some time, he viewed all the approaches he 
had experienced from this clinician as ‘disengaging’ and had declined them all.   
 No, he was a complete bumbling arse to be fair, and that switched you off a bit. He 
had no bedside manner at all [...] well the major problem with that particular, is he 




The potentially negative aspects of an approach involving an existing relationship 
with a practitioner were highlighted directly by one parent who was also a qualified 
nurse.    
It’s difficult really because I know some CF teams do their own research anyway and 
I know of an incident another CF mum I speak to [...] she's actually moved his care 
now because she felt that the consultant was only treating in a certain way because 
of his research, she just felt his care was being sort of moulded to suit the research 
that was going.  I think external sources doing clinical trials and things is probably 
better, I think just to say stop sort of biased results [...] I think I'd question it more if 
it came from the team, just because I'd feel like well "Is it their research, or is it an 
external source doing the research?"  I'm just suspicious like that I think myself. 
Mother (Becky 4y) 
She described the importance of separating clinical research from the clinical team 
and was very conscious of being unduly influenced by a known member of the CF 
team. In spite of this ‘suspicion’, she also recognised the complexity of the situation, 
stating that ‘somebody’s got to mention it’. Furthermore, she recognised how an 
‘external source’ in the form of a ‘stranger with a clipboard’ might not be ideal for a 
‘major clinical trial’ and there may be a need for a ‘more personable approach and a bit of 
familiarity’. 
The quote below highlights tensions between feeling at ease with a known 
practitioner while implying that it may be easier to say no to someone you don’t 





It would be good to have maybe a mixture so you could talk to someone in your team 
about exactly what it is and get more detail and information and you might ask them 
questions that you perhaps wouldn't ask a stranger you know but I think maybe it's 
good to sort of you could actually have that neutral person there, that you don't, you 
know don't have a connection with and you can say well no I am not interested in 
that. Megan (26y) 
However, no adult or parent informant described feeling any direct pressure from 
the CF team to consent. In addition, accounts illustrated that informants were aware 
that they were ‘definitely within our rights to say no’. Equally, no child indicated that 
they felt under any pressure from either practitioners, or their parents, and all but 
the youngest positioned themselves as having an active share in the decision-
making. This finding was corroborated further by all parents, acknowledging their 
child ‘has to have a choice whether he wants to take part or not’.   
Nonetheless, some informants suggested how ‘saying no to somebody in the CF team 
would be more difficult’ compared to an unknown researcher. While others, suggested 
the converse situation, viewing saying no to a practitioner who knew them and 
understood their situation as ‘less awkward’. Several adult informants implied this 
familiar context might have precipitated their decision to decline. Also, several 
parents noted that because the trial had been offered to them by a member of the CF 
team whom they respected and trusted, this signalled that the CF team thought the 
trial was the best option to take. Furthermore, some informants spoke of wanting ‘to 
give something back’ to the CF team for the gratitude they felt for receiving the ‘best 
care available’. However informants’ motivation to ‘give something back for the care 
you’ve received’ appeared personally located, rather than connected to the actions of 
the CF team. Adopting ‘a mixture’ of someone from the team and a ‘neutral person’ 




6.2 Impact of relationships: practitioners’ perspectives 
6.2.1 Familiarity 
A comparable social discourse was evident across practitioners’ accounts. 
Resembling patients, they acknowledged that recruitment usually occurred within 
an existing relationship or closely connected to the clinical context. Practitioners also 
suggested it would be ‘strange’ to do anything else within a ‘stable population who the 
team knows very well’. In the context of these long-standing relationships practitioner 
assumptions closely mirrored those of patients, believing patients would expect, or 
even express, a preference to deal with people ‘who they knew’,  at least in the first 
instance.  
For the most part, practitioners viewed approaching known patients about clinical 
research as easier and less ‘awkward‘, compared to approaching someone unknown. 
They spoke of this in the same way that clinical communication, in general, would 
feel ‘more comfortable’ with a known patient. Several practitioners expressed 
reluctance or ambivalence about giving that responsibility away, implying it would 
not feel fair to the families or themselves as a practitioner. 
I wouldn’t want to give that responsibility away. I know the family, know the 
background; the family knows them as well and so having that element of trust that 
is already in place. [...] If it’s someone that you don’t know then the family might 
well say well what does C1 say about it, you know or what do the permanent 
members of the team say about it.  So I think they would often, the families know the 
consultants all really well, they know us all by our first names, so they would, they 




However, other practitioners assumed that in the security and familiarity of the CF 
clinic, where conversing with a variety of ‘medical people’ was the norm ‘one more 
person’ would be ‘nothing heavy’ for many patients. 
They are used to coming to clinic aren't they are used to meeting medical people they 
are used to being in that environment and it's a lifelong thing for most of them [...] 
so it's just one more person that is going to pop in and have a word, so there is 
nothing heavy about it.  Nurse 6 (adult) 
Comparable to patients, practitioners acknowledged the importance of the 
unfamiliar researcher being introduced by a known CF practitioner to foster 
receptivity and instil ‘confidence’ in both the recruiter and the trial. 
It takes a long time to build relationships up with CF patients, and they don’t like 
change, so a new face coming in can put the barriers straight up. And so I would go 
in and say look this is one of the girls you know, I am virtually saying I support her 
on what she is doing and you know I can stay in with you or I can leave and they go 
no, no, you go off and do it that way. Nurse 1 (child) 
Practitioners implied these introductions helped to legitimise the research as 
something ‘credible’ and trustworthy and part of ‘the system’ as opposed to being 
offered something ‘leftfield’ ‘out of the blue’ or ‘off Tin Pan Alley’. Their accounts 
illustrated how these introductions conveyed both tacit and overt endorsements of 
the practitioner and the study, promoting an individual’s receptivity to the idea of 
engaging with research. Indeed, one practitioner viewed this strategy as an ethical if 




Coming from the team that know them first, has always got to be the way to do it, 
because in theory that's how it should be any way through ethics [...]it's better that 
way anyway if it's somebody they know and understand what their role in the 
system is, talks to them first, it always helps. Doctor 3 (child) 
When practitioners moved away from describing recruitment within the ease of an 
existing relationship, such as those typical in the CF context, it was something that 
became much more ‘difficult’ and potentially ‘awkward’. One practitioner who was 
currently involved in mostly approaching patients whom he knew, something 
which he viewed as unproblematic, contrasted this role with the position of 
recruiting patients to ‘acute studies’. Within an acute situation, in which emotions are 
typically heightened, time constraints apply, and the patient is unknown, this 
practitioner perceived recruitment in this context as the ‘coalface’ of recruitment. 
One practitioner stressed the discomfort he felt when he had felt obligated to take 
the responsibility of recruiting to a study which ‘effectively involved cold calling’ 
patients, identified through a database.  For this practitioner, asking a stranger ‘out 
of the blue’, disconnected from the clinical context, was perceived as something 
difficult compared to the relative ease of approaching a known patient within a 
routine format. 
Despite practitioners identifying contexts which eased or challenged optimal 
recruitment, some indicated that the recruitment discussion was out of their ‘comfort 
zone’, and that of most practitioners. While practitioners recognised how 
recruitment was easier with patients who they knew, they indicated that the change 
in dynamic in which they were asking patients to ‘put themselves out’ or ‘help out’ 




Some suggested that individuals involved in recruitment, particularly recruitment 
outside of an existing clinical relationship, required skills over and above those 
needed in the routine clinical context. A sentiment which was comparable to 
patients’ expectation that practitioners involved in recruitment, particularly those 
not known by the patients would need to go the extra distance for recruitment to be 
successful. Their accounts also highlighted particularly qualities, skills or aspects of 
interpersonal interactions that they regarded as facilitators during research 
invitations and instrumental to successful recruitment.  
6.2.2 Right person skills  
Practitioners across settings viewed the tenets of competent clinical communication 
in routine clinical settings as guiding how research offers should be made. The 
significance of establishing rapport and initiating interaction before going straight 
into details of the study was highlighted by several practitioners  
So you need to start this just almost like personal communication skills, then you 
start to know that patient a bit [...] Doctor 2 (adult) 
 
Often people go straight in with, I'm here, I'm doing this study, and I've looked at 
your notes, and you meet the, you know.  It is about hello, tell me about your 
disease, do you know; get a bit of them talking first, and then the patient believes 
that you're interested in their disease.  Doctor 6 (adult) 
Many practitioners felt the role of recruiting required the ‘right person skills’, which 
was comprised of exceptional communication skills. Despite the evident additional 
complexity of having to negotiate both the child and parent involvement in trial 




levels at the same time’ as an expected, almost taken-for-granted competency for 
practitioners working in child health. However, like the adult practitioners, they 
recognized how effective communication was essential for successful recruitment. 
6.2.3 Facilitating a patient’s sense of being valued  
Corresponding with patients’ accounts, many practitioners emphasised the 
importance of conveying a shared understanding of the patient's illness, in which 
they were both knowledgeable and empathetic during their interaction.  
You've got to have a little bit of a knowledge about the background of the 
disease[...]Just because it gives you a general knowledge about the disease and the 
disease process and having some empathy with the child and the parent.  
Nurse 3 (child) 
Some practitioners emphasised the need to be as accommodating as possible to both 
offset the burden of asking people to  ‘put themselves out’ and to ensure individuals 
felt valued, which practitioners believed was ‘especially’ important in the context of 
CF due to their ‘many problems'. One practitioner implied that without an 
individualised approach, recruiting patients may become comparable to ‘factory 
work’, in which patients may feel like ‘a number’ being used for the production of 
scientific knowledge, rather than being  personally valued. 
Several practitioners believed successful recruitment was conditional on an 
interactional encounter in which the practitioner can elicit the patients’ values, 




You just need to understand what their issues are, the same as a clinical 
consultation and most of the time doctors talk to patients and they talk about 
listening, but they don't bother.  And, actually, that's what you've got to do. If you 
want to sort out the medical problems and recruitment, you need to listen to what 
they're saying and make sure whatever you say back addresses the concerns which 
they might be telling you overtly or covertly.  But you've just got to work out 
what's important to them. Doctor 3 (child) 
6.2.4 Tailoring and reassurance 
Practitioners talked of the importance of ‘preparation’ before the approach. Where 
possible this included finding out about any ‘family nuances’ or ‘difficulties, being 
knowledgeable about the study and being aware of the patient's medical history 
and past clinical experiences.  
I have already rehearsed in my mind what I will be saying anyway. I will, of course, 
want to know the background of the families […] anything that might colour their 
judgement about it.  So there is definitely some preparation to be done. 
Doctor 8 (child) 
Several practitioners indicated that if trial discussions could be embedded within 
the ‘clinical interface’ rather than a ‘bolt-on’, this dynamic had the potential to 
highlight the relevance of the trial, ease interaction and increase the likelihood that 
the individual would consent. 
Normally raise it in the day to day clinic setting [...] In general, you can either do 
the business of the day, how they are, etc., etc.  Having said that, sometimes it works 
better if there is a specific thing about that patient, like they're saying, I find these 




that opportunity to say... that's interesting because we've got a study and the 
companies have listened to us, and this is a drug that's once a day, and then it's, oh 
that's interesting, tell me about it [...]If there is a link, then I think you're more 
likely to recruit. Doctor 6 (adult) 
Practitioners felt that recruiting within an existing clinical relationship enabled them 
to tailor interactions according to individuals’ needs, which made them feel ‘a little 
bit more confident’ during recruitment, this in turn helped a patient to have ‘more 
confidence in them’. Practitioners approaching a patient or family for the first time 
spoke of using either information provided by the clinical team to tailor discussions, 
or using medical notes to  ‘get the story straight in your mind’ and ensure they were 
aware of any particular issues.  
I would be given the information and anything I might need to know [...] I would 
very much do it on what the [clinical practitioners] terms were actually so it might 
be for example that… a family is having trouble adjusting, or it might be the family 
is having trouble with school [...] so I tend to be kind of be guided by what the other 
professionals tell me really, who do know the families. Nurse 4 (child) 
Unlike doctors who ‘had a reason to be talking to the patient about their condition’, 
research nurses did not appear to have at their disposal the same ‘clinical lead in’. In 
contrast, these practitioners described shadowing outpatient clinics, making 
themselves available to patients and being introduced to patients by known 





6.2.5 Downsides to familiarity 
Practitioners whose primary role was the provision of care, while they accepted the 
need for research also recognised that without additional ‘back-up’ from specialist 
researchers, it was both frustrating and unworkable to manage both roles 
effectively. One nurse recounted her frustration at missing potential recruits for a 
study during clinic because she physically did not have the time to see everybody 
and clinic duties took priority. 
Practitioners expressed ambivalence about their ‘dual role’ where they were required 
to ‘wear two hats’, that of a practitioner and a researcher (which I examine in more 
detail in the section on trust). To address these concerns, some practitioners 
advocated a combined approach involving both the clinical team and outside 
researchers working in partnership as the best strategy for successful recruitment.  
It’s good to have both because that way hopefully you can capture the wider 
audience, but I think by having the specialist [practitioner] involved as well, she 
knows the patients inside out, and she will be able to… or he will be able to know 
who would be suitable to be approached by a stranger, and who needs to be 
approached by the nurse that they know them… bearing in mind their whole 
background and their history.  Nurse 5 (adult) 
This approach ensured a wider audience was captured while also tailoring 





6.3 Trust and a fair offer: patients’ and parents’ perspectives 
Integral to an informant’s view of a fair research offer were explicit or implicit 
portrayals of ‘trust’ in social relations and the broader social system in which 
research invitations were situated. These perceptions of trust were not only viewed 
by informants as something which increased their receptivity and engagement 
during trial approaches, they were also seen as something which off-set risks and 
uncertainty associated with trials and instilled belief in the value of the trial. 
It was evident from informants’ accounts that interpersonal trust was 
predominantly related to past and on-going social relations within the clinical 
context, involving practitioners responsible for caring for themselves or their child. 
One parent described what this concept of trust meant to her as follows: 
It feels like you are going to fall backwards and you have got a big soft bed to land 
on, they are that strong and united as a team, and everyone is involved, you haven’t 
just got one person, that looks after you, everyone is involved in it. And even though 
there are lots and lots of children that they look after with cystic fibrosis they still 
make you feel like an individual, you know like they are dealing with you and not a 
number of people.  And they come out… a phone call away basically I will phone 
them, and they will be out the same day […]they will just come out for reassurance 
and to make you feel happier, yes. I have built up that… that trust with them really 
and I go with anything that they say because they wouldn’t do anything to harm 
her, to put her in harm’s way, or anything and they are working towards this… this 




In describing trust as something which had ‘ built up’ over time, this mother 
illustrated a feeling of resilience and depth; and this depth of quality was paralleled 
in other adult and parent accounts.  
Obviously, we’ve got a, a big trust with the CF centre you know, and over the years 
that, you know if,  I wouldn’t be here if it probably wasn’t for the  CF centre so, you 
know, you’ve got to think that they’re … obviously, they wouldn’t do something to 
harm you.  It would always be like, you know, something, that is to your benefit, so 
it was kind of like, you know I felt I had trust in that [...] John (33y) 
Perceptions of trust conveyed in adults’ accounts appeared qualitatively 
indistinguishable from parents’ conceptions of trust. However trust as a concept 
was much less apparent in children’s accounts and was mostly implicit, except for 
older teenagers and therefore will be examined separately at the end of this section.  
Parents’ and adults’ accounts illustrated an expectation or assumption that the same 
duty and quality of care would be applied by practitioners in both the research and 
the clinical contexts.  
I feel more reassured because I know the individuals, who normally approach me, 
and I know how meticulous they normally are, and I know in any other respect of 
my care that they go through the right channels.  So I think it, within the CF Team 
is particularly reassuring. Craig (44y) 
Informants believed that practitioners they knew, who were responsible for their 




He wouldn’t allow anything that he didn’t think was… that’s what I feel anyway, I 
have never asked him about it, but that’s the way I feel that he wouldn’t let… if he 
thought it would if it were to harm you in any way, he probably wouldn’t let you do 
it anyway.  David (40y) 
The fact that consultants were aware or directly involved in a trial or study instilled 
a belief, or expectation, in patients and parents that their own, or their child’s 
welfare, had been taken into consideration and that the trial would be to their 
benefit. 
I think that that was why he was offering us the trial was because he thought it 
[TORPEDO-CF] was the best. Mother (Alice 3y) 
 
If you trust somebody, you're more receptive to what they say, because…  I mean 
obviously, she sees a lot of patients, but you kind of have a belief that she wants what 
is best for Harry because she knows him as a little person, rather than just a number 
[...] Mother (Harry 1y) 
This view is especially prominent in some parent accounts of children who were too 
young to be involved in the recruitment process and those who described never 
saying ‘no to anything’.  For these parents, trust in the CF team appeared to be 
central to countering worries about doing ‘what’s best’ or the ‘right thing’. A belief 
that the CF team would ‘ultimately do what is best’ for their child, was fundamental to 
their decision to allow their child to participate. Nevertheless, these parents also 




I doubt they [the CF team] would consider it if they didn’t think that it would be a 
benefit for one and for number two it would be safe because they are recommending 
it to you. So I trust that. Mother (Nathan 16y) 
 
I suppose it’s down to the trust again, isn’t it. I would assume that Peter’s CF 
consultant wouldn’t put Peter through anything that is going to make him go worse, 
or anything that they do is going to be of benefit for Peter, it’s not going to 
disadvantage.  I hope that that is what it would be.  So I think I would support them 
and go along with it, and trust their, what they say really. Mother (Peter 12y) 
For informants who had declined research invitations, or those that had experienced 
stressful or less than ideal health care encounters, expressions of trust appeared the 
most tenuous and direct expressions of trust were either absent from or less notable 
in their accounts. For instance, Helen described feeling respect and trust for her 
current doctor but felt that over the years she had experienced certain inadequacies 
in her care and felt that this pervasive trust could cloud judgement on things and 
she described adopting a more pragmatic view over time.  
What I now have found is that  what I've realised, as much as I say about I've got 
my respect for my consultant, I've got my respect for my team, and I trust them.  At 
the end of the day, I am just one patient out of 300 or a 1,000, whatever they look 
after [...] so I still have to think for myself, my consultant actually could retire 
tomorrow, or go to another placement.  He doesn't think about me; he doesn't 
actually think actually Helen’s relied on me for twenty years of our lives.  You still 
have to have that realisation, and I think sometimes you get clouded with that. 
Helen (34y) 
Parents and adult patients were also influenced by a broader institutional trust - 




trust in the research regulatory system in place within the NHS and the 
pharmaceutical industry. Numerous parents had experience of working within the 
healthcare system, and these individuals emphasised their confidence in the 
research regulatory system, at the same time recognising how people who did not 
have the same insights might be more concerned about safety. 
I know how difficult it is to do research and all the hurdles you have got to jump to 
even get the kind of ethical committee to agree to it and stuff, so I think that is more 
of a concern for  Alice’s dad that is, obviously it could be something that could end 
up being detrimental but, I have explained to him, and I know that it’s impossible to 
even get agreement if there is  even the slightest chance that it’s not providing them 
with the best quality of care[...] Mother (Alice 3y) 
This parent, a nurse, believed that practitioners ‘can’t do research if it’s going to be 
detrimental to participants health’. However, other parents who were not health care 
professionals also echoed this sentiment of placing trust in the regulatory system as 
well as members of the CF team. 
I’m pretty sure that the pharmaceutical companies wouldn’t trial a medication on a 
child do you know what I mean if there was any major problems.  I know it goes 
through lots of vigorous tests before it even reaches human testing [...] 
Mother (Dylan 2y) 
Some individuals viewed institutional trust as enough to instil reassurance about 
the legitimacy and quality of a trial, whether or not the person introducing it was 
known. One participant equated the CF centre to ‘a little cocoon’ in which he felt safe 




individuals also felt that if clinical research was raised other than on this ‘familiar 
turf’, they would immediately be ‘more wary’ and ‘more dubious’ about taking part. 
Furthermore, for some parents, trust extended to any research that was introduced 
to them via the CF centre.  One informant reflected on how being approached in the 
familiar context of the CF clinic provided a ‘subconscious’ assurance and personal 
motivation to take part. While this informant viewed himself as having a positive 
disposition to clinical research, he viewed research advertised outside of the CF 
setting as something he probably wouldn’t be interested in. 
You’re more comfortable if it’s done on familiar turf, like in the clinic, that gives 
certain assurance that the people approaching you are known by the clinic people, 
that’s a subconscious thought really because I, I don’t think like that, I don’t give it 
any thought when somebody approaches me but I imagine that actually if it wasn’t  
in that situation, maybe I’d feel a bit more wary […]I’d probably be  a bit more wary 
about something that’s generally advertised. I’d be less thrilled to take part in a 
study that had been advertised and was run completely separately.  In fact, I 
wouldn’t be interested, completely separately from the clinic. Francis (63y) 
6.4 Trust and family relations 
For the most part, data showed that a child’s trust or deference on parental direction 
and support was central to their ease with research invitations. However, some 
younger informants’ conveyed a sense of trust, in both their parents and in their 
doctor, as being influential in their decision to participate.  
Furthermore, some adults and occasionally parents spoke of depending on their 




how they drew on their every day decision-making patterns to make sense of their 
responsibility in the research context. For example, Mia described how all decisions 
she made in life constituted a ‘team’ effort including her mother, her partner and 
herself. 
We've always kind of worked as a bit of a team, and still now like I don't make a lot 
of decisions without talking to my mum about them.  Just about anything, not just 
health-related [...]  I think I need to talk it through myself a lot of the time, and just 
to hear if someone else says ‘oh what are you doing? ‘Or, ‘Yeah, I'm doing it, and 
that's fine, that's a good idea’, just that bit of reassurance, I think, so I still do that 
now. Mia (25y) 
In contrast, Megan saw the responsibility for research decisions as largely just hers, 
linked to her personal responsibility for managing to her own condition. However, 
she acknowledged that whether she would involve others in the decision-making 
process was, in part, determined by the potential impact of the research decision on 
those people around her. 
I ask his opinion but I think as an adult the sort of major decision is just mine and I 
just take it you know whether I want to or not [...] because in the end it is my body 
and it's my condition  [...] If it involved a lot of my time and a lot of our travelling 
up and down then I would obviously have to sort of say to him well you know what 
do you think about this but I think if it was something more sort of straightforward 
that I can just do without impacting anyone around me then I take the decision.  
Megan (26y) 
Nonetheless, unlike a child’s reliance on their parent's support, an adult’s reliance 




illustrated how they were accustomed to deciding for themselves in both the clinical 
and the research. Consistent with adult data, parent and child data demonstrated 
that the extent a child relied upon, or was directed by, their parents mirrored 
normal family patterns of decision-making which varied with the characteristics of 
the ‘family set-up’ and their age and developmental stage.  
I think it’s your family setup as well because some mums I know are very controlling 
even if the child is like Ellie’s age 14, I do know of some mums that the child doesn’t 
go out, doesn’t have many friends and just goes everywhere with mum.  
Mother (Ellie 14y) 
 
I suppose it’s what kind of house you grow up in and what rules you have.  
Mother (Daniel 11y) 
For instance, when younger children illustrated being unconcerned and ‘quite happy’ 
to ‘go with it’ and trust what their parents had decided, their parents 
correspondingly positioned themselves as taking the lead role within the family 
situation. Nevertheless, the extent and nature of the youngest informants trust, or 
reliance, on their parents’ direction in the research context were difficult to interpret 
through interview content alone. As younger children provided minimal, or no, 
detail about trial discussions. Even so, some insights into the nature of their 
involvement could be derived from parents’ accounts and contextual data.  One 
parent indicated how she had encouraged her son’s involvement in clinical research, 
a pattern mirrored in the context of this study interview, in which she provided 
encouragement and support for her son. 
I sat down and spoke to Jack about it, and we discussed it, and I said what do you 




kind of ok[...]  He knew that he would be trying something and maybe it would help 
him when he gets older and… I think he kind of thought oh ok then [...]    
Mother (Jack 8y) 
Jack displayed an unconcerned awareness of having taken part in a clinical trial and 
deference and reliance on his mother's support and guidance. This finding was 
mirrored in the accounts of other younger informants and parents. Parents of older 
teenagers generally accepted that they were no longer in control and their children 
were no longer dependent on them. They positioned themselves accordingly, taking 
a ‘back seat’ in the research context as they had done in other areas of their life. 
She is nearly 17 she has got to make some decisions now, haven’t you really, got to 
decide for yourself about lots of things. Mother (Amy 16y) 
All teenagers indicated that they would still discuss research decisions with their 
parents and value their opinion even where they made the decision themselves. For 
older teenagers, conceptions of trust mirrored those found in adult and parent 
accounts, including references to both interpersonal and institutional trust. The 
oldest teenager, whose parents declined to be interviewed, perceived the decision as 
being shared between her and her parents, but she indicated that she trusted her 
parents to perform an initial level of screening to check the trial was reasonable for 
her to consider in the first place. 
It was, both mine and my parents, of course, my parents had to discuss it first, to see 
whether they would want me to do it or whether they thought it was ok for me to do 




Consistent with adult and parent accounts, teenager accounts of interpersonal trust 
were connected to the duration and success of the relationship with the CF team. 
For instance Ben’s trust in the clinical team provided his justification to ‘always say 
yes’, allowing him to acquiesce to these ‘offers’. 
I know all the CF team, and I have known [CF nurse] for nearly 17 years, so there is 
that, whatever, I have practically trusted [CF nurse] with all the decisions she has 
made for me, and like whenever there is an offer like that, she has always asked me to 
see if I wanted to do it and I have always said yes.  Ben [16y] 
Similarly, Kirsty’s perception of risk was mediated by an assumption of trust in the 
medical profession. 
 Well they are doctors aren’t they, you are supposed to trust them [....]thinking oh 
they won’t put me in harm’s way will they [...] the basics are you are a doctor, you 
are supposed to help people, so you are not going to give me something that is going 
to kill me. Kirsty (16y) 
Some parent and child accounts illustrated how family patterns were shifting. For 
instance, during one joint interview, a parent expressed concern at no longer being 
needed or entrusted with the responsibility of research decisions, prompted by both 
her sons developing independence and the CF team’s encouragement that the child 
with CF does so. 
And she [CF practitioner] said you do realise [...] age thirteen did she say, he is 
going to be getting called in by himself [...] to the doctors room by himself. And I feel 
like that’s a hard thing, to be sort of discarded in a way shall we say, because you 




just want to speak to Peter, and then you will be brought in and told. And I know 
it’s to get him ready to go onto the adult clinic she said, but I still think that is a 
hard thing to be told [...] to be, ‘Oh Peter what do you think about this trial, don’t 
worry what your mum says, we don’t, she hasn’t got a say in it, I think that is going 
to be a hard thing, to sort of go, hang on a minute, I am his mum [...]  
 Mother (Peter 12y) 
At this point in the interview, this parent changed the focus of the interview to a 
direct dialogue with her son.  
Mother (Peter 12y): So how would you feel being asked to do a trial without me 
being there?   
Peter: Don’t know. 
Mother: Would you feel that you are able to sort of speak up for yourself and decide?  
Peter: Yes, but (...) but I would ask you, it would be better if you knew what 
it was and all that. 
During this exchange, Peter was placed in a sensitive position on hearing his 
mother’s concerns about future changes, yet anticipated that he would be able to 
‘speak up and decide’ while still valuing his mother’s involvement. Throughout the 
interview, Peter and his mother referred to changes in their patterns of decision 
making that were already afoot, with Peter becoming more knowledgeable and 
increasingly aware of his independence, while his mother was in the process of 
priming herself and Peter for further changes in how they would make decisions.  
Peter appeared to negotiate all these interactions sensitively with respect and 
concern for his mother’s needs while conveying a clear sense of his developing 




in which young people were careful to uphold their parents’ desire to be wanted 
and relied upon, illustrating diplomatic management of sensitive situations in 
which family roles were in transition.  
These findings were supported by practitioner data which indicated that children in 
the ‘in-between’ period, somewhere before the teenage years while being 
comparatively reliant on their parent's influence and direction were also in a period 
of transition. However, some practitioners inferred that depending on a child’s 
stage of development and family pattern, children during this ‘in-between’ period 
were generally more inclined to acquiesce to parental influence and take part in a 
trial that their parents believed ‘they should take part in’.  
Mum's always in charge, isn't she, yeah [...] we’re very influential, aren't we, as 
parents.  Nurse 3 (child) 
 
If you’re a nine-year-old kid and your parents really think you should take part in 
the trial, they make sure you take part in the trial, and you say yes, and you sign 
your consent form kind of. Doctor 4 (child)  
Consistent with parent and teenager accounts, practitioners viewed their trial 
discussions as more or less comparable to discussions with adult patients. 
We have had some teenagers that I have spoken to about the trial, you know one 
would talk to them in almost the same way you would talk to the adults because they 
are very, you know they are very well versed in CF by that stage   




The influence of a child’s family set-up on the nature of a child’s involvement in the 
research context was inextricably linked to their developmental stage, personal 
experiences of clinical research and existing level of involvement in the clinical 
context. 
6.5 Trust and recruitment success: practitioners’ perspectives 
Practitioners implied that in the context of CF they viewed clinical relationships as 
distinct from those in other contexts, owing to the longevity and intensity of these 
relationships in CF. They emphasised how knowing and caring for individuals with 
such a serious condition created an intense on-going clinical relationship. It had also 
fostered trust, albeit that this had ‘taken time to build’.  Throughout their accounts, 
practitioners alluded to an ‘element of trust’ as being central to the success of these 
long-term relationships and to ‘recruitment successes’, both regarding the ease of the 
recruitment encounter and the likelihood that an individual would agree to the 
research offer. 
TABLE 6.1: The centrality of trust to ‘recruitment success' 
 
The reason people go into trials, mostly, is because they trust the people asking them, on the whole […]  
Doctor 3 (child) 
 
From a parent’s point of view, I think if it was coming from somebody that they knew and they trusted clinically, 
they would probably feel more comfortable about saying yes. Doctor 5 (child) 
 
Your recruitment success, always comes down to how much they trust in your judgement, if you say would you 
do this, and they trust you I think they often will do it, whereas if they don’t know you from Adam, just some 
random person comes up they won’t, you know they will say no.  Doctor 7 (adult) 
 
Our recruitment in a CF unit relates to if they know the people running the unit, trust them, and they are 







While practitioners recognised that patients often declined when they were 
approached by someone they knew or ‘trusted clinically’, they believed that patients 
would generally feel more ‘comfortable about saying yes’ to someone they trusted. 
Furthermore, practitioners also assumed that patients would be more inclined to 
trust practitioners who had ‘looked after them for some time’. 
Within the context of a trusting relationship practitioners also felt that patients were 
motivated by ‘wanting to help’ practitioners as individuals. 
The patients know me, they trust me and they will do things for me [...], and it's 
taken me a few years but now a lot of the patients know me, but it takes time to build 
that relationship [...], but I think it's quite a compliment that they know who you are 
and that they're wanting to take part and they're wanting to help you.   
Nurse 3 (child) 
 
They did it because they really liked her, and you made a difference to people and 
that, so for difficult studies, it's invaluable to have a, you’ve got to have the right 
person. Doctor 3 (child) 
While likability and trust were viewed by some practitioners as components of 
‘recruitment success’, based on the assumption that patients are less likely to take part 
in a study if they did not like, or trust, the person asking them, other practitioners 
were concerned about this situation. These practitioners described unease with 
regards to balancing their research and clinical roles. This unease was manifested in 
practitioners’ accounts as both personal discomfort about their position and 




dynamic that existed during recruitment which involved asking them ‘for a favour’, 
rather than the typical provider role, as the source of this discomfort.  
I have found it a bit uncomfortable, that kind of that dual role and then asking them 
to take part, in a study and I think the reason it feels uncomfortable is partly because 
it feels a bit like asking for a favour, or for asking for some of their time[…]  
AHP (adult) 
A further concern expressed by some practitioners was a patient’s susceptibility to 
overlooking the potential risks, in a context in which a patient’s primary motivation 
to participate was to help out a trusted practitioner.  
You have to really be careful because if you enter them in a trial there is a risk 
involved and you cannot guarantee there will not be any potential harm to this child 
and they have to be aware of that in many ways.  And that’s where you then think, 
like, I don’t want you to do this as a favour to me.  If you want it because you think 
it might be good and you want to help science and everything, then I’m really happy, 
but I don’t want it just because I’m suggesting it and you feel obliged to do me that 
favour. Doctor 4 (child) 
In addition, several practitioners recognised that patients might feel pressurised in 
the context of longstanding trusting clinical relationships, arising from a sense of 
being  ‘indebted’,  ‘obliged’  or ‘beholden’ to reciprocate for the care they had received. 
Practitioners also spoke of people who may view declining participation as 
somehow, ‘letting you down if I don't do this trial for you’ or being concerned ‘they 




In the main practitioners described their principal means of countering such a sense 
of obligation was to put a great deal of emphasis on the voluntary nature of the 
request and to emphasise that declining would have no negative consequences. 
The one thing I always stress and I usually stress it more than once when I am 
discussing things with people, is to say look you know, I promise you that even if 
you say no [...] even if you don’t take part it’s not going to make any difference to 
me, because I am still going to be your [practitioner] and I am still going to be 
looking after you, and I am not going to look after you any differently.  
Doctor 5 (child) 
Some practitioners spoke of the benefits of a ‘clean researcher’ in which patients had 
no attachment, or dependence, on the practitioner responsible for recruitment. 
However, there was a converse situation that resonated with the perspectives of 
some patients, who felt more comfortable saying no to a trusted practitioner. 
Furthermore, in the context of an existing clinical relationship, one practitioner 
spoke in detail about ‘protecting’ a parent from saying ‘yes for the wrong reasons’ to an 
invitation for her 4-year-old daughter to participate in the TORPEDO-CF trial. This 
practitioner believed the parent, who had been initially approached by someone 
unfamiliar, had felt obligated to participate and this practitioner herself felt she ‘was 
being pressurised to get her into the study’. In this situation, she spoke of her duty to 
enable the mother to make a decision that was ‘the right thing to do’ at that time, 
which in this case the practitioner felt was to start a course of IV antibiotics and 




These findings illustrated both the perceived significance of trust in relation to 
‘recruitment successes’ but also the sensitivity of the situations where practitioners 
felt they had to tread carefully. 
If you have got a good relationship with the family they trust you and I think that’s 
so important that they will be guided by you but I know how far to go, not 
overstepping it. Nurse 1 (Child) 
6.6 Summary 
A social discourse was demonstrated by informants’ emphasis on the significance of 
feeling ‘at ease’, ‘comfortable and ‘reassured’ during recruitment encounters and this 
was central to how informants made sense of research invitations. Furthermore, 
notwithstanding the variety of research experiences, considerable commonality 
existed within this discourse. In the main, this commonality could be explained 
through the impact of the social relationships within the recruitment encounter and 
the broader social context in which these research invitations were made. Trust was 
also central to how informants constructed a fair offer, which included interpersonal 
trust between participant and recruiter and the broader concept of institutional 
trust. Trust, as seen by the emphasis informants placed on being approached by a 
familiar member of the CF team who was responsible for their care, or their child’s 
care, was significant in how informants made sense of the approach and subsequent 
participation decisions. 
Patients and families gained reassurance by being approached about something 
non-routine in a context they were familiar with. Furthermore, the qualities patients 




insights into qualities which had the potential to optimise the social context of 
recruitment. These qualities were the reason informants expressed a preference for 
research to be raised within an existing clinical relationship, and were also 
prioritised as integral to successful approaches by new practitioners. While an 
optimal approach alone was not enough to secure an individual’s participation, 
successful approaches helped to maintain open, receptive attitudes to the idea of 
engaging with research and ensured future approaches did not feel burdensome.  
Many practitioners also highlighted the significance of competent clinical 
communication skills for ‘sorting out’ recruitment and providing the framework for 
how successful research offers should be made. 
In addition to providing comfort and reassurance for informants during the 
approach, trust also appeared to ease or lighten the load of shouldering the 
decisional responsibility, particularly for parents. Informants who had consented to 
trials typically couched ideas about costs and benefits in a framework of trust, 
which included both interpersonal and institutional dimensions and parental trust 
for younger informants. To what extent their trust in the recruiting practitioner 
allowed these informants to acquiesce to the invitation will be examined in the 
discussion. However, what is clear is that trust was pivotal to informants’ 
satisfaction with the approach and their interpretations of a fair offer. 




CHAPTER 7: FINDINGS 
WHEN IS A RESEARCH OFFER FAIR - A PSYCHO-MORAL DISCOURSE?  
7.0 Introduction 
In this chapter, I will describe the findings which characterised the moral and 
psychological dimensions of informants’ accounts of a fair offer. This psycho-moral 
discourse was by no means clear-cut and informants’ portrayal of their decision to 
participate in a clinical trial was as a nuanced ‘really personal decision’ in which moral 
and psychological dimensions were typically interlinked. This discourse was also 
closely interwoven with informants’ personal weighing up of tangible costs and 
benefits associated with trial procedures (rational discourse) and the social context 
of recruitment (social discourse). Nonetheless in this chapter I aim to clarify the 
overarching patterns characteristic of this discourse  
Central to this psycho-moral discourse was how informants worked to explain what 
they perceived as a research invitation which they felt comfortable accepting or in 
the case of practitioners one that they felt comfortable offering. This discourse was 
aligned with their personal moral identity and self- interests. Informants’ who had 
agreed to participate emphasised the morality of their decision, viewing research 
participation as a common good, something they felt a sense of moral responsibility 
towards. They also emphasised the significance of hope and the maintenance of an 
optimistic outlook in making sense of their decision to participate. Practitioners also 
spoke of the importance of personal judgments concerning the ‘morality of the study’ 
which enabled them to feel comfortable about approaching patients and present the 




In this chapter I first present the patient and parent findings before turning to the 
practitioner findings. As convergences across adult and paediatric settings were 
prevalent in relation to this dimension of their accounts, my presentation of the 
findings reflects this by largely covering both settings jointly.   
7.1 Patients’ and parents’ perspectives: a moral discourse 
7.1.1 Research as a common good 
Medical research was accepted by informants as a way to ensure that treatments 
continued to improve and advance, and they considered it ‘a vital’ part of the 
medical profession.  
I think it’s needed; it’s obviously needed and … without research you wouldn’t move 
on really would you. David (40y) 
 
You have got to do it; you have got to progress because if you don’t, you are not 
going to learn anything, nothing is going to be developed, I think it’s massively 
important [...] Mother (Jack 8y) 
 
All this new stuff is less time consuming, so I can sort of do it on the way to school 
[...] I can see such a massive difference from when I was a little kid to now even. 
Amy (16y) 
Teenagers with direct research experience typically expressed a view which was 
consistent with parent and adult accounts. Children also conveyed research as 
something which had the potential to make them ‘get better’ in the future and help 
them ‘get well’ and viewed research as something essentially good. However, their 




integral to informants’ accounts was a broad acceptance of clinical research as 
necessary to sustain improvements in healthcare. A view which I interpreted as 
reflecting informants’ overarching acceptance of clinical research as a common or 
public good, something they believed to be in the interests of all.   
 Informants indicated how their disposition towards clinical research and trials had 
developed over time and was something, which was continually being shaped by 
ongoing experiences and personal circumstances.  Before being approached, or 
becoming more informed about clinical trials, some informants accepted that trials 
were something they hadn’t   ‘taken an interest in’ or something they ‘didn’t 
particularly agree with’, often due to the prerequisite animal testing or personal costs 
involved. Faced with a new situation, they accepted that one’s views ‘just change on 
everything’. 
Not only did an informant’s emphasis on their belief in clinical research as a 
common good shift according to their life experiences, but their views also varied 
throughout the course of an interview. For instance, one family, at the start of the 
interview highlighted their ‘pro-research’ attitude as being influential to their 
commitment to ‘wanting to help’ for the ‘bigger picture’. Following reflections on a 
burdensome first study for their daughter, their discourse shifted to positioning 
research as something that ‘at the end of the day, nobody likes to do', and that the 
situation feels different ‘when it comes to your own child’. Those who had never been 
approached about a clinical trial or who had declined trial participation talked 
about clinical trials in less appealing or more ambivalent terms. These individuals  
described trials as ‘technically beneficial’ or a ‘necessity’, and as something that 




While informants accepted the necessity of clinical trials to generate medical 
knowledge, they also expressed caution relating to the inherent uncertainty 
underpinning clinical trials and the testing of new medicines. They illustrated an 
awareness of the negative public image attached to clinical trials and that not all 
were intrinsically good. Both parent and adults made references to what appeared 
to be the now-infamous ‘Northwick Park trial’11 and an awareness of the negative 
stereotypes often associated with clinical trials. 
Father (Harry 1y): If you say clinical trials to somebody or trial, they think, whoa!  
Mother: Yeah, guinea pigs, yeah.   
 
I'd seen things in the paper about it, a good few years ago there were some people all 
their heads had blown up like raspberries, you never read good things in the papers 
do you [...] Father (Joseph 5y) 
 
You occasionally get the odd horror stories in the press of drug trials and things, so I 
think these days there is always somebody who is going to come up with a horror 
story of something [...] Gareth (40y) 
For some informants, the value of research was reinforced by witnessing first-hand 
the introduction of new and improved treatments. Consequently, they were able to 
make a connection between progress in treatment and clinical research 
achievements, providing tangible endorsements of the value of research. 
                                                     
11 An independent phase I trial conducted by Paraxel involving eight male paid healthy volunteers. 
The six volunteers who took the drug experienced serious life-threatening adverse reaction to the drug 




DNase that’s quite new to Amy now, and that is amazing, DNase is amazing stuff.  
And even like the physio techniques, have all changed now [...] but again that would 
have been trials, to do things like that. Mother (Amy 16y) 
Some individuals also spoke of the value of treatment advancements from research 
in relation to increasing life expectancy for people with CF, with many adult 
individuals describing how they had exceeded their predicted life expectancy. 
The way it’s progressed so much over the last I mean every year they have said life 
expectancy increases, and obviously, that is down to the medication and the care 
which changes obviously because people take part in research […] Mother (Lily<1y) 
Even though an individual’s emphasis on the value of research was variable, an 
acceptance of clinical research as a common good, vital to ensure the progression of 
healthcare was evident across accounts. On its own, a positive personal disposition 
towards clinical research was not sufficient to amount to a fair research offer. 
Nevertheless, attitudes towards research did appear to influence initial receptivity 
to engagement with research and provided an essential foundation for an 
individual’s construction of a fair offer. 
7.1.2 A moral responsibility to contribute to a common good  
Patients and parents accepted that research participation carried uncertainty, yet 
they recognised research as something valuable which ‘has got to be done’ to ‘make 
things better’ and ‘improve things for the future’. Some equated participation in 
research with charitable deeds and hence as ‘doing their part’ for people with CF, 
comparable to ‘sticking ten quid in a charity pot at the end of the week’. Consequently, 




contingent on viewing an individual willingness to engage with research as a form 
of moral ‘responsibility’ or  social ‘duty’, in which everybody should try and do their 
share. The emphasis informants placed on a sense of moral responsibility to 
contribute to the common good  was variable with some viewing research 
participation as a ‘duty’,  ‘task’ or  even an  ‘obligation’, something that they felt they 
‘should do’ if in a position which enabled them to do so. The unifying concept within 
this discourse was the moral value informants assigned to participating in clinical 
research and a corresponding moral responsibility to engage with clinical research.  
However, this view appeared to be complicated by the particular context of CF. 
Informants expressed concern that things might ‘stagnate’ or stop improving for 
future generations if people weren’t willing to participate in clinical trials. 
Informants also spoke of being ‘grateful’ to imagined ‘people’ who had contributed to 
the development of current CF treatments, feeling gratitude and a moral 
responsibility to continue to this ‘cycle’ for imagined future individuals and families. 
The fact that Harry is able to take part in it I feel that we're almost giving something 
back by letting him take part [...] Harry gets the treatment that he does now, because 
other people have undergone this sort of thing, and we're so grateful that people do, 
so of course we'd like do whatever we can [...] Mother (Harry 1y) 
 
The way I see it if people hadn't done trials,  things like creon and different things 
like that, I wouldn't have benefitted, so I suppose it's part of the cycle really sort of 
trying to make sure that people in the future benefit as I have benefited from people 




Some informants also offered a spiritual and philosophical take on the situation, 
speaking of helping with research as being part of a ‘life cycle, do good, and you’ll get 
good,’ conveying a moral responsibility akin to reciprocity. 
For some individuals, an awareness of the relatively small population of CF patients 
heightened their sense of moral responsibility to participate in clinical research. 
Consequently, some felt a more pressing responsibility where a trial was struggling 
to recruit or was specifically targeted at patients like them. Informants’ motivation 
‘to give something back’ often also extended to the Hospital and the CF team 
managing their own or their child’s care.  
We’d do anything to help them back for everything they have done for us[...]I just 
wish I could do more, you know, we are just so grateful to them, they have just been 
fantastic […] Mother (Amy 16y) 
For some older adults, their sense of  gratititude and moral responsibility  to  give 
something back appeared to be  particularly keenly felt  due to: the many years of 
treatment they had received; an awareness of the vast improvements in CF care and 
life expectancy, and awareness that other people with CF were not as fortunate as 
themselves, both in terms of longevity and level of disability. 
I’ve been part of a CF clinic, as a paediatric and as an adult, for the best part of forty 
odd years, forty-five years.  When I first started, it was very much children, but you 
didn’t really see anybody over ten.  As I’ve got older, hopefully, the people around 
me have got older but there are less and less of us every year, and I just feel a little 
bit that you’ve got to give something back.  You know, I mean I’ve taken all the the 
care from people doing it before me, so I just feel a little bit of obligation that if I can 




An individual’s sense of moral responsibility was further complicated in the context 
of parents, who had to balance their own values with the needs of their child and 
their responsibility as a parent. Balancing these multiple factors had the potential to 
result in decisional conflicts for some parents. For instance, one parent questioned 
whether she had the balance right between taking the lead role in decision-making 
and her tendency to say ‘yes, yes we will do that trial’ without always saying to her 
son ‘what do you think’. 
 I sort of maybe do it a bit wrong myself because I go, yes, yes, we will do that trial, 
we will do it, and I don’t always say what do you think Peter, do you want to be put 
through that [...] because my heart would say, well yes you should take part, it’s 
important we should, without stopping and thinking hang on, what has Peter got to 
go through. Really so I suppose I am pretty selfish that way because I want the cure, 
so we are going to do that trial [...] Mother (Peter 12y) 
 
This parent viewed this tendency to say yes to trials as being driven by both a sense 
of moral responsibility to help other families with CF and her desire to find a cure 
for CF, motivations which she positioned as being ‘pretty selfish’. 
7.1.3 A moral education   
For some adults, their sense of moral responsibility to engage with clinical research 
had begun with a kind of ‘moral education’ from their parents that mirrored a 
process of enculturation to clinical research. They recalled how as children they 
were made aware of the personal and social significance of taking part in clinical 
trials. 
My mum said, Kate, you know, they wouldn’t, you know all these things wouldn’t 





My mum just encouraged that you know obviously if you didn’t do these kind of 
things then you know, if no one ever did them, no one would get any benefit out of 
them. […] John (33y) 
These adults acknowledged how this powerful moral message had ‘stuck with them’ 
ever since childhood and influenced their attitude and subsequent participation in 
many trials and studies. In contrast to this early introduction to the necessity of 
research, other adult informants reflected on how their parents had shouldered the 
‘worry’ of CF while they were younger.  Now as adults their sense of moral 
responsibility to help with research was more keenly felt. 
I never really considered CF as an issue because my mum and dad did all the 
worrying for me. So as soon as I become an adult and had responsibilities that I was 
like, a) felt that I had responsibility to other people to try and push my own 
treatment forward but also decided that I was, I wanted to be involved in trials […]. 
Alex (29y) 
Resembling the moral education adults described receiving from their parents, 
parents within this sample also spoke about a moral training they either had begun 
or that they anticipated they would begin when their child was old enough. Parents 
described how this education would involve guiding and preparing their child 
about the value of participating in research which they equated to promoting ‘good 
morals’. 
If you can almost sell it to your child as in, you know, tell them that they're doing a 
really good thing, then it can promote their sense of wellbeing as well when they're 




responsibility as a citizen and about helping others out and promoting good morals 
in them as well. Mother (Harry 1y) 
 
I would encourage her to take part in anything that is going to benefit, especially 
stuff I suppose that is still going to benefit her, that is I would encourage that even 
more, but even if it’s not going to benefit her but will benefit others then I still think 
it’s important. Mother (Alice 3y) 
When this moral training would be initiated by parents was dependent on a number 
of factors including developmental stage, the value of a particular trial, personal 
belief system and the family dynamics. Prior to a child being ready to take on board 
the moral dimension of trial participation, parents spoke of the importance of 
‘quantifying’ and ‘explaining to the child what was ‘going to happen’ in quite tangible 
terms. Particularly for children who were not yet teenagers, parents described 
extending research discussions to include a moral education, which was consistent 
with their own personal values and ‘family set-up’. For some parents, this began with 
a discussion about research in general, not connected to the specifics of a trial. 
We have talked about it quite a lot about research in general because if we don’t have 
research, then things don’t get found out and things don’t… they don’t go on. So it 
has a knock-on effect for everyone and Rachael included.   
Mother (Rachael 10y) 
However, for some these discussions were only prompted by the specifics of a trial. 
In this situation, the value attached to certain trials appeared to be most influential 
in shaping the nature of the discussion. One parent described how the ‘moral 
education’ she provided for her daughter, to enable her to understand the value of 




something she wished she ‘didn’t have to do this with my eight year old daughter’. This 
parent indicated how she felt constrained by having to educate her daughter about 
the value of research in relation to her condition, due to this parent’s belief in the 
promise and potential of this particular trial, which she viewed as being potentially 
‘huge’.  
When we went to the trial last year when she was eight and we had to talk to her a 
little bit more about CF because she had to have an understanding of the importance, 
because as soon as we said to her, “There will be blood tests,” she was like, “No, I 
don’t want to do it.”  So we had to try, without scaring her, we had to pitch it right 
where she understood that if she could consider doing this trial she’d be helping her 
and lots and lots of other people like her, she’d be part of doing something huge, first 
thing to correct a gene ever for CF [...]   Mother (Emily 9y) 
In contrast, some parents described being selective about what they felt their child 
needed to know in order for them to accept the research offer as something 
reasonable. 
I have told him, we are doing these trials to try and find a cure and if people don’t 
step forward and do these trials there will not be a cure. So that is about as much as 
our Daniel needs to know to go… yes, all right yes.  He doesn’t need to go into 
specifics of what exactly like he knows he is having an inhaler, and he just thinks he 
is having an inhaler and he hopes it will make him a bit better kind of thing.  
Mother (Daniel 11y) 
Some parents spoke of negotiations with their child including a theoretical 
discussion about why research was needed and the aim of the trial, without going 




their child had initiated. For instance, one family spoke of how their daughter from 
a young age has always preferred to be talked to ‘as an adult because that’s the kind of 
person she is’. Other parents assumed that living with a serious lifelong illness 
potentially resulted in children having to ‘grow-up’  earlier than their healthy 
contemporaries because ‘they’re  talked to by adults a lot more’  and ‘ given more 
responsibility’. 
Conversely, some parents wanted to protect their children from the burden and 
responsibility of living with a lifelong condition, aiming to preserve a sense of 
‘normality’ for as long as they could. One parent spoke about how she was holding 
back information she thought he did not need to know yet, or did not feel 
comfortable with him knowing.  
 I relay it to Jack because I always kind of keep it all a little bit and even CF to a 
certain extent if it’s not majorly affecting anything at the minute and for as long as I 
can keep it like that then I will do.  Because I know what the ..... I can see over there, 
but we are not going there yet. Mother (Jack 8y) 
This parent stated she was not ready to ‘go there yet’ implying she was not yet 
emotionally ready to consider the potential severity of her son’s condition. This was 
supported by her acknowledgement that she had not ‘ever said the word cystic fibrosis 
to’ her son until he was seven, when during his annual review he asked his mother 
‘why are we here’. When they got home she:   
‘explained to him you have got something called cystic fibrosis, you know when you 
get poorly a lot, that is  why you need extra medicines and occasionally you need IVs 
just to make you better, ok have you got any questions, and he just said ‘oh I think it 




For some parents of children in the ‘in between’ years, constructing fair involvement 
was perceived as ‘hard for parents to pitch it right’. This intricacy was in part related to 
the recognition that ‘at the end of the day’ it was their responsibility to act in their 
child’s best interests and make the ‘right decision’. Furthermore, parents’ 
negotiations and their child’s involvement were bounded by what parents wanted 
their child to know or the child needed to know about the ‘seriousness’ of their 
condition.  
7.1.4 ‘An inner glow’ from contributing to a common good  
Informants who had agreed to take part in clinical research viewed their 
participation as something virtuous, indicating that there was ‘a sense of fulfilment’, 
‘inner glow’ or ‘feel good’ factor, from participating in something of value.  
I can’t say yes, I will lead a better life because of it, but it gives you a sense of 
fulfilment that you’ve done something that maybe somebody else can have a bit of 
advantage over.  But it’s not a personal thing; I haven’t said, you know I’m not 
fussed that the advantage is for me. Tim (49y) 
 
I think you get a, an inner glow, however small, that you’ve taken part. 
 Francis (63y) 
While an informant’s motivation to contribute to a common good could be equated 
to a form of altruism, a ‘feel good factor’ derived from upholding a sense of moral 
responsibility comprised an important intrinsic or psychological pay-off. 
Consequently, informants’ moral accounts of their decision to participate typically 




If people don’t take part in these things and aren’t willing to be selfless to a point, then 
it ain’t going to advance, and you’re not going to find the cures [...] Adam (19y) 
For example, Kate who had taken part in several clinical trials perceived her 
psychological motivation to ‘feel good about myself’ by helping future generations as 
being partly ‘selfish’. 
I feel like I owe it to all the people in the past that have done things that I have 
benefited from, so it’s sort of like a payback you know and I know that I will be 
helping so it makes me feel good about myself because I know that I am helping 
future generations of people with CF, so it is quite a selfish thing I think. Kate (29y) 
I viewed informants’ references to a ‘selfish’ motivation as an acknowledgement of 
this intrinsic pay-off which they derived from contributing to something they 
regarded as both socially desirable and morally valuable.  
If there is anything that you can do, just a little, little tiny, tiny little little thing that 
in 10 years time, because Jack and 3,000 other children have had this certain inhaler 
we know that it is going to help not just your child but kids that are being born now 
with CF, you can’t not do it really I don’t think. Mother Jack (8y) 
I viewed the number of people this parent hoped to help in the future as conferring 
the value of participating in a clinical trial and her corresponding sense of personal 
satisfaction from taking part. Similar to adult and parent accounts, some older 
children also implied that they derived a feel-good factor from contributing to 
something worthwhile. For instance, Rachael’s father directly reinforced the value 
of her current participation in a nebulised drug trial and Rachael requested this 




Father (Rachael 10y): But with Rachael’s doing this inhaler for 20 seconds a day 
which is basically is all it is, we don’t know how many people it’s going to help at the 
end of the day, so for 20 seconds a day, you don’t know how many people you are 
helping, Rachael.You could be helping thousands just doing that, not just you… do 
it for yourself. 
Rachael: Can you put this bit in it?  
Emma: Yes I will put this bit in. 
Clare, who had been approached to take part in two clinical trials, described taking 
part as both helping herself and ‘millions’ of other people.   
I like the fact that they have done, that they do the trials and because it makes me 
think that you know I can provide answers for other patients with cystic fibrosis and 
that I am not just helping myself it’s helping millions of other people as well.  
Clare (17y) 
Again, the number of people Clare hoped to help appeared to confer the value she 
assigned to trial participation and her personal satisfaction at being part of 
something worthwhile. Some parents and children also described feeling ‘quite 
lucky’ or ‘honoured’ to have been invited to take part in clinical trials. 
We feel quite lucky that we’ve taken part. I think it’s important to then think in 
Dylan’s  growing up that he was important in finding out something quite vital to 
the functioning of, treating quite a common [infection], well for CF people, and how 
the NHS deals with it. Mother (Dylan 2y) 
 
 I was particularly; I was quite honoured that they’d thought of us [...] I felt quite 




Consequently, informants’ accounts conveyed interdependence between the value 
they placed on research and the intrinsic pay-off or feel-good factor they derived 
from participating.  Moreover, the greater value individuals placed on research, the 
more emphasis they placed on their moral responsibility to participate in research. 
 7.1.5 Making sense of saying no: balancing personal interests and responsibility:  
In a context where informants positioned research as a valuable activity, to which  
they ascribed some sense of moral responsibility to participate, guilt could arise 
when an individual felt it was in their child’s or their own best interests to decline 
participation.  
I did feel guilty, and I did say, “We would do anything for Emily and anything for 
the CF community, we did the London trial, but this particular time we have to opt 
out because we want to do what we feel is right for Emily right now”, and that’s 
why we declined it [TORPEDO-CF] [...] Mother (Emily 9y) 
 
Part of me felt guilty for saying no, but it was Mia’s  interest for me that, we wanted 
it, we wanted it rid, rid of it didn’t we. Father (Mia 8y) 
In this situtaion, an individual often employed a guilt discourse to make sense of 
their discomfort at turning down something they believed to be morally valuable.  I 
interpreted these references to guilt as an indication that these individuals 
acknowledged the moral value of trial participation yet this had to be balanced 
against their other responsibilities and their personal interests. How individuals 
made sense of their participation decision was typically multi-dimensional 
involving a series of trade-offs extending beyond a moral discourse. For parents 




and this often superseded their moral responsibility to take part. Nevertheless they 
often employed a guilt discourse to make sense of turning down something they felt 
they had a moral responsibility to be part off. This discourse was most prominent in 
individuals who had emphasised the moral responsibility they felt towards 
participating in clinical research, and often it was parents who did so rather than 
patients. Indeed some parents conveyed their responsibility to participate as feeling 
almost obligatory. Consequently avoiding an anticipated feeling of guilt was an 
important motivation in their decision to allow their child to participate in clinical 
research.  
I did initially feel a bit obliged to say yes [...] it’s just, you know you don’t like to say 
no to people, and it was in the back of my mind worrying about side effect and things 
like that. But then after thinking you know going along the lines again if nobody 
does anything, nothing will change, and treatment will always be the same, and 
nothing will get advanced. Mother (Nathan 16y) 
Teenagers and adults also conveyed a sense of moral responsibility to contribute to 
something that they believed to be of value that had the potential to improve the 
lives of people with CF in the future. Therefore, their decisions to decline also 
resulted in a moral ‘wrestling’ and a sense of feeling ‘guilty’. Adults who had 
conveyed a more reticent or ambivalent attitude towards research equally expressed 
a moral responsibility that they ‘should take part’ to help themselves and others. One 
informant countered this sense of responsibility by imagining ‘loads’ of other people 
willing to take part or that an alternative method of conducting the research existed 




I just don’t volunteer because I’m sure there’s loads of other people that are out there 
probably would volunteer over me [...] I’m sure if I don’t take part there’ll still be 
another way for them to do the research[…] Sara (30y) 
Some informants worked hard to morally defend their decision to decline a 
particular study in relation to other studies that they had already participated in. 
Several informants indicated that they had taken part in this study to compensate 
for the trials or studies they had turned down in the past.  
Informants indicated that there was no external pressure surrounding trial 
participation decisions by stating that the CF team ‘were quite happy if I said no’ and 
that ‘nobody made them feel like that’. Hence, it seemed that their sense of guilt was 
personally derived, a view that ‘you can’t expect everybody else to find the information’ 
or ‘to do the work’. Some informants also expressed concern about what ‘other people 
might think’ or the personal discomfort of having ‘to say no to people’. 
It is possible that references to guilt were employed as a performative device to 
enable informants to present themselves as a good person, even though they had 
said no to something they believed to be a virtuous act. It is equally possible that 
references to guilt represented intrinsic cognitive discomfort or ‘cognitive 
dissonance’ (Festinger 1957)12, which resulted from the difficult situation of trying to 
balance an individual’s moral integrity and self- interests. Consequently, these 
accounts highlighted the tension between what is theoretically ‘something good’ and 
                                                     
12 Cognitive dissonance refers to an emotional state which occurs when an individual holds attitudes, 
beliefs or behaviours, which are not consistent and are in disharmony (dissonance)  (Gawronski & 




a personal reticence about what may be involved at an individual level in a context 
of uncertainty. 
7.2 Patients’ and parents’ perspectives: a psychological discourse 
7.2.1 ‘Hoping for the best’  
A moral responsibility to contribute to the continued research effort in cystic fibrosis 
was an important foundation of a fair research offer, yet always threaded through 
this moral discourse were various strands of hope. 
Personal expressions of hope were emphasised where individuals had agreed to 
participate, and were less prominent in informants’ accounts of trials that had been 
declined.  In the first instance, as discussed in the rational discourse, individuals, 
who had consented, indicated how they ‘hoped for the best’ while accepting that there 
were no guarantees.   
Mother (Rachael 10y): I think that people have to make sure that they realise that 
it’s not going to make an effect sometimes […] 
Father: It’s just, something she does, every day.  
Rachael: Just hope for the best.  
 
When we were discussing it [the TORPEDO-CF trial] at the hospital we said you 
know it’s not going to be detrimental to Alice’s  health but it’s not going to improve 
her health going on it necessarily, but like they said if they can know from this trial 
in a few years time whether it’s better to get them in for IVs then that will affect her 
in the long term  and if they find that it is more effective, that they have IVs then 
that is good because it means they will have to work at getting them in quicker […] 




A hope for the best personal outcome typically included an acceptance of the 
broader future aims of the research. Furthermore a personal motivation to help 
‘other people’ as well as themselves, or their child, appeared inseparable from a 
personal sense of hope. However, no account of their decision to participate in 
clinical research was solely based on the ‘bigger picture’ or common good. 
I just see it as a benefit for everybody really, for everyone with CF not just, not just 
for Isabel. Mother (Isabel 1y) 
In the context of physically demanding novel trials such as early phase gene 
therapy, personal motivations and conceptions of hope appeared even more 
involved. These informants described how they held onto a hope for personal 
benefit, despite being fully aware that this was unlikely and not the objective of the 
trial. Nonetheless, this improbable hope and a physically demanding time-
consuming trial were buoyed up with a combination of other personal motivations 
in addition to contributing to the ‘bigger picture’.  For instance, these informants 
described the psychological satisfaction derived from of being part of something 
‘revolutionary’  that may add up to finding a cure for CF. 
What were the important factors in deciding to go to the next stage?  
 
Self-gain partly, […] because this was a safety trial I knew that I was definitely 
going to get a dosage of gene therapy and I knew it wasn’t going to do much because 
it’s just one dose, but just to say that yes I know I have had a dose of gene therapy 
and it just sounds ridiculous doesn’t it but just to have that experience and to say I 
was part of it and I had yes that was my main motivation[…] To be able to say oh I 
was part of helping find a cure for CF; I think that is the biggest ego thing you can 





I guess a little bit of me thought well maybe I will get a small benefit. I just found it, 
personally I found it fascinating, like antibiotics trials, I would happily get involved 
with them, but they are not like, you know antibiotics have been around a long time 
it's nothing revolutionary, but for me, the idea of trying to treat someone at a 
genetic level, like at the very building blocks of any person like you know that's kind 
of, that's science fiction really and just to be part of it. Whether it did anything or 
not just to, that people are even attempting that was quite exciting to go and see. 
Alex (29y) 
I viewed these acknowledgements of small hopes for personal benefit as not based 
on misunderstanding or misconception, but as informed individuals actively 
choosing to hold on to the possibility of self-gain and a position of optimism. 
Furthermore, the psychological benefits emphasised within these accounts were 
present to counter any disappointment and helped sustain their motivation, 
however small. 
For the most part, individuals perceived an awareness that research is on-going, 
aimed at trying to improve treatments, as something potentially reassuring and   
something that served as a ‘confidence-booster’ and source of hope for some 
individuals. 
I think it is quite important for some trials to be advertised. I know that research is 
happening in general , you know sometimes you can think well what is actually 
happening out there, how we are progressing forward, so I think from that point of 




Patients, or parents, who had declined all offers to participate in research described 
being happy to be approached, perceiving the process as something constructive, 
‘they’re trying’, and the approaches don’t do ‘any harm’. In fact, most patients and 
parents valued being offered the choice to participate in research and perceived 
being approached as being ‘kept in the loop’ and avoiding ‘missing out’ or being ‘left 
out’. 
How individuals negotiated  hope was central to their view of a fair offer. A more 
far-reaching concept of hope was much less prominent in the accounts of 
individuals who had declined most research invitations and individuals who 
appeared more reticent about engaging with research. For instance, Sara had 
declined several trials due to a lack of ‘appeal’ or interest and her concern about 
taking time out of work. While she viewed research as essentially ‘helping’ her 
account did not convey an optimistic view of the promise of clinical research, and 
she failed to see the direct impact of research on her life at the moment. For 
individuals that had turned down a research invitation, the costs associated with 
participation had been viewed as outweighing any anticipated hope for personal 
benefit.  
7.2.2 ‘Keeping our spirits up’: hope as coping  
While many informants conveyed a hopeful attitude that research will lead to future 
improvements, for some informants actively engaging with research was positioned 
as an important ‘way of coping with the whole CF thing’ because ‘the truth of it is, in the 
end, it's going to lead to death’. 
The fact that you are taking part, it’s a bit of optimism a bit of light at the end of this 




thing … there is nothing positive about it whatsoever, so any little bit of positiveness 
you can get out of it, just makes your day that bit more, come on… let’s keep going, 
keep going, just keep plugging away and see what happens. Mother (Jack 8y) 
Participating in clinical research was conveyed as something positive to counter the 
negativity connected to this ‘ongoing, life-threatening’ condition. Accounts illustrated 
‘a bit of optimism’ and something to ‘keep your spirits up’ combined with the tangible 
act of engaging in something worthwhile, comprised interrelated sources of hope. 
This sense of empowerment derived from a hopeful outlook and active engagement 
was present across subgroups, it was most prominent in parents’ accounts and the 
least prominent in children’s.  
Throughout their narrative, parents called attention to the immense psychological 
impact and the ‘overwhelmingness’ of caring for a child with CF.  Correspondingly, 
their engagement with clinical research was positioned as providing an important 
aspect of their emotional defence to this demanding responsibility. One parent had 
described how she had created a ‘hope board’ as a way to cope with her daughters’ 
diagnosis.  She described how she had ‘cut printed things out, positive things, and stuck 
them all on this card’.  A novel mutation-specific clinical trial considered the nearest 
thing to a cure, was viewed as the most ‘positive thing’ on her board. Engaging with 
research was considered by parents as an important coping strategy, to counter their 
distress, and provide them with a sense of control, ‘taking something positive’ from 
their child’s illness, which they viewed as an ‘awful disease’. 
7.2.3. ‘Pinning hopes on a cure’ 
Informants’ perceptions of hope were complicated by the public perception of the 




heightened in the context of CF care, due to CF being the first gene for a human 
disease to be discovered and hence the first condition to offer the promise of gene 
therapy (Riordan et al., 1989; Kerem et al, 1989). For some informants, the 
identification of the ‘genetic code’ for CF and the expectation of related curative 
treatments provided a tangible basis for their sense of hope. 
When she was diagnosed, and I was thinking oh my God no, there is just no hope, 
and then [...] the genetic code was unblocked or recognised, or whatever the word is 
and then it was, you know, it was like a speeding train really [...]  Well once that 
was done that’s when all the possibilities became real. Mother (Amy 16y) 
Adult informants remembered the excitement expressed by their parents around the 
possibility of a cure following the discovery of ‘the CF gene’.  
I would have been 7 when the CF gene was discovered, and I remember my parents 
being really excited like, you know oh a cure must be round the corner [...]   
Kate (29y) 
For many informants, a sense of hope gained from an expectation of treatment 
progression through research was inseparable from a hope for a cure.  
We’re desperate for a cure, and if nobody does research then they will never find a 
cure, so I think that’s the main driving thing to it really. Mother (Daniel 11y) 
 
As parents, the only hope you have is for a cure, and without research, without 





To do with CF, it’s obviously always working towards a cure, and any research is 
good research [...] Luke (22y) 
For these informants, treatments with a curative potential were an optimistic 
prospect providing the impetus for their engagement with research and influencing 
their receptivity to clinical trials and clinical research per se. 
Within the child sample, only older teenagers directly spoke about the curative 
potential of clinical research.  
It’s a good thing, definitely, because it means that people like myself we can have 
more advanced treatment, in the long run, you know and eventually maybe find a 
cure or things that will prevent us getting more infections [...] Clare (17y) 
One teenager and her mother during a joint interview described holding on to the 
possibility of a cure as a ‘lifeline’ and something that ‘gives us hope’. At times during 
their narrative, they implied their hopeful attitude might be idealistic, but this 
concern was countered by the significance they attributed to the therapeutic value 
of holding on to this level of optimism. A similar sentiment was echoed within other 
accounts. 
Mother (Amy16y):  About 15 years ago I first was aware of the possibility of gene 
therapy, but it was so far away then and...  
Amy: And now it’s so close.  
Mother:  And now it is so close. We have just got to keep her well enough; you 
know until it comes, and well always of course  
Amy: Always, but just something to work towards, keep yourself well, sort 




Mother: I know Amy ... yes exactly it is absolutely, well it’s a lifeline.  
Amy: It is.  
Mother:  It is such a positive thought because when Amy was diagnosed there 
weren’t really, well there is no cure now at the moment, and that is the nearest thing 
in Amy’s lifetime that there is going to be to a cure and we call it the cure don’t we?  
Amy: It will be, won’t it for me. 
Furthermore, this family indicated their sense of hope derived from the curative 
potential of future treatments had provided an incentive or ‘goal’ to work towards, 
facilitating adherence to ‘relentless’ treatment regimes which could ‘drive you mad’. 
This parent described how, like other teenagers within this sample, her daughter 
had experienced a period of non-compliance during her early adolescence which 
had resulted in a significant deterioration in health and reduction in lung function. 
If you want to stand a chance and you know Amy is 17 on Friday, so you know if 
you do it, you will keep well you know, and all the lovely new stuff coming along.  
Mother (Amy 16y) 
A notable shift in focus occurred during the interview, from disclosure to direct 
dialogue with Amy (underlined section in the quote) which served to accentuate the 
significance this parent placed on her daughters continued adherence to her 
treatment regime, to stay as well as she could for whatever the future might hold. 
Often united with an individual’s personal sense of hope attached to the promise of 
new therapies, was unease regarding fair access to the potential benefits of these 




‘unfairness’ and disappointment at the inequity of opportunity to take part in 
innovative trials such as the ‘gene therapy trial’, due to being in the ‘wrong area’. 
In terms of the gene therapy trials, it is a bit frustrating that just because I don’t live 
in London, I can’t take part in them. So it does seem unfair sometimes that you are 
limited by where you live but I guess that really can’t be helped and when they do a 
bigger study ,you like to think that everyone will have the accessibility to take part in 
it […] Molly (24y) 
For some adult informants who had witnessed first-hand the high expectations and 
the unrealised promise of gene therapy their accounts typically conveyed a more 
cautious attitude towards the promise of a cure. Several adults who had ‘pinned their 
hopes’ on a cure being ‘round the corner’, acknowledged how this had resulted in 
disappointment and an ambivalent attitude towards clinical trials and their 
engagement with research. 
I don't look at it too deeply, because the only reason why I say that is because I 
looked at this article quite a few years ago now, and they were like, oh, we're going to 
find a cure in five years, and that's stuck with me, and it's like, and I don't feel very 
close [...]I don't read too much into research at the minute, because I think you, it 
builds up your hopes a little bit and I think people can read into it too much.  
Joanne (23y)  
 
I really don’t know what’s going on out there for research.  Obviously, gene therapy 
that’s one thing, but I really don’t know what’s going on if I’m honest.  I try and 





While these informants still accepted research as valuable, overly optimistic claims 
of research had reduced their sense of hope derived from the expectations of 
research. Their accounts illustrated the ‘flipside’ to hope, wherein disappointment or 
disillusionment had the potential to act as a deterrent to their commitment to 
research.  
Other informants, while disappointed by the slower than hoped for progress of gene 
therapy, also recognised the personal significance of wishful thinking with regards 
to the promise of future treatments. Consequently, many informants occupied a 
middle ground, in which they embraced the optimism of scientific ambition but had 
tempered their expectations about the possibility of a cure in line with current 
evidence.  
These trials they are doing at the moment for this gene therapy where they are 
hoping to find a cure for CF[...] it’s just hearsay at the moment I think more so than 
anything it’s just people wishing that that is going to be. Mother (Isabel 2y).  
These individuals accepted that a cure was unlikely to be realised in their own or 
their child’s lifetime, yet it still provided an effective motivational resource for their 
engagement with research and managing their life with CF. However, some 
individuals expressed concern regarding the continued focus on the prospect of a 
cure, despite the lack of results, both in terms of psychological impact of unrealistic 
hope and the allocation of research resources.  
Concern was expressed that this type of research soaked up vast amounts of money, 
leading to the neglect of other important areas of research which had the potential 




It’s  kind of going down the wrong track, they haven’t got it right yet, and they keep 
pumping out for money and I think the thing with the CF trust, that I get annoyed 
about with the trials is, they have really, obviously they have spent a lot of money on 
the gene therapy trials, but they kind of put all the money to that pot so research on 
other areas which is really important for CF care, they have kind of let go by, so like 
the nutrition, the digestive side, stuff on diabetes, there is not enough research on 
there, so it’s more kind of find  a cure but forgetting about the people that are already 
here. Laura (24y) 
Some individuals advocated for a more honest dialogue, expressing concern that 
‘talk about a  cure’ may be both enticing and responsible for fuelling ‘false hope'. They 
spoke of the importance of being ‘realistic’ about the low likelihood of a cure for CF 
in their life-time - though they also recognised that this might impact on some 
people’s receptivity to clinical research. 
 
7.3 Practitioners’ perspectives: a psycho-moral discourse 
7.3.1 Research as a common good  
Consistent with the perspectives of patients and families, the foundation of a 
practitioner’s view of a fair research offer, rested on their acceptance of clinical 
research as a common good, necessary to ensure the improvement of clinical 
treatments. Reflecting over long-standing professional careers, practitioners 
identified improvements in practice as being related to new knowledge gained 
through research. They also acknowledged that advancements in medical 




The whole of medicine depends on people taking part in trials, in order to advance 
knowledge [...] Doctor 12 (adult) 
 
I think that research is vital if we are going to be improving our care as the years go 
by […] Doctor 1 (child) 
Paediatric practitioners drew upon the exemplary success of treatments for acute 
lymphoblastic leukaemia (ALL) achieved through paediatric oncology trials to 
validate their belief in the value of clinical trials. 
The only way that we are going to get better treatments is by doing research and you 
know I think the best study, the best example of studies, for early oncology studies 
you know, ALL where you know treatments got much, much better and that's only 
through every patient being entered into clinical trials, and I think that's the way 
forward for the rest of medicine. Doctor 9 (child) 
In contrast, adult CF practitioners were more inclined to draw on the success 
achieved through research within the specialty of CF, now no longer considered a 
condition of childhood, to underpin their belief in clinical trials. 
Cystic fibrosis for me embodies the way medicine should go with research, because in 
the eighties, it was a bit ‘the poor dying children’, we've just got to do whatever we 
can because they're going to die’. So, people would do amazing, you know you'd 
throw a treatment at them with no evidence whatsoever, and it was well meaning, 
but it never got us anywhere.  So I've seen the change of saying......no, okay there are 
limited numbers but you can do trials and you can sort out what's best and let's 




While practitioners conveyed an acceptance of the research endeavour as a common 
good, necessary to uphold the progress narrative of modern medicine, they also 
recognised how both practitioners’ and patients’ views on clinical research were 
variable and dependent on experiences and awareness. For instance, several 
practitioners reflected how at times they ‘sensed’ patients’ levels of trust and 
receptivity to research in some ways mirrored the ebb and flow of research scandals 
in the media.  
I think it's slightly harder well, it is definitely harder than it was twenty years ago, 
but things like Alder Hey and, and Northwick Park, and Bristol Children's and 
things like that, started people asking more questions.  But that's eased off a bit in 
the last few years […] and you get a feeling that people are keener again to 
participate in trials. Doctor 3 (child) 
Practitioners also acknowledged that their views on research had changed over time 
according to experience. With several reflecting on times when they had felt more 
negatively towards research. 
If you want progress, you have to do research.  It’s not just something horrible that 
you have to do because it looks well on your CV or something like that anymore, but 
it is really something where you go, “Well, actually in the long-run this is the only 
way how we can move survival and patient quality of life in CF care forward if we 
do proper controlled research . Doctor 4 (child) 
Other practitioners spoke of how they had witnessed other professionals’ reluctance 
to engage with research, viewing research as an ‘obstacle in the way of clinic’ due to 
lack of awareness and understanding of ‘the benefits of it’. Suggesting research may 




7. 3.2 Why be a recruiter: balancing responsibility and personal interest  
Resembling patient and parent accounts, practitioners also constructed a moral 
dimension to their engagement with research. Practitioners’accounts conveyed an 
interrelated professional and moral  sense of responsibility to engage in research, as 
failing to do so may result in giving treatments that aren’t ‘actually good’. 
I can certainly look back in my career and think about how things have evolved, why 
they have changed […] some of the things that we used to do that we don't do 
anymore because we know through research and studies that they weren't actually 
good […] if we don't do any research then we are not going to change are we and we 
are not going to improve. Nurse 6 (adult) 
Improvements in treatments, derived from the ‘worthwhile’ endeavour of clinical 
research was identified by most practitioners as a key motivation towards their 
engagement with clinical research. 
What drew me to research was really that possibly you can improve things for people 
and make a difference [...] Nurse 4 (child) 
 
I am very interested in research, and I want my patients to have a better treatment 
that is the ultimate thing [...] Doctor 2 (adult) 
Nevertheless, consistent with patient and parent accounts an underlying belief in a 
contribution to a common good, alone was not enough to sustain a practitioner’s 
engagement with research. Practitioners acknowledged a personal expectation or 
‘need to get something out of’ their engagement with research. Personal interests were 




‘motivations’ which included such things as: ‘interest’ ‘something different’  ‘money’ and 
‘personal, academic development’. Without these expectations being met, practitioners 
indicated that the role of recruitment may be viewed as another ‘chore’ amidst more 
pressing clinical responsibilities and that ‘altruism’ alone was not enough to counter 
this tension. Practitioners viewed altruistic motivation as equivalent to contributing 
to generalized aims of research or what I have referred to as a common good. 
Comparable to patients and families, practitioners were unlikely to take on extra 
tasks solely for the common good, for little or no personal return. 
The sort of expectation that everybody does research is daft really because they need 
to get something out of it, I think […] The incentive is not great, other than 
altruism, and when you're really busy, altruism sometimes plays second fiddle to 
everything else. Doctor 3 (child) 
Practitioners also spoke of a professional requirement to engage in clinical research, 
and some described feeling a degree of pressure from fellow professionals to be 
involved in research at certain times during their career.  
Time was also typically viewed by practitioners as something which was in short 
supply and a constraint to engaging with research activities. How clearly 
practitioners’ research responsibilities were demarcated within their professional 
role, determined how reasonable they perceived there research responsibility to be. 
Consequently, for a practitioner whose position was research-based such as the role 
of ‘research nurse’, time as a constraint did not feature in their accounts. However, 
for those without clear research roles, time for research was constrained leading to 
conflicting priorities and a sense of tension concerning research duties while also 




It’s time consuming when you haven’t got time in your week dedicated to doing 
research then you are having to fit it in, amongst other things and it makes it hard 
[...]  Doctor 12 (adult) 
Practitioners whose salary was not dependent on research implied that it was a 
reasonable assumption that research would take a lower priority than clinical 
commitments.  
If you are a senior lecturer or a clinical lecturer or a clinical scientist, your life does 
depend on research, you know you have got to be publishing the papers to justify 
your salary [...] Doctor 5 (child) 
Even where practitioners had some form of ‘protected time’ for research related tasks, 
they pointed out that in reality, this time was inadequate or not truly protected in 
the demanding clinical environment where practitioners viewed their patients 
clinical needs as being ‘paramount'. However, practitioners spoke of time for 
research as a flexible resource, which could expand or contract depending on the 
perceived fairness of the situation. In situations where personal interests, 
professional responsibility and the value of the trial outweighed additional 
commitments of research, practitioners indicated that time was found.  Nonetheless, 
they accepted that time could only be stretched so far and even where studies were 
considered to be worthwhile, additional resources may be necessary to buy more 
time to meet the demands of recruitment. 
7.3.3 ‘The morality of the study’  
In addition to a moral and professional responsibility to contribute to the research 




individual studies. This involved personal judgements centred on ‘the morality of the 
study’, that is to say, whether practitioners viewed the research to be ‘decent and 
meaningful’. Despite all the clinical research being described as having passed the 
ethical scrutiny of a committee review, they spoke of the additional moral 
judgements they made about the worthiness of each individual study or trial. 
Practitioners indicated that they would be reluctant to be involved in or ‘ask anybody 
to participate in a study’ they ‘didn’t think was appropriate and of good quality’. 
 I would like to know that, I would like to believe that I felt that this was the right 
thing to do. It goes back to the morality of the actual study I suppose.  
Doctor 1 (child) 
 
First perception is whether you really believe in the study for which you are 
recruiting, which I think makes a difference [...] you need to sort of believe that this 
is going to help Doctor 11 (child) 
Other motifs of ‘the morality of a study’ included a hypothesis which they could 
‘embrace’ and a trial design they understood and agreed with. 
When you think about taking part in a study you have to, embrace the hypothesis of 
the study because if it’s not one with which you agree, then I think ethically you 
wouldn’t want to, you just couldn’t participate.  So it’s a question that you have to 
believe is a genuine question, and with a trial design that you would be happy to put 
your patients forward for. Doctor 10 (child) 
Some practitioners identified ‘sufficient funds and resources’ as being integral to 
research of value and something which needed to be guaranteed before accepting a 




trials, particularly if they felt the study design was questionable. One practitioner 
recollected how during a time at a GP practice, she had struggled with the morality 
and fairness of ‘a double blind placebo’ asthma trial, which ultimately, she avoided 
referring potential participants to.  She described the trial as primarily a ‘money 
making venture’ which potentially involved leaving a symptomatic child, with no 
preventative treatment. Now as a CF practitioner, while she accepted the need for 
clinical trials, she did not want to be placed in such a position again, where her 
primary role to care for patients was being compromised by research 
responsibilities which she believed diverged from this role. 
 I wouldn't like to be put in that position that I was put in when I worked in general 
practice. And I think if anything, that really I think over exposed me to that and put 
me off [...] So then when somebody says oh about some research you sort of almost 
like, you go into shut down and you sort of fold your ears in and think I don't really 
want to like get involved with this because I am busy looking after my patients 
because that is what we do. Nurse 6 (adult) 
Practitioners also indicated how shifting economic and political influences on the 
research ‘industry’ had the potential to influence their perceptions surrounding the 
morality of particular studies. For instance, one practitioner conveyed an obligation 
to participate in commercial studies to accumulate the economic resources to 
facilitate research in line with his personal interests. 
I don't do commercial studies because I love commercial studies; so, in the past, I did 
them because they raised money that allowed me to do the research I wanted to do.  
And I do them now because I have to do them to be seen to be contributing to the 




research in which I can then go and get money to do the stuff I want to do which is 
non-commercial stuff […] The money flows from recruitment.  
Doctor 3 (child) 
7.3.4 Making sense of recruitment: the morality of marketing 
Practitioners engaged in a moral and psychological deliberation to formulate their 
role in the process of recruitment, a role that they recognised as requiring a different 
‘balance’ to routine clinical consultations. Their accounts also illustrated how they 
dealt with the significant ‘change in focus’ which occurs in the clinical relationship 
during trial recruitment, which involves asking patients to ‘put themselves out’ or to 
do something extra to their necessary treatment. 
Many practitioners viewed recruitment as ‘ultimately their responsibility’ to ensure 
eligible patients are offered the ‘choice’ or ‘option’ to participate in a trial. 
Every family has their own nuances, and they are you know there are always 
difficulties of one form or another. I think that one has to at least let the families 
know about the trial and then, give them the choice. Doctor 10 (child) 
 
It is an important as part of a patients’ journey and their treatment, giving them the 
choices. Nurse 2 (adult) 
Some practitioners moved away from a more neutral framing of recruitment as an 
option or choice to the more positive framing of recruitment as offering an 
‘opportunity’ for patients to try new drugs coming on to the market or a ‘chance they 




You certainly give everybody a chance because if they were actually eligible and the 
right criteria then that's...their decision, not mine and the fact is that they deserve 
the chance to know about it. Nurse 6 (adult) 
 
I never apologise for introducing the possibility of being in a research study.  To me, 
it's an opportunity for a person with CF to kind of get the access to a new treatment. 
Having said that, you always have to be aware when you're doing studies; it may 
not always be doing good and [...] look we appreciate all the effort you put in, in 
these trials and some of them aren't going to show a benefit, that's why we do a trial.  
Doctor 6 (adult) 
Some practitioners used a marketing discourse to denote this shift in position from 
one in which they are offering something the patient ‘needs’ or that is the ‘right thing 
to do’ for that patient, to one in which they were no longer in this position, but rather 
they are offering something that is primarily to inform future knowledge. From this 
position, the practitioner viewed themselves as a type of ‘salesman’ with a particular 
‘product to sell’ and a ‘pitch’ or ‘patter’ to be ‘prepared’ and ‘fine-tuned’. 
It's like a salesman; it's difficult to sell a product if you don't believe in it [...] You 
need to know your study, you need to understand what you're talking about, 
because you've got to be able to sell your product very positively and confidently, 
and knowledgably. Nurse 3 (child) 
 
I would have to do the looking into it [...] so that I knew exactly what I was doing 
and what it was about and believe in it really so that you can sell it.  
 Nurse 2 (adult) 
Equivalent to the preconceptions of a reputable salesman these accounts conveyed a 




discussed previously. However, the standard assertive persuasive techniques that 
are often associated with business were reconciled with the requirements of 
informed consent by practitioners advocating a form of ‘unbiased clinical marketing’ 
or ‘fair marketing’. 
Its sort of a clinical marketing, research marketing, without being biased but just 
saying, you know your child may be able to be included in this study, would you like 
to know more about it. Doctor 1 (child) 
 
Practitioner accounts illustrated how ‘fair marketing’ involved both a ‘difficult’ and 
‘different balance’ requiring a ‘positive and neutral’ position. 
 
You need to keep a different balance, just because you believe in something you can’t 
just force or talk more about the positive things of the study, when you are 
approaching the parents, that sometimes can be a bit subjective[...]and I think it can 
be a bit difficult, we are all human beings [...]  Doctor 11 (child) 
This is a position which was open to personal interpretation, requiring a balance 
that was viewed as being hard to maintain. The concept of remaining positive and 
neutral was captured by this practitioner’s illustration of how he might convey a 
study to a potential participant.  
I will indicate that this study is one that we support and the study is one that we, 
it’s a genuine question that we genuinely want to answer so that if they feel able to 
participate then, that would be very helpful.  But also if they wish not to participate 
then, then I am not going to think any worse of them, and the team will still care for 




This balance was even more difficult for those practitioners who felt the ‘pressure of 
numbers’.  
There's a pressure on us for recruitment, no doubt.  The companies always have 
deadlines, and I suspect that we are a bit more pressured than perhaps we'd like [...] 
Doctor 6 (adult) 
Practitioners spoke about ‘onerous numbers’, achieving ‘targets’ or upholding 
recruitment, reputations and some emphasised the scientific, personal and economic 
requirement of achieving recruitment targets more than others. Those practitioners 
who were able to distance themselves from this pressure were less ‘stressed by it’ or 
‘worried if people say no’.  
The practitioners’ discourse on unbiased marketing also moved into the realm of 
advocating research participation as a common good and something morally 
commendable. Practitioners spoke of providing a ‘convincing argument’ about why a 
trial is needed whilst emphasising the generalised aims of research whereby ‘people 
are actually helping the community’, rather than themselves. 
Many families are happy to help if you know you can make a convincing argument 
that knowing this would you know further science and could help other children. 
Doctor 8 (child) 
One practitioner compared recruitment to an act of inviting individuals to act 




If you look at reported reasons for taking part in research, altruism and wanting to 
improve things comes out top, top of the list most of the time.  And so there is, I 
think, a greater perception of doing their bit just like blood donoring and giving 
blood, and things like that, than we give the public credit for it, I think [...] as long as 
they're not going to come to harm, and it's not going to be totally, all-consuming, 
they'll do it and they'll volunteer to do their bit in the majority of cases  
Doctor 3 (child) 
Viewing trial participation as a morally commendable action some practitioners 
were inclined to regard the process of recruitment as akin to asking ‘a favour’ as 
opposed to selling a product.  
I always think it’s the patients doing us the favour that they go through this and 
they do it for us and for themselves, but I always say to them, “You’re doing me a 
favour, or you’re doing us a favour if you’re doing that.  You need to be aware of 
that.  You could just sit in your chair and wait until the drug’s ready in two years’ 
time and then just take the benefits from other people being in the trial.  So I’m very 
grateful that you’re doing us this favour.”  I can’t forget that.  That it’s them giving 
up their time and their efforts and everything. Doctor 4 (child) 
In the context of trials with little, or no, potential therapeutic benefit, positioning 
recruitment as comparable to asking for a favour could be seen as ethically 
preferable, compared to instilling or perpetuating unrealistic hope or expectation of 
potential individual therapeutic benefits. Nonetheless, viewing recruitment as akin 
to ‘doing a great favour’ brought into view the reciprocal nature of the favour and 
potential sense of obligation or indebtedness. Practitioners recognised that 




treated differently if they declined a trial. A view which may be more keenly felt in 
a long-standing clinical relationship.  
You have to be careful of, people... some people take the view, I'm letting you down if 
I don't do this trial for you, and you've got to be careful of pushing people when they 
really don't want to. Doctor 6 (adult) 
Stressing or even over stressing the voluntary nature of the proposition was 
considered an integral component to the fair marketing of research. Indeed, one 
practitioner inferred that he had found that emphasising the voluntary nature was 
not only at the heart of a fair offer but also proved to be an effective marketing 
strategy of its own. 
I always tell people who start working with me, is the key thing is not to be 
pushy[...] The more you almost put them off, the more comfortable they feel [...]And 
the more you give them an option to get out, the less likely they are, is my 
experience. Doctor 3 (child) 
However, some practitioners recognised the difficulty in ensuring that there is no 
pressure, whilst also conveying the value of participating in a trial.  
They need to know there is absolutely no obligation or pressure and it’s difficult 
because you don’t want to put everybody off, well if there is no pressure I won’t do it 
[...] Doctor 5 (child) 
In order to make sense of recruitment, practitioners had to balance their belief in the 




practitioners constructed the ‘right way’ was nuanced according to their personal 
values and their conception of the value of the trial. 
7.3.5 A fair selection 
Some practitioners emphasised a moral responsibility to try to avoid being ‘selective’ 
due to prior knowledge of patients and to aim to approach potential participants 
‘fairly and squarely’. Several practitioners’ accounts resonated with the findings from 
the patients and families accounts, with a view that patients want to know about 
trials and valued being asked. 
We try not to be selective in terms of personality or whatever; we go down our, 
we've got our patient list [...] I am coming to believe that people want to know about 
the trials. If they're eligible, give them the choice [...] in general I think there is little 
harm in the information that a trial's going on. Occasionally, patients benefit from 
the ‘oh they thought of asking me’.  Doctor 6 (adult) 
While practitioners implied a moral responsibility of fair selection, they also 
indicated this responsibility was mitigated by the pragmatics of clinical duties, time 
constraints, their duty or care and concerns over potential trial burden. A concept of 
fair selection was further complicated in the context of a particular class of trials 
which practitioners referred to as ‘wonder drug trials’. They positioned ‘disease 
modifying’ or mutation specific targeted novel drugs with a corrective potential as 
being eligible for this distinction. Following the discovery of the ‘CF gene’ in 1989 
these targeted approaches are aimed at improving the mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, which are now well 




Alton, 2013). The most frequently cited of these trials were the ‘Vertex13 trials’, which 
practitioners identified as commercial trials requiring competitive recruitment 
strategies. 
The Vertex study is that there's a lot of publicity about on the forums and the 
internet and they think it's going to be disease modifying ‘stroke’ cure, they use the 
word cure, which I don't encourage, they're queuing up for those.  Doctor 6 (adult) 
 
The recent studies on these new correctors and potentiators with CF they have they 
have had no trouble recruiting at all. Doctor 9 (child) 
In stark contrast to other types of trials, practitioners remarked that there were not 
enough of these trials for the numbers of patients who wanted to participate, in 
either the paediatric or adult settings. Practitioners also speculated that increasing 
public awareness and trial experience might be leading to patients being drawn to 
trials that they have judged will give them the greatest likelihood of a significant 
personal benefit to their health.  
That's why recruitment for some trials is just not as fast, because if people think it's 
a real disease modifying... I mean we are getting to the stage now with it, oh it's 
another nebulised antibiotic.  Whereas, oh something that affects the gene, is that a 
potential cure, queue up. People are getting selective; they'll buy in to the trial that 
they think is going to give them the best return.  Doctor 6 (adult) 
                                                     
13  Vertex is an American-based pharmaceutical company, which since 2014 has been involved in the 




Furthermore, despite practitioners’ reluctance to speculate about the curative 
potential of these drugs, they understood the desire of patients and parents to focus 
on the promise of cure or the life changing potential of these novel drugs. Adult 
practitioners also described patients as being ‘quite desperate for a cure’ due to their 
deteriorating health. 
A lot of patients, of course, they are desperate for a cure, and they will latch on to 
things, and you can see that for most of our patients, apart from there is one group, 
one gene type that they are almost ready to go with something for that group of 
patients. The majority of them which is Delta 508 which is the most common and 
more severe they are nowhere near to finding anything to help with those patients. 
And of course, some of them are, they are quite desperate for something […] 
Nurse 6 (adult) 
A patient’s hopefulness for promising treatments was complicated by the disparity 
between the treatments available for individuals with different CF gene mutations, 
with the most severe and the most common gene mutation being the furthest away 
from life changing treatments. Some practitioners described how patients felt 
marginalised or undervalued when they were not made aware of, or given the 
opportunity to enter these ‘wonder drug trials’. Some conveyed a sense of 
disappointment on behalf of their patients that these opportunities were not 
available.  
They have to put up with so much, and I know how willing they all would be, they 
are always asking, with the different trials that are going on with the nebulised 
treatments, they are having some good results, and they come, and they say when 





If there is anything you know they will ask about it I think because we don't really 
have access to it [the trial] you know I am always saying well we won't get asked 
because we are not big enough centre and I think they feel like the second class 
citizens because they are not part of these big centres that always get all the 
renowned things really. Nurse 5 (adult) 
One practitioner described how an individual was ‘really really angry’ about not 
being informed about an ongoing ‘wonder drug’ trial at her CF centre, despite this 
patient not being eligible at the time of the trial. Practitioners also expressed concern 
about the effort and hope patients were prepared to invest in these ‘wonder drug 
trials’, whatever the costs. 
Gene therapy, for instance, people were really keen to get on that trial because they 
think, oh its gene therapy, but a lot of them are going to be doing a lot of work for the 
study […]. Doctor 6 (adult) 
One practitioner openly described ‘struggling’ to balance a family’s right to know 
about ‘a wonder drug trial’ that they were eligible for, with her concern about the 
burden of the trial for this particular family. 
As kind of a responsible researcher I was struggling with that one 
because[…]sometimes you just think, I don’t know, have I got the right to sort of 
say, “This trial’s going on, but you’re not in it because I don’t think it’s feasible that 
you travel to London all the time,” or should it be their decision. Doctor 4 (child) 
As it turned out, the trial was employing competitive recruitment practices and the 
trial became full before they ‘might have been able to get somebody in’. This 




the families ended and his responsibility to empower families to engage with 
research began, illustrated the psychological and moral intricacy of being a 
‘responsible researcher’ in an ever-changing research environment.  
7.4 Summary 
All informants across all sub-groups conveyed moral and psychological dimensions 
to their construction of a fair research offer. For the patient group, an acceptance of 
both the dependency of medical progress on clinical research and the optimism of 
scientific ambition characterised this discourse. The two most prominent features of 
this discourse were a sense of moral responsibility and the processes of hope. 
Informants rarely conformed to the normative assumption that patients enter trials 
expecting a direct clinical benefit. Rather, these individuals hoped for the best 
personal outcome, a hope which was bolstered by a broader sense of optimism 
related to the promise of progression through research. Remaining hopeful that a 
‘vested interest’, in their own or their child’s condition would ensure potential future 
benefits for themselves and other people with CF, seemed a realistic prospect, given 
that many individuals with CF are now living into adulthood (CF Trust, 2017). 
Furthermore, an informants’ sense of hope was typically reinforced by a broader 
moral motivation, or obligation to participate for a common good and fulfil their 
share of this responsibility. Informants also accepted that progression is dependent 
on willing volunteers and from this stance, their sense of hope was enmeshed with a 
moral responsibility to be a willing participant. A sense of hope derived from the 
promise of research became all the more real when they became one of the willing 
participants. In many respects informants’ accounts of their acceptance of research 
as a common good parallel the views embodied within current research practices 




research participation as contributing to the improvement of future treatments and 
something morally commendable rather than morally obligatory. Nevertheless, at 
times informants spoke of their sense of moral responsibility in terms that were 
more pressing – that is, as a sense of ‘duty’ or ‘obligation’ to participate.   
Consistent with patients and parents, practitioners’ accounts of trial recruitment 
also included a psychological and moral dimension, albeit from the other side of the 
exchange. Practitioners had to balance their personal interests with the interests of 
their patients in order to negotiate their role as a ‘responsible researcher’, amidst a 
changing personal career trajectory and shifting research environment. 
Consequently, their formulation of recruitment oscillated between unbiased 
marketing, asking a favour, invoking moral responsibility, or a virtuous act. This 
fluctuation reflected the delicate balance required within this distinct clinical 
encounter in which a practitioner must balance trial uncertainty, the generalised 
aims of research, and their duty to provide optimal care and their own personal 
values and interests. This discourse also highlighted the work that practitioners 
engaged in well before they ever embarked on recruiting a patient to particular 
study, to make sense of both the right way of approaching people and the fairness 




CHAPTER 8: DISCUSSION 
8.0 Introduction  
The main findings of the case study are brought together in this chapter and 
discussed within a conceptual framework developed from them. I will consider the 
wider relevance of the findings in relation to the existing literature before examining 
the implications of the findings for policy and practice and future research. I will 
then discuss the study’s strengths and limitations, make suggestions for future 
research and provide a brief conclusion.  
8.1 Study Findings  
An exploratory qualitative case study in a stable underrepresented population was 
carried out to provide a detailed, in-depth understanding of the nature and 
complexity of the phenomenon of trial recruitment. Aligned with a constructionist 
position, the aim of this case study methodology was not to discover an external 
reality but to construct a clearer picture of the phenomenon under investigation 
through integrating interpretations of situation and context (Stake, 1995). It is rare 
for there to be a single explanation for any aspect of the social world, and this study 
was no exception. Firstly, these findings characterised trial recruitment as a complex 
psycho-social phenomenon. I found that informants’ negotiation of the recruitment 
process was multidimensional and variable according to attitudes, experiences, 
personal circumstances and trial design. Informants engaged in weighing up a 
multitude of factors which involved intricate trade-offs and personal value 
judgements, and which were socially situated according to the family context, 





Nevertheless, this exploratory qualitative case study was able to offer a fresh look at 
this complexity. Explanations in qualitative research are usually framed as 
conjectures rather than accounts of deterministic causes and involve making an 
argument or ‘case’ (Ritchie et al., 2014; Strauss & Corbin, 1998; Stake, 1995). My case 
for understanding how people make sense of clinical trial invitations was centred on 
informants’ constructions of a ‘fair research offer’. This investigation indicated that 
informants worked to construct satisfactory accounts of their decision to consent or 
decline which centred on personal perceptions of fairness. 
These personal judgements of fairness could be understood according to three 
prominent interrelated conceptual patterns or discourses I discerned from 
informants’ accounts of recruitment – a rational, social and a psycho-moral 
discourse. The rational discourse illustrated how informants used their ‘logical head’ 
to ‘weigh up’ the costs and benefits, to assess the safety or worth of a particular trial 
or study. The social discourse illustrated how informants’ accounts of recruitment 
were contextually and relationally dependent, within which a framework of trust 
was pivotal. The psycho-moral discourse illustrated how informants worked to 
construct a moral and psychological account of their recruitment experience, in 
which a sense of moral responsibility and psychology of hope were most significant. 
From a constructionist position, these discourses are best viewed as interpretive 
devices that illustrate a set of tendencies as to how informants made sense of trial 
recruitment. How any individual orientated themselves to the idea of being a 
human subject was dependent on how they actively constructed their accounts in 
relation to these three prominent discourses, which were common across accounts. 
There was a multitude of factors which had the potential to influence how 




perceptions relating to a participant’s health status; ii) trial design and, iii) an 
individual’s personal circumstances including their roles or responsibilities, that is, 
whether they were acting as a practitioner, parent, an autonomous adult or a child 
within a family context (Figure 8.1). 
Informants made personal judgements of fairness which took different forms 
depending on their personal circumstances and sense of responsibility. Parents 
acting on behalf of infants and young children focused on acting in the child’s best 
interest, which involved balancing both parental responsibilities and personal 
values. Parents of older children focused on negotiating the young person’s level of 
involvement in decisions according to pre-existing family dynamics.  
































Adult patients balanced their health status, past research experience and personal 
values to make sense of and respond to the invitation to enter a trial. Practitioners 
illustrated the delicate balance required for the ‘unbiased marketing’ of trials, in 
which they considered their duty of care to patients, inherent trial uncertainty, ‘a 
pressure of numbers’ and their own personal values.  
8.1.2 A rational discourse: ‘weighing things up’.  
For the most part patients and parents were keen to present themselves as rational 
decision-makers, describing themselves as engaging in a careful, deliberate 
weighing up of the costs and benefits in which judgement of risks were prioritised. 
Informants wanted to ensure that the trial participation was not going to be 
detrimental to their health. They also wanted to ensure the trial was something of 
value and worthy of their time and effort. Practitioners were also keen to ensure 
that trials they had agreed to become involved in were not too onerous for their 
patients. 
 While informants understood that in principle randomisation was the fairest way to 
conduct meaningful research they also accepted how personally the design had the 
potential to feel unfair. Certain trial designs, such as a cross-over trial or preference 
trial where everybody had a chance of receiving the new treatment or their 
preferred treatment, seemed intuitively fairer compared to the ‘lottery’ of the 
standard RCT. Consequently, how informants negotiated the risks and uncertainties 
inherent in clinical trials was central to their view of a research invitation they felt 
comfortable accepting.  
Patients and families spoke of the significance and expectation of being given 




acknowledged their legal obligation to provide adequate, impartial information. 
Consequently, an aspect of their accounts corresponded to normative models of 
decision-making (Hardman, 2009; Madsen et al., 2007) which presupposes that a 
‘rational’  autonomous patient facing a research invitation will take account of all 
the available information and assess the likelihood of tangible risks and benefits.  
Patients and parents embraced a more far-reaching version of autonomy as 
relational and interdependent, as opposed to the view of autonomy as 
(independent) self-determination (Kukla, 2005). This view of autonomy extended 
beyond trust based on tangible information and incorporated both trust in their 
judgements and trusting deference towards practitioners. Equally, practitioners 
recruiting within an existing relationship were more comfortable tailoring 
information according to individual needs; prioritising respect for a patients’ or 
parents’ preference for the level of information, as opposed to attempting to achieve 
a one size fits all ‘valid’ consent. Furthermore an (independent) self-determination 
version of autonomy was not meaningful in the family setting, where findings 
illustrated how children worked in partnership with parents and practitioners.  
Medico-legal requirements relating to the informed consent process were 
considered essential to authenticate a research offer as something legitimate and 
trustworthy, and hence integral to the construction of a fair research offer. How 
informants negotiated their engagement with trial information varied according to 
their own personal values and priorities and was subjective and contextually 
dependent. Making sense of trial recruitment involved a complex set of 
interdependencies, which extended beyond the rational consideration of trial 
information and procedures, and was also intertwined with social, psychological 




As extensive research exists detailing how many patients and families  fail to 
achieve the level of understanding researchers have deemed necessary for ‘valid’ 
consent (Dawson, 2009; Sugarman et al., 2005; 1999; Simon et al., 2003; Corrigan et 
al., 2003; Ondrusek et al., 1998), this study did not focus on understanding per se. 
However, these findings provide insights into why many participants may fail to 
fully understand all aspects of a trial and their recruitment. Clearly, if an individual 
chooses not to engage with the trial material, they will be unable to obtain full 
knowledge of the information. 
8.1.3 A social discourse: ‘feeling comfortable and valued’ 
The findings illustrate the significance of considering trial recruitment as a social 
interaction involving a ‘human approach’ with successful recruitment resulting in a 
mutually agreed ongoing relationship, rather than simply focusing on the point of 
consent and numbers accrued. Furthermore informants emphasised the importance 
of recruitment that involved an interactional dialogue, which facilitated open 
discussion, in which concerns could be adequately addressed, rather than simply 
imparting formulaic information.  
Interpersonal qualities of the recruitment exchange had the potential to influence an 
individual’s initial receptivity and engagement with the idea of participating in a 
trial. These findings also suggest that the socio-emotional character of the exchange 
was particularly significant where an individual’s belief in research was tenuous, or 
past clinical experiences had been problematic or where emotion was heightened. 
Practitioners viewed recruitment as being outside of their comfort zone and 
highlighted the significance of tenets of competent communication, such as 




recruitment. Informants indicated there was a ‘right way’ to conduct recruitment 
which involved someone very approachable who was engaging with the ‘right 
person skills’, and the expectation that the recruiting practitioner should go the extra 
distance to ensure a successful social exchange in a less familiar context. 
 Integral to this successful approach was the importance of informants feeling 
valued, which was conveyed by a face-to-face approach wherein a practitioner was 
prepared to give them time and consideration according to their needs and 
priorities. Informants were  reassured by the association of a practitioner involved 
in their care or recruitment occurring within a familiar context, in which research 
was presented as something endorsed, valued and part of the system, as opposed to 
something ‘out of the blue’ and ‘left field ’. However familiarity also had the potential 
to blur the distinction between research and clinical care, serving to downplay the 
value of the trial or participation in it. 
Parents and practitioners viewed a process of trust as crucial to their construction of 
a fair research offer and practitioners viewed it as a principal reason why patients 
and parents agreed to take part in clinical trials. Informants’ perceptions of trust 
extended from parental trust in the family context, to interpersonal and institutional 
trust. On the whole informants trusted the practitioners who were inviting them. In 
situations where a recruiting practitioner was unknown, informants spoke of the 
significance of trusting the hospital and the research infrastructure. Trust instilled 
confidence and had the potential to counter concerns about risk and uncertainty. 
Trust also appeared to ease the cognitive effort of the decision-making 
responsibility, which was particularly valuable in the context of parents of infants, 
who described a heightened sense of responsibility to act in their child’s best 




trial was evident in the context of trials that informants had declined. Practitioners 
worked hard to maintain their trustworthiness by engaging in their own personal 
balancing of harms and benefits. On occasions, practitioners deemed an offer as 
unfair for a particular patient at a given time, resulting in a decision not to approach 
them.  There were also instances where practitioners viewed specific trials as having 
sufficient harms or insufficient benefits, for the trial not to be taken on at a particular 
centre or to be taken on with a reduced commitment. 
In the CF setting, trial recruitment typically occurred within a familiar clinical 
setting, which highlighted the significance of trust and continuity in the recruitment 
context. Being invited to become a ‘human subject’ or inviting someone to become a 
‘human subject’ required a patient, parent or practitioner to go outside their usual 
roles and responsibilities. To make sense of this novel situation, informants drew on 
the social norms of the healthcare and family context.  
8.1.4 Psycho-moral discourse: ‘Doing my bit and hoping for the best’  
A unifying strand throughout informants’ accounts was their work to construct an 
offer which was aligned to their values and personal interests. Where individuals 
had agreed to participate in a trial they emphasised the judgements they had made 
concerning moral responsibility and    hope, but such accounts were less prominent 
in the accounts of informants who had declined.  
Many informants compared a willingness to take part in research as akin to   having 




inseparable from  the warm glow’14 derived from partaking in something perceived 
as morally commendable. A view which ran counter to that of altruism as an 
intrinsically selfless act.  Informants spoke of contributions to furthering research, 
not as altruistic but as fulfilling a moral responsibility , one in which everybody 
should try and ‘do their bit’ and ‘give back’, to reciprocate for the previous 
contributions of others to research and care.  
Hope was also a significant factor in the construct of a fair research offer and 
extended beyond a personal hope for the best personal outcome, to include a belief 
in a personal and generic progress narrative of modern medicine and the 
psychology of an optimistic, hopeful outlook. Hope also had a therapeutic value in 
countering the interpretation of risk and the uncertainty of trial participation, and 
equally in countering the uncertainty of living with an altered future.  
Psychological and moral dimensions of informants’ accounts were often constructed 
prospectively, rather than as post-hoc rationalisation. For instance, some informants 
spoke about how they had discussed the meaning of participating in research prior 
to the invitation, in which they had positioned research participation as something 
morally good and a source of hope. Furthermore, adult informants spoke about how 
they had been enculturated to the value of research participation when they were 
younger. Parents within this sample also talked about their role as a moral educator, 
                                                     
14 In contrast to the standard notion of altruism involving behaviours which benefit another at a cost to 
oneself and without rewards, the notion of ‘impure altruism’ or ‘warm glow’ suggests  a self interested 
motive or ‘satisfaction of conscience’ derived from ‘doing the right thing’ or having ‘done their bit’ 





in which they had gradually trained their child about the importance of 
participating in research. 
Informants spoke of participation in research as contributing to  a common good, 
while remaining hopeful for the best personal outcome, as inseparable and aligned 
with their personal ‘selfish’ interests. Both of these were positioned as important 
motivational resources in their decision to participate. Consequently their accounts 
did not indicate  discrete motives of ‘self-interest’ or ‘altruism’, but rather an 
interrelated psycho-moral  discourse in which informants were working to make an 
invitation to be a ‘human subject’ personally meaningful.  
Practitioners regarded a patient’s hope for the best personal outcome when 
participating in a trial as ‘human nature’.  Indeed, it could be argued that the whole 
of the research enterprise is based on the hope or expectation of progression. 
Furthermore, while practitioners accepted the scientific principle of equipoise, they 
remained hopeful like patients and parents that the trial drug or intervention would 
prove to be effective. Practitioners indicated that it would feel unethical to enter a 
patient into a trial which they did not believe or hope that the trial drug had the 
potential to work.  While hope defined by a practitioner is typically viewed as a 
something rational and underpinning the aim of research, hope expressed by a 
patient or parent has the potential to enter into the realms of misconception.  
Practitioners also had to negotiate the inherent ethical tension concerning their duty 
of care to their patients and the requirement to engage in research to further 
scientific knowledge as a ‘responsible researcher’. Consequently they also drew on a 
psycho-moral discourse to negotiate this disparity, which varied according to their 




repertoire they used to describe the recruitment process which included marketing 
metaphors, highlighting the exchange dimension or the cost of helping by 
describing research invitations as ‘asking for a favour’. This variability in how 
practitioners constructed recruitment reflected their work to accommodate the 
change in dynamics which occurs in the context of recruitment. Consistent with 
patients’ accounts, an altruistic motive, to contribute to the common good, was not 
enough to construct their view of a fair research offer. They also judged the study in 
relation to their own personal interests and what they hoped to achieve by 
committing to a trial and their engagement with research was nuanced and 
personally negotiated. For instance, personal orientations to a particular trial in 
which personal equipoise was tenuous, or a practitioner had a concern regarding 
cost-benefit ratios, had the potential to influence a practitioner’s commitment to and 
faith in a trial. 
Informants’ accounts of research participation conveyed a sense of personal 
grappling, reflecting the delicate balance required to negotiate personal interests in 
the context of uncertainty, responsibilities and hope. A degree of therapeutic 
optimism seemed necessary for both a practitioner to accept ‘the morality of a study’ 
and for a patient to accept the potential burden of trial participation, because 
without a belief that the trial could lead to something better in the future, what 
would be the point of trying.  
 I viewed this psycho-moral  discourse as reflecting the cognitive work in which 
potential participants and recruiters must engage, to feel at ease and free from 





8.2 Main findings in relation to the existing literature 
8.2.1 What makes research feel fair: a personal balance account  
The findings of this study correspond with the existing evidence which characterise 
trial recruitment as a challenging, intricate phenomenon which is contextually 
defined (Tromp et al., 2016; Ulrich et al., 2012; Truong et al., 2011; Fayter et al., 2007). 
How an individual decides whether to take part in clinical research has typically 
been defined as involving the weighing up of a multitude of factors, a process that 
has been described in the literature as a ‘clustered reasoning’ (Ulrich et al, 2012; 
Townsend & Cox, 2013; Madsen et al, 2007; Verheggen et al, 1998; Snowdon et al, 
1997). 
Academics and practitioners have been grappling with the morality of performing 
experiments on human subjects for more than a century (Brown et al., 2004). 
Similarly, informants in this study, like those in other studies, also grappled with 
the dilemmas involved in making sense of the role of ‘human subject’, ‘volunteer’ or 
‘research participant’.  I viewed informants as grappling with these dilemmas in 
much the same way as a regulator or bioethicist grapples with the standards 
required to deem a research protocol as ethical. Moreover, informants’ accounts of 
how they judged the fairness or acceptability of a research offer often reflected 
elements of the wider ethical framework used to determine what makes research 
involving human subjects ethical. 
Medical ethics like other ethical discourses is concerned with the rightness and 
wrongness of action and although informed by moral debate, it typically operates 
within an established framework of values (Mason & McCall Smith, 2006). A system 




(2001) has become pervasive within the bioethical literature, based on the four 
principles or ‘pillars’: autonomy, beneficence, non-maleficence and justice. While 
not always explicitly stated within ethical guidelines for clinical research, this 
framework is used to determine the standards necessary for the ethical development 
and implementation of research protocols (Mason & McCall Smith, 2006; Emanuel, 
2000). Despite this wider framework informing the ethical conduct of research, the 
principle of autonomy translated into the doctrine of informed consent has become 
central in debates about what makes clinical research ethical and is the overarching 
principle upon which the process of recruitment is understood (Kukla, 2005; 
Emanuel, 2000). Nevertheless, findings from this study support the view that what 
makes research fair or acceptable for a patient, parent and practitioner include and 
extend beyond the confines of autonomy, to include a more far-reaching ethical 
framework. In some respects, informants’ personal judgments of fairness mirrored 
facets of the broader framework of values underpinning medical ethics, including 
the four ‘pillars’.  
In the first instance, informants wanted to know the risk of harm and an acceptable 
cost-benefit ratio was essential to their construction of a fair offer. Informants also 
emphasised the significance of action which foregrounded their individual welfare, 
such as displays of empathy, competence, trustworthiness, and the establishment 
and maintenance of meaningful relationships. Informants perceived research as 
something valuable personally, scientifically and for the wider CF community. 
Assurance that the research was something of value and that they, the participant 
would be valued, were important to informants in countering the inherent 
uncertainties in clinical trials. Informants viewed receiving accurate information as 
integral to a fair offer and indicated the importance of having the self-determination 




informants also spoke about the fair selection of participants and how the benefits 
and burdens of research should be distributed equitably. 
This study adds to the literature which emphasises the work people must do to 
establish a personally meaningful,view of the role of a ‘human subject’ (Cox & 
McDonald; 2013; McCann et al., 2013; Madsen et al., 2007; Morris & Balmer, 2006). 
Consistent with findings in the empirical literature this study showed how 
informants engaged in a ‘balancing of options’ that extended beyond a rational 
consideration of trial information and procedures to include personal value 
judgments (Ulrich et al., 2012; Madsen et al., 2007; Verheggen et al., 1998). How 
patients, parents and practitioners thought about research participation often 
paralleled how researchers and bioethics determine what makes research ethical or 
‘fair’. However, informants were judging what makes an individual research offer 
personally ‘fair’ for themselves, rather than applying broad objective standards of 
ethical acceptability in the case of research regulators. Nonetheless, the values 
inherent in both situations coincided, indicating that these broader principles 
resonate with personal morals and that it is not only researchers and bioethicists 
who think about research ‘ethically’. 
8.2.2 Balancing risk, hope, and a sense of responsibility 
Rationalising risk was central to how informants initially made sense of research 
invitations. The centrality of ‘risk behaviour’ and ‘uncertainty reduction’ has been 
reported elsewhere in the literature, particularly in the context of individuals living 
with uncertain futures and conditions such as CF and HIV (Lowton, 2005; Mueller, 
2004). In the literature, self-interest and altruistic motives have also typically been 
identified as important constructs for understanding why people volunteer to take 




2011; Costenbader et al., 2007; Gammelgaard et al., 2006;  Edwards et al., 1998; 
Cassileth et al., 1982). These motives have often been presented as competing or 
distinct. 
It could be argued that a patient who undergoes extra blood tests while taking an 
experimental drug with uncertain clinical harms and benefits performs a purely 
altruistic act. However, for informants in this study, costs and benefits extended 
beyond the narrow lists of tangible risks and benefits detailed in study 
documentation, to include the therapeutic value of hope and the fulfillment of 
taking part in something worthwhile. Also, many informants spoke of other 
indirect, immediate personal benefits such as meeting new people, being part of 
something revolutionary and extra monitoring. 
While for some informants, particularly adults, their sense of hope had been 
disrupted by the unrealised promise of gene therapy, parents’ and adults’ 
psychological and moral accounts of their decision to participate in clinical research 
were mostly indistinguishable. If altruism is not something that another person can 
volunteer on someone’s behalf (Spriggs, 2006), it would have been reasonable to 
anticipate a difference across adult patient and parents’ accounts. Furthermore, 
parents spoke of their role as a moral educator, in which they had gradually 
enculturated their child to the moral responsibility of participating in research, a 
view contrasting with the position that altruism is an intrinsic hard-wired 
motivational state (Batson, 2014; Preston, 2013). In addition, the role of the volunteer 
was viewed as something personally rewarding providing an ‘inner glow’, a finding 
which contrasts with the standard view of ‘altruistic’ acts as behaviours which 




In the field of biology, researchers have drawn on the concept of reciprocal altruism 
to accommodate the disparity between the promotion of self-interest and the 
interests of others. (Silk, 2013; Trivers, 1971). This idea of reciprocity or reciprocal 
altruism is also thought to provide a more meaningful construct to understand 
patients’ motivations to take part in clinical trials than altruism (Locock & Smith, 
2011; Dixon-Woods & Tarrant 2009). Proponents of this concept assert that 
individuals are willing to incur costs if there is a chance the altruistic act will be 
reciprocated in the future. Such a sense of reciprocity was evident in this study’s 
findings, in which informants spoke of being part of a ‘cycle’ in which they 
expressed gratitude to past generations of research participants who had 
contributed to improvements in treatment and a sense of responsibility to continue 
this cycle. Comparable findings have also been reported in qualitative recruitment 
literature regarding reciprocal aspects of altruism (McCann et al. 2010; Jansen 2009; 
Simon et al., 2006). Unlike altruism, reciprocity implies a degree of personal benefit, 
albeit an imagined future benefit. Nonetheless, reciprocity is still dependent on an 
altruistic act, and immediate personal interests are not typically considered. 
Moreover, empirical evidence in the context of blood donation, considered to be an 
archetypal altruistic act (Titmus, 1971), has shown that a number of related 
processes are involved as opposed to a single construct (Evan & Ferguson, 2014). 
Also within the recruitment literature, there is inconsistency and variability in how 
altruism is constructed (Truong et al., 2011; Simon et al., 2006; Garcea, 2005). 
Therefore, it is plausible that those findings and the findings from this study 
indicate that viewing altruism as a singular construct is not adequate to account for 
the positive personal and social benefits derived from contributing to a common 
good  (Batson, 2014; Preston, 2013; Scott & Seglow, 2008). Furthermore labelling an 




ways that the informants in this study made sense of a research invitation and their 
own related interests, concerns and potential vulnerability. 
 
Informants’ accounts of their motive to contribute to the common good,  and fulfil a 
moral responsibility were interwoven with various  interrelated intrinsic pay-offs 
Consequently these findings provided further insights into related concepts, 
particularly ‘weak’ and ‘conditional altruism’ that have been developed to explain 
the relationship between self-interest and altruism, (Canvin & Jacoby, 2006; McCann 
et al. 2010). Rather than viewing self-interest or altruism as dichotomous constructs, 
the findings of my study indicate that they are part of the same psycho-moral 
process. Furthermore, these findings align with a growing body of work that 
foregrounds patients’ perspectives on responsibility in health research. Within this 
work, personal motivations are positioned as part of the wider system of  shared 
values, moral responsibility and social exchange (Cox & McDonald, 2013; Locock & 
Smith, 2011; Dixon-Woods & Tarrant, 2009) as opposed to what has become ‘reified’ 
as altruism in the recruitment literature (A Jacoby, personal communication). 
 
The comparative focus of this study was instrumental in questioning the value of 
singular constructs such as altruism for understanding trial participation. 
Informants in this study made sense of trial recruitment according to conceptual 
patterns or discourses in which centred on an interrelated rational, social and 
psycho-moral discourse.  
8.2.3 Recruitment as a social exchange 
Findings from this study concurred with empirical evidence which has illustrated 
the significance of viewing patients’ and parents’ engagement with research as the 




& McDonald, 2013; McGregor et al., 2010). Accordingly, tenets of proficient clinical 
communications including feeling socially comfortable and  valued, necessary for 
the establishment of a social relationship, were prioritised by patients, parents and 
practitioners over those required for imparting the ‘hard facts’ (Salmon & Young, 
2009; Bensing et al., 2003). Consistent with existing evidence, patients and parents 
prioritised feeling ‘socially comfortable and appropriately valued’ and the 
importance of a sense of being cared for, in their decisions about whether to 
participate in clinical research. (McCann et al., 2013; Morris & Balmer, 2006; Wilcox 
et al., 1996).  The significance of such ‘socio-emotional’ aspects of interpersonal 
exchanges has been reported across various health contexts including pre-term 
labour, oncology and stroke trials (Mangset et al., 2008; Madsen et al., 2007; Kenyon 
et al., 2006). 
Patients and parents stressed the significance of meaningful engagement both with 
practitioners involved in the research and the very enterprise of research. This social 
exchange view highlights the significance of the establishment of direct social 
relationships upon which the success of recruitment rests (McGregor et al., 2010). 
Emotions are important in sustaining exchange relationships, with positive feelings 
such as enthusiasm or satisfaction being essential in their maintenance (Lawler, 
2001; Lawler& Thye, 1999). This view appeared particularly important for younger 
informants who emphasised the significance of research being ‘fun’, ‘exciting’ and 
different to routine clinical care. 
Consistent with social exchange theories, the present study findings indicate the 
centrality of trust in the establishment and maintenance of research relationships 
(Lawler, 2001). Trust is regarded as lying at the heart of research on human subjects 




operates in practice is much less clear (McDonald et al., 2008). Findings from this 
study provided insights into mutual understanding and trust within the family unit, 
the significance of interpersonal trust between families and the clinical team, as well 
as informants overarching trust in the hospital and research infrastructure. They 
support a view of trust as a temporal, multi-dimensional phenomenon (Khodyakov, 
2007) in which trust is a process formed according to strong and weak interpersonal 
ties; and which has the potential to influence the development and maintenance of 
relationships. This framework also acknowledges that trust may be based on 
societal institutions such as, public services or government policies. Within the 
context of CF clinical relationships, due to their longevity and intensity, mirrored 
family relationships typically based on thick interpersonal trust. This depth of trust 
contributed to patients’ and parents’ social ease and potential acquiescence to 
research invitations. Nonetheless, thick interpersonal trust also enabled 
practitioners to support families to make the ‘right’ decision. 
Informants expressed an overarching trust and faith in the research endeavour and 
the scientific integrity of research. Aligned with this position is the view of research 
participation as a ‘normative ideal’ valued as a ‘social responsibility’ or ‘moral duty’ 
due to the expected future beneficial outcomes for the community (Fry, 2008). This 
view resonates with Dixon-Woods & Tarrant’s (2009) concept of research 
participation as a ‘collaboratively orientated action’. Despite most informants 
positioning trial participation as contributing to the public good, their decision to 
engage in a particular trial was still personally negotiated and contingent on 
judgements of personal costs and benefits and the establishment of a social 
relationship. However, for individuals who were the most receptive to research, it 




valuable component of their personal trajectory for living with CF or parenting a 
child with CF. 
8.3 Potential Vulnerabilities 
Central to the development of the conceptual framework were insights gained from 
comparing how parents, children, adults and practitioners experienced trial 
recruitment. This drew attention to potential vulnerabilities that arise within the 
research context. These vulnerabilities were apparent in relation to: 
 informants’ personal expectations of a trial and potential misconceptions 
 high hopes and disappointment in ‘wonder drug’ trials and future research 
 trust and acquiescence to research invitations during recruitment in a 
familiar setting  
 additional  complexities in the child  setting   
8.3.1 Personal expectations of a trial: a trial as the best option 
Potential vulnerabilities arose with regards to informants’ blurring of the 
distinctions between the research and clinical role of recruiting practitioners. This 
vulnerability was conveyed by informants’ belief that a trial had been offered 
because the recruiting practitioner thought it was their best option or in their best 
interests. This finding is consistent with the therapeutic misconception literature in 
which a patient’s expectation that a doctor will always act in their best interests is 
viewed as contributing to a therapeutic bias within the research context (Lidz et al., 
2002). Within the CF setting where recruitment typically took place in the context of 
an existing long-term clinical relationship, this expectation was heightened due to 





However, informants’ reading of the situation appeared too nuanced to be seen as a 
straightforward misunderstanding, as their expectation of a duty of care was 
typically interwoven with indirect benefits, linked to a belief in the value of the trial 
and hope for future personal benefits. Furthermore, decisions about whether a 
patient’s expectation of optimal care in the research context should be considered a 
misconception also hinges on faith in the principle of equipoise. Advocates of the 
principle of equipoise believe that RCTs are consistent with a practitioner’s duty of 
care, as no patient is knowingly given an inferior treatment (Freedman, 1987). 
Furthermore, one view of the therapeutic misconception is that whatever the 
benefits of a trial, clinical research involves giving up some benefits that are 
ordinarily part of routine care (Lidz et al., 1982). While this may be true concerning 
tangible trial related procedures, more important to many patients and families, 
were the indirect benefits of trial participation. Informants in this study were clear 
that the trial might not bring them direct clinical benefits and that the goal was to 
improve treatments in the future, even though many also hoped for the best 
personal outcome. However, they were aware of the increased monitoring within a 
trial, the feel good factor of contributing to something worthwhile and that they 
could return to standard therapies if their own or their child’s health deteriorated. 
Child informants also identified indirect benefits relating  to trial participation, such 
as the opportunity to have their routine clinical visits combined with the trial, which 
they perceived as being more fun and more relaxed than regular clinic visits. If 
patients and families perceived indirect benefits of trial participation as 
outweighing the costs of trial participation, to view this as a misconception seems 





8.3.2 Hope and disappointment  in ‘wonder drug’ trials 
Potential vulnerabilities arose with regards to informants’ high hopes in the promise 
of advancing biotechnologies and ‘targeted therapies’ involving mutation specific 
treatments (Brodlie et al., 2015). This vulnerability was conveyed by informants in 
their acknowledgement of their desire to ‘pin their hopes’ on the potential of future 
research and their concern regarding the negative impact of ‘false hopes’. For many 
informants, particularly parents, their hope in the capabilities of research and the 
potential of the curative potential of future therapies provided the ‘driving force’ for 
their engagement with all research. Informants also described how they were 
prepared to negotiate higher risks for trials with high hopes. Indeed, some 
practitioners expressed concern about families’ and patients’ optimism and 
willingness to put themselves out for the sought after ‘wonder drug trials’. These 
findings regarding informants’ hope in the capabilities of future research is 
consistent with what has been labelled in the literature as the ‘collective therapeutic 
misconception’ (Woods et al., 2014; Dresser, 2002). This concept refers to an over 
optimistic view of the promise of research, which has the capability of biasing an 
individual’s perceptions about clinical research.  
The distinct context of CF, in which the possibility of ‘finding a cure’ was made 
more real with the landmark discovery of the first gene for a human disease 
(Pearson, 2009; Porteous & Dorin, 1990), presented additional intricacies to an 
individual’s optimism. Adult informants had witnessed first-hand the unrealised 
promise of gene therapy, which for some had led to disappointment, and a more 
cautious attitude. Similarly, practitioners described their sadness at the unfulfilled 
expectations of gene therapy to provide a cure, particularly in CF where hope can 
become desperation given the ever present knowledge that the condition is life 




research and held on to an optimistic outlook. Although adults informants were not 
as motivated towards research as the parents in this sample, who emphasised an 
optimist view of the promise of clinical research and cited their hope for a cure as a 
key motivator for their engagement with research.  
However, parents were often conscious that their views were overly optimistic - this 
was a view they had actively chosen to adopt as a way of coping. Despite the 
burden of the decision-making responsibility and the high emotional demands of 
caring for a child with CF, research participation provided parents with a sense of 
agency in an emotive context, in which at times, they felt powerless. Trial 
participation in many ways became an important component of parents’ personal 
experiences of parenting a child with CF, and they viewed being approached about 
a clinical trial as a significant event, particularly the first invitation. Parents also 
gained an intrinsic ‘feel good factor’ that they were doing something good both for 
their child’s future health and for society. At times, parents themselves appeared to 
be acting as advocates for research, and there was a sense in which the more value 
they placed on something, the more value it had. This value was important in 
creating a sense of hope or therapeutic optimism for the future of their children. 
For some parents, an overly optimistic outlook for future research provided them 
with their ‘only hope’ for their child to have a normal life expectancy. These findings 
lead me to question the validity of simply compartmentalising overly high, idealistic 
hope as a misconception, or cognitive bias, because by doing so we may be failing to 
recognise a psychological need for hope in parents and patients as a way of 
managing life with an uncertain future. A similar concern has been raised in the 
empirical literature in the context of adult patients enrolling for oncology trials 
(Ulrich et al., 2012). Furthermore, if parents have insight into this overly optimistic 




for coping rather than a misunderstanding (Weinfurt, 2004).  The alternative of a 
realistic outlook but an inability to cope may be rational but ethically questionable 
for a parent or patient who has to live with daily uncertainty about the future. 
Nonetheless, in the paediatric context, parents’ enthusiasm was potentially 
problematic due to concerns that they are a ‘vulnerable’ group who are particularly 
susceptible to coercion and undue influence. For trials they viewed as offering great 
promise, parents were prepared to convince their child, a process which they 
described as a form of moral training.  Practitioners also acknowledged that for the 
most part, parents were more ‘keen’ to participate in clinical research compared to 
children who often required ‘a bit of convincing’. However, all but the youngest 
children in this sample accepted clinical research as something essentially helpful 
and indicated they were at ease with the nature of their involvement.  
Whether this parental moral training of children in relation to trials should be 
considered as coercion is a sensitive matter, raising questions around respect for 
personal family value systems and the boundaries of parental and research 
responsibilities (Woods et al. 2014; Bluebond-Langer, 2005; Leiken, 1993). Parents’ 
commitment to medical research was strongly motivated by a desire to support 
research that represented possible benefits for their child - a realistic prospect given 
the long-term nature of the condition and current advancements. However, this 
analysis showed how susceptibility might arise around balancing the value and 
burden of the things a child is convinced to do.   
An additional vulnerability was linked to the promise of new therapies in a context 
of limited access to the on-going spate of ‘wonder drug trials’. For the most part, 




were concerned about the equity of access to these trials. Indeed, some described 
these ‘cutting edge’ trials as having great promise and prestige, but as the trials 
tended to be limited to leading research hospitals, these descriptions were often 
accompanied with a sense of missed opportunity or inequity of access. In 
competitive pharmaceutical trials with the number of eligible potentially willing 
participants often exceeding the number of places avialable, a converse problem to 
the conventional ‘pressure of numbers’ and focus on recruitment rates arises. This 
concerns fair selection and equity of access to the potential benefits of research. This 
problem brought into view the role of the ‘responsible researcher’, where the 
practitioner must balance the principles of fair selection and a duty of care. If 
knowledge about trials is considered to be a ‘right’, the question of universal 
ethically acceptable selection procedures may come under further scrutiny, 
particularly in the context of promising ‘wonder drug trials’. 
8.3.3 Trust and  acquiesence 
With regards to the relational aspects of recruitment and the social context of the 
research invitation potential vulnerabilities arose.  Within the reassuring, familiar 
CF setting at times parents and adults illustrated trusting deference and 
acquiescence of research invitations. Similarly, deference and acquiescence was 
evident in the accounts of child informants but expressed in relation to their reliance 
and dependency on their parent's guidance and support in the research context. 
These findings regarding deference and acquiescence could be understood as 
supporting the view that trust is fundamental to clinical research and to informants’ 
decisions to participate in clinical research (McDonald et al., 2008). Individuals 
volunteer for research because they trust that their participation will lead to 
knowledge that will help to improve treatment for future patients and they trust 




interpersonal and institutional trust was pivotal to informants’ satisfaction with the 
approach and their interpretation of a fair research offer.  However these findings 
could also be viewed as being consistent with the therapeutic misconception 
literature, particularly as it pertains to patients underestimating the risk associated 
with trial participation (Lidz et al., 2004). In  CF, where recruitment typically took 
place in the context of a trusting clinical relationship, an informant’s trusting 
deference could be interpreted as tantamount to a misconception.  
Informants who had been approached on numerous occasions implied that they had 
become habituated to research invitations. A similar finding has been reported by 
Lowton (2005) in which CF patients conveyed an ‘ease’ in being involved in 
research.  Resembling Lowton’s (2005) findings, some informants in this study 
indicated that past positive research experiences, combined with an approach by 
someone trusted, reduced the cognitive and emotional work they engaged in when 
approached about a new study, potentially leading to less vigilance about potential 
risks. However, this habituation usually occurred in relation to simpler studies or 
low-risk trials. For the most part patients, and parents’ prioritization and personal 
judgements of risk - and trusting deference to health professionals and the hospital 
infrastructure - usually coexisted.  
A further vulnerability concerning trust arose from the intensity and longevity of 
the clinical relationship in CF, in which patients and families may experience a 
particularly strong sense of obligation to the clinical team. Moreover, within a 
context such as CF, a sense of obligation was also heightened for some informants, 
due to a concern that others may not take their fair share of the research 
responsibility. While most patients and families spoke about feeling comfortable 




inclined to feel a sense of obligation to the clinical team. However, this obligation 
was personally orientated and was typically combined with a wider moral 
responsibility to contribute to the common good and take part in something 
worthwhile. In addition, being approached by a trusted practitioner instilled their 
faith in the potential value of the research and the socio-emotional reassurance they 
derived from being approached by someone known, fostered their receptivity to the 
trial. Ultimately, the extent to which an individual’s decision-making involves 
trusting deference to health professionals and whether this is viewed as a 
‘misconception’ reflects the ongoing debates about the limits of informed consent 
and definitions of autonomy (Corrigan et al., 2009; Manson & O’Neill, 2007; Kukla, 
2005). 
8.3.4 The ‘complexity’ of the child setting  
Within this study, the special ‘complexity’ that is often attributed to trial 
recruitment in the paediatric setting (Gibson et al., 2011; Caldwell et al., 2004; 
Punch, 2002; Olechnowicz et al., 2002) was most notable in the accounts of parents. 
The responsibilities associated with the role of parenthood, which is 
characteristically viewed as an ‘extraordinarily demanding undertaking’ (Blustein, 
2012), were heightened in the context of CF. Furthermore, parents constructed their 
responsibility in line with normative assumptions around acting in the best interests 
of their child. This exacting high ideal, of parental authority, which it has been 
argued is too demanding (Salter, 2012; Blustein, 2012) served to emphasise the 
weight of responsibility parents felt in this uncertain context. 
Parents’ concerns for whether their actions in relation to research were the best for 
their child were particularly intense when their child was too young to be involved 




the emotional context appeared to reduce parents’ confidence in their ability to ‘do 
the right thing’. By placing their trust in the CF team and the hospital that has been 
caring for them, parents reduced the emotional burden of this onerous 
responsibility. However, further complications arose when a child was considered 
ready to be involved in research discussions. From this point, parents’ 
responsibilities extended to include negotiating both their child’s best health 
interests and the psycho-social best interests of the child and the wider family. How 
parents negotiated these interests and their child’s involvement was influenced by 
the age and developmental stage of their child and their interpretation of their role 
as parents, which determined the family dynamics or ‘family set-up ’.  
These findings parallel previous evidence on the acute sense of responsibility felt by 
parents to do the right thing in an uncertain trial context (Stewart et al., 2012; 
Woodgate & Yanofsky, 2010; Shilling & Young, 2009; Snethen et al., 2006; Pletsch & 
Stevens, 2001). However, the comparative focus made parents’ vulnerability all the 
more apparent when compared to the noticeably less ‘complex’ view of 
responsibility in the accounts of child and adult patients. 
Aligned to parents’ responsibility was a child’s dependency on the authority of their 
parents, which included different degrees of negotiation and sharing, through to 
autonomous decision-making, comparable to that found in the accounts of adult 
patients. The balance of a child’s responsibility and dependency in the research 
context was primarily determined by their family’s model for managing roles and 
responsibilities, and this balance mirrored the child’s involvement in wider clinical 
decisions. That is, these children had become accustomed to patterns of 
communication in the clinical setting, and as recruitment typically occurred in this 




This finding is consistent with previous evidence on the importance of considering 
existing family dynamics in the recruitment context (Oulton et al., 2016; Madden et 
al., 2016; Snethen et al., 2006; Broome & Richards, 2003), which have led to 
recommendations to move towards a family approach to consent, and to relaxing 
the distinction between assent and consent (Foreman, 1999; Gibson et al., 2011). 
However, children are socialised to respect the role and authority of parents and 
other adults (Rossi et al., 2003; Leiken 1993; Susman et al., 1992) and there is concern 
that a more family orientated consent may potentially weaken the child’s voice and 
increase a parent’s influence in discussions (Balen et al., 2006; Alderson, 1999). 
While a sensitive respect of family dynamics appeared integral to meaningful 
recruitment in the child setting, where these factors are in tension, the significance 
of assent comes into play as a strategy or safeguard to prevent family coercion or 
undue influence (Simon et al., 2004). This study supports the view that for children 
to participate in the decision-making process in a meaningful way, the existing 
family dynamics need to be respected, at the same time as ensuring that decisions 
are free from coercion and the child is aware of the procedures they are expected to 
undergo (Madden et al., 2016; Bluebond-Langer et al., 2005). 
This study also supported other findings indicating that children’s experiences were 
more influential on their level of involvement and awareness than their age and 
developmental stage (Broome et al., 2001). Children appeared capable of 
understanding what they were supported and permitted to know, or what the 
situation dictated that they needed to figure out at a particular time. Parents were 
instrumental in shaping broad patterns of involvement, particularly for children 
who were not yet teenagers. Parents and practitioners recognised that sometimes 
parents preferred to protect their children from certain information, particularly in 




These families illustrated a bounded type of sharing in which parents engaged in a 
lot of work to establish the terms of the negotiation, involving a delicate balance of 
nurturing and protective roles. 
The accounts of some of the older children illustrated additional intricacies 
regarding the evolving family relationships, in which roles and responsibilities were 
transitioning. Teenagers described how they still felt reliant on their parents, yet 
parents and practitioners often felt duty bound to encourage autonomy. 
Furthermore, a potentially overlooked tier of ‘complexity’ in the paediatric setting 
was a child’s sense of responsibility towards their parents. Children negotiated their 
roles according to changing circumstances and expectations, which at times 
required them to engage in a tactful and restrained presentation of their developing 
autonomy to diplomatically manage their parents’ feelings. Comparable findings 
have been reported elsewhere in the literature involving children with life-
shortening illness, and research invitations where children have been shown to 
respect and act to preserve the social order of their families (Bluebond-Langer et al., 
2005). However, this study also highlighted the extent that adult patients similarly 
deferred to social influences when making decisions concerning participation in 
trials (Dixon-Woods & Tarrant; Leiken, 1993) many still relying on parental support. 
Moreover, a trusting deference to practitioners and the institutional field were 
integral to parents’ and adult patients’ construction of a fair offer. The difference in 
the child sample was that their deference was mainly to parents rather than to a 
practitioner or institution. 
An important distinction between adult patients’ and the accounts of parents and 
children was adult informants’ emphasis on current ‘stage of health’ and the 




of their deteriorating health, time constraints and more intensive treatment 
compared to the child sample. Therefore adult patients emphasised the need for 
research of high value or with a significant return, to be able to offset these burdens, 
or looked for research in which their efforts were valued accordingly. In some 
respects, due to the deteriorating course of the illness, adult CF patients appeared 
more vulnerable than children. While both children and individuals with an 
incurable health condition comprise ‘vulnerable’ groups according to research  
regulation (Declaration of Helsinki, 2013; Corrigan et al., 2009; ICH GCP, 1996) these 
findings support the view for a more reasoned, nuanced understanding of 
vulnerability (Nuffield Council on Bioethics, 2015; CIOMS, 2016; Sieber, 2008).  
Additional complexity in the child setting,  at least in relation to practitioners’ 
accounts of their role, was largely unsupported by the present study. Paediatric 
practitioners viewed navigating the dynamics of families as part of their daily work 
and did not foreground it as something more complex compared to adult 
practitioners. Nevertheless, comparable to the parents’ accounts of their 
interpretation of their role in the research context both the paediatric and adult 
practitioners’ accounts conveyed an overarching complexity in relation to their 
balancing of multiple roles. This complexity was evident in how practitioners 
constructed their responsibility in research, where they had to promote the best 
interests of their patients and achieve the role of a ‘responsible researcher’. To navigate 
this complexity, practitioners spoke about the significance of assessing the worth 
and morality of the study, judgements which were based on the fusions of 
professional and personal values to determine the fairness of a research offer. An 
additional tier of complexity for practitioners, whose role was not predominantly 
research-based, was linked to the professional return for their engagement within 




recruiting patients can be challenging both intellectually and emotionally (Lawton 
et al., 2015; Donovan 2014; Tomlin et al., 2014; Ziebland et al., 2007).  
In summary this study has extended recruitment research beyond looking at either 
adult or child factors (Simon et al., 2004) and in doing so it has illustrated how 
meaning is negotiated according to the ‘social realities of family life’ (Bluebond-
Langer et al., 2005). The findings show that the ways in which adult patients made 
sense of recruitment shared many common features with children’s accounts. Adult 
patients and some children, particularly teenagers, alike judged a research offer in 
terms of its fairness, and this judgement typically hinged on whether they 
considered the trial or study to be worth their time or effort. These judgements 
seemed less onerous than those of parents, who typically had more stringent 
aspirations in trying to make the ‘right’ or the ‘best’ decision on behalf of their child. 
This is not to say that these adults and teenagers took their decision-making lightly, 
but that they made sense of these decisions relative to their particular situation. 
Adult patients had more clinical and research experiences and appeared more 
accustomed to making difficult decisions compared to both parents and children; 
while children’s decision-making was founded heavily on trust. In contrast, parents 
had to balance their own child’s immediate and future ‘best interest’, with their 
values. Consequently, their decisions appeared weightier compared to those of 
adult and child patients.  
8.4 Implications of this study 
This section explores the potential implications of the findings of this study for 




8.4.1 Recruitment Policy 
According to the regulatory and ethical literature, the ideal recruit to a clinical trial 
is voluntary, competent, adequately informed and eligible. In contrast to this 
idealised view of research ‘participants’, this study emphasised the additional 
significance of feeling comfortable, valued, secure, engaged, empowered and 
supported to be part of something that makes sense and is of value to themselves 
and others. How patients, families and practitioners negotiated the fairness of a 
research offer was according to their personal interests, which extended beyond the 
medico-legal requirements of informed consent, to include the social context and a 
broader psychological and moral dialogue. Consequently, these findings suggest 
there may be a need to broaden policy on ‘recruitment’ to ensure that ‘patient’s 
perspectives’ inform the guiding principles of trial recruitment. Predominant 
discourses on recruitment focus on the number of participants accrued, informed 
consent, and recruitment strategies, which do not adequately capture how 
recruitment is constructed by those involved. For these informants, meaningful 
engagement was at the centre of their construction of a fair research offer.  
If recruitment is viewed as meaningful engagement, the definition of ‘successful’ 
recruitment changes. From a discourse on accrual, successful recruitment is 
typically seen as a patient’s enrolment in a trial, with recruitment strategies 
primarily aimed at increasing recruitment rates. In contrast, the discourse on 
informed consent is first and foremost concerned with strengthening the ethical 
conduct of research, with successful recruitment equating to a patient's full 
understanding of the twenty points of informed consent. For these patients and 
families, feeling valued and a belief that they would potentially be taking part in 





Meaningful engagement captured both the direct personal engagement with the 
recruiter to make sense of the research offer and a more far-reaching engagement 
with the wider enterprise of research. Positive engagements were valued, even 
where patients were not in a personal position to participate; they remained more 
receptive and open to future research offers following successful engagements. In 
relation to an individual’s wider engagement with research and their belief in a 
progress narrative of modern medicine, the fairness of the promises, expectations or 
access to the benefits of medical research were all aspects of meaningful 
engagement. 
These findings indicated that recruitment policy will benefit from the continued 
development and implementation of practices which foster engagement with 
research, in which the meaning of research is made more visible and tangible. The 
advance of online resources (e.g. I am Research campaign, NIHR, 2017; 
Heathtalk.org, DIPEX, 2001), which share the views of others who have participated 
in research, appear to represent a significant development in this area which is 
reinforced by the findings of this study. However, patients and families expressed a 
reticence about pursuing information about clinical trials independently, without 
the assurance of their practitioner. This potentially brings into question campaigns 
directed at encouraging individuals to be proactive in their engagement with 
research (e.g. the “Ok to ask”  about clinical research campaign, NIHR, 2014). 
Patients’ families and practitioners in this study spoke of how the interpersonal 
quality of the approach instilled both value in them as potential participants, and 
the value and integrity of the trial itself.   
Further developments may include accounts of trial participation described by 




resources and trial information web links. Currently, due to concerns about coercion 
and impartiality, ethical committees will only permit tangible costs and benefits 
together with an acknowledgement of the generalised aims of research to be 
included in a patient information leaflet. However, the indirect benefits of trial 
participation are typically how an individual makes sense of the experience and 
constructs their view of a fair offer.  Furthermore, for a child who may have 
difficulty relating to an abstract concept of a clinical trial or the idea of future 
benefits, knowing what the experience of participating in a clinical trial feels and 
looks like from the perspective of another child has the potential to provide 
information in a way that is more meaningful to them.  
Concerns regarding trial recruitment have been a long-time issue, with recruitment 
of large enough numbers becoming increasingly difficult and these findings could 
help with this issue. In summary, this study lent support to existing empirical 
evidence, emphasising the need to support positive experiences and sustained, 
meaningful engagement with research (Gillies & Entwistle, 2012). However, to 
reconceptualise recruitment within a broader framework of meaningful engagement 
would require potential policy changes and a change in how the discourse and 
knowledge on recruitment are constructed. 
8.4.2 Recruitment Practice  
These findings indicated that a high level of proficiency in clinical communication 
was required for optimal recruitment, which may not be achievable through 
standard clinical communication training. A practitioner, during a recruitment 
encounter, must navigate the socio-emotional needs of a patient and the various 
biases that may arise from the framing and imparting of medico-legal information. 




patient was unknown, and the practitioner was unaware of personal or medical 
issues which had the potential to influence the interaction. These findings indicated 
that where possible, there should be close collaboration between  individuals  
involved in the recruitment process and clinicians involved in a patient's care, to 
ensure awareness of social, clinical needs or any issues which may require ‘special 
management’  e.g. a needle phobia and employment issues.  
Consistent with trial communication research, this study highlighted the 
significance of acknowledging recruitment as a sequence of moves in which first 
and foremost a recruiter must establish a shared understanding of the patient’s 
illness or health status relevant to the trial (Brown et al., 2004). In addition to an 
empathetic understanding of an individual’s current health status, patients and 
families spoke about the importance of feeling comfortable and valued. Moreover, a 
face-to-face approach was considered essential by patients and parents in an 
emotional context or if the practitioner was unfamiliar to the patient. These findings 
also suggest that discussing an individual’s usual approach to decision-making has 
the potential to facilitate personalised understanding and satisfaction with the 
engagement and the decision-making process. Involvement in the decision process 
at the patients’ and parents’ preferred level was identified as particularly important 
for ‘meaningful’ recruitment in the family context.  
This study suggests that the way people are initially approached, ‘first impressions' 
and the selected informational content and emotional tone of that initial 
engagement have the potential to influence the establishment and maintenance of 
the research relationship, integral to successful recruitment. Therefore, recruitment 




that privileges open discussion rather than practitioners approaching the situation 
as one where the onus is simply on giving or imparting information.   
Informants viewed trust as essential to successful recruitment and this was crucial 
in how comfortable patients felt with the initial approach. The context of CF in 
which ongoing care is centred on trusting relationships provided insights into the 
prerequisites for trust or the motifs of trustworthiness which included: 
 Empathetic engagement 
 Display of knowledge, competency and sensitivity 
 Evidence of regulation  
 Evidence of qualification, clinical and research experience. 
 Evidence of connection with the hospital. 
 Track record in research  
I hope that a published summary of my study findings will be informative and 
beneficial to researchers engaged in the task of ‘recruiting’ participants to trials or 
those who are about to embark on the task. These findings will also have particular 
relevance to practitioners working in the field of CF and other chronic conditions.  
8.5 Strengths and limitations 
As described in Chapter 1, the aim of this study was to use a case study of an 
underrepresented clinical population, to generate theoretical and empirical insights 
into the phenomenon of trial recruitment. Consequently, it is important to consider 
the strengths and limitations of using CF as a case study to examine trial 




The case of CF provided an opportunity to compare recruitment experiences across 
adult and child settings within an easily defined patient group. The comparative 
focus of this case study, while adding additional layers of complexity to the data-set, 
provided an essential analytical tool in developing insights into the phenomenon of 
trial recruitment. Multiperspective interviewing from both sides of the recruitment 
exchange enabled a more nuanced and holistic understanding of trial recruitment 
than would have been achieved if only one side of the exchange had been explored. 
A pluralistic approach to analysis was able to highlight the contradictory, labile 
nature of people making sense of their social world, holding multiple positions and 
attitudes at one time. A purely conceptual or thematic analysis of recruitment might 
have failed to capture the personal, dynamic, situated experience of recruitment.  
While a strength of this case study was the use of qualitative interviews, which 
ensured aspects of recruitment important to informants were included, a reliance on 
retrospective interviewing did not prove particularly conducive to eliciting the 
youngest participants’ experiences of research. Parents in this study indicated that 
they had engaged with their child about clinical research from a young age but it 
was unclear how these children viewed this involvement since their accounts were 
significantly less detailed. Ethnographic studies which include observations of 
recruitment consultations and follow families through their trial experience from 
the point that a trial is first raised could be a way to access young children’s trial 
experiences. This method would counter the limitations of the present case study 
design and enable a child to share their view in real-time rather than having to rely 
on cognitive abilities to recollect trial experiences.  
My reliance on third party sampling, involving various levels of gate-keeping, must 




interviews. Several CF centres declined for unclear reasons, and the recruitment 
process at each CF centre was entirely dependent on who the practitioners chose to 
approach. While I aimed to sample purposively to access a broad range of views, 
including those who had declined clinical trials, the final sample was weighted 
towards individuals with a more positive disposition to research. Furthermore, 
many parents within this sample spoke about initiating a form of moral training 
with their children and were also committed to negotiating their child’s 
involvement in research discussions and indeed in this study.   
Several practitioners declined to participate and those who did participate, for the 
most part, had a positive attitude towards clinical research, while acknowledging 
that other colleagues held less positive views. Therefore, it is possible that my 
findings over-represent the views of individuals with a positive leaning towards 
clinical research. Despite this, the study did contain numerous informants who were 
less encouraging about clinical research and several patients and families had 
declined clinical research in the past including some that had declined all 
invitations. Overall this case study comprised a large, rich, triangulated data set 
based on informants who were drawn from ten CF centres across seven regions in 
the U.K. Therefore I believe that this sample provided enough heterogeneity to 
assume these findings will have relevance to the broader CF context. Furthermore, 
the findings of this case study resulted in the advancement of an early effort to 
develop a conceptual framework, able to characterise how individuals make sense 
of their decision to engage with clinical research which included rational, social and 
psycho-ethical dimensions.  
Nonetheless, the potential transferability of the study findings to other health 




community. CF comprises a distinct chronic, life-limiting condition. It is typically 
diagnosed at birth, which gives rise to intensive health care relationships that span 
an individual’s life. While the symptoms of cystic fibrosis can vary greatly from one 
individual to another, it typically comprises a multi-system disorder often affecting 
the lungs and pancreas, eventually resulting in life-threatening complications. 
However, due to advancements in treatments and knowledge made through 
research, the outlook and overall quality of life for individuals with CF has 
improved considerably. One important development has arisen in relation to 
infection control guidelines. Consequently, patients are advised not to meet face-to-
face with other people with CF due to the serious health risks associated with cross 
infection (CF Trust, 2017). As a result of these guidelines, social support within the 
CF community offers special challenges for patients, families and practitioners. 
Therefore, a CF patient, taking part in research may endorse being part of a 
particular community in ways that are different compared to other patient groups.  
Trusting clinical relationships are viewed by patients, families and practitioners as 
integral to successful CF care and these trusting relationships often extend to the 
research context. Many CF patients and families have also witnessed first-hand the 
developments in CF treatments made though research and remain hopeful for 
further improvements both for themselves and other people with CF. Moreover, the  
serious health risks associated with cross-infection mean that social support within 
the CF community largely exists virtually via social media platforms or through 
correspondence. Consequently, it is conceivable that within this particular health 
context the constructs of hope, trust and sense of responsibility are more 
pronounced for patients, families and practitioners, compared to other contexts, and 
particularly compared to acute or comparatively minor health situations. However, 




constructs used to  make sense of recruitment it also provided insights into the 
potential vulnerabilities in this act of making sense. The ethical concern most widely 
cited in the literature, that of patients sacrificing themselves for the benefit of future 
patients, was unfounded. Informants were not passive research subjects who were 
forfeiting their personal interests. Rather, they actively and consciously engaged in 
making sense of their research invitation, in line with their personal interests. 
Nonetheless, vulnerabilities were evident around hope, trust and duty, where high 
hopes could lead to disappointment, trust could turn to acquiescence and 
responsibility could lead to obligation.  
The particular case of CF also captured a diverse range of trial and research 
experiences across an individual’s life course, including ‘run of the mill’ antibiotic 
trials to revolutionary ‘wonder drug trials’. Furthermore, situating these findings 
within   the qualitative literature, particularly studies involving long-term 
conditions (including various types of cancer) suggests the key discourses and 
constructs developed from this study resonate with and unite existing evidence (e.g. 
Hallowell et al 2016; Cox & McDonald, 2013; Locock & Smith, 2011;McCann et al., 
2010; Dixon-Woods & Tarrant, 2008; Madsen et al, 2007). Nonetheless further 
research is needed to establish the extent this conceptual framework is transferable 
to other health contexts and the priority placed on these key discourses and in 
particular how hope, trust and sense of a moral responsibility feature in other 
contexts. 
In summary as an interpretive endeavour, I accepted that my account of recruitment 
did not represent an external reality but rather my goal was to use CF as a case 
study to construct a clearer picture of the phenomenon, to further empirical and 




critical stance towards taken-for-granted knowledge and current discourses on 
recruitment,  with my overall aim of informing understanding from insights gained 
from individuals with direct experience of the process. An idealised view of 
recruitment may exist within regulatory and ethical discourses; this case study 
draws attention to the importance of viewing recruitment as a social process and the 
requirement for knowledge of trial recruitment to be informed by the social actions 
of those involved.  
8.6 Future Research  
While a person’s disposition to live in hope is often equated with the human ‘drive 
to survive’ and have ‘something to live for’ (Martin, 2014: Bruhn, 1984), the 
construct of hope in the context of clinical trials would benefit from further 
investigation. These findings suggest that high hope, rather than representing a 
therapeutic misconception or misunderstanding, were tangible benefits of trial 
participation satisfying distinct psychological needs of patients and families. Further 
exploration into the therapeutic value of hope in this context, combined with 
research examining the psychological impact of participating in research, may be 
important to ensure that potential participants are adequately supported 
throughout the research process. 
This research also provided important insights into vulnerabilities which may occur 
during the recruitment process. Further exploration is needed into how best to help 
practitioners understand and respond to these vulnerabilities. While the study 
provided insights into the significance of the interpersonal context of recruitment. 
Further research is needed on communication practices that facilitate or 




developing a clearer understanding of ‘optimal messaging and communication 
processes’ during recruitment (Thorne et al., 2013). 
Within the child context, if parents are viewing assent as a form of moral training, 
further research may be necessary to understand how children perceive this moral 
education. Further exploration of parents’ and children’s views of a family-based 
model of consent and approaches which rely on the consent of competent children 
would also help to develop an understanding of how best to support families in 
their engagement with clinical research. 
Evidence from this study and existing evidence indicates that the role of a ‘recruiter’ 
has the potential to be both emotionally and intellectually demanding (Lawton et al. 
2015; Donovan et al. 2014). Consequently, future research, examining the emotional 
and psychological demands of recruiting patients to clinical trials is essential to 
ensure the development of ways to support the role of ‘responsible researcher’ in an 
ever-changing research environment. 
These findings also suggest there may be potential to explore personal perceptions 
of fairness in the context of trial recruitment, within the framework of empirical 
ethics, a practical methodology which has been developed to integrate ethical theory 
with data from the social sciences (Frith, 2012; Borry et al., 2005). Empirical ethics is 
a significant move in bioethics to ensure ethical principles are informed by people’s 
moral beliefs and to prevent ethical theory from being too abstracted or dogmatic 
(de Vries et al., 2011).  
In the context of clinical trials, two aspects of the principle of justice or ‘fairness’ 




process (Tilburt, 2007; Powers, 1998). Fair outcomes refer to either equal distribution 
of benefits and burdens of research, and fair process refers to the conditions under 
which individuals are selected and recruited to a study (Tilburt et al., 2007). While 
regulatory bodies may assume a fair process to recruitment is achieved by following 
the customary procedures of informed consent, my findings suggest that people’s 
beliefs about recruitment extended beyond the view of autonomy embraced by the 
doctrine of informed consent reflecting a wider ethical framework. Rather these 
findings suggest that people’s belief about their engagement with clinical research 
centred on personal perceptions of fairness. These perceptions included whether 
they felt the approach was reasonable, the risks were justifiable or whether they 
believed they had moral responsibility or duty ‘to do their bit’ in the practice of 
research.  
Despite the principle of justice and fairness being considered integral to the research 
process (Emanuel et al., 2000; Powers, 1998), people's actual moral beliefs about the 
perceptions of fairness in the context of clinical research have not been examined in 
a framework of empirical ethics. Owing to the increasing curative potentials of 
developing biotechnologies, understanding personal perceptions of fairness may 
become all the more significant for research regulators. An empirical ethical analysis 
on this dataset in the future or similar qualitative evidence has the potential to 
extend our understanding of the fair process in clinical research beyond informed 







How we understand the phenomenon of trial recruitment depends on how the 
tensions and uncertainties inherent in clinical trials are managed and by whom. 
Equally, how ‘successful’ recruitment is defined, depends upon whose 
interpretations this definition is based. Within this study, my aim was to inform our 
understanding of recruitment by accessing the perspectives of the individuals 
directly involved. The findings of this study support the view that the ‘desire for 
experimental participation’ is a legitimate interest of patients, particularly in the 
context of uncertain health (Feenberg, 1992). 
Informants’ motivations to participate stemmed from a basic appeal to fairness 
which was underpinned by an acceptance of research as a ‘normative ideal’ or 
moral responsibility and something which ‘gives people hope’ (Weisfield, et al., 
2012; Fry, 2008; Harris, 2005). Viewing research as a form of duty and a source  of 
hope was heightened within the context of a serious incurable condition in which 
clinical research has lead to significant increases in life-expectancy and where there 
are a limited number of potential participants. Nevertheless, while an informant’s 
acceptance of the value and necessity of clinical research was at the heart of their 
construction of a fair offer, complexity arose for potential participants when 
negotiating the space between what is ‘something good’ and a personal reticence 
about the uncertainty inherent in clinical trials.  
These findings confirm the value of understanding and appreciating the complexity 
of an individual’s perceptions and interpretations of trial recruitment - a complexity 
that is mirrored in the literature, which indicates a ‘mixed and uncertain picture’, 




2012). These findings indicate that trial recruitment is a complex social phenomenon 
involving ‘a series of purposive and coincidental events, some situational, some 
intrapersonal and some interpersonal, all of which are embedded in a real-life 
context’ (Stake, 2005).  
While the accrual and protection discourse is essential to ensuring the scientific and 
ethical integrity of clinical research is upheld, findings from this study indicate that 
personal meaning was at the heart of a fair research offer. Individuals and families 
approached about trials wanted to be part of something of value and to be valued, 
engaging in what they believe is a worthwhile collaborative endeavour. The 
findings have implications for understanding recruitment and raise questions about 
the appropriateness of generic checklists and guidelines for enhancing and 
supporting the recruitment process. With continued research efforts, an increasingly 
rich holistic picture of recruitment is being achieved in which the subtleties and 
overarching dimensions of this challenging phenomenon can be better understood 
and supported appropriately. Deciding to take part in a clinical trial was 
constructed as something ‘really personal’, in which individuals drew upon elements 
from social, rational and psycho-ethical discourses to make sense of this unusual 
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# Search  Comments Results 
1 exp clinical trial/ or exp clinical trial, phase 
i/ or clinical trial, phase ii/ or clinical trial, 
phase iii/ or clinical trial, phase iv/ or exp 
controlled clinical trial/ or exp randomized 
controlled trial/ 
Searched as  Medical Subject Heading 
(MeSH) term (Medline is manually 
indexed with  MeSH terms which can 
be used as a thesaurus to facilitate 
searching  
Clinical trial searched as as publication 
type, i.e. reports of a specific clinical 
trial 
Definition exploded i.e. results 
retrieved using the selected term and 
all of its more specific terms. 
792867 
2 exp clinical trials as topic/ or exp clinical 
trials, phase i as topic/ or exp clinical trials, 
phase ii as topic/ or exp clinical trials, phase 
iii as topic/ or exp clinical trials, phase iv as 
topic/ or exp controlled clinical trials as 
topic/ or exp feasibility studies/ or exp 
human experimentation/ 
Searched as MeSH term: Clinical trial 
as topic i.e. for general design, 
methodology, economics, etc. of clinical 
trials. Definition exploded 
348856 
3 exp Patient Selection/ or trial 
recruitment.mp. 
Patient selection searched as MeSH 
term and trial recruitment searched as 
default keyword search in Ovid [multi-
purpose (.mp)] set of fields includes -
Original Title, Abstract, and Subject 
Heading.  Definition exploded 
50635 
4 ('randomi*ed controlled trial*' RCT or 
'clinical trial*' or 'trial*'OR 'controlled 
trial*').mp. [mp=title, abstract, original title, 
name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept, rare disease 
supplementary concept, unique identifier] 
Keywords searched as free text words 807048 
5 exp Qualitative Research/ or 
qualitative.mp. 
Searched as MeSH term and default 
keyword search in Ovid. Definition 
exploded 
117764 
6 Interview/ or interview*.mp. Searched as  default  keyword search in 
Ovid 
237499 
7 exp Nursing Methodology Research/ or 
constant comparative.mp.   
 
Nursing Methodology Research 
searched as MeSH term. Definition 
exploded.  Constant comparative 
searched as keyword search in Ovid.  
16751 
8 grounded theory.mp. 
  
Searched as keyword search in Ovid. 5333 
9 
narrative.mp. or exp Personal Narratives/ 
or exp Physician-Patient Relations/ 
Personal Narratives and Physician-
Patient Relations searched as MeSH 
term. Definitions exploded. Narrative 
searched as keyword search in Ovid. 
73800 




Cultural/ MeSH term. Ethnography searched as 
keyword search in Ovid. 
11 thematic analysis.mp. Searched as keyword search in Ovid. 3421 
12 
 
attitudes.mp. or Attitude/ 
Searched as MeSH term and keyword 
search in Ovid. 
157550 
13 
focus groups.mp. or Focus Groups/ 
Searched as MeSH term and keyword 
search in Ovid. 
21213 
14 (recruit* or enrol* or particip* or 'informed 
consent' or consent or declin*).mp. 
[mp=title, abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept, rare disease 
supplementary concept, unique identifier] 
Keywords searched as free text words 1193659 
15 (experienc* or understand* or concern* or 
view* or perspective* or opinion* or perce* 
or account* or reason* or motivat* or 
barrier*).mp. [mp=title, abstract, original 
title, name of substance word, subject 
heading word, keyword heading word, 
protocol supplementary concept, rare 
disease supplementary concept, unique 
identifier] 
Keywords searched as free text words 3289832 
16 
1 or 2 or 3 or 4 
Search for research focusing on some 
aspect of clinical trials 
1183703 
17 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 Filtering for qualitative research 527293 
18 
14 and 15 and 16 and 17 
Filtering for qualitative research on 




Search limited to articles containing  
trial in title, to focus search to 
qualitative research on trial recruitment 
169359 
20 18 and 19  2882 
 



































Topic Guide for Interviewing Parents 
 
This topic guide is only an outline of the possible questions and prompts that may be used 
and will be adapted according to the needs/preferences/experiences of each participant. The 
ordering of questions may vary according to the family’s priorities.  
There is no right or wrong answers to any of these questions I am interested in finding out 
your views and experiences of clinical trials and research in general. 
 
General family background:  
I will always give people the opportunity to provide any back ground information which they think 
may be helpful with regards to this study 
 
General introduction to views/experiences of clinical trials:  
 
1. If you wouldn’t mind could you tell me a little bit about what the term clinical trial 
means to you/ what comes to mind when I mention the term clinical trial, have you 
heard this term before? Would you mind telling me a little bit about that?   
2. Can I ask you to cast your mind back to when you first heard about the term clinical 
trial? Can you tell me a little bit about that? 
3. Have your views towards clinical trials changed since you first heard about them. 
Can you tell me a little bit about that?  
4. If not mentioned already ask if their child has (yourself/other family member anyone you 
know) ever been approached to take part in a clinical trial? 
 If yes, maybe 
The following questions will depend on how long ago the patient family took part in a trial. It 
may be appropriate to focus on one particular trial e.g. the most recent or the trial the family 
choose to discuss? 
Trial discussion  
1. If you wouldn’t mind, can I ask you to think about  and talk me through (explain in 
your own words) how you came to be invited to take part in a clinical trial  
2. When the idea of being in a clinical trial was first raised, what thoughts went 
through your mind? 
3. Is there anything about the discussion(s) that sticks in your mind particularly?  
4. Was there anything during the discussion(s) about trial that you weren’t expecting? 
5. Is there anything about how the trial was explained that could have been handled a 
bit differently? 
6. Has your {child’s name} been present when the subject of clinical trials has been 
raised, were they able to o take part in the discussion?  
7. How did you find discussing  the clinical with {child’s name} present?  
Can you tell me a little bit about how your child was included in the discussion? 
8. Who has generally brought up the subject of clinical trials? How do you think 




9. Did you know {name of recruiter} before he/she approached you about taking part 
in a clinical trial? 
10. Did you or your child have any other discussions with the 
doctors/nurses/researchers about taking part in the clinical trial(s) while you were 
trying to decide?  
Trial design: 
1. In your own words, can you tell me a little bit about the trials your child has taken 
part in? 
2. How did you feel about the different aspects of the trial?  
If necessary, prompt with key features of the trial only if they have previously been 
mentioned. How was it is decided what treatment was given? What did you think 
when (name of a consultant) told you about that? 
Probe on trial design e.g. randomisation, treatment preference, study duration, the number of 
additional appointments. 
3. Did you think that over when you were making your decision? Can you tell me a 
little bit about that? 
4. What other aspects did you consider when deciding?    
5. Did you ask all of the questions that you wanted to about the trial? How did you 
feel {name of recruiter} dealt with your questions. 
6. In general, how would you describe your experience of being approached to take 
part a clinical trial 
The child:  
Omit questions 1 – 5 if inappropriate: 
1. I’d like to ask a few questions about {child’s name} if that is OK. Did you discuss the 
trials with {child’s name}?  
2. What were his/her views? 
3. Did she/he have any particular concerns? Probe for whether they felt their concerns were 
the same or different to their concerns? 
4. Did you involve {child’s name} or any other family member in the decision making 
at all? Can you tell me a little bit about this? 
5. How do you think {child’s name} feels about {trial name}/the decision that was 
made? 
6. How did you feel his/her needs were dealt with when you were approached about 
clinical trials in the past, is there anything you would change? 
Decision Making: 
1. Can you tell me a little bit about how you made your decision whether to go into the 
trial or not 
2. In making your decision about taking part in clinical trials what sort of things did 
you consider? 




4. Was it something that you had to think about for long? How did you find deciding?  
5. Was there anything you found particularly helpful in making up your mind? Was 
there anything you found unhelpful? 
6. Apart from {name of recruiter} did you discuss it with anyone else? Can you tell me 
a little bit about that?  
7. Did you ever feel under pressure when you were trying to make up your mind?  
8. Did you feel that you were able to say no?  
9. Did you feel you had enough time to think things over properly? 
10. Now that a little time has passed, how do you feel about the decision you made? 
11. Do you think that parents should always make that choice rather than the doctors? 
Can you tell me a little bit about why you feel that way? 
The information sheet: 
1. Did you receive an information leaflets about the clinical trial you have been 
approached about? Did you get a chance to look over it? What did you think of it? 
2. Were they helpful/ unhelpful/ unclear/ was there anything you would change about 
the leaflets ? 
3. Did you use the information sheet to help you to make your mind up about the 
study? {If so} did it help you at all? 
4. In making your decision, what would you say was the most useful source of 
information? 
5. How did you feel about the amount of information you received, both written 
information and the discussions you had with the trial staff. 
Views on research: 
1. In what type of research studies are you most interested in participating  
2. What do you think about medical research involving people in general?  
3. Has your experience with the clinical trials your child/yourself have taken part in 
influenced your views on research at all? In what way? 
 
Amount and type of research (This may need to come earlier and will depend on the 
informantsearly responses) 
 
1. Has your child been approached to take part in more than one trial, how many 
trials, can you tell me a little bit about each trial and what you decided?  
2. How did the trials differ? 
May be appropriate to enquire about any other requests for research e.g. Survey, 
questionnaires, interview studies? 
What did you think about being asked to take part in this study (CACE study), have 
you ever taken part in other similar studies/ interview studies? 






Views on research: (This may need to come earlier and will depend on the informants 
early responses) 
 
1. Do you know how it gets decided how a piece of research is OK to do? 
2. Prompt research regulation, ethics committees, etc. Do you feel reassured that there is 
something in place? 
3. What motives do you think doctors have for planning and conducting clinical trials? 
4. If I can ask you now to look into the future, maybe two or three years time. If the 
trial you/your child has taken part in, came into your mind, would there be things 
that you would be curious about? Would you want to know about the outcomes of 
the trial? 
5. Is there anything else that you think is important to mention or anything you would 















Transcription notation and identification codes 
The transcription notation for this study was adapted from Silverman (1993, 2006) 
Code Description 
[   ] Overlapping speech 
 
 




Indicates elapsed time in silence in tenths of a second 
WORD 
 
Capitals except at the beginnings of lines, indicate especially loud 
sounds relative to the surroundings 
 
(   ) 
 
Indicates transcribers inability to hear what was said 
(word) 
 
Indicates possible hearings  
((   )) 
 
Transcriber’s transcription rather than actual transcriptions, e.g. of 




An abrupt cut-off of the sound in progress 
… 
 
Speech trailing off 
Study identification codes  
Each participant that took part in this study was assigned a study identification code, which 
was used to label the audio files, transcribed interviews, socio-demographic forms and 
consent forms. 
Each identifying code contained the following information and is displayed as such: 
CF Centre/ paediatric or adult/ participant/ interview / age of patient 
A P M 1 2 
Therefore the identification code: Ap-M1-2 refers to a research participant who is the first 
mother (M1) to be interviewed, who has of a 2 year old child attending a paediatric CF 
centre at Trust/hospital A at the time of the interview. 
 
If the mother and father were interviewed together the identification code for this interview 
identification code would be:  Ap-M1-F1-2 
 
 M was used to identify the mother 
 F  was used to identify the father 
 K was used the child or young person attending a paediatric CF centre 

















Field notes (Clare age 17) 
Negotiating a meeting 
The interview was arranged through communication with both Clare and M5 (Clare's 
mother). M5 encouraged direct liaison with Clare, regarding the time date and location of 
the interview, whilst implicitly indicating that she would like some involvement in the 
process. This was in part exhibited by only being provided with Clare’s mother’s mobile. 
Therefore, prior to arrival at the ward, I contacted Clare’s mother who then contacted Clare 
to inform her of my arrival.  
My perception of Clare’s mother’s actions was to fulfil the role of protector/ gatekeeper 
implicit/inherent in the role of parent, whilst simultaneously supporting and respecting 
Clare’s autonomy and independence as a young person with legal rights etc. This carefully 
crafted involvement by M5 was mirrored during the interview process and was in part 
guided/instructed by Clare.  
Negotiating recruitment in practice 
My own process of recruitment provided me with insights into ‘recruitment’ per se.  The 
idea of an 'infinity mirror'  relating to studying the never-ending   process which makes 
much human research possible,   was put into my mind by a colleague. During my 
experience of approaching Clare for this study I was conscious of respecting the existing 
family dynamics, whilst also being aware of Clare’s full legal autonomy regarding consent to 
research at the age of 17 and my role as a researcher in respecting this autonomy. 
Interview setting  
Clare had requested that I visit her on the ward for the interview as she had recently been 
admitted for a routine course of IV antibiotics. At age 17 Clare was still attending the 
Paediatric hospital in the region, the transitional process to adult services occurs somewhere 
between the age 16-18. During this admission, Clare stayed on the ward for IV treatments 
followed by an overnight stay. During the day Clare attended 6th form college where she 
was studying for her A levels. This appeared to be the normal routine for Clare during 




the hospital, rather than returning home and it was something to do while she was on the 
ward. Understandably for most people an interview in their own home was selected as it 
was considered the most convenient as 'another trip’ to the hospital outside routine clinic 
appointments was regarded as an inconvenience. For Clare however, at this time it was 
more convenient for her for me to visit her at the hospital 
Clare had a single room so confidentiality was maintained. However I felt slight concern 
about my position, when nurses entered Clare's room to administer her treatment and I 
offered to leave the room, however Clare told me it was fine for me to stay. Clare seemed 
unconcerned by my presence during treatment, which I tentatively interpreted as Clare 
constructing medical interventions as a routine, everyday part of her daily life and 
something she did not want to be a hindrance to her activities of daily living. For things to 
be achieved,  she had to effectively assimilate treatments (including hospital admissions) 
into her everyday life e.g. attending college while at hospital, taking part in a research 
interview whilst an inpatient in hospital. The admission appeared to be constructed by Clare 
as a routine almost 'mundane' part of her life, which contrasted with my conceptions of a 
hospital admission, involving heightened stress and an extraordinary event. 
The interview  
Clare appeared very relaxed and happy to get started with the interview once I had 
gone over the details of the study again. Half way through the interview Clare’s 
mother knocked on the door and Clare gave her permission to enter. I briefly 
paused the recorder and introduced myself and Clare appeared to instruct her mum 
to the bathroom (attached to Clare's room only). I asked Clare if she would like her 
mother to join us in the interview but Clare said it was fine to continue. Halfway 
through the interview Clare’s mother came out of the bathroom and sat on a chair 
next to Clare, where she remained as a silent observer for the remainder of the 
interview.  Clare appeared relaxed and open throughout the interview and her 
manner appeared unaffected by the arrival of her mother. I anticipated that Clare’s 




mother appeared to strategically adopt a low profile under the discrete instruction 
of Clare. Again  I interpreted this behaviour as fulfilling the parental role of 
protecting and monitoring whilst remaining sensitive and respectful to Clare’s 



















Mother (Tom <1yr) 
Tom is 8 months old, the youngest child in the sample to have been approached directly 
about trial participation and Tom’s mother acknowledged that she was only just getting 
used Tom’s diagnosis. She indicated that she has never really thought about research before 
and was largely unfamiliar with the term clinical trial.  TORPEDO trial was her first 
experience of being approached about a clinical trial. I questioned the influence of level of 
adjusted to a CF diagnosis and the possibility that having the trial raised at this early stage 
may have been too much to take in or deal with at this stage. 
Comparison with other families re. adjusting to being a parent of a child with CF 
 Alice’s (3y) mother described Alice’s father as ‘still struggling to come to terms with it 
(CF)’. 
 The father of Harry (1yr) ‘...you find out your child's got cystic fibrosis, it is like the end of 
the world and you go through a grieving process. ‘ 
This parents period of adjust with her son’s diagnosis combined with her lack of research 
experiences together appear to have contributed to her initial reticence about the trial. 
Comparable to parents she makes a distinction between the acceptability of research for 
herself and research for her child. This parent does not appear to be aversive to the concept 
of research per se, revealed by her agreement to talk with student Drs and her 
acknowledgement that ‘she’ would be happy to take part in research if it would help people. 
Nonetheless she is much more reticent about allowing Tom to take part in research while he 
is so young and unable to be involved in the decision-making process. She suggests 9 or 10 
may be an appropriate age to involve children in research, when she perceived children are 
old enough to have a say themselves. 
Three weeks prior to the trial being raised this parent referred to a traumatic blood test her 
son had had to endure. This experience was constructed as the main reason for this parent’s 




the trial. Tom’s mother appeared clear about the randomised nature of treatment allocation 
and indicated that she was aware that if she agreed to the trial she wouldn’t have a choice 
with regards to which treatment Tom received. She did not allude to the concept of 
equipoise, nonetheless she mentioned that that she was aware Tom didn’t have to have IVs 
(implying that she understood that there was no preferential treatment) then she would opt 
for the one that didn’t involve needles. The only way to guarantee this was to decline the 
trial (as this involved not being allowed to choose) and opt for oral medication. 
This mother described the approach for TORPEDO-CF comprising a telephone call from a 
Dr she had never met before and had been sent the information via the post, and then 
subsequently phoned to discuss her decision. She did not express any direct negativity about 
the approach, but when asked about ways to improve the approach, she stated that she 
would have preferred the trial to have been raised in person by somebody she knew from 
the CF team. She described feeling comfortable saying no, and she did not feel under any 
pressure when making the decision and she felt she had enough time to make her decision.  
 
Tom’s mother also constructed the invitation as akin to Tom ‘being used as a guinea pig’, 
despite the study comprising a phase IV trial of approved standard treatments for 
pseudomonas.  Although she did not have any experience of either treatment she had a 
strong preference to avoid going into hospital and avoid any more ‘traumatising Tom with 
needles and stuff’. She also described how other family members had been supportive of her 
decision and had agreed with her view to avoid Tom being used like a guinea pig. In 
addition at the time of recruitment she could not see any direct or future benefits for Tom 
participating in the trial.  However since the oral medication did not eradicate the infection, 
Tom has had to have IVs anyway and the line was fitted whilst Tom was under a general 
anaesthetic. M4 reflected on how participation in the trial might have resulted in the 
infection being treated ‘better’.  Nonetheless M4 implied discomfort with her proxy role 
while Tom does not have a voice and suggested it would be preferable to wait until Tom is 
older and he can have a say in the decision.  She spoke of how making a proxy decision on 













Description of RCT 
Clinical trials are used to compare different treatments to see which one works best. 
Clinical trials are carried out because doctors are unsure which treatment works 
best. For example clinical trials may be used to compare whether treatment A or 
treatment B works best. Randomised Controlled T rials or RCTs for short, are the 
most widely used type of clinical trials.  
If you were approached about a clinical trial, it would be up to you to decide 
whether or not to take part. 
In a study with two treatment groups half (50%) of the people in the study would be 
given (Treatment A) and the other half would be given (Treatment B), so there 
would be a 50/50 chance of you getting either treatment group. If you were to agree 
to take part in an RCT, you would not be able to choose which treatment you get. 
You would be randomly allocated to one of two treatment groups. The decision of 
which of the two treatments you would receive would be made by chance (this is 
called ‘randomisation’).  
If it were left to doctors or researchers to decide they might (consciously or 
unconsciously) put patients who were more likely to get better into a particular 
group. This would make the trial unreliable - no one would be able to tell if the new 
treatment really works.   
